

19-21
GIUGNO
ROMA

UNIVERSITÀ CATTOLICA
DEL SACRO CUORE
CENTRO CONGRESSI
EUROPA

16° CONGRESSO NAZIONALE

ICAR

Italian Conference on AIDS and
Antiviral Research

2024



Presidenza del Congresso

A. Cingolani, Roma
A. Di Biagio, Genova
M. Farinella, Roma
G. C. Marchetti, Milano

RESEARCH and CARE: FROM BENCH, TO BEDSIDE, TO COMMUNITY



UNIVERSITÀ
CATTOLICA
del Sacro Cuore



Con il Patrocinio di



Consiglio Nazionale
delle Ricerche

ROMA



Università
di Genova

UNIVERSITÀ
DEGLI STUDI
DI MILANO

OSPEDALE POLICLINICO SAN MARTINO
Sistema Sanitario Regione Liguria
Istituto di Ricovero e Cura a Carattere Scientifico

Sistema Socio Sanitario
Regione
Lombardia
ASST Santi Paolo e Carlo

SISTEMA SANITARIO REGIONALE
IRCCS
LAZZARO SPALLANZANI



Promosso da



e da
INMI, Istituto Nazionale per le Malattie Infettive
Lazzaro Spallanzani IRCCS
ISS, Istituto Superiore di Sanità
AMCLI, Associazione Microbiologi Clinici Italiani
SIICA, Società Italiana di Immunologia, Immunologia
Clinica e Allergologia

SIMaST, Società Interdisciplinare per lo Studio delle
Malattie Sessualmente Trasmissibili
SITA, Società Italiana per la Terapia Antinfettiva
Antibatterica Antivirale Antifungina
SIV-ISV, Società Italiana di Virologia - Italian Society
for Virology
ANLAIDS, Associazione Nazionale per la Lotta
contro l'AIDS ETS
ARCIGAY, Associazione LGBTQIA+ Italiana APS
ARCOBALENO Aids ODV
ASA, Associazione Solidarietà AIDS-ODV

C.I.C.A., Coordinamento Italiano delle case alloggio
per persone con HIV/AIDS ETS
EpaC, Associazione EpaC ETS
LILA, Lega Italiana per la Lotta contro l'AIDS Onlus
Mario Mieli, Circolo Cultura Omosessuale Mario
Mieli APS
Milano Checkpoint, Associazione Milano
Checkpoint ETS
NADIR, Associazione Nadir ETS
NPS Italia, Network Persone Sieropositive APS
PLUS, Rete persone LGBT+ sieropositive APS

Scientific Program

Seguici su



www.icar2024.it





Inquadra il QRcode
e scarica l'App



Inquadra il QRcode
e collegati al sito web

Official Journal of the Conference:

Sexually Transmitted Infections

<https://sti.bmj.com/>

dal 16/07/2024

Seguici su



#icar2024

Sede Congressuale

**UNIVERSITÀ CATTOLICA DEL SACRO CUORE
CENTRO CONGRESSI EUROPA**

Largo Francesco Vito, 1
00168 Roma

Provider e Segreteria Organizzativa

Effetti srl

Via G.B. Giorgini, 16 - 20151 Milano

Tel. +39 02 3343281 - Fax +39 02 38002105 - icar@effetti.it - @ICARcongress



Endorsement

INSTITUTIONS



UNIVERSITÀ
CATTOLICA
del Sacro Cuore



Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Università Cattolica del Sacro Cuore



UNIVERSITÀ
DEGLI STUDI
DI MILANO



SCIENTIFIC SOCIETIES

- AISF**, Associazione Italiana per lo Studio del Fegato
- AMCLI**, Associazione Microbiologi Clinici Italiani
- SIICA**, Società Italiana di Immunologia, Immunologia Clinica e Allergologia
- SIM**, Società Italiana di Microbiologia
- SIMaST**, Società Interdisciplinare per lo Studio delle Malattie Sessualmente Trasmissibili
- SIMEU**, Società Italiana Medicina d'Emergenza-Urgenza
- SIMIT**, Società Italiana di Malattie Infettive e Tropicali
- SITA**, Società Italiana per la Terapia Antinfettiva
- SIV-ISV**, Società Italiana di Virologia - Italian Society for Virology

PATIENT AND COMMUNITY ASSOCIATIONS

- ANLAIDS**, Associazione Nazionale per la Lotta contro l'AIDS ETS
- ARCIGAY**, Associazione LGBTQIA+ Italiana APS
- ARCOBALENO Aids ODV**
- ASA**, Associazione Solidarietà AIDS-ODV
- C.I.C.A.**, Coordinamento Italiano delle case alloggio per persone con HIV/AIDS ETS
- Differenza Lesbica**, Associazione Arci, culturale laica, antifascista, antirazzista per le donne lesbiche, bisessuali, transessuali
- EpaC**, Associazione EpaC ETS
- Fondazione Villa Maraini ETS**, Agenzia Nazionale di Croce Rossa Italiana per la cura dalle dipendenze patologiche
- Gay Center/Gay Help Line**, casa di tutte le persone LGBT+ (lesbiche, gay, bisex e trans)
- IAPAC**, International Association of Providers of AIDS Care
- LILA**, Lega Italiana per la Lotta contro l'AIDS Onlus
- Mario Mieli**, Circolo Cultura Omosessuale Mario Mieli APS
- Milano Checkpoint**, Associazione Milano Checkpoint ETS
- MIT**, Movimento Identità Trans, Associazione di promozione sociale
- NADIR**, Associazione Nadir ETS
- NPS Italia**, Network Persone Sieropositive APS
- PLUS**, Rete persone LGBT+ sieropositive APS



Comitato Scientifico

Presidenza del Congresso

Antonella Cingolani, Roma
Antonio Di Biagio, Genova
Massimo Farinella, Roma
Giulia Carla Marchetti, Milano

Segreteria Scientifica

Chiara Agrati, Roma
Mara Biasin, Milano
Paolo Bonfanti, Monza
Andrea Calcagno, Torino
Giulia Valeria Calvino, Roma
Antonella Castagna, Milano
Annamaria Cattelan, Padova
Francesca Ceccherini Silberstein, Roma
Benedetto Maurizio Celesia, Catania
Paola Cinque, Milano
Nicola Coppola, Napoli
Gabriella d'Ettore, Roma
Simona Di Giambenedetto, Roma
Nicoletta Frattini, Milano
Anna Maria Geretti, Roma
Cristina Gervasoni, Milano
Enrico Girardi, Roma
Giovanni Guaraldi, Modena
Miriam Lichtner, Latina
Sergio Lo Caputo, Foggia
Giordano Madeddu, Sassari
Paolo Maggi, Caserta
Valentina Mazzotta, Roma
Ada Moznich, Milano
Silvia Nozza, Milano
Ilenia Pennini, Padova
Stefano Rusconi, Legnano MI
Maria Santoro, Roma
Annalisa Saracino, Bari
Loredana Sarmati, Roma
Barbara Suligoi, Roma
Valentina Svicher, Roma
Lucia Taramasso, Genova
Camilla Tincati, Milano
Daria Lucia Trabattoni, Milano
Alessandra Vergori, Roma
Maurizio Zazzi, Siena

Presidente ICAR

Franco Maggiolo, Fabriano TR

Segreteria Corsi pregressuali

Claudia Alteri, Milano
Francesca Bai, Milano
Eleonora Cimini, Roma
Giuseppina Giupponi, Como
Stefania Piconi, Lecco
Carmela Pinnetti, Roma
Carolina Scagnolari, Roma
Nicola Squillace, Monza

Comitato Annuale di Programma (CAP)

Massimo Andreoni, Roma
Andrea Antinori, Roma
Antonella Castagna, Milano
Annamaria Cattelan, Padova
Salvatore Cecere, Bologna
Antonella Cingolani, Roma
Antonio Di Biagio, Genova
Massimo Farinella, Roma
Franco Maggiolo, Fabriano TR
Giulia Carla Marchetti, Milano
Paolo Meli, Bergamo
Cristina Mussini, Modena
Roberto Parrella, Napoli
Carlo Torti, Roma
Maurizio Zazzi, Siena

SPC

(Scientific Programme Committee)

Massimo Andreoni, Roma
Andrea Antinori, Roma
Guido Antonelli, Roma
Matteo Bassetti, Genova

Coordinatore Abstract

Antonio Di Biagio, Genova

Paolo Bonfanti, Monza
Stefano Bonora, Torino
Sergio Carbonara, Bari
Arnaldo Caruso, Brescia
Antonio Cascio, Palermo
Antonella Castagna, Milano
Francesco Castelli, Brescia
Annamaria Cattelan, Padova
Benedetto Maurizio Celesia, Catania
Antonella Cingolani, Roma
Massimo Clementi, Milano
Andrea Cossarizza, Modena
Marco Cusini, Milano
Antonella d'Arminio Monforte, Milano
Antonio Di Biagio, Genova
Giovanni Di Perri, Torino
Massimo Di Pietro, Firenze
Vincenzo Esposito, Napoli
Enrico Girardi, Roma
Andrea Gori, Milano
Sergio Lo Caputo, Foggia
Paolo Maggi, Caserta
Franco Maggiolo, Fabriano TR
Giulia Carla Marchetti, Milano
Claudio Maria Mastroianni, Roma
Cristina Mussini, Modena
Silvia Nozza, Milano
Giuseppe Nunnari, Messina
Saverio Parisi, Padova
Giustino Parruti, Pescara
Carlo Federico Perno, Roma
Massimo Puoti, Milano
Giuliano Rizzardini, Milano
Stefano Rusconi, Legnano MI
Laura Sighinolfi, Ferrara
Guido Silvestri, Atlanta USA
Barbara Suligoi, Roma
Marcello Tavio, Ancona
Carlo Torti, Roma
Maurizio Zazzi, Siena



CsC**(Community
sub-Committee)****Alberto Bignardi**, Bologna
Giulia Valeria Calvino, Roma**Daniele Calzavara**, Milano
Maria Grazia Di Benedetto, Catania
Massimo Farinella, Roma
Nicoletta Frattini, Milano
Ivan Gardini, Forlì**Sandro Mattioli**, Bologna
Paolo Meli, Bergamo
Ada Moznich, Milano
Stefano Patrucco, Torino
Filippo Schloesser, Roma**Faculty****Chiara Agrati**, Roma
Claudia Alteri, Milano
Adriana Ammassari, Roma
Emanuele Andreano, Siena
Massimo Andreoni, Roma
Andrea Antinori, Roma
Spinello Antinori, Milano
Guido Antonelli, Roma
Alessandra Bandera, Milano
Michele Bartoletti, Rozzano MI
Simone Beretta, Monza
Alessandra Maria Bianchi, Milano
Mara Biasin, Milano
Teresa Bini, Milano
Paolo Bonfanti, Monza
Stefano Bonora, Torino
Veronica Bordoni, Roma
Alberto Borghetti, Pisa
Maurizia Brunetto, Pisa
Bianca Bruzzone, Genova
Andrea Calcagno, Torino
Annapaola Callegaro, Milano
Giulia Valeria Calvino, Roma
Daniele Calzavara, Milano
Antonella Camposeragna, Roma
Anna Caraglia, Roma
Sergio Carbonara, Bisceglie BT
Giampiero Carosi, Brescia
Enrico Caruso, Milano
Antonio Cascio, Palermo
Mario Cascio, Milano
Antonella Castagna, Milano
Annamaria Cattelan, Padova
Roberto Cauda, Roma
Francesca Ceccherini Silberstein, Roma
Salvatore Cecere, Bologna
Benedetto Maurizio Cesia, Catania
Giovanni Cenderello, Sanremo IM
Massimo Cernuschi, Milano
Marta Ciambella, Roma
Eleonora Cimini, Roma**Antonella Cingolani**, Roma
Paola Cinque, Milano
Mario Salvatore Clerici, Milano
Nicola Coppola, Napoli
Maria Luisa Cosmaro, Milano
Andrea Cossarizza, Modena
Alessandro Cozzi-Lepri, London UK
Antonella d'Arminio Monforte, Milano
Antonio D'Avolio, Torino
Gabriella d'Ettore, Roma
Sara De Biasi, Modena
Giuseppe De Socio, Perugia
Elisabetta Degasperis, Milano
Antonio Di Biagio, Genova
Simona Di Giambenedetto, Roma
Giovanni Di Perri, Torino
Margherita Errico, Milano
Vincenzo Esposito, Napoli
Marco Falcone, Pisa
Massimo Farinella, Roma
Micol Ferrara, Torino
Emanuele Focà, Brescia
Giorgia Fracca, Milano
Nicoletta Frattini, Milano
Roberta Gagliardini, Roma
Massimo Galli, Milano
Sara Gandini, Milano
Giuseppe Gentile, Roma
Ivan Gentile, Napoli
Anna Maria Geretti, Roma
Cristina Gervasoni, Milano
Andrea Giacomelli, Milano
Vania Giacometti, Milano
Maddalena Giannella, Bologna
Nicola Gianotti, Milano
Enrico Girardi, Roma
Corrado Girmenia, Roma
Nicolò Girometti, London UK
Giuseppina Giupponi, Como
Giovanni Guaraldi, Modena
Giovanni Guidotti, Roma**Roy M. Gulick**, New York USA
Roberto Gulminetti, Pavia
Marco Iannetta, Roma
Chiara Iaria, Palermo
Francesca Incardona, Roma
Giuseppe Lapadula, Monza
Alessandra Latini, Roma
Adriano Lazzarin, Milano
Filippo Leserri, Roma
Miriam Lichtner, Latina
Sergio Lo Caputo, Foggia
Andrea Lombardi, Milano
Francesca Lombardi, Roma
Giordano Madeddu, Sassari
Paolo Maggi, Caserta
Franco Maggiolo, Fabriano TR
Francesco Maraglino, Roma
Giulia Carla Marchetti, Milano
Esteban Martinez, Barcelona ES
Claudio Maria Mastroianni, Roma
Sandro Mattioli, Bologna
Domenico Mavilio, Rozzano MI
Giovanni Mazzola, Caltanissetta
Francesco Mazzotta, Firenze
Valentina Mazzotta, Roma
Sheena McCormack, London UK
Sofia Mehiel, Bologna
Paolo Meli, Bergamo
Marzia Mensurati, Roma
Marco Merli, Milano
Jovana Milic, Modena
Ana Milinkovic, London UK
Annalisa Mondì, Roma
Antonia Monopoli, Milano
Davide Moschese, Milano
Ada Moznich, Milano
Camilla Muccini, Milano
Cristina Mussini, Modena
Emanuele Nicastrì, Roma
Silvia Nozza, Milano
Giuseppe Nunnari, Messina

Valeska Padovese, Malta
Roger Paredes, Badalona ES
Saverio Parisi, Padova
Roberto Parrella, Napoli
Ilenia Pennini, Padova
Carlo Federico Perno, Roma
Eskild Petersen, Aarhus DK
Caroline Petitdemange, Paris FR
Stefania Piconi, Lecco
Alessandra Pierangeli, Roma
Carmela Pinnetti, Roma
Nicoletta Policek, Edimburg UK
Massimo Puoti, Milano
Laura Amelia Rachele Rancilio, Milano
Diego Ripamonti, Bergamo
Roberta Rovito, Milano

Stefano Rusconi, Legnano MI
Francesco Saladini, Siena
Romina Salpini, Roma
Maria Santoro, Roma
Annalisa Saracino, Bari
Loredana Sarmati, Roma
Carolina Scagnolari, Roma
Filippo Schloesser, Roma
Alessandro Sette, La Jolla USA
Elham Shamsara, Tübingen DE
Antonietta Spadea, Roma
Vincenzo Spagnuolo, Milano
Nicola Squillace, Monza
Maria Grazia Strepparava, Milano
Barbara Suligoj, Roma
Valentina Svicher, Roma

Lucia Taramasso, Genova
Lara Tavoschi, Pisa
John Thornhill, London UK
Camilla Tincati, Milano
Giusy Tiseo, Pisa
Carlo Torti, Roma
Daria Lucia Trabattoni, Milano
Ombretta Turriziani, Roma
Emanuela Vaccher, Aviano PN
Luisa Verga, Monza
Alessandra Vergori, Roma
Illaria Vicenti, Siena
Alan Winston O'Keefe, London UK
Donatello Zagato, Milano
Maurizio Zazzi, Siena

Abstract Reviewers

Isabella Abbate, Roma
Chiara Agrati, Roma
Claudia Alteri, Milano
Guido Antonelli, Roma
Daniele Armenia, Roma
Lorenzo Badia, Imola BO
Alessandra Bandera, Milano
Mara Biasin, Milano
Teresa Bini, Milano
Paolo Bonfanti, Monza
Stefano Bonora, Torino
Alberto Borghetti, Pisa
Giorgio Bozzi, Milano
Bianca Bruzzone, Genova
Andrea Calcagno, Torino
Annapaola Callegaro, Milano
Giulia Valeria Calvino, Roma
Daniele Calzavara, Milano
Antonella Castagna, Milano
Dario Cattaneo, Milano
Annamaria Cattelan, Padova
Manuela Ceccarelli, Enna
Francesca Ceccherini Silberstein, Roma
Benedetto Maurizio Cesia, Catania
Giovanni Cenderello, Sanremo IM
Massimo Cernuschi, Milano
Stefania Cicalini, Roma
Antonella Cingolani, Roma
Paola Cinque, Milano
Nicola Coppola, Napoli

Maria Luisa Cosmaro, Milano
Andrea Cossarizza, Modena
Alessandro Cozzi-Lepri, London UK
Gabriella d'Ettore, Roma
Antonio Di Biagio, Genova
Massimo Farinella, Roma
Carlo Ferrari, Parma
Giorgia Fracca, Milano
Nicoletta Frattini, Milano
Roberta Gagliardini, Roma
Anna Maria Geretti, Roma
Cristina Gervasoni, Milano
Andrea Giacomelli, Milano
Nicola Gianotti, Milano
Enrico Girardi, Roma
Andrea Gori, Milano
Giovanni Guaraldi, Modena
Simone Lanini, Udine
Miriam Lichtner, Latina
Giuseppina Liuzzi, Roma
Sergio Lo Caputo, Foggia
Lucia Lopalco, Milano
Giordano Madeddu, Sassari
Paolo Maggi, Caserta
Franco Maggiolo, Fabriano TR
Giulia Carla Marchetti, Milano
Maria Mazzitelli, Padova
Valentina Mazzotta, Roma
Paolo Meli, Bergamo
Valeria Micheli, Milano

Davide Moschese, Milano
Ada Moznich, Milano
Silvia Nozza, Milano
Giuseppe Nunnari, Messina
Gian Carlo Orofino, Torino
Ilenia Pennini, Padova
Carmela Pinnetti, Roma
Pierluca Piselli, Roma
Massimo Puoti, Milano
Diego Ripamonti, Bergamo
Roberto Rossotti, Milano
Stefano Rusconi, Legnano MI
Francesco Saladini, Siena
Maria Santoro, Roma
Annalisa Saracino, Bari
Loredana Sarmati, Roma
Vincenzo Spagnuolo, Milano
Nicola Squillace, Monza
Barbara Suligoj, Roma
Valentina Svicher, Roma
Lucia Taramasso, Genova
Camilla Tincati, Milano
Carlo Torti, Roma
Daria Lucia Trabattoni, Milano
Ombretta Turriziani, Roma
Alessandra Vergori, Roma
Illaria Vicenti, Siena
Maurizio Zazzi, Siena



Care Colleghe e Colleghi,

Con immenso piacere vi diamo il **Benvenuto a Roma** ad **ICAR 2024**.

“Research and care: from bench, to bedside, to community” è il claim che sostiene la **16° edizione del Congresso** e che caratterizzerà il programma scientifico, promuovendo la riflessione sull'importanza della ricerca per raggiungere il prendersi cura in senso globale della persona.

Riteniamo che il prendersi cura della persona con HIV necessiti di una sinergia tra ricerca di base, ricerca clinica e costante interazione bidirezionale con la comunità di persone che vivono con HIV. Per garantire una visione della ricerca sempre strettamente legata alla clinica con l'obiettivo di migliorare la vita delle persone che vivono con HIV.

Inoltre, l'emergenza di nuove infezioni a trasmissione sessuale, la disponibilità di molecole, strategie terapeutiche e di prevenzione innovative, consentiranno di ampliare il programma verso nuove sfide scientifiche proiettate verso un futuro estremamente stimolante.

Nelle tre giornate congressuali - caratterizzate da un approccio **abstract-driven** - i temi **HIV/AIDS, SARS-CoV-2, epatiti, infezioni sessualmente trasmesse, virus emergenti e/o riemergenti, vaccini, infezioni nell'immunocompromesso**, saranno al centro del dibattito scientifico.

Con questo spirito, forti del percorso, dell'esperienza e del riscontro acquisiti in questi anni, manteniamo intatto l'impegno verso i giovani ricercatori, il personale sanitario non-medico, la Community, la società civile attraverso le **Scholarship, ICAR-CROI Awards, i premi per migliori abstract, il Contest RaccontART e il Community Village**.

Un **ringraziamento speciale** va al Comitato ed alla Segreteria Scientifica, al Coordinatore Abstract ed ai Revisori, agli Organismi di Governo ICAR, a SIMIT, alle Associazioni Pazienti e di Comunità, alle Istituzioni e Società Scientifiche, agli Studenti, le Scuole e le Giurie del Concorso RaccontART ed, infine, agli Sponsor che ci hanno consentito di ospitare centinaia di partecipanti.

Un'importante novità: per la prima volta gli abstract accettati (per un massimo di 300) **verranno pubblicati sulla Rivista indicizzata BMJ Sexually Transmitted Infections (STI)** e pubblicati come supplemento online.

Continuate a seguirci sul sito e sui social per tutti gli aggiornamenti!

Nice to **ICAR** you!

I Presidenti



Antonella
Cingolani



Antonio
Di Biagio



Massimo
Farinella



Giulia Carla
Marchetti



19-21
GIUGNO
ROMA

UNIVERSITÀ CATTOLICA
DEL SACRO CUORE
CENTRO CONGRESSI
EUROPA

16° CONGRESSO NAZIONALE



**Italian Conference on AIDS and
Antiviral Research**

20
24



Presidenza del Congresso

A. Cingolani, Roma
A. Di Biagio, Genova
M. Farinella, Roma
G. C. Marchetti, Milano

RESEARCH and CARE: FROM BENCH, TO BEDSIDE, TO COMMUNITY

PROGRAM AT A GLANCE

ORARI	AULA LAZZATI	AULA BAUSOLA	AULA 5	AULA 6	AULA 7	AULA GERMANIA
11.30-15.00						14.00-15.00 PARALLEL SESSION Investigator Meeting Studio Woddol
15.00-17.30	PRE-CONFERENCE ADVANCED COURSE Ageing in people with HIV: a feasible challenge	PRE-CONFERENCE ADVANCED COURSE Immune response in viral infections: where we are with new knowledge	SPECIAL SESSION RaccontART Contest Awards: incontro con le scuole finaliste e premiazione	PRE-CONFERENCE ADVANCED COURSE Complexities of HIV management: when the going gets tough... the tough get going!	PRE-CONFERENCE ADVANCED COURSE Addressing viral persistence today and tomorrow	
	AUDITORIUM					
18.00-19.00	SYMPOSIUM  How to meet patient needs in PWH?					
19.00-20.45	<p>ICAR 2024 OPENING SESSION</p> <p><i>Chairs: A. Cingolani, A. Di Biagio, M. Farinella, G.C. Marchetti</i></p> <p>19.00-19.15 Introducing ICAR 2024: Chairs' welcome addresses</p> <p>19.15-19.20 SIMIT President welcome addresses R. Parrella</p> <p>19.20-19.40 Authorities' welcome addresses R. Bellantone, A. Gasbarrini</p> <p>19.40-19.50 RaccontART: the three Winners A. Lazzarin</p> <p>Keynote Lectures: The Year of PrEP </p> <p><i>Chair: A. Antinori</i></p> <p>19.50-20.10 Mauro Moroni Memorial Lecture: "Ending HIV through PrEP: the impact of PrEP on the trajectories of new infections" <i>S. McCormack</i></p> <p><i>Chair: S. Mattioli</i></p> <p>20.10-20.30 Giulio Maria Corbelli Memorial Lecture: "The era of PrEP: time to end the AIDS crisis?" D. Calzavara</p> <p>20.30-20.45 Closing remarks</p>					
20.45-22.30	ICAR 2024 Welcome Reception					

- CONFERENCE SESSIONS
- SYMPOSIUM - EXPERT MEETING
- SPONSORED SESSIONS
- ORAL COMMUNICATIONS
- SHORT COMMUNICATIONS
- THEMED DISCUSSION
- PARALLEL SESSIONS



LUNCH TIME 12.30-14.30

ORARI	AULA LAZZATI	AULA BAUSOLA	AULA 5	AULA 6	AULA 7	AULA GERMANIA
09.00 10.00	Keynote Lectures C. Mussini and R. Paredes					
10.05 11.05	SYMPOSIUM The role of non-biomedical primary prevention in the end HIV strategies	SYMPOSIUM Back to the future of COVID-19: virus evolution, host susceptibility and clinical peculiarities	EXPERT MEETING Winning cardiometabolic comorbidities in HIV: the best place for doravirine		THEMED DISCUSSIONS People living with HIV: thinking of QoL	
11.10 12.10	SYMPOSIUM Are three-drug ARV regimens still needed for long term treatment success?	SYMPOSIUM Infectious disease management in patients living with onco-hematological malignancies: focus on COVID-19 and invasive fungal infections (IFI)	ORAL COMMUNICATIONS HIV epidemiology and testing promotion	ORAL COMMUNICATIONS Immune responses to vaccination and emerging infections		
12.15 13.15	SYMPOSIUM Three elephants in the room: clinical approach to the most relevant comorbidities related to HIV infection	EXPERT MEETING COVID-19 risk assessment and prophylaxis in fragile population	EXPERT MEETING PrEP and more	ORAL COMMUNICATIONS Long Acting injectables: the Italian experience	SHORT COMMUNICATIONS Novel insights in the management of chronic viral hepatitis	
13.15 14.15		SHORT COMMUNICATIONS Sexual health and love's labours	SHORT COMMUNICATIONS PrEParing for the future of prevention	THEMED DISCUSSIONS Antiretroviral therapy: thinking of durability	SHORT COMMUNICATIONS HIV associated comorbidities: interplaying matters	
14.20 15.20	SYMPOSIUM AND ORAL COMMUNICATIONS Real-world experiences with TAF-based regimens	SYMPOSIUM Antiviral treatment of COVID-19 for fragile people in the current era	ORAL COMMUNICATIONS Virology and pharmacology across the spectrum of HIV treatment	EXPERT MEETING Optimizing the management of patients with skin and soft tissue infections (ABSSSI): focus on fragile population		
15.25 16.25	SYMPOSIUM Clinical HIV: looking ahead	SYMPOSIUM AND ORAL COMMUNICATIONS COVID-19 and post-Covid conditions in 2024: data from the EuCARE Consortium	EXPERT MEETING Tailoring of antiretroviral therapy in PWH who go through therapeutic failure. Experts panel discussion on real clinical scenarios	ORAL COMMUNICATIONS Modern challenges in sexual health	SHORT COMMUNICATIONS Factors affecting treatment success: from pharmacology to drug resistance	15.25-17.25 SPECIAL SESSION Approaching Chemsex user: a multidisciplinary practice
16.30 17.30	SYMPOSIUM The future of STI prevention and care: one size does not fit all		ORAL COMMUNICATIONS The complexities of HIV infection	ORAL COMMUNICATIONS Immunological features in people living with HIV	SHORT COMMUNICATIONS COVID-19 Unmasked: role of immunity and early treatment	
17.35 18.30	SPECIAL SESSION ICAR-CROI Awards 2024					
18.30 19.30				PARALLEL SESSION Screening HIV nei PS Incontro SIMIT/SIMEU	PARALLEL SESSION Meeting Prestigio	PARALLEL SESSION Stercoinvolta

PROGRAM AT A GLANCE

Giovedì 20 Giugno



LUNCH TIME 12.30-14.30

ORARI	AULA LAZZATI	AULA BAUSOLA	AULA 5	AULA 6	AULA 7	AULA GERMANIA
08.00 09.00						PARALLEL SESSION Investigator Meeting of EDOLAS Study
09.00 10.00	Keynote Lectures E. Petersen and A. Sette					
10.05 11.05	SYMPOSIUM From RCT to clinical practice: evidences in treatment and in prevention of LA regimens		EXPERT MEETING Vaccination in immunocompromised people: let's protect the vulnerable	ORAL COMMUNICATIONS Tailored approaches to antiretroviral therapy		
11.10 12.10	11.10-12.35 SYMPOSIUM Deep into HIV treatment Guidelines	11.10-12.50 MEET THE EXPERT AND ORAL COMMUNICATIONS Critical clinical aspects underlining the control of viral hepatitis and emerging viral infections	SPECIAL SESSION Vaccines Pipeline: a glimpse of the future	ORAL COMMUNICATIONS Awareness in Sexual Health: U=U and prevention	10.30-11.30 SHORT COMMUNICATIONS Hot topics in the epidemiology of relevant chronic and respiratory viral infections	
					11.35-12.35 THEMED DISCUSSIONS Because the virus matters	
12.15 13.15	12.40-13.40 SYMPOSIUM HIV, lights and shadows on new treatment strategies: focus on new drug classes	12.55-13.55 SYMPOSIUM New knowledge in chronic viral infections (HBV, HDV, CMV)	12.35-13.35 EXPERT MEETING The unheard voices. Perspectives of "difficult" patients			
13.20 14.00			13.40-14.50 MEET THE EXPERT DREAM AND THEMED DISCUSSIONS Crossing borders and fighting inequalities		13.00-13.50 SHORT COMMUNICATIONS Bridging innate and adaptive immunity in viral infections	13.20-14.20 PARALLEL SESSION Meeting Community - Report campaign "U=U: impossibile sbagliare"
14.00 15.00	13.50-15.00 SYMPOSIUM Striving for an HIV cure: from post-treatment control to a natural cure	ORAL COMMUNICATIONS A tale of two pandemics: molecular insights on SARS-CoV-2 and HIV		ORAL COMMUNICATIONS PrEP and prevention strategies	ORAL COMMUNICATIONS HIV associated comorbidities: matters of the heart	
15.05 16.05	SYMPOSIUM Meet the Expert in HIV	ORAL COMMUNICATIONS What is left to say on COVID-19 today?	ORAL COMMUNICATIONS HIV associated comorbidities: pressing matters	ORAL COMMUNICATIONS Highlighting the diversity of people living with HIV	SHORT COMMUNICATIONS Stigma, awareness and education	
16.10 16.30	SPECIAL SESSION ICAR 2024 Awards and Closing remarks					



19-21
GIUGNO
ROMA

UNIVERSITÀ CATTOLICA
DEL SACRO CUORE
CENTRO CONGRESSI
EUROPA

16° CONGRESSO NAZIONALE



**Italian Conference on AIDS and
Antiviral Research**

20
24



Presidenza del Congresso

A. Cingolani, Roma
A. Di Biagio, Genova
M. Farinella, Roma
G. C. Marchetti, Milano

RESEARCH and CARE: FROM BENCH, TO BEDSIDE, TO COMMUNITY

**PRE-CONFERENCE
ADVANCED COURSES**

**PRE-CONFERENCE ADVANCED COURSE** 15.00-17.30**AULA LAZZATI****Ageing in people with HIV: a feasible challenge**

Chairs: Giuseppina Giupponi (Como), Filippo Leserri (Roma), Nicola Squillace (Monza)

Ageing is a physiologic process consisting of physical and mental changes. It is primarily influenced by a genetic factors but also by various external factors including diet, exercise, stress, and smoking. HIV infection has been associated with early ageing. Frailty is a clinically state increased vulnerability, resulting from age-associated declines in physiologic reserve and function across multiple organ systems, such that the ability to cope with everyday or acute stressors is compromised. Frailty is strictly associated with ageing and quality of life. Peoples living with HIV (PWH) are at increased risk of myocardial infarction: a recent trial has confirmed a beneficial impact of statin therapy also in PWH older than 40 yo with a low cardiovascular risk. Other comorbidities such as diabetes, hypertension and depression contribute to polypharmacy in PWH. The aim of the course is to analyze the principle issues regarding Ageing in PWH and how to manage them focusing on practical recommendations.

15.00-15.30	Results of a Survey about Quality of Life in persons with HIV	N. Policek, Edimburg UK
15.30-16.00	What is frailty and how can we prevent and manage it?	J. Milic, Modena
16.00-16.10	Discussion	
16.10-16.40	Less is more: how can we manage polypharmacy in persons with HIV?	M. Ferrara, Torino
16.40-17.10	If I feel sad, what should I do? Depression burden in persons with HIV	M.G. Strepparava, Milano
17.10-17.30	Discussion	

**PRE-CONFERENCE ADVANCED COURSE** 15.00-17.30**AULA BAUSOLA****Immune response in viral infections: where we are with new knowledge**

Chairs: Eleonora Cimini (Roma), Stefania Piconi (Lecco)

In the host, innate and adaptive immunity are the arms of a functional and well-organized immune response against several pathogens. Beside immune system, inflammation protects the host by eliminating pathogens, repairing damaged tissue, and restoring homeostasis. Inflammasome is the core component of the inflammatory response, having a crucial role in resisting pathogenic infections and maintaining immune homeostasis by releasing inflammatory soluble factors. An overactive inflammasome can also trigger a cytokine storm, leading to various inflammatory diseases and exacerbating tissue damage. During viral infections, a balanced immune/inflammatory response is prominent in resolving the infection. Innate immunity implements non cellular/cellular strategies to eliminate viruses in the early stage of infection, by priming specific T and B cells responses in the resolving phase. Viruses are able to modify host's immune response both in acute/chronic phases of infection, by evolving mechanisms to evade or to hyperactivate immune response by damaging the host. T cells have a pivotal role in controlling infectious diseases and cancer. Chimeric antigen receptor T-cells (CAR-T) therapy has emerged as a highly efficacious treatment modality for refractory and relapsed hematopoietic malignancies in recent years. Thus, it seems likely that engineered, re-directed T cells will also be able to control these diseases when naturally occurring T cells fail. A successful effector CAR-T cell therapy is designed to kill every cancer or virus-infected cell in the patient. By understanding the biology of naturally occurring T cells, these advances will help the field to engineer better T cells to function in a wide array of disease areas. In this pre-congress course we will deepen the innovative diagnostic and therapeutic aspects in the control of acute and chronic viral infections in view of the clinical and pathogenetic relevance of the host's immune response during viral infections.

15.00-15.30	Innate immunity and inflammation	R. Rovito, Milano
15.30-16.00	Adaptive immune response in viral infections: T and B lymphocytes	S. De Biasi, Modena
16.00-16.30	Monoclonal antibodies in viral infections	E. Andreano, Siena
16.30-17.00	Novel T-cell therapies in viral infections	V. Bordoni, Roma
17.00-17.30	Discussion	



**PRE-CONFERENCE ADVANCED COURSE** 15.00-17.30**AULA 6****Complexities of HIV management: when the going gets tough...
the tough get going!***Chairs:* Teresa Bini (Milano), Carmela Pinnetti (Roma)

The aim of this pre-congressional course is to reflect on some topics in the management of HIV infection of high clinical complexity. The simultaneous presence of multiple comorbidities can create extreme difficulties for clinicians in the daily clinical management of the person living with HIV. The course is aimed at young infectivologists who will be able to interactively discuss with tutors the approach of five different HIV-related issues. The course aims to critically analyse diagnostic and therapeutic choices in order to synthesise practical management principles useful in clinical practice.

- 15.00-15.20 **Saturday Naive Fever: when two (or more) infections are better than one** A. Mondì, Roma
Background:
This case study analyses the simultaneous presence of multiple opportunistic infections during a recent HIV diagnosis. This case report will allow a discussion of the main diagnostic tests, differential diagnosis and timing of initiation of the different therapies.
- 15.20-15.30 **Discussion**
- 15.30-15.50 **Atypical mycobacteriosis yes or not: that is the question** A. Giacomelli, Milano
Background:
This case report is about a male patient who has been diagnosed with late HIV infection, visceral KS and IRIS-atypical mycobacteriosis. The patient presented with fever and lymphadenopathy after cART introduction; an initial worsening of symptoms with abdominal pain needed a surgical operation and several modifications of antimycobacterial therapy. The clinical presentation of IRIS and mycobacteriosis, as well as the difficulties in the diagnosis and in the choice of the correct antimycobacterial treatment, are discussed.
- 15.50-16.00 **Discussion**
- 16.00-16.20 **End-stage liver disease in HIV: when and how to get ready for transplant?** M. Merli, Milano
Background:
Liver transplant in PWH increased significantly in the last 20 years, thanks to the improvements in antiretroviral treatment and prolonged survival. The coinfection with HDV, the alcohol-related liver disease and the increasing prevalence of non-alcoholic fatty liver disease are the current major determinants of end-stage liver disease. HBV/HDV coinfection may have a more aggressive and often unpredictable course in PWH, making liver transplantation the only curative strategy, with success rates related to both transplant timing and patients overall condition (both clinical and social) at the time of transplantation. This clinical case is about a HBV/HDV coinfecting PWH who underwent liver transplant and describes the complications that an ID physician has to manage when caring a PWH undergoing liver transplant.
- 16.20-16.30 **Discussion**
- 16.30-16.50 **Empathetic Care in Action: Navigating the Complex Journey of Transgender
Individuals Living with HIV** G. Lapadula, Monza
Background:
The analysis of this clinical case aims to review the clinical management of a transgender PWH. The main screening tests for infectious and oncological pathologies, the choice of antiretroviral therapy and the social issues of retention in care will be discussed.
- 16.50-17.00 **Discussion**
- 17.00-17.20 **What ulcer can I do for you?** N. Girometti, London UK
Background:
This clinical case is about a male patient that presented at HIV/GUM outpatient clinic for genital warts; the physical examination instead showed several genital ulcerations and unilateral vision loss. The patient has been diagnosed with syphilis some years before, but he hadn't be advised to start PrEP. HIV rapid test was positive and later malignant syphilis with optic neuritis was diagnosed. Differential diagnoses of genital ulcers are illustrated and the need of STI testing and PrEP in preventing HIV infection is discussed.
- 17.20-17.30 **Discussion**



**PRE-CONFERENCE ADVANCED COURSE** 15.00-17.30**AULA 7****Addressing viral persistence today and tomorrow****Chairs:** Claudia Alteri (Milano), Carolina Scagnolari (Roma)

The last decade has seen a profound change in our understanding of viral persistence as a much more dynamic picture of the reservoir emerged. The mechanisms that prevent HIV and HBV eradication have been redefined, as well as their role in chronic immune activation and inflammation. At the same time, the COVID-19 global pandemic caused by the SARS-CoV-2 reopens questions about the ability of some RNA viruses to drive chronic symptoms by persisting in certain body sites or tissue reservoirs after acute infection. In summary, viral persistence is undoubtedly complex and multifaceted process, but if approached from the right angle, can yield many clues for the identification of new weapons and new curative strategies to counteract it. Thus, this course is shedding light on the state of the art as well as the most recent discoveries and fascinating innovations in HIV, HBV, HDV persistence and post-COVID-19 syndrome. It uncovers putative links between viral persistence, viral evolution, host immune status, and protective immunity to guide and direct future basic science and clinical research priorities.

15.00-15.50 HIV-1: markers for persistence, latency and resistance15.00-15.20 **The virological point of view**

O. Turriziani, Roma

15.20-15.40 **The clinical point of view**

M. Iannetta, Roma

15.40-15.50 **Discussion****15.50-16.40 HBV/HDV: from virology to pathophysiology**15.50-16.10 **The virological point of view**

R. Salpini, Roma

16.10-16.30 **The clinical point of view**

E. Degaspero, Milano

16.30-16.40 **Discussion****16.40-17.30 SARS-CoV-2: evolution and monitoring**16.40-17.00 **The virological point of view**

A. Pierangeli, Roma

17.00-17.20 **The clinical point of view**

A. Lombardi, Milano

17.20-17.30 **Discussion**

19-21
GIUGNO
ROMA

UNIVERSITÀ CATTOLICA
DEL SACRO CUORE
CENTRO CONGRESSI
EUROPA

16° CONGRESSO NAZIONALE



**Italian Conference on AIDS and
Antiviral Research**

20
24



Presidenza del Congresso

A. Cingolani, Roma
A. Di Biagio, Genova
M. Farinella, Roma
G. C. Marchetti, Milano

RESEARCH and CARE: FROM BENCH, TO BEDSIDE, TO COMMUNITY

SCIENTIFIC PROGRAM

**decimo
concorso
artistico**

**Infezioni
Sessualmente
Trasmesse
HIV
COVID-19**

**Arti
audiovisive**

Arti visive

**Fashion
design**

**Altre
espressioni
letterali**

**raccont
ART**

La Giuria Artistica

Alessandro Castellano *Graphic Designer*

Nefeli Misuraca *Montatrice e regista di cortometraggi*

Francesco Suriano *Scrittore di teatro, sceneggiatore e regista*

Vincenzo Porcelli *Produttore cinematografico*

La Giuria Tecnico-Scientifica

Giulia Valeria Calvino *ANLAIDS, Roma*

Anna Caraglia *Direzione prevenzione sanitaria - Ministero della Salute, Roma*

Francesca Ceccherini Silberstein *Università degli Studi di Roma Tor Vergata, Roma*

Antonella Cingolani *Fondazione Policlinico Universitario Agostino Gemelli, Roma*

Paola Maria Cinque *Università Vita-Salute San Raffaele, Milano*

Maria Luisa Cosmaro *LILA, Milano*

Alfredo D'Ari *Ministero della Salute, Roma*

Giovanni Del Bene *ANLAIDS, Milano*

Antonio Di Biagio *Ospedale Policlinico San Martino, Genova*

Margherita Errico *NPS Italia, Milano*

Massimo Farinella *Mario Mieli, Roma*

Nicoletta Frattini *ASA, Milano*

Rosario Galipò *ANLAIDS, Roma*

Giuseppina Giupponi *LILA, Como*

Adriano Lazzarin *IRCCS Ospedale San Raffaele, Università Vita-Salute, Milano*

Donatella Mainieri *ANLAIDS, Milano*

Giulia Carla Marchetti *ASST Santi Paolo e Carlo, Università degli Studi di Milano, Milano*

Paolo Meli *Associazione Comunità Emmaus, Bergamo*

Silvia Nozza *IRCCS Ospedale San Raffaele, Università Vita-Salute, Milano*

Stefano Patrucco *ARCOBALENO Aids ODV, Torino*

Francesca Vichi *Ospedale Santa Maria Annunziata, Bagno a Ripoli FI*

Donatello Zagato *ASA, Milano*

**SPECIAL SESSION** 15.00-17.30**AULA 5****“RACCONTART” CONTEST AWARDS:
INCONTRO CON LE SCUOLE FINALISTE
E PREMIAZIONE****Chairs:** Anna Caraglia (Roma), Francesca Ceccherini Silberstein (Roma), Margherita Errico (Milano)

Giunto alla decima edizione e destinato agli studenti degli Istituti Scolastici Superiori, il Contest artistico RaccontART rappresenta un'occasione unica e preziosa di formazione e informazione in tema di HIV, Infezioni Sessualmente Trasmesse e COVID-19. Questa sessione è dedicata alla presentazione delle Opere finaliste in concorso, selezionate dalle Giurie Artistica e Tecnico-Scientifica. Al termine della Sessione, verranno premiati i primi tre classificati.

15.00-15.30	Introduzione a cura dei Presidenti ICAR 2024	A. Cingolani, Roma; A. Di Biagio, Genova M. Farinella, Roma; G.C. Marchetti, Milano
15.30-15.40	Introduzione e presentazione della Giuria Artistica e Tecnico-Scientifica	A. Caraglia, Roma; F. Ceccherini Silberstein, Roma; M. Errico, Milano
15.40-17.00	Presentazione delle Opere finaliste al Concorso a cura degli Istituti Scolastici	
17.00-17.15	Premiazione primi 3 classificati	A. Lazzarin, Milano
17.15-17.30	Conclusioni	

**Gli Istituti Scolastici
e le opere finaliste**

I.I.S. Caterina Caniana Bergamo

I.I.S. M.K. Gandhi Besana Brianza MB

Liceo Artistico Brera Milano

Liceo Artistico Michelangelo Buonarroti Latina

Liceo Artistico Orioli Viterbo

Liceo Artistico Simone Weil Treviglio BG

Liceo Leonardo da Vinci Jesi



**PARALLEL SESSION** 14.00-15.00**Investigator Meeting Studio Woddol****AULA GERMANIA**

Chairs: Antonella Cingolani (Roma), Francesca Lombardi (Roma)

**SYMPOSIUM** 18.00-19.00**How to meet patient needs in PWH?****AUDITORIUM**Chairs: Giulia Carla Marchetti (Milano), Cristina Mussini (Modena) *With an unrestricted educational grant from Gilead Sciences*

The current HIV care paradigm goes beyond the concept of suppression of plasma HIV-RNA viral load and recovery of CD4+T cells by also taking into consideration all those factors, pharmacological and non pharmacological, general or tailored to the individual, that make long-term success of antiretroviral therapy (ART) possible. In this context, a person-centered approach must meet the needs and expectations of people with HIV (PWH) in order to ensure their long-term therapeutic success. The symposium aims to provide new knowledge about HIV and hepatitis viruses, especially in the most difficult-to-treat populations, such as PWH with suboptimal adherence and PWH with HBV/HDV coinfection. Through an interactive talk, experts will discuss current and future challenges and innovative strategies that can address the unmet needs of PWH, including those with HBV/HDV coinfection, by supporting individuals to overcome clinical issues and improve outcomes and quality of life.

18.00-18.15	Optimizing antiretroviral treatment in PWH with a personcentered approach	A. Antinori, Roma
18.15-18.30	The importance of forgiveness for the sustained HIV virologic suppression	F. Maggiolo, Fabro TR
18.30-18.45	Improving outcomes of HBV/HDV infection among PWH	M. Puoti, Milano
18.45-19.00	Discussion	A. Antinori, Roma; F. Maggiolo, Fabro TR G.C. Marchetti, Milano; C. Mussini, Modena; M. Puoti, Milano





ICAR 2024 OPENING SESSION 19.00-20.45

AUDITORIUM

Chairs: Antonella Cingolani (Roma), Antonio Di Biagio (Genova),
Massimo Farinella (Roma), Giulia Carla Marchetti (Milano)

19.00-19.15

Introducing ICAR 2024: Chairs' welcome addresses

19.15-19.20

SIMIT President welcome addresses *R. Parrella, Napoli*

19.20-19.40

Authorities' welcome addresses *R. Bellantone, Roma; A. Gasbarrini, Roma*

19.40-19.50

RaccontART: the three Winners *A. Lazzarin, Milano*

19.50-20.30 **Keynote Lectures: The Year of PrEP**



19.50-20.10

Chair: Andrea Antinori (Roma)

Mauro Moroni Memorial Lecture

Ending HIV through PrEP: the impact of PrEP on the trajectories of new infections *S. McCormack, London UK*

Two European PrEP trials confirmed the high biological efficacy of PrEP in 2015, boosting prevention efforts. The French government responded quickly and implemented a national programme through hospital clinics. The UK government stalled, but the sexual health clinic network supported those able to access PrEP through personal purchase of drug online at affordable prices. The Community raised awareness and charities supported those unable to purchase drug themselves. The impact on new infections was clear at clinic level, and now in national surveillance data. Even in the context of 95:95:95 for diagnosed: on treatment: undetectable, PrEP has an impact. However, there is room for improvement as we're still not diagnosing HIV quickly enough, and shifting social norms would really help in this space, particularly with respect to migrant populations.

20.10-20.30

Chair: Sandro Mattioli (Bologna)

Giulio Maria Corbelli Memorial Lecture

The era of PrEP: time to end the AIDS crisis? *D. Calzavara, Milano*

PrEP represents one of the greatest opportunities among the strategies we currently have to prevent HIV infection. The social and anthropological impacts of PrEP have generated an enhanced understanding of people's sexualities. These are experience with more self-determination and empowerment, creating opportunities for educational interventions, both in personal and collective perspectives. However, this extraordinary tool could be much more powerful. At the moment the application and distribution of PrEP patchy and unevenly distributed within the national prevention system. The result is that its revolutionary power is still underutilized and largely inaccessible.

20.30-20.45

Closing remarks *A. Cingolani, Roma; A. Di Biagio, Genova; M. Farinella, Roma; G.C. Marchetti, Milano*

20.45-22.30

ICAR 2024 Welcome Reception



**KEYNOTE LECTURES** 09.00-10.00**AULA LAZZATI**

Chairs: Antonella d'Arminio Monforte (Milano), Carlo Torti (Roma)

09.00-09.30 **Bridging to the future with long-acting therapies**

C. Mussini, Modena

Recently, the field of anti-HIV therapy has been further revolutionized by the introduction of long-acting ART. The combination of CAB and RPV represents the first approved injectable long-acting ART for PWH. This combination has demonstrated high efficacy and safety in both registration and real-life studies. Despite the well-known advantages of the CAB/RPV injectable regimen, such as convenience, privacy, stigma reduction, and improved medication management, there are still some barriers to its widespread use. The lecture will provide a summary and update on currently available long-acting antiretrovirals, as well as those in development, and will discuss the challenges involved in their effective implementation.

09.30-10.00 **Harnessing the microbiome in HIV vaccine responses**

R. Paredes, Badalona ES

In the setting of HIV infection, specific microbiome signatures have been linked, on the one hand, to disease progression and on the other, to immune-mediated viral control. Given its key role in shaping the host's adaptive immune response and in modulating the inflammation, the microbiome may be exploited to provide new opportunities to pursue an HIV cure.

**SYMPOSIUM** 10.05-11.05**AULA LAZZATI****The role of non-biomedical primary prevention in the end HIV strategies**

Chairs: Massimo Farinella (Roma), Enrico Girardi (Roma)

Information, education and interventions to promote behavior changes have been the cornerstone of HIV prevention for more than two decades. Since 2010 UNAIDS program has called for the inclusion of antiretroviral treatment as a key pillar in the global strategy to control the spread of HIV infection, thus supporting the concept of treatment as prevention. More recently, Oral preexposure prophylaxis (PrEP) has been demonstrated to be highly efficacious and often effective in public health. In this context nonbiomedical interventions for primary prevention, are often seen as having a marginal role in the context of HIV elimination program, although it seem unlikely that biomedical interventions alone will eventually lead to ending the HIV epidemic. In this round table we will discuss the evidence base and the potential impact of several aspects of non-biomedical primary prevention including comprehensive sexuality education, communication for young people through social media and interventions for vulnerable population such as migrants.

ROUND TABLE10.05-10.15 **Sexuality education: the EduforIST project**

L. Tavoschi, Pisa

10.15-10.25 **Social effectiveness and communication among young people**

A. Camposeragna, Roma

10.25-10.35 **Migrant populations**

A. Saracino, Bari

10.35-10.45 **Transgender populations**

S. Mehiel, Bologna; A. Monopoli, Milano

10.45-11.05 **Discussion****SYMPOSIUM** 10.05-11.05**AULA BAUSOLA****Back to the future of COVID-19: virus evolution, host susceptibility and clinical peculiarities**

Chairs: Giordano Madeddu (Sassari), Alessandra Vergori (Roma)

The SARS-CoV-2 epidemic has been changing over time, and COVID-19 is transforming from a pandemic to an endemic disease. A great number of genotypic sequences have demonstrated the evolutionary distance of SARS-CoV-2 from 2019 to date. A deep insight into the mechanisms of viral evolution, from the natural selection of advantageous variants to the emergence of drug resistance, will be useful to understand changes in transmissibility, disease severity and immune escape. To date, COVID-19 burden has disproportionately affected the immunocompromised individuals. Therefore, the knowledge of immunogenicity elicited by natural infection and vaccines among them might be relevant for effective management, in terms of booster vaccination, preexposure prophylaxis, early access to treatment, and appropriate inpatients care. Post Acute Sequelae of COVID-19 (PASC) represent a mental health challenge, with neuropsychiatric problems that display a novel model of post-viral brain involvement. COVID-19 is associated with the release of pro-inflammatory cytokines that can induce various biological dysregulations, including brain tissue injury. Neuroinflammation may additionally accelerate the progression of various neurodegenerative and neuropsychiatric complications. The goal of the last section of the meeting is to update and discuss mechanisms of long-term mental health issues in people with PASC.



10.05-10.20	Key drivers of SARS-CoV-2 evolutionary direction: from natural selection to drug-resistance	M. Zazzi, Siena
10.20-10.25	Discussion	
10.25-10.40	COVID-19 tie break: a hard shift for immunocompromised patients	C. Agrati, Roma
10.40-10.45	Discussion	
10.45-11.00	Pathways and markers of virus and immune-related CNS injury in long-COVID	S. Beretta, Monza
11.00 - 11.05	Discussion	



EXPERT MEETING 10.05-11.05

AULA 5

Winning cardiometabolic comorbidities in HIV: the best place for doravirine

Chair: Cristina Mussini (Modena)

With an unrestricted educational grant from MSD Italy

Discussants: Antonella Castagna (Milano), Simona Di Giambenedetto (Roma), Roberta Gagliardini (Roma), Cristina Gervasoni (Milano)

This session aims to contribute to understanding the positioning of doravirine in clinical practice and the possibility of including this NNRTI in ART regimens to improve long-term follow-up. In particular, two randomized trials, DRIVE-FORWARD and DRIVE-AHEAD, suggest that doravirine is a viable option for ART, with a particular benefit to the metabolic health of people with HIV due to its excellent metabolic profile, particularly with respect to lipids and body weight. Metabolic health refers to a clinical construct that considers the net advantage for the patient regarding multiple metabolic parameters captured by body composition data (including BMI and visceral and liver fat accumulation), lipid fractions, glucose and insulin resistance, kidney function, and bone turnover. Moreover, metabolic health is not just the absence of metabolic diseases but rather a road map for healthy living. The pathway to improve metabolic health includes lifestyle interventions and a proactive antiretroviral approach to be considered in a patient-centred intervention.



THEMED DISCUSSIONS 10.05-11.05

AULA 7

People living with HIV: thinking of QoL

Chairs: Roberto Gulminetti (Pavia), Vincenzo Spagnuolo (Milano)

10.05-10.08 **Introduction**

R. Gulminetti, Pavia; V. Spagnuolo, Milano

TD 1

10.08-10.15 Efficacy, safety and metabolic changes at 6-months after switch to long-acting injectable CAB/RPV: results from an observational prospective multicenter study

C. Bartalucci^{1,2}, L. Taramasso², E. Ricci³, A. De Vito⁴, N. Squillace⁵, S. Ferrara⁶, E. Pontali⁷, G. Cenderello⁸, G.F. Pellicanò⁹, E. Sarchi¹⁰, F. Lagi¹¹, E. Salomoni¹², M.A. Carleo¹³, O. Bargiacchi¹⁴, G. Madeddu⁴, A. Cascio¹⁵, B. Menzaghi¹⁶, G.V. De Socio¹⁷, K. Falasca¹⁸, P. Bonfanti⁵, A. Di Biagio^{1,2}

¹Department of Health Sciences (DISSAL), University of Genoa, Genoa, Italy, ²Department Infectious Disease Clinic, IRCCS Ospedale Policlinico San Martino, Genoa, Italy, ³Fondazione ASIA, Milan, Italy, ⁴Unit of Infectious Diseases, Department of Medicine, Surgery and Pharmacy, University of Sassari, Italy, ⁵Infectious Disease Unit, Fondazione IRCCS San Gerardo dei Tintori, Monza - University of Milano-Bicocca, Monza, Italy, ⁶Unit of Infectious Diseases, Department of Clinical and Experimental Medicine, University of Foggia, Foggia, Italy, ⁷Department of Infectious Diseases, Galliera Hospital, Genoa, Italy, ⁸Infectious Diseases Department, Sanremo Hospital, Sanremo, Italy, ⁹Unit of Infectious Diseases, Department of Human Pathology of the Adult and the Developmental Age 'G. Barresi', University of Messina, Messina, Italy, ¹⁰Infectious Diseases Unit, S. Antonio e Biagio e Cesare Arrigo Hospital, Alessandria, Italy, ¹¹AOU Infectious and Tropical Diseases, Careggi Hospital, Florence, Italy, ¹²SOC 1 USLCENTRO FIRENZE, Unit of Infectious Diseases, Santa Maria Annunziata Hospital, Florence, Italy, ¹³Infectious Diseases and Gender Medicine Unit, Cotugno Hospital, AO dei Colli, Naples, Italy, ¹⁴Unit of Infectious Diseases, Ospedale Maggiore della Carità, Novara, Italy, ¹⁵Unit of Infectious Diseases, Department of Health Promotion, Mother and Child Care, Internal Medicine and Medical Specialties, University of Palermo, Palermo, Italy, ¹⁶Unit of Infectious Diseases, ASST della Valle Olona – Busto Arsizio, Varese, Italy, ¹⁷Unit of Infectious Diseases, Santa Maria Hospital, Perugia, Italy, ¹⁸Clinic of Infectious Diseases, Department of Medicine and Science of Aging, G. D'Annunzio University, Chieti-Pescara, Chieti, Italy



2024

- TD 2** 10.15-10.22 **Patient-reported outcomes (PROs) in people living with HIV treated with long-acting injectable antiretroviral therapy (LAI-ART)**
 S. Arsuffi¹, C. Mazzi², S. Calza³, G. Tiecco¹, R. Fazio⁴, G.M. Piccardi⁴, C. Anzoni¹, M. Di Gregorio¹, S. Rapino¹, I. Polesini¹, F. Castelli¹, E. Quiros-Roldan¹, E. Focà¹
¹Clinica di Malattie Infettive e Tropicali, Università degli Studi di Brescia e ASST Spedali Civili di Brescia, Italy, ²Dipartimento di Scienze Cliniche e Sperimentali, Università degli Studi di Brescia, Italy, ³Unità di Biostatistica e Biomatematica e Unità di Bioinformatica, Dipartimento di Medicina Molecolare e Traslaazionale, Università degli Studi di Brescia, Italy, ⁴Unità Operativa Farmacia Aziendale, ASST Spedali Civili di Brescia, Italy
- TD 3** 10.22-10.29 **Enhancing adherence and treatment satisfaction in people living with HIV: the impact of cabotegravir plus rilpivirine longacting in real life**
 R. Schiavoni^{1,2}, V. Busin⁴, D. Malucelli⁵, L. Taramasso¹, L. Mezzogori^{1,2}, C. Bartalucci^{1,2}, L. Labate¹, S. Bianchi¹, S. Beltramini⁴, F. Mina⁴, M. Bassetti^{1,2}, A. Di Biagio^{1,2}
¹IRCCS Ospedale Policlinico San Martino, Genoa, Italy, ²Department of Health's Sciences, University of Genoa, Italy, ³Clinica Malattie Infettive, IRCCS Ospedale Policlinico San Martino, Genoa, Italy, ⁴Pharmacy Unit, IRCCS Ospedale Policlinico San Martino - Genoa, Italy, ⁵Deenova srl – Piacenza, Italy
- TD 4** 10.29-10.36 **Clinical experience with Doravirine: real-life study of therapeutic efficacy and influence on metabolic profile of dual versus triple antiretroviral regimens in a tertiary hospital of Milan**
 R. Nardo, L. Gazzola, T. Bini, G. Marchetti
 University of Milan, San Paolo Hospital, Milan, Italy
- TD 5** 10.36-10.43 **Rapid ART initiation and Retention in care of people living with HIV: a six-years observational study in foreigners versus Italian-borne**
 L. Gazzola¹, R. Nardo¹, A. Tavelli², A. Maschi², T. Bini¹, G.C. Marchetti¹
¹University of Milan, Infectious Disease Unit, Milan, Italy, ²University of Milan, Milan, Italy
- 10.43-11.05 **Discussion**



SYMPOSIUM 11.10-12.10

AULA LAZZATI

Are three-drug ARV regimens still needed for long-term treatment success?

Chairs: Roberto Gulminetti (Pavia), Cristina Mussini (Modena)

Sponsored by ViiV Healthcare

In recent decades, the needs of people living with HIV have evolved as life expectancy has greatly increased. Current ARV regimens are required to meet the ambitious goal of long-term treatment success: to do so, they must guarantee high genetic barrier to resistance, long-term efficacy, optimal long-term safety and tolerability, simplicity and ensure good quality of life. Over the last years, we have witnessed the latest evolution of ART, with the development of two drug regimens capable of ensuring high rates of treatment success, at similar levels to three drug regimens, but with less ARV agents. The aim of this round table is to critically discuss the role of DTG/3TC as a two-drug regimen capable of ensuring long term treatment success.

- 11.10-11.15 **Opening and introduction** R. Gulminetti, Pavia; C. Mussini, Modena
- ROUND TABLE**
- 11.15-11.25 **Potency and barrier to resistance of DTG/3TC** D. Ripamonti, Bergamo
- 11.25-11.35 **Sustained virologic efficacy over time with DTG/3TC** S. Di Giambenedetto, Roma
- 11.35-11.45 **Long term tolerability of DTG/3TC** G. d'Ettore, Roma
- 11.45-11.55 **Quality of life and people satisfaction with DTG/3TC** A. Vergori, Roma
- 11.55-12.10 **Discussion and take-home messages** Moderators: R. Gulminetti, Pavia; C. Mussini, Modena
 Discussants: G. d'Ettore, Roma; S. Di Giambenedetto, Roma; D. Ripamonti, Bergamo; A. Vergori, Roma



**SYMPOSIUM** 11.10-12.10**AULA BAUSOLA****Infectious disease management in patients living with onco-hematological malignances: focus on COVID-19 and invasive fungal infections (IFI)**

Chair: Maddalena Giannella (Bologna)

With an unrestricted educational grant from Gilead Sciences

The session aims to reflect on the urgency of improving the management of fungal infections and Covid-19 in hematology patients who face unique challenges related to compromised immune system resulting from chemotherapy treatments, malignant hemopathy, and HSCT. In this context, the onset of invasive fungal infections represents a significant threat, bringing with it the risk of serious complications and even mortality in an already vulnerable population. The global emergency of Covid-19 has further complicated the situation for hematology patients, making it crucial to deep into the relationships between immunocompromise and viral infection and potential complications resulting from drug-drug interactions (DDIs). Managing these dual threats requires indepth understanding, targeted treatment plans, and appropriate clinical care. There is a need to define best practices in the diagnosis and treatment of invasive fungal infections, as well as the unique challenges in managing SARS-CoV-2 infection in hematological patients. Multidisciplinary collaboration between different professional figures is an essential element to guarantee complete assistance aimed at preventing complications and containing drug resistance, especially with regards to fungal infections.

11.10-11.20	Clinical features and management: a multidisciplinary approach	M. Giannella, Bologna
11.20-11.40	Clinical debate on COVID-19	M. Bartoletti, Rozzano MI; G. Tiseo, Pisa
11.40-12.00	Clinical debate on invasive fungal infections (IFI)	M. Bartoletti, Rozzano MI; G. Tiseo, Pisa
12.00-12.10	Practical considerations	M. Giannella, Bologna

**ORAL COMMUNICATIONS** 11.10-12.10**AULA 5****HIV epidemiology and testing promotion**

Chairs: Anna Maria Geretti (Roma), Ilenia Pennini (Padova)

11.10-11.15	Introduction	A.M. Geretti, Roma; I. Pennini, Padova
OC 1	11.15-11.25 Measuring HIV knowledge and attitudes in the healthcare setting: Italian results from an ECDC/EACS survey <i>M. Mazzitelli¹, M. Trunfo², A. Mendez Lopez³, E. Martinez⁴, T. Noori⁵</i> ¹ Infectious and Tropical Diseases Unit, Padua University Hospital, Italy, ² Infectious Disease Unit, Amedeo di Savoia hospital, Department of Medical Science, University of Turin, Turin, Italy, ³ Department of Preventive Medicine, Public Health and Microbiology, Autonomous University of Madrid, Spain, ⁴ Hospital Clínic, University of Barcelona, Barcelona, Spain; and CIBER de Enfermedades Infecciosas (CIBERINFEC), Instituto de Salud Carlos III, Madrid, Spain, ⁵ European Centre for Disease Prevention and Control	
OC 2	11.25-11.35 Modena and Emilia Romagna HIV Surveillance: the application of ECDC HIV Modelling Tool <i>M. Menozzi¹, A. Cervo¹, G. Cuomo¹, M. Digaetano¹, B. Fontana², A. Soffritti², E. Massimiliani³, V. Borghi², G. Guaraldi², C. Mussini²</i> ¹ Infectious Diseases Unit, University Hospital Policlinico of Modena, Italy, ² Infectious Disease Unit, University of Modena and Reggio Emilia, Italy, ³ Public health department, Emilia Romagna Region, Italy	
11.35-11.39	Discussion	
OC 3	11.39-11.49 HIV testing in Italian community and outreach sites: COBATEST network, 2020-2023 <i>P. Meli¹, I. Mercurio¹, L. Cosmaro², M. Cernuschi³, D. Calzavara⁴, N. Frattini⁴, R. Reposi⁴</i> ¹ Bergamo Fast-track City, Bergamo, Italy, ² Fondazione LILA, Milano, Italy, ³ ASA Milano, Milan, Italy, ⁴ Milano Checkpoint, Milan, Italy	
OC 4	11.49-11.59 Estimating the potential health economic value of universal opt-out HIV testing in emergency departments in Italy: A modelling study <i>A. d'Arminio Monforte¹, G. d'Ettore², G. Galardo³, A. van Doornewaard⁴, E. Lani⁴, E. Kagenaar⁴, S. Huntington⁴, J. Jarret⁵, M. RuF⁶, W. Ricciardi⁶</i> ¹ University of Milan, Milan, Italy, ² Sapienza University of Rome, Rome, Italy, ³ Hospital Policlinico Umberto I, Rome, Italy, ⁴ Aquarius Population Health, London, United Kingdom, ⁵ Gilead Sciences, London, United Kingdom, ⁶ Università Cattolica del Sacro Cuore, Rome, Italy	
11.59-12.03	Discussion	
12.03-12.10	Conclusion	A.M. Geretti, Roma; I. Pennini, Padova



**ORAL COMMUNICATIONS** 11.10-12.10**AULA 6****Immune responses to vaccination and emerging infections**

Chairs: Mara Biasin (Milano), Andrea Cossarizza (Modena)

11.10-11.15 **Introduction**

M. Biasin, Milano; A. Cossarizza, Modena

OC 5**11.15-11.25 Humoral and cellular immune response after one year from Mpox virus infection**V. Mazzotta¹, G. Matusali², E. Cimini³, F. Colavita², R. Casetti³, C. Pinnetti¹, A. Mondì¹, A. Bettini², V. Bordoni⁴, G. Grassi³, G. Prota⁵, S. Vita⁶, N. Nicastri⁶, E. Girardi⁷, C. Agrati⁴, F. Maggi², A. Antinori¹¹Clinical Department, INMI-IRCCS Lazzaro Spallanzani, Rome, Italy, ²Laboratory of Virology, INMI-IRCCS Lazzaro Spallanzani, Rome, Italy, ³Laboratory of Cellular Immunology and Pharmacology, INMI-IRCCS Lazzaro Spallanzani, Rome, Italy, ⁴Unit of Pathogen Specific Immunity, IRCCS Ospedale Pediatrico Bambino Gesù, Rome, Italy, ⁵Biological Bank, INMI-IRCCS Lazzaro Spallanzani, Rome, Italy, ⁶Scientific Direction, INMI-IRCCS Lazzaro Spallanzani, Rome, Italy**OC 6****11.27-11.37 Anti-MPXV humoral and cellular immune response one year after mpox infection or MVA-BN vaccination**V. Mazzotta¹, E. Cimini¹, G. Matusali¹, A. Oliva¹, F. Colavita¹, R. Casetti¹, A. Mondì¹, S. Meschi¹, D. Goletti¹, C. Agrati², E. Girardi¹, A. Sette³, A. Grifoni³, F. Maggi¹, A. Antinori¹¹National Institute for Infectious Diseases Lazzaro Spallanzani IRCCS, Rome, Italy, ²Bambino Gesù Children's Hospital, Rome, Italy, ³La Jolla Institute for Allergy and Immunology, La Jolla, CA, USA**OC 7****11.39-11.49 SARS-CoV-2 spike protein and plasma from COVID-19 patients induce extracellular traps by myeloid-derived suppressor cells**G. Grassi¹, S. Gili¹, R. Casetti¹, Z. Percario², N. Tumino³, P. Vacca³, S. Notari¹, V. Bordoni⁴, E. Cimini¹, F. Cristofanelli¹, D. Rubino⁵, F. Nonini⁵, E. Affabris², L. Marchioni⁵, C. Agrati⁴, A. Sacchi²¹Cellular Immunology and Pharmacology Laboratory, National Institute for Infectious Diseases Lazzaro Spallanzani, IRCCS, Rome, Italy, ²Molecular Virology and Antimicrobial Immunity Laboratory, Department of Science, Roma Tre University, Rome, Italy, ³Immunology Research Area, Innate Lymphoid Cells Unit, IRCCS, Bambino Gesù Children's Hospital, Rome, Italy, ⁴Oncoematologia e Officina Farmaceutica, IRCCS, Bambino Gesù Children's Hospital, Rome, Italy, ⁵Clinical Division, National Institute for Infectious Diseases Lazzaro Spallanzani, IRCCS, Rome, Italy**OC 8****11.51-12.01 Antiretroviral therapy restores naïve T cell frequencies and functionality in PLWH**B. Dallan¹, M. Campagnaro¹, E. Gallerani¹, D. Proietto¹, R. Cultrera³, M. Libanore⁴, L. Sighinolfi⁴, S. Ghisellini⁵, S. Llewellyn-Lacey⁶, V. Appay⁷, D. A. Price^{6,8}, F. Nicoli¹, A. Caputo¹, D. Segala²¹Laboratory of Biochemistry, Immunology and Microbiology (BIM), Department of Chemical, Pharmaceutical and Agricultural Sciences, University of Ferrara, Ferrara, Italy, ²Department of Translational Medicine, University of Ferrara, Italy; Infectious Diseases Unit, Azienda Ospedaliero-Universitaria di Ferrara, Italy, ³Department of Translational Medicine, University of Ferrara, Italy; Infectious Diseases-Primary and Community Health Care Dept, Azienda Unità Sanitaria Locale di Ferrara, Italy, ⁴Infectious Diseases Unit, Azienda Ospedaliero-Universitaria di Ferrara, Italy, ⁵Laboratory of Clinical Pathology, University Hospital St. Anna, Ferrara, Italy, ⁶Division of Infection and Immunity, Cardiff University School of Medicine, Cardiff, UK, ⁷Université de Bordeaux, CNRS UMR 5164, INSERM ERL 1303, ImmunoConcEpT, Bordeaux, France, ⁸Systems Immunity Research Institute, Cardiff University School of Medicine, Cardiff, UK12.03-12.10 **Conclusion**

M. Biasin, Milano; A. Cossarizza, Modena

**SYMPOSIUM** 12.15-13.15**AULA LAZZATI****Three elephants in the room: clinical approach to the most relevant comorbidities related to HIV infection**

Chairs: Paola Cinque (Milano), Nicoletta Frattini (Milano)

Although highly effective and well-tolerated therapies are now available, people with HIV continue to be at increased risk of developing certain comorbidities. In particular cardiovascular diseases, cancers and mental health conditions. The aim of the symposium will be to explore the latest evidence that attempts to explain the underlying causes of this phenomenon.



- 12.15-12.30 **Lipids or inflammation: which is the main driver of cardiovascular events in person with HIV?** G. De Socio, Perugia
- 12.30-12.35 **Discussion**
- 12.35-12.50 **Mental health at the intersection of social and medical factors** A. Winston O'Keefe, London UK
- 12.50-12.55 **Discussion**
- 12.55-13.10 **"Did we really break down the walls?" Lymphoproliferative disorders in person with HIV today** L. Verga, Monza
- 13.10-13.15 **Discussion**

**EXPERT MEETING** 12.15-13.15**AULA BAUSOLA****COVID-19 risk assessment and prophylaxis in fragile population****Chairs:** Alessandra Bandera (Milano), Paolo Bonfanti (Monza)

COVID-19 remains a significant risk for the immunocompromised for being hospitalized or dying from severe SARS-CoV-2 infection, given their poor responsiveness to vaccination or impaired immunity after natural infection. Therefore, passive immunization through long-acting monoclonal antibodies (mAbs) offers a needed approach by pre-exposure prophylaxis (PrEP), a novel preventive strategy for high-risk populations. This session will present updated data on the anti-SARS-CoV-2 drug sipavibart, a long-acting neutralizing human monoclonal antibody directed against new emerging SARS-CoV-2 variants, which can potentially be used to protect immunosuppressed people from severe disease. Current characterization of risk assessment among immunocompromised persons, new results of sipavibart from randomized clinical and immunobridging trials, and implementation strategy of pre-exposure prophylaxis with monoclonal antibodies in the clinical and public health setting will be the main topics of the session designed to optimize the prevention approach of SARS-CoV-2 in high-risk population.

- 12.15-12.35 **Risk assessment of immunocompromised people at risk of severe SARS-CoV-2 infection** E. Girardi, Roma
- 12.35-12.55 **Update on sipavibart in SARS-CoV-2 pre-exposure prophylaxis** A. Antinori, Roma
- 12.55-13.15 **Round Table: Implementing strategies and access of persons with hematologic conditions to COVID-19 monoclonal antibody prophylaxis** Discussants: C. Girmenia, Roma
M. Mensurati, Roma; R. Parrella, Napoli

**EXPERT MEETING** 12.15-13.15**AULA 5****PrEP and more****Chairs:** Giulia Valeria Calvino (Roma), Benedetto Maurizio Celesia (Catania)

Numerous efforts have been made to reduce new HIV infections, AIDS cases, and HIV-related deaths in our country. Among various strategies, starting from 2023, Pre-Exposure Prophylaxis for HIV (PrEP) for key populations has become fully reimbursed by the National Health Service (SSN). This has led to a progressive increase in requests for access to the program and the establishment of dedicated clinics throughout the national territory, even in facilities where clinics for Sexually Transmitted Infections and Preventive Strategies were absent or only serving few users. The "PrEPParati" project was therefore conceived to create a training and discussion opportunity among specialists from centers with longer experience to guide, support, and address the challenges and difficulties of these new needs and realities. This session aims to present the highlights and most interesting aspects of what was discussed during the project in order to share this valuable experience with the goal of creating a more uniform and comprehensive implementation within the field of STIs and PrEP.

- 12.15-12.20 **Introduction**
- 12.20-12.40 **Complex PrEP Clinic: beyond a pill there's an unmet clinical need** N. Girometti, London UK
- 12.40-12.45 **Discussion**
- 12.45-13.05 **Roadmap for implementing PrEP and STIs services in your clinic: the "PrEPParati" Project** D. Moschese, Milano
- 13.05-13.10 **Discussion**
- 13.10-13.15 **Take-home messages**

**2024**

**ORAL COMMUNICATIONS** 12.15-13.15**AULA 6****Long Acting injectables: the Italian experience**

Chairs: Teresa Bini (Milano), Diego Ripamonti (Bergamo)

12.15-12.20 **Introduction**

T. Bini, Milano; D. Ripamonti, Bergamo

OC 9**12.20-12.30 One-year of long-acting cabotegravir and rilpivirine in people with HIV and a long exposure to antiretroviral therapy: data from the SCohoLART study***C. Muccini¹, N. Gianotti¹, S. Diotallevi¹, R. Lolatto¹, V. Spagnuolo¹, D. Canetti¹, S. Bagaglio¹, V. Gordo Perez¹, T. Clemente², M. Bottanelli², C. Candela², S. Nozza^{1,2}, A. Castagna^{1,2}*¹Department of Infectious Diseases, IRCCS San Raffaele Scientific Institute, Milan, Italy, ²Vita-Salute San Raffaele University, Milan, Italy**OC 10****12.32-12.42 Effectiveness of long-acting ART with cabotegravir/rilpivirine in the Icona Cohort***R. Gagliardini¹, S. De Benedittis², A. Tavelli², G. Lapadula³, V. Mazzotta¹, E. Bruzzesi⁴, A. Cervo⁵, G. Carrozzo⁶, A. Saracino⁷, S. Rusconi⁸, G. Marchetti⁹, F. Ceccherini-Silberstein¹⁰, A. Antinori¹, A. d'Arminio Monforte², C. Muccini⁴ on behalf of Icona Foundation Study Group*¹National Institute for Infectious Diseases Lazzaro Spallanzani, IRCCS, Roma, Italy, ²ICONA Foundation, Milan, Italy, ³IRCCS Fondazione San Gerardo dei Tintori, University of Milano Bicocca, Monza, Italy, ⁴Vita-Salute San Raffaele University, IRCCS Ospedale San Raffaele, Milan, Italy, ⁵University Hospital of Modena, Infectious Diseases Clinic, Modena, Italy, ⁶Department of Infectious Diseases, ASST Fatebenefratelli Sacco, Luigi Sacco Department of Biomedical and Clinical Sciences, University of Milan, Milan, Italy, ⁷Clinic of Infectious Diseases, Department of Precision and Regenerative Medicine and Ionian Area, Polyclinic of Bari, University Hospital Polyclinic, University of Bari, Bari, Italy, ⁸Infectious Diseases Unit, Ospedale Civile di Legnano, ASST Ovest Milanese, and DIBIC, Università degli Studi di Milano, Milan, Italy, ⁹Clinic of Infectious Diseases, ASST Santi Paolo e Carlo, Department of Health Sciences, University of Milan, Milan, Italy, ¹⁰Department of Experimental Medicine, University of Rome "Tor Vergata", Rome, Italy**OC 11****12.44-12.54 Cabotegravir-rilpivirine long-acting injectable regimen: an analysis of the causes of interruption and impact of genotypic drug resistance in a multicentric cohort***G. Canavesi¹, M. Mena¹, E. Zaninetta², L. Gazzola², T. Bini², G. Bo³, D. Arrue Diaz³, G. Orofino³, A. De Vito⁴, G. Madeddu⁴, C. Grillo⁵, C. Bartalucci⁶, F. Centorrino⁶, N. Squillace⁷, P. Bonfanti⁷, S. Rapino⁸, G. Tiecco⁸, E. Focà⁸, M. Menozzi⁹, F. Caldara Bonaura⁹, G. Guaraldi⁹, S. Lo Caputo⁵, A. Di Biagio⁶, S. Rusconi¹*¹Infectious Diseases Unit, ASST Ovest Milanese, Legnano General Hospital and DIBIC, University of Milan, Italy, ²Infectious Diseases Unit, ASST Santi Paolo e Carlo, San Paolo Hospital and Dipartimento di Scienze della Salute, University of Milan, Italy, ³Infectious Diseases Unit, Amedeo di Savoia Hospital and University of Turin, Italy, ⁴Infectious Diseases Unit, Azienda Ospedaliera Universitaria di Sassari and University of Sassari, Italy, ⁵Infectious Diseases Unit, Azienda Ospedaliero-Universitaria "Ospedali Riuniti" di Foggia and University of Foggia, Italy, ⁶Infectious Diseases Unit, Ospedale Policlinico San Martino and University of Genoa, Italy, ⁷Infectious Diseases Unit, IRCCS San Gerardo dei Tintori and University of Milan-Bicocca, Monza, Italy, ⁸Infectious Diseases Unit, Spedali Civili di Brescia and University of Brescia, Italy, ⁹Infectious Diseases Unit, Azienda Ospedaliera-Universitaria di Modena and University of Modena and Reggio Emilia, Italy**OC 12****12.56-13.06 Pittsburgh sleep quality index (PSQI) changes in virologically suppressed people living with HIV switching to long acting cabotegravir and rilpivirine***A. Dargenio¹, N. De Gennaro¹, M. Polisenò¹, F. Balena¹, D. Fiordelisi¹, V. Spada¹, G. Romita¹, G. Guido¹, F. Di Gennaro¹, G. Bruno², M.A. Purgatorio², G.B. Buccoliero², A. Saracino¹*¹Clinic of Infectious Diseases, Department of Precision and Regenerative Medicine and Ionian Area (DiMePRe-J), University of Bari "Aldo Moro", Bari, Italy, ²Infectious Diseases Unit, San Giuseppe Moscati Hospital, Azienda Sanitaria Locale Taranto, Taranto, Italy13.08-13.15 **Conclusion**

T. Bini, Milano; D. Ripamonti, Bergamo

**SHORT COMMUNICATIONS** 12.15-13.15**AULA 7****Novel insights in the management of chronic viral hepatitis**

Chairs: Nicola Coppola (Napoli), Valentina Svicher (Roma)

12.15-12.18 **Introduction**

N. Coppola, Napoli; V. Svicher, Roma

SC 1**12.18-12.25 Experience from a single centre on HBV seroconversion in people living with HIV and HBV: the relevance of individual clinical history***M. Simion, A. Soffritti, A. Tili, M. Menozzi, G. Cuomo, M. Digaetano, C. Mussini*

Operative Unit of Infectious Diseases, University of Modena and Reggio Emilia, Modena, Italy



- SC 2** 12.27-12.34 **Safety and effectiveness of switching PWH with occult HBV infection to tenofovir-sparing regimens**
V. Malagnino¹, A. Giacomelli², R. Rossotti³, A. Tavelli⁴, A. Calcagno⁵, A. Santoro⁶, G. Calleri⁵, A. Vergori⁷, A. Cervo⁸, V. Svicher⁹, M. Puoti³, A. d'Arminio Monforte⁴, L. Sarmati¹, A. Cozzi-Lepri¹⁰, on behalf of Icona Foundation Study Group
¹Clinical Infectious Diseases, Department of System Medicine, Tor Vergata University, Rome, Italy, ²III Infectious Diseases Unit, ASST FBF-Sacco, Milan, Italy, ³Department of Infectious Diseases, ASST Grande Ospedale Metropolitano Niguarda, School of Medicine and Surgery, Milan, Italy, ⁴ICONA Foundation, Milan, Italy, ⁵Unit of Infectious Diseases, Department of Medical Sciences, University of Turin, Amedeo di Savoia Hospital, Turin, Italy, ⁶Clinica di Malattie Infettive, ASST Santi Paolo e Carlo-Presidio Ospedaliero San Paolo, Milano, Italy, ⁷Clinical Infectious Diseases Department, National Institute for Infectious Diseases Lazzaro Spallanzani IRCCS, Rome, Italy, ⁸Unit of Infectious Diseases and Infection Control, ISMETT-IRCCS Istituto Mediterraneo per i Trapianti e Terapie ad Alta Specializzazione, Palermo, Italy; University Hospital of Modena, Infectious Diseases Clinic, Modena, Italy, ⁹Department of Biology, Tor Vergata University, Rome, Italy, ¹⁰Centre for Clinical Research, Epidemiology, Modelling and Evaluation (CREME), Institute for Global Health, University College London, London, United Kingdom
- SC 3** 12.36-12.43 **Occult HBV infection and archived resistance to 3TC could predict virological failure during 3TC/DTG maintenance antiretroviral therapy: a retrospective study**
S. Occhineri¹, A. Palomba¹, T. Matucci¹, M.L. Vatteroni², L. Del Bono¹, M. Polidori¹, R. Iapoce¹, A. Borghetti¹, M. Falcone¹
¹U.O. Malattie Infettive, Azienda Ospedaliera Universitaria Pisana, Pisa, Italy, ²U.O. Virologia, Azienda Ospedaliera Universitaria Pisana, Pisa, Italy
- SC 4** 12.45-12.52 **Risk of Hepatitis B reactivation in people with HIV (PWH) with isolated anti-core antibody (HBcAb) after switch to 2DR strategies with lamivudine(3TC)/dolutegravir(DTG)**
P.F. Salvo¹, V. Iannone¹, R.A. Passerotto¹, F. Lamanna¹, E. Visconti², F. Lombardi², C. Torti^{1,2}, S. Di Giambenedetto^{1,2}, G. Baldin²
¹Dipartimento di Scienze Mediche e Chirurgiche, Università Cattolica del Sacro Cuore, Rome, Italy, ²UOC Malattie Infettive, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome, Italy
- SC 5** 12.54-13.01 **HDV persistence is sustained by HBsAg mainly derived from integrated HBV-DNA and is independent from the extent of HBV reservoir**
S. D'Anna¹, L. Piermatteo¹, G. Brancaccio², E. Teti³, A. Di Lorenzo³, I. Grossi¹, G. Torre¹, V. Malagnino³, M. Iannetta³, F. Ceccherini-Silberstein⁴, C. Pasquazzi⁵, U. Cillo⁶, A. Vitale⁶, E. Gringeri⁶, M. Magrofuoco⁶, M. Pacenti⁷, L. Baiocchi⁸, S. Francioso⁸, I. Lenzi⁸, A. Koffas⁹, A.M. Geretti¹⁰, M.L. Abate¹¹, A. Olivero¹¹, G.B. Gaeta¹², L. Sarmati³, M. Rizzetto¹¹, U. Gill⁹, P. Kennedy⁹, G.P. Caviglia¹¹, V. Svicher¹, R. Salpini¹
¹Department of Biology, Tor Vergata University, Rome, Italy, ²Department of Molecular Medicine, Infectious Diseases, University of Padua, Padua, Italy, ³Infectious Diseases Unit, University Hospital of Rome Tor Vergata, Rome, Italy, ⁴Department of Experimental Medicine, University of Rome Tor Vergata, Rome, Italy, ⁵Sant'Andrea Hospital, Rome, Italy, ⁶Hepatobiliary Surgery and Liver Transplantation Unit, Department of Surgery, Oncology and Gastroenterology, University of Padua, Padua, Italy, ⁷Microbiology and Virology Unit, Padova University Hospital, Padua, Italy, ⁸Hepatology Unit, Policlinico Tor Vergata, Rome, Italy, ⁹Blizard Institute, Barts and The London School of Medicine and Dentistry, Queen Mary University of London, London, United Kingdom, ¹⁰Department of Systems Medicine, Infectious Disease Clinic, University of Rome Tor Vergata, Rome, Italy, ¹¹Department of Medical Sciences, University of Turin, Turin, Italy, ¹²Infectious Disease Unit, University L. Vanvitelli, Naples, Italy
- SC 6** 13.03-13.10 **Heterogeneity in the diagnostic sensitivities of HDV RNA quantification assays used in clinical practice in Italy: data from the first national quality control multicenter study**
R. Salpini¹, L. Piermatteo¹, G.P. Caviglia², A. Bertoli^{3,4}, M.R. Brunetto⁵, B. Bruzzone⁶, A. Callegaro⁷, C. Caudai⁸, D. Cavallone⁵, L. Chessa⁹, F. Coghe¹⁰, N. Coppola¹¹, N. Cuomo¹², S. D'Anna¹, M. Di Stefano¹³, F. Facchetti¹⁴, C. Farina¹⁵, D. Ferraro¹⁶, E. Franchin¹⁷, D. Francisci¹⁸, S. Galli¹⁹, A. R. Garbuglia²⁰, W. Gennari²¹, V. Ghisetti²², P. Lamperico^{14,23}, N. Marascio²⁴, S. Menzo²⁵, V. Michel²⁶, G. Niro²⁷, A. Olivero², P. Paba⁴, C.I. Palermo²⁸, O. Palmieri²⁷, S. Paolucci²⁹, M. Pisaturo¹¹, T. Pollicino³⁰, G. Raffa³⁰, G. Torre¹, O. Turriziani³¹, S. Uzzau³², M. Vatteroni³³, M. Zazzi³⁴, A. Craxi¹⁶, F. Ceccherini-Silberstein³, Valentina Svicher¹ on behalf of the Virology Italian Network Vironet C
¹Department of Biology, University of Rome "Tor Vergata", Rome, Italy, ²Department of Medical Sciences, University of Turin, Turin, Italy, ³Department of Experimental Medicine, University of Rome "Tor Vergata", Rome, Italy, ⁴Unit of Virology, Tor Vergata Polyclinic Foundation, Tor Vergata University, Rome, Italy, ⁵Dept of Clinical and Experimental Medicine, University of Pisa and Hepatology Unit and Laboratory of Molecular Genetics and Pathology of Hepatitis Viruses, Pisa University Hospital, Italy, ⁶Department of Health Sciences, University of Genoa, Genoa, Italy, ⁷Medicina di Laboratorio, ASST Bergamo Est, Bergamo, Italy, ⁸Microbiology and Virology Unit, Siena University Hospital, Siena, Italy, ⁹Dipartimento di Scienze Mediche e Sanità Pubblica Università di Cagliari, AOU Cagliari, Italy, ¹⁰Microbiologia, Azienda Ospedaliero-Universitaria di Cagliari, Italy, ¹¹Department of Mental Health and Public Medicine, Section of Infectious Diseases, University of Campania Luigi Vanvitelli, Caserta, Italy, ¹²Microbiology and Virology Unit, Domenico Cotugno Hospital, Naples, Italy, ¹³Clinical and Surgical Sciences, Section of Infectious Diseases, University Hospital "Riuniti" of Foggia, Foggia, Italy, ¹⁴Division of Gastroenterology and Hepatology, Foundation IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy, ¹⁵Microbiology and Virology Unit, ASST "Papa Giovanni XXIII", Bergamo, Italy, ¹⁶Section of Microbiology and Clinical Microbiology, Department of Health Promotion, Mother and Child Care, Internal Medicine and Medical Specialties, PROMISE, University of Palermo, Palermo, Italy, ¹⁷Department of Molecular Medicine, University of Padova, Padova, Italy, ¹⁸Infectious diseases laboratory, Santa Maria della Misericordia Hospital, Perugia, Italy, ¹⁹Operative Unit of Clinical Microbiology, IRCCS S. Orsola-Malpighi University Hospital, Bologna, Italy, ²⁰Laboratory of Virology, "Lazzaro Spallanzani" National Institute for Infectious Diseases, IRCCS, Rome, Italy, ²¹Molecular Microbiology and Virology Unit, Department of Laboratory Medicine and Pathological Anatomy, Azienda Ospedaliero Universitaria di Modena, Modena, Italy, ²²Laboratory of Microbiology and Virology,



Amedeo di Savoia Hospital, ASL Città di Torino, Turin, Italy, ²³CRC "A. M. and A. Migliavacca" Center for Liver Disease, Department of Pathophysiology and Transplantation, University of Milan, Milan, Italy, ²⁴Unit of Clinical Microbiology, Department of Health Sciences, "Magna Graecia" University, Catanzaro, Italy, ²⁵Department of Biomedical Sciences and Public Health, Università Politecnica Delle Marche, Ancona, Italy, ²⁶Laboratory of Clinical Microbiology, Virology and Bioemergencies, Ospedale Sacco, Milan, Italy, ²⁷Division of Gastroenterology and Endoscopy, Fondazione IRCCS "Casa Sollievo della Sofferenza", San Giovanni Rotondo, Italy, ²⁸Policlinico Universitario "Gaspare Rodolico", Catania, Italy, ²⁹Microbiology and Virology Unit, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy, ³⁰Department of Clinical and Experimental Medicine, University Hospital "G. Martino" Messina, Messina, Italy, ³¹Department of Molecular Medicine, Sapienza University of Rome, Rome, Italy, ³²Department of Biomedical Sciences, University of Sassari, Sassari, Italy, ³³Virology Unit, Pisa University Hospital, Pisa, Italy, ³⁴Department of Medical Biotechnology, University of Siena, Siena, Italy

13.12-13.15 **Conclusion**

N. Coppola, Napoli; V. Svicher, Roma

**SHORT COMMUNICATIONS** 13.15-14.15**AULA BAUSOLA****Sexual health and love's labours**

Chairs: Maria Luisa Cosmaro (Milano), Alessandra Latini (Roma)

13.15-13.18 **Introduction**

M.L. Cosmaro, Milano; A. Latini, Roma

SC 7 13.18-13.25 **A hidden challenge: STIs detection prevalence during nPEP follow up. A retrospective analysis**

N.B. Bana^{1,3}, *G. Cavazza*^{1,3}, *E. Di Gennaro*^{1,3}, *F. Peracchi*^{1,3}, *C. Baiguera*¹, *A. Raimondi*¹, *F. D'Amico*¹, *A. Nava*², *D. Fantì*², *M. Puoti*^{1,3}, *R. Rossotti*¹

¹Department of Infectious Diseases, ASST Grande Ospedale Metropolitano Niguarda, Milan, Italy, ²Department of Clinical Microbiology, ASST Grande Ospedale Metropolitano Niguarda, Milan, Italy, ³School of Medicine and Surgery, University of Milano Bicocca, Milan, Italy

SC 8 13.27-13.34 **Increasing Gonorrhea and Chlamydia infections observed in MSM in the early 2024**

*C. Stingone*¹, *F. Pimpinelli*², *R.J. Riveros Cabral*², *E.E. Abri*², *L. Gianserra*¹, *G. Prignano*², *E. Giuliani*¹, *M. Giuliani*¹, *M.G. Donà*¹, *M. Zaccarelli*¹, *A. Latini*¹

¹UOSD Dermatologia MST e Malattie Tropicali San Gallicano Dermatological Institute IRCCS, Rome Italy, ²UOSD Microbiologia e Virologia San Gallicano Dermatological Institute IRCCS, Rome, Italy

SC 9 13.36-13.43 **Sexually transmitted infections in men-who-have-sex-with-men with HIV resistant to tenofovir/emtricitabine and/or cabotegravir**

T. Clemente^{1,2}, *M. Bellomo*², *A.R. Raccagni*^{1,2}, *R. Lolatto*², *S. Diotallevi*², *R. Papaioannu Borjesson*^{1,2}, *C. Maci*^{1,2}, *M. Negri*^{1,2}, *G. Torkjazi*³, *E. Messina*², *S. Bossolasco*², *A. Castagna*^{1,2}, *S. Nozza*^{1,2}, *V. Spagnuolo*²

¹Vita-Salute San Raffaele University, Milan, Italy, ²Infectious Diseases, IRCCS San Raffaele Scientific Institute, Milan, Italy, ³Facoltà di Medicina e Chirurgia, Università La Sapienza, Rome, Italy

SC 10 13.45-13.52 **Applying IANS consensus guidelines for anal cancer screening to men who have sex with men living with HIV: a focus on the HRA referral rate**

M.G. Donà^{1,2}, *M. Benevolo*², *F. Rollo*², *E. Giuliani*¹, *M. Giuliani*¹, *P. Giorgi Rossi*³, *C. Stingone*¹, *L. Gianserra*¹, *M. Zaccarelli*¹, *A. Latini*¹

¹San Gallicano Dermatological Institute IRCCS, Rome, Italy, ²IRCCS Regina Elena National Cancer Institute, Rome, Italy, ³Epidemiology Unit, Azienda Unità Sanitaria Locale-IRCCS di Reggio Emilia, Reggio Emilia, Italy

SC 11 13.54-14.01 **Inadequate compliance with STIs vaccinations among individuals attending a sexually transmitted infection clinic**

G. Cavazza^{1,2}, *N.B. Bana*^{1,2}, *F. Peracchi*^{1,2}, *E.D. Gennaro*^{1,2}, *A. Mulè*³, *L. Dentì*⁴, *C. Baiguera*¹, *M.C. Moiola*¹, *A. Raimondi*¹, *M. Merli*¹, *R. Rossotti*¹, *M. Puoti*^{1,2}

¹Department of Infectious Diseases, ASST Grande Ospedale Metropolitano Niguarda, Milan, Italy, ²Department of Health Science, University of Milano-Bicocca, Milan, Italy, ³Department of Clinical and Experimental Sciences, Unit of Infectious and Tropical Diseases, University of Brescia and ASST Spedali Civili di Brescia, Brescia, Italy, ⁴Unit of Infectious and Tropical Diseases, University of Sassari, Sassari, Italy

SC 12 14.03-14.10 **Doxycycline post-exposure prophylaxis (DoxyPEP) real-life effectiveness in a cohort of men who have sex with men in Milan, Italy**

*A.R. Raccagni*¹, *S. Diotallevi*², *R. Lolatto*², *E. Bruzsesi*¹, *G. Catalano*¹, *I. Mainardi*¹, *C. Maci*¹, *C. Candela*¹, *C. Muccini*¹, *A. Castagna*^{1,2}, *S. Nozza*^{1,2}

¹Infectious Diseases Unit, Vita-Salute San Raffaele University, Milan, Italy, ²Infectious Diseases Unit, IRCCS San Raffaele Scientific Institute, Milan, Italy

14.12-14.15 **Conclusion**

M.L. Cosmaro, Milano; A. Latini, Roma



**SHORT COMMUNICATIONS** 13.15-14.15**AULA 5****PrEParing for the future of prevention**

Chairs: Miriam Lichtner (Latina), Paolo Meli (Bergamo)

13.15-13.18 **Introduction**

M. Lichtner, Latina; P. Meli, Bergamo

SC 13 13.18-13.25 **Impact of PrEP cost on prophylaxis initiation in an Italian centre***S. Venturelli¹, L. Mezzadri², N. Bana², L. Comi¹, F. Borghi¹, A. Ouabou¹, D. Ripamonti¹*¹Infectious Diseases Unit, ASST Papa Giovanni XXIII, Bergamo, Italy, ²School of Medicine and Surgery, University of Milano-Bicocca, Monza, Italy**SC 14** 13.25-13.32 **5 years activity of the Bergamo Fast Track City network: from 2019 looking toward the future***I. Mercurio¹, M. Bonomi¹, P. Meli², D. Meli², F. Maggiolo³, C. Pellegris⁴, E. Zanetti⁴, R. Carissoli⁵, N. Butta⁵*¹Croce Rossa Italiana - Comitato di Bergamo, Italy, ²Cooperativa Don Giuseppe Monticelli, Italy, ³Bergamo Fast-Track City, Italy, ⁴Associazione Comunità Emmaus, Italy, ⁵Arcigay Bergamo Cives, Italy13.32-13.36 **Discussion****SC 15** 13.36-13.43 **How the perception of PrEP has changed in the PrEP Point Plus (PPP) user group***S. Mattioli¹, S. Cecere¹, S. Maugeri¹*

Plus – Persone LGBT+ Sieropositivo – aps, Italy

SC 16 13.43-13.50 **Factors associated with PrEP start after nPEP conclusion. A retrospective analysis***N.B. Bana^{1,3}, G. Cavazza^{1,3}, E. Di Gennaro^{1,3}, F. Peracchi^{1,3}, C. Baiguera¹, A. Raimondi¹, F. D'Amico¹, A. Nava², D. Fantì², M. Pucci^{1,3}, R. Rossotti¹*¹Department of Infectious Diseases, ASST Grande Ospedale Metropolitano Niguarda, Milan, Italy, ²Department of Clinical Microbiology, ASST Grande Ospedale Metropolitano Niguarda, Milan, Italy, ³School of Medicine and Surgery, University of Milano Bicocca, Milan, Italy13.50-13.54 **Discussion****SC 17** 13.54-14.01 **Interest for long-acting PrEP use in the Italian LGBTQIA+ community: a multicentric survey***M. Stizoli¹, A. Tavelli¹, F. Leseri¹, L. del Negro¹, P. Vinti³, M. Barracchia¹, M. Falaguasta⁴, V. Mazzotta⁵*¹Plus Roma, Rome, Italy, ²Fondazione Icona, Milan, Italy, ³Milano Check Point ETS, Milan, Italy, ⁴Anlaid Padova, Padua, Italy, ⁵UOC Immunodeficienze virali, INMI Lazzaro Spallanzani IRCCS, Rome, Italy**SC 18** 14.01-14.08 **What about a change? A survey in PrEP users about interest in injectable Long-Acting agents***A. Bianchi^{1,3}, A. Tavelli¹, R. Rossotti^{1,2}, E. Caruso¹, D. Calzavara¹, P. Testoni^{1,3}, P. Vinti¹, A. De Bona^{1,4}, A. Soria^{1,5}, D. Moschese^{1,6}, D. Tesoro^{1,4}, C. Muccini^{1,7}, A. Cingolani⁸, M. Cernuschi^{1,3,7}*¹Milano Check Point ETS, Milano, Italy, ²ASST Grande Ospedale Metropolitano Niguarda, Milano, Italy, ³ASA ODV, Milano, Italy, ⁴ASST Santi Paolo e Carlo, Milano, Italy, ⁵IRCCS San Gerardo dei Tintori, Monza, Italy, ⁶ASST Fatebenefratelli Sacco, Milano, Italy, ⁷IRCCS Ospedale San Raffaele, Milano, Italy, ⁸IRCCS Fondazione Policlinico Universitario Gemelli - Università Cattolica del sacro Cuore, Roma, Italy14.08-14.12 **Discussion**14.12-14.15 **Conclusion**

M. Lichtner, Latina; P. Meli, Bergamo

**THEMED DISCUSSIONS** 13.15-14.15**AULA 6****Antiretroviral therapy: thinking of durability**

Chairs: Giordano Madeddu (Sassari), Franco Maggiolo (Fabro TR)

13.15-13.18 **Introduction**

G. Madeddu, Sassari; F. Maggiolo, Fabro TR

TD 6 13.18-13.25 **Durability of doravirine-dolutegravir dual combination in a multicenter cohort of elderly people with HIV***M. Mazzitelli¹, C. Cozzolino², C. Gervasoni³, S. Pagano³, S. Reato³, D. Ripamonti⁴, L. Comi⁴, G. Sterrantino⁵, F. Lagi⁵, A. Cascio⁶, M. Trizzino⁶, V. Iannone⁷, D. Farinacci⁷, V. Baldo², A. Cattelan¹*¹Infectious and Tropical Diseases Unit, Padua University Hospital, Padua, Italy, ²Department of Cardiothoracic and Vascular Sciences and Public Health, Padua University, Italy, ³Gestione Ambulatoriale Politerapie Outpatient Clinic and Department of Infectious Diseases, ASST Fatebenefratelli Sacco University Hospital, Milan, Italy, ⁴Infectious Diseases Unit, ASST Papa Giovanni XXIII Hospital, Bergamo, Italy, ⁵Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy, ⁶Infectious Diseases Unit, ARNAS Civico-Di Cristina-Beneferatelli Hospital, Palermo, Italy, ⁷Institute of Clinical Infectious Diseases, Catholic University of the Sacred Heart, Policlinico Gemelli, Rome, Italy

- TD 7** 13.25-13.32 **Comparing the efficacy and safety of dolutegravir+lamivudine vs bicitegravir/emtricitabine/tenofovir alafenamide fumarate as first-line regimens in a multicenter cohort**
 A. Ciccullo¹, G. Balducci², A. Giacomelli³, F. Lagi⁴, D. Moschese⁵, S. Rusconi⁶, G. Sterrantino⁴, A. Borghetti⁶, S. Antinori³, C. Mussini⁷, S. Di Giambenedetto²
¹UOC Malattie Infettive, PO San Salvatore, L'Aquila, Italy, ²Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy, ³Department of Infectious Diseases, ASST Fatebenefratelli Sacco University Hospital, Milan, Italy, ⁴Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy, ⁵Infectious Diseases Unit, ASST Ovest Milanese Ospedali Legnano, and DIBIC, University Milan, Legnano, Italy, ⁶Infectious Diseases Unit, Azienda Ospedaliero Universitaria Pisana, Pisa, Italy, ⁷Azienda Ospedaliero Universitaria di Modena, Clinica Malattie Infettive e Tropicali, Modena, Italy
- TD 8** 13.32-13.39 **Similar Efficacy, Safety and CD4 T cell increase up to Week 96 observed in Fostemsavir (FTR) based regimens from the BRIGHT study and Dolutegravir (DTG) based regimens from the VIKING-3 study in multidrug resistant (MDR) HIV-1 individuals**
 A. Castagna¹, N. Gregori², I. Marconi², F. Du³, B. Li³, M. Wang³, B. Jones⁴, M. Prakash⁴, A. Clark⁴
¹Vita-Salute San Raffaele University, Milan, Italy/ Infectious Diseases, IRCCS San Raffaele Scientific Institute, Milan, Italy, ²ViiV Healthcare, Italy, UK, ³GSK, Collegeville, PA, USA, ⁴ViiV Healthcare, Brentford, UK
- TD 9** 13.39-13.46 **Exploring the Use of Darunavir Boosted plus Dolutegravir in Highly Treatment-Experienced HIV Population: A Retrospective Cohort Study**
 A. De Vito^{1,2}, G. Moi¹, M. Menozzi³, A. Bezenchek⁴, D. Stanev⁵, N. Cuomo⁶, A. Raddi⁶, F. Stefanelli⁷, M. Guardiani⁸, E. Tortellini⁹, M. Cerchiaro⁹, G. Brucci⁹, P. Fusco¹⁰, S. Rotundo¹⁰, G. Stella¹¹, A. Cozzi-Lepri¹², B. Rossetti¹¹, A. Di Biagio⁹
¹Unit of Infectious Disease, Department of Medicine, Surgery and Pharmacy, University of Sassari, Sassari, Italy, ²PhD School in Biomedical Science, Biomedical Science Department, University of Sassari, Sassari, Italy, ³AOU Policlinico di Modena, University of Modena and Reggio Emilia, Modena, Italy, ⁴IIPRO-InfarmaPRO S.r.l., Rome, Italy; EuResist Network GEIE, Rome, Italy, ⁵Gran Sasso Science Institute GSSI, L'Aquila, Italy, ⁶UOC Microbiologia e Virologia, Azienda Ospedaliera dei Colli - Presidio "D. Cotugno", Napoli, Italy, ⁷IRCCS Ospedale Policlinico San Martino, Italy, ⁸Dipartimento di sanità pubblica e malattie infettive, Policlinico Umberto I, Italy, ⁹Infectious Diseases Unit, San Martino Policlinico Hospital - IRCCS for Oncology and Neuroscience, Genoa, Italy, Department of Health Sciences (DISSAL), University of Genoa, Genoa, Italy, ¹⁰AOU Renato Dulbecco, Magna Græcia University of Catanzaro, Italy, ¹¹Infectious Disease Department, USL SUDEST, Toscana, Misericordia Hospital, Grosseto, Italy, ¹²Centre for Clinical Research, Epidemiology, Modelling and Evaluation (CREME) Institute for Global Health UCL, London, UK
- TD 10** 13.46-13.53 **Real-world data on the effectiveness and safety of bicitegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) in people with HIV (PWH): 24-month full dataset results of the Italian BIC-STaR cohort**
 S. Rusconi¹, G.C. Marchetti², D. Canetti³, V. Esposito⁴, E. Quiros-Roldan⁵, B. Candelaesi⁶, A. Saracino⁷, V. Malagnino⁸, A. Antinori⁹, A. Marongiu¹⁰, L. Albini¹¹, R. Caldera¹¹, G. Forcina¹¹, G. Di Perri¹²
¹Infectious Diseases Unit, ASST Ovest Milanese - DIBIC, University of Milan, Milan, Italy, ²Clinic of Infectious Diseases, Department of Health Sciences, University of Milan, "ASST Santi Paolo e Carlo", Milan, Italy, ³Clinic of Infectious Diseases, IRCCS San Raffaele Scientific Institute, Milan, Italy, ⁴Infectious Diseases and Gender Medicine Unit D. Cotugno Hospital-A.O. dei Colli, Naples, Italy, ⁵Division of Infectious and Tropical Medicine, ASST Spedali Civili, Brescia, Italy, ⁶Infectious Diseases Clinic, Department of Biological Sciences and Public Health, Marche Polytechnic University, Ancona, Italy, ⁷Division of Infectious Diseases, Bari University Hospital, University of Bari, Bari, Italy, ⁸Infectious Diseases Clinic, University Hospital "Tor Vergata", Rome, Italy, ⁹HIV/AIDS Department, National Institute of Infectious Diseases, L. Spallanzani, IRCCS, Rome, Italy, ¹⁰Gilead Sciences Europe Ltd, Stockley Park, Uxbridge, UK, ¹¹Gilead Sciences Srl, Milan, Italy, ¹²Department of Medical Sciences, Infectious Diseases, University of Turin, Turin, Italy

13.53-14.15 **Discussion****SHORT COMMUNICATIONS** 13.15-14.15**AULA 7****HIV associated comorbidities: interplaying matters**

Chairs: Giovanni Cenderello (Sanremo IM), Chiara Iaria (Palermo)

13.15-13.18 **Introduction**

G. Cenderello, Sanremo IM; C. Iaria, Palermo

SC 19**13.18-13.25 Lipids, weight gain and Body Mass Index in ARV experienced PLWH treated with Doravirine-based treatments: a comparison between dual or triple regimens vs Bicitegravir based triple regimen**A. Masiello¹, V. Iodice¹, B. Menzaghi², L. Taramasso³, R. Bellagamba⁴, C. Molteni⁵, G.F. Pellicano⁶, N. Squillace⁷, E. Sarchi⁸, F. Lagi⁹, A. Cascio¹⁰, M.A. Carleo¹¹, B.M. Celesia¹², E. Salomoni¹³, S. Ferrara¹⁴, E. Pontali¹⁵, G.V. De Socio¹⁶, G. Madeddu¹⁷, M. Franzetti¹⁸, S. Martini¹⁹, K. Falasca²⁰, G. Orofino²¹, O. Bargiacchi²², D. Fiordelisi²³, G. Angioni²⁴, G. Cenderello²⁵, L. Calza²⁶, A. Di Biagio²⁷, P. Bonfanti²⁸, P. Maggi¹, for the CISA Study Group

¹Infectious Diseases Unit, AORN Sant'Anna e San Sebastiano, Caserta, Italy, ²Unit of Infectious Diseases, ASST della Valle Olona – Busto Arsizio (VA), Italy, ³Infectious Diseases Unit, Ospedale Policlinico San Martino - IRCCS per l'Oncologia, Genoa, Italy, ⁴National Institute for Infectious Diseases Lazzaro Spallanzani Institute for Hospitalization and Care Scientific, Roma, Lazio, Italy, ⁵Unit of Infectious Diseases, A. Manzoni Hospital, Lecco, Italy, ⁶Unit of Infectious Diseases, Department of Human Pathology of the Adult and the Developmental Age 'G. Barresi', University of Messina, Messina, Italy, ⁷Infectious Disease Unit, Fondazione IRCCS San Gerardo dei Tintori, Monza, Italy, ⁸Infectious Diseases Unit, S. Antonio e Biagio e Cesare Arrigo Hospital, Alessandria, Italy, ⁹AOU Infectious and Tropical Diseases, Careggi Hospital, Florence, Italy, ¹⁰Unit of Infectious Diseases, Department of Health Promotion, Mother and Child Care, Internal Medicine and Medical Specialties, University of Palermo, Palermo, Italy, ¹¹Infectious Diseases and Gender Medicine Unit, Cotugno Hospital, AO dei Colli, Naples, Italy, ¹²Unit of Infectious Diseases, Garibaldi Hospital, Catania, Italy, ¹³SOC 1 USL-CENTRO Firenze, Unit of Infectious Diseases, Santa Maria Annunziata Hospital, Florence, Italy ¹⁴Unit of Infectious Diseases, Department of Clinical and Experimental Medicine, University of Foggia, Foggia, Italy, ¹⁵Department of Infectious Diseases, Galliera Hospital, Genoa, Italy, ¹⁶Unit of Infectious Diseases, Santa Maria Hospital, Perugia, Italy, ¹⁷Unit of Infectious Diseases, Department of Medicine, Surgery and Pharmacy, University of Sassari, Italy, ¹⁸UOC Malattie Infettive, ASST Ovest-Milanese, Ospedale Nuovo di Legnano, Legnano, Italy, ¹⁹Infectious Disease Unit, University Hospital Luigi Vanvitelli, Naples, Italy, ²⁰Clinic of Infectious Diseases, Department of Medicine and Science of Aging, G. D'Annunzio University, Chieti- Pescara, Chieti, Italy, ²¹Division I of Infectious and Tropical Diseases, ASL Città di Torino, Italy, ²²Unit of Infectious Diseases, Ospedale Maggiore della Carità, Novara, Italy, ²³Department of Biomedical Sciences and Human Oncology, Clinic of Infectious Diseases, University of Bari "Aldo Moro", Bari, Italy, ²⁴Infectious Diseases Unit, SS Trinità Hospital, Cagliari, Italy, ²⁵Infectious Diseases Department, Sanremo Hospital, Sanremo, Italy, ²⁶Department of Medicine and Surgical Sciences, Clinics of Infectious Diseases, S. Orsola-Malpighi Hospital, "Alma Mater Studiorum" University of Bologna, Bologna, Italy, ²⁷Department of Health's Sciences, University of Genoa, Genoa, Italy, ²⁸University of Milano-Bicocca, Monza, Italy

SC 20

13.27-13.34 Dyslipidemia and real-life prescription of statins among People Living With HIV enrolled in Archi Prevalent cohort

B.M. Celesia¹, S. Martin², E.D. Ricci³, L. Galli⁴, A. Masiello⁵, C. Muccini⁴, S. Zacà⁶, S. Ferrara⁷, G. Di Filippo⁸, M.S. Paternò Raddusa¹, A. Tartaglia⁹, R. Basile¹⁰, D. Angiletta⁶, A. Castagna⁴, P. Maggi^{2,5}

¹Unit of Infectious Diseases, Department of Clinical and Experimental Medicine, ARNAS Garibaldi Hospital, University of Catania, Catania, Italy, ²Department of Mental Health and Public Medicine, Section of Infectious Diseases, University of Campania, Luigi Vanvitelli, Naples, Italy, ³Fondazione ASIA Onlus, Milan, Italy, ⁴Clinic of Infectious Diseases, San Raffaele Scientific Institute, Vita-Salute San Raffaele University, Milan, Italy, ⁵AORN Sant'Anna e San Sebastiano of Caserta, Caserta, Italy, ⁶Department of Emergency and Organ Transplantation, University of Bari School of Medicine, Bari, Italy, ⁷Department of Medical and Surgical Sciences, Section of Infectious Diseases, University of Studies of Foggia, Foggia, Italy, ⁸Department of Medicine and Surgery, Section of Infectious Diseases, University Federico II of Naples, Napoli, Italy, ⁹Azienda Ospedaliera di Foggia, Foggia, Italy, ¹⁰Section of Infectious Diseases, Grande Ospedale Metropolitano, Bianchi Melacrinò Morelli, Reggio Calabria, Italy

SC 21

13.36-13.43 The dangerous liaisons: Correlation between lipid profile, subclinical atherosclerosis, hepatic steatosis and hepatic fibrosis in PLWH

A. Masiello¹, S. Ferrara², A. Tartaglia³, V. Iodice¹, F. Laguardia⁴, A. Boccia⁴, I. Capriglione⁴, F. Simeone¹, A. Iodice¹, P. Maggi¹

¹Infectious Diseases Unit, AORN Sant'Anna e San Sebastiano, Caserta, Italy, ²Unit of Infectious Diseases, Department of Clinical and Experimental Medicine, University of Foggia, Foggia, Italy, ³ASL Foggia, Italy, ⁴Infectious Disease Unit, University Hospital Luigi Vanvitelli, Naples, Italy

SC 22

13.45-13.52 A 48-week randomized controlled study of a home-based, app-monitored physical exercise intervention for older people with sarcopenia (Grow Your Muscle - GYM study): Preliminary results on muscle function and body composition at Week-12

F. Marmondi^{1,2}, L. Galli¹, C. Inzaghi³, C. Cerizza², G. Annicchiarico¹, A. Baglivi¹, L. Della Torre¹, R. Vercesi^{1,2}, A. Castagna^{1,4}, C. Sciorati⁵, L. Zagato⁶, G. Banfi^{3,4}, M. Bonato^{3,7}, P. Cinque^{1,2}

¹IRCCS San Raffaele Scientific Institute, Unit of Infectious Diseases, Milan, Italy, ²IRCCS San Raffaele Scientific Institute, Unit of Neurovirology, Milan, Italy, ³IRCCS Istituto Ortopedico Galeazzi, Milan, Italy, ⁴Vita-Salute San Raffaele University, Milan, Italy, ⁵IRCCS San Raffaele Scientific Institute, Unit of Innate Immunity and Tissue Remodeling, Milan, Italy, ⁶IRCCS San Raffaele Scientific Institute, Unit of Genomics of Renal Diseases and Hypertension Unit, Milan, Italy, ⁷Università degli Studi di Milano, Department of Biomedical Sciences for Health, Milan, Italy

SC 23

13.54-14.01 Changes in bone mineral density in antiretroviral therapy-naïve people living with HIV-1 aged over 50 years and starting bicitgravir/emtricitabine/tenofovir alafenamide

L. Calza, M. Giglia, V. Colangeli, F. Baldasso, M. Cantini, I. Grassi, A. Poma, S. Cretella, P. Viale

Unit of Infectious Diseases I, IRCCS S.Orsola Hospital, University of Bologna, Bologna, Italy

SC 24

14.03-14.10 Evolution of anal HPV infection and HPV-related squamous intraepithelial lesions in a cohort of PLWH: is there a benefit of HPV vaccination?

A. Bailoni^{1,2}, M. Sambo^{1,2}, A. D'Antiga¹, F. Panza^{1,2}, E. Morelli^{1,2}, M. Zanchi^{1,2}, G. Giuliano^{1,2}, F. Mariani³, S. Lazzi^{1,4}, F. Montagnani^{1,2}, M. Tumbarello^{1,2}, M. Fabbiani^{1,2}

¹Department of Medical Biotechnologies, University of Siena, Siena, Italy, ²Infectious and Tropical Diseases Unit, Siena University Hospital, Siena, Italy, ³General Surgery and Surgical Oncology Unit, Siena University Hospital, Siena, Italy, ⁴Pathological Anatomy Unit, Siena University Hospital, Siena, Italy

14.12-14.15

Conclusion

G. Cenderello, Sanremo IM; C. Iaria, Palermo



**SYMPOSIUM AND ORAL COMMUNICATIONS** 14.20-15.20**AULA LAZZATI****Real-world experiences with TAF-based regimens**

Chair: Simona Di Giambenedetto (Roma)

With an unrestricted educational grant from Gilead Sciences

Discussants: Roberta Gagliardini (Roma), Andrea Giacomelli (Milano)

TAF stands as a pivotal advancement in the management of HIV. Its introduction marks a significant milestone for achieving long-term treatment success in PWH. The symposium aims to present and discuss RWE of TAF-based regimens in HIV management across diverse patient populations and healthcare settings. By informing evidence-based decision-making, the symposium seeks to optimize patient care, leading to improved treatment strategies and outcomes for PWH.

14.20-14.30 **PWH: present and future clinical scenario**

S. Di Giambenedetto, Roma

Clinical experiences in real-life settings**OC 13****14.30-14.40 Efficacy of switching to bicitgravir/emtricitabine/tenofovir alafenamide in people living with HIV with pre-existing NRTI resistances: a real-life experience**L. Mezzogori¹, B. Bruzzone², F. Stefanelli², M. Zazzi³, L. Taramasso¹, R. Schiavoni¹, C. Bartalucci¹, L. Labate¹, N. Randazzo², F. Maggiolo⁴, M. Bassetti^{1,5}, A. Di Biagio^{1,5}

¹Department of Specialist Medicine, Infectious Disease Clinic, IRCCS Ospedale Policlinico San Martino, Genoa, Italy, ²Hygiene Unit, IRCCS Ospedale Policlinico San Martino for Oncology and Neurosciences, Genoa, Italy, ³Department of Medical Biotechnologies, University of Siena, Siena, Italy, ⁴Independent Contractor, Italy, ⁵Department of Health Sciences (DISSAL), University of Genoa, Genoa, Italy

OC 14**14.40-14.50 Adherence of single tablet antiretroviral regimens in the clinical setting: forgiveness does matter**V. Maccario, M. Ferrara, M. Maunero, G. Trevisan, G. Accardo, F. Barrera, E. Clemente, M. Tettoni, L. Trentini, G. Di Perri, A. Calcagno, S. Bonora
Unit of Infectious Diseases, Department of Medical Sciences, University of Torino, Torino, Italy**OC 15****14.50-15.00 Changes in Body mass index and lipid profile in PWH switching to a regimen without TAF vs PWH continuing TAF. Data from a real-life setting**N. Squillace¹, L. Taramasso², E. Ricci³, B. Menzaghi⁴, G. De Socio⁵, G. Orofino⁶, B.M. Celesia⁷, E. Sarchi⁸, S. Piconi⁹, G. Pellicano¹⁰, L. Attala¹¹, A. Di Biagio², P. Bonfanti¹, for the CISA Study Group

¹Infectious Diseases Unit Fondazione IRCCS, San Gerardo dei Tintori-University of Milano-Bicocca, Monza, Italy, ²Infectious Diseases, San Martino Hospital Genoa, University of Genoa, Genoa, Italy, ³Fondazione ASIA Onlus, Buccinasco, Milano, Italy, ⁴Unit of Infectious Diseases, ASST della Valle Olona – Busto Arsizio, Varese, Italy, ⁵Unit of Infectious Diseases, Santa Maria Hospital, Perugia, Italy, ⁶Division I of Infectious and Tropical Diseases, ASL Città di Torino, Italy, ⁷Unit of Infectious Diseases, Garibaldi Hospital, Catania, Italy, ⁸Infectious Diseases Unit, S. Antonio e Biagio e Cesare Arrigo Hospital, Alessandria, Italy, ⁹Unit of Infectious Diseases, A. Manzoni Hospital, Lecco, Italy, ¹⁰Infectious Diseases, G. Martino Hospital -University of Messina, Messina, Italy, ¹¹Unit of Infectious Diseases, Santa Maria Annunziata Hospital, Florence, Italy

15.00-15.20 **Discussion and final considerations**

S. Di Giambenedetto, Roma; R. Gagliardini, Roma; A. Giacomelli, Milano

**SYMPOSIUM** 14.20-15.20**AULA BAUSOLA****Antiviral treatment of COVID-19 for fragile people in the current era**

Chairs: Andrea Antinori (Roma), Annamaria Cattelan (Padova)

With an unrestricted educational grant from Pfizer

After the third year of the COVID-19 pandemic, most of the severe COVID-19 burden falls upon immunocompromised patients who cannot mount an endogenous immune response after both vaccination and/or natural infection. SARS-CoV-2 tends to establish persistent infections in patients who are immunocompromised (IC), where disease recovery and viral clearance are needed to initiate further lines of immunosuppressive treatments for the underlying disorder. Since ritonavir-boosted nirmatrelvir is a recognized highly effective oral antiviral therapy for COVID-19, with a large supporting evidence, it should be strongly considered for patients who are immunocompromised if there are no potential drug-drug interactions or if the potential interactions can be safely managed. This session will review more recent data from scientific research and the evidences in the real-world setting.

14.20-14.25 **Introduction**

A. Antinori, Roma; A. Cattelan, Padova

14.25-14.45 **From high-risk patients to persistent infection: focus on COVID-19 in the immunocompromised persons**

M. Falcone, Pisa

14.45-14.50 **Discussion**14.50-15.10 **Antiviral treatment of COVID-19: insights from controlled trials and real-world evidence**

V. Mazzotta, Roma

15.10-15.15 **Discussion**15.15-15.20 **Take-home messages**

A. Antinori, Roma; A. Cattelan, Padova



**ORAL COMMUNICATIONS** 14.20-15.20**AULA 5****Virology and pharmacology across the spectrum of HIV treatment**

Chairs: Guido Antonelli (Roma), Andrea Calcagno (Torino)

14.20-14.25 **Introduction**

G. Antonelli, Roma; A. Calcagno, Torino

OC 16 14.25-14.35 **Do low-frequency drug-resistant HIV-1 variants have a role on first-line INSTI-containing regimens? A case-control study from the ICONA cohort**
 D. Armenia¹, G. Marchegiani², D. Spalletta², L. Carioti², A. Tavelli³, M.C. Bellocchi², V. Spagnuolo⁴, V. Mazzotta⁵, E. Quiros-Roldan⁶, V. Bono⁷, S. Carrara⁵, S. Lo Caputo⁸, A. Cozzi-Lepri⁹, A. d'Arminio Monforte³, F. Ceccherini-Silberstein², S. Rusconi¹⁰, M.M. Santoro², on behalf of the ICONA Foundation Study Group

¹Saint Camillus International University of Health Sciences, Rome, Italy, ²University of Rome "Tor Vergata", Rome, Italy, ³Icona Foundation, Milan, Italy, ⁴Infectious Diseases, IRCCS San Raffaele Scientific Institute, Milan, Italy, ⁵National Institute of Infectious Diseases Lazzaro Spallanzani IRCCS, Rome, Italy, ⁶University of Brescia and ASST Spedali Civili di Brescia, Brescia, Italy, ⁷ASST Santi Paolo e Carlo, University of Milan, Milan, Italy, ⁸Clinic of Infectious Diseases, Department of Clinical and Surgical Sciences, University of Foggia, Foggia, Italy, ⁹Centre for Clinical Research, Epidemiology, Modelling and Evaluation (CREME), Institute for Global Health, University College London, London, UK, ¹⁰Infectious Diseases Unit, Ospedale Civile di Legnano, ASST Ovest Milanese, and DIBIC, Università degli Studi di Milano, Milan, Italy

OC 17 14.35-14.45 **Long Acting Cabotegravir and Rilpivirine plasma and intracellular pharmacokinetics in the Clinical Setting**

M. Ferrara¹, V. Maccario¹, F. Barrera¹, L. Ponzetta¹, L. Di Girolamo¹, D. Arrue Diaz¹, M. Tettoni¹, L. Trentini¹, G. Orofino², S. Soloperto³, D. Maiese³, A. De Nicolò³, A. D'Avolio³, A. Calcagno¹, S. Bonora¹

¹Unit of Infectious Diseases, Department of Medical Sciences, University of Torino, Torino, Italy, ²Unit of Infectious Diseases, Amedeo di Savoia Hospital, ASL Città di Torino, Italy, ³Laboratory of Clinical Pharmacology and Pharmacogenetics, Department of Medical Sciences, University of Torino, Torino, Italy

14.45-14.49 **Discussion**

OC 18 14.49-14.59 **Network analysis of proviral DNA mutations in People with 4-class-resistant HIV-1: Data from the PRESTIGIO Registry**

S. Diotallevi¹, D. Armenia², T. Clemente³, F. Saladini⁴, S. Rusconi⁵, L. Calza⁶, A. Cervo⁷, M. Zazzi⁴, R. Lolatto¹, M.C. Bellocchi⁸, G. Marchegiani⁸, L. Carioti⁸, E. Fronti⁹, M. Ficon¹⁰, V. Spagnuolo¹, A. Castagna³, M.M. Santoro¹¹, L. Farina¹² for the PRESTIGIO Registry GROUP

¹Infectious Diseases, IRCCS San Raffaele Scientific Institute, Milan, Italy, ²Saint Camillus International University of Health Sciences, Rome, Italy, ³Vita-Salute San Raffaele University, Milan, Italy, ⁴University of Siena, Siena, Italy, ⁵Ospedale Civile di Legnano, DIBIC University of Milan, Legnano, Italy, ⁶Policlinico Sant'Orsola-Malpighi, Bologna, Italy, ⁷Azienda Ospedaliera Universitaria Policlinico di Modena, Modena, Italy, ⁸Department of Experimental Medicine, University of Rome "Tor Vergata", Rome, Italy, ⁹Azienda Ospedaliera Universitaria di Parma, Parma, Italy, ¹⁰Azienda ULSS 9 Scaligera, Verona, Italy, ¹¹University of Rome Tor Vergata, Rome, Italy, ¹²Department of Computer, Control and Management Engineering, Sapienza University of Rome, Rome, Italy

OC 19 14.59-15.09 **The in vitro genetic barrier to resistance of lenacapavir is not affected by viral subtype or heavy treatment exposure**

C. Paletti¹, N. Bartolini¹, F. Giammarino^{1,2}, F. Saladini¹, I. Vicenti¹, L. Fiaschi¹, C. Biba¹, I. Varasi¹, F. Garcia³, A.G. Marcelin⁴, M. Zazzi¹, V. Spagnuolo⁵, E. Focà⁶, S. Rusconi⁷

¹Department of Medical Biotechnologies, University of Siena, Siena, Italy, ²Division of Infectious Diseases, Department of Medicine Huddinge, Karolinska Institutet, Stockholm, Sweden, ³Hospital Universitario Clinico San Cecilio, Clinical Microbiology, Granada, Spain; Instituto de Investigación Ibs. Granada, Spain - Ciber de Enfermedades Infecciosas, Ciberinfec, Madrid, Spain, ⁴Sorbonne Université, INSERM, Institut Pierre Louis d'Epidémiologie et de Santé Publique, AP-HP, Hôpital Pitié-Salpêtrière, Laboratoire de virologie, Paris, France, ⁵Infectious Diseases, IRCCS San Raffaele Scientific Institute, Milan, Italy, ⁶Unit of Infectious and Tropical Diseases, Department of Clinical and Experimental Sciences, University of Brescia and ASST Spedali Civili di Brescia, Brescia, Italy, ⁷Infectious Diseases Unit, ASST Ovest Milanese, Legnano General Hospital and DIBIC, University of Milan, Milan

15.09-15.13 **Discussion**15.13-15.20 **Conclusion**

G. Antonelli, Roma; A. Calcagno, Torino



**EXPERT MEETING** 14.20-15.20**AULA 6****Optimizing the management of patients with skin and soft tissue infections (ABSSSI): focus on fragile population**

Chairs: Antonio Cascio (Palermo), Sergio Lo Caputo (Foggia)

With an unrestricted educational grant from Angelini Pharma

Acute bacterial skin and skin structure infections (ABSSSI) represent a significant burden on the healthcare system, with increasing incidence and severity, particularly in fragile population, such as the elderly, multi-treated, drug addicts, or people with neuropsychiatric problems. The involvement of resistant organisms, particularly methicillin-resistant *Staphylococcus aureus*, presents additional challenges in the management of these patients, as well as the need of a multidisciplinary approach. The long-acting lipoglycopeptide dalbavancin with activity against Gram-positive organisms, including MRSA, may offer the opportunity for earlier hospital discharge and be considered in the outpatient setting, including home health care, outpatient infusion clinics, or in the emergency department to avoid delay in treatment and prevent inpatient hospital admissions, which represents a relevant issue particularly in patients at high risk of complications.

- 14.20-14.30 **Introduction: Gram+ infections, the importance of a specialistic network** A. Cascio, Palermo
S. Lo Caputo, Foggia
- 14.30-14.50 **Effectiveness of long-acting antibiotic therapy: clinical and real-life evidences** I. Gentile, Napoli
- 14.50-15.10 **The long-acting diagnostic-therapeutic path of patients with Gram+ infections: indications for clinical practice** S. Carbonara, Bisceglie BT
- 15.10-15.20 **Take-home messages** A. Cascio, Palermo; S. Lo Caputo, Foggia

**SYMPOSIUM** 15.25-16.25**AULA LAZZATI****Clinical HIV: looking ahead**

Chairs: Cristina Gervasoni (Milano), Sergio Lo Caputo (Foggia)

The current clinical landscape of HIV encompasses several noteworthy areas of interest. These include managing opportunistic infections, which continue to occur due to a significant number of individuals experiencing AIDS-defining illnesses as well as addressing new challenges related to expanding access to transplantation for selected HIV patients. Despite advances in antiretroviral therapy, surgical techniques, and post-operative care, concerns remain regarding organ rejection, opportunistic infections, and drug interactions. The symposium will focus on gaining new insights into opportunistic infections like tuberculosis and cryptococcosis, and making advances in organ transplantation for person living with HIV. Careful patient selection, close monitoring, and tailored immunosuppressive therapy will be given particular attention.

- 15.25-15.40 **What is still to be done in solid organ transplantation for person living with HIV** G. Guaraldi, Modena
- 15.40-15.45 **Discussion**
- 15.45-16.00 **Can person living with HIV benefit from short strategies for preventing and treating tuberculosis?** G. Di Perri, Torino
- 16.00-16.05 **Discussion**
- 16.05-16.20 **Can person living with HIV benefit from short therapy in cryptococcal meningitis?** S. Antinori, Milano
- 16.20-16.25 **Discussion**

**SYMPOSIUM AND ORAL COMMUNICATIONS** 15.25-17.30**AULA BAUSOLA****COVID-19 and post-Covid conditions in 2024: data from the EuCARE project**

Chairs: Francesca Ceccherini Silberstein (Roma), Giulia Carla Marchetti (Milano)

SARS-CoV-2 and its continuous evolution still pose scientific questions and challenges, including those related to its immune pathogenesis and to long-COVID. The pandemic also highlighted the need for research on areas like vaccine hesitancy and non pharmacological interventions, e.g. in school. Thanks to a large international collaboration, the EuCARE project is trying to provide advances in a wide variety of SARS-CoV-2 variants related topics.



- 15.25-15.40 **International collaboration for pandemic preparedness: the EuCARE Project** F. Incardona, Roma
- 15.40-15.45 **Neutralizing antibody response to the latest SARS-CoV-2 lineages (WP2)** M. Zazzi, Siena
- 15.45-16.00 **Discussion**
- OC 20** 16.00-16.10 **Interplay between gut-barrier dysfunction, microbial translocation, microbioma and SARS-CoV-2 RNAemia in acutely ill unvaccinated COVID-19 individuals developing long-covid**
R. Rovito, M. Augello, S. Marozin, V. Bono, A. Santoro, C. Tincati, F. Bai, G. Marchetti, for the EuCARE Study Group
Clinic of Infectious Diseases and Tropical Medicine, San Paolo Hospital, ASST Santi Paolo e Carlo, Department of Health Sciences, University of Milan, Milan, Italy
- OC 21** 16.12-16.22 **Trajectories of the Post COVID-19 condition**
F. Bai, A. Santoro, M.F. Greco, M. Sala, R. Castoldi, R. Rovito, G. Marchetti, on behalf of the EuCARE project
Clinic of Infectious Diseases, San Paolo Hospital, ASST Santi Paolo e Carlo, University of Milan, Italy
- 16.24-16.39 **In-hospital mortality study results (WP3 > Hospitalised)** A. Cozzi-Lepri, London UK
- 16.39-16.54 **Real-time modelling of SARS-COV-2 variants** E. Shamsara, Tübingen DE
- 16.54-17.09 **Exploring mental health of students in association with SARS-CoV-2 preventive measures (WP4)** S. Gandini, Milano
- 17.09-17.30 **Discussion**



EXPERT MEETING 15.25-16.25

AULA 5

Tailoring of antiretroviral therapy in PWH who go through therapeutic failure. Experts panel discussion on real clinical scenarios

Chairs: Antonella Cingolani (Roma), Antonio Di Biagio (Genova) *With an unrestricted educational grant from Gilead Sciences*

While modern antiretroviral therapy has been progressing towards increased potency, convenience and durability, controversies in HIV virology and pharmacology remain. This expert meeting focuses on four specific clinical issues: how to manage PWH with drug resistance, low-level viremia, PWH who discontinued long-acting therapies, and PWH with comorbidities and polypharmacy. The goal of this expert meeting is to discuss open controversies in HIV, through an experts panel, to identify timely, appropriate, and individualized treatment approach for these complex clinical scenarios.

- 15.25-15.30 **PWH with resistance associated mutations** S. Rusconi, Legnano MI
- 15.30-15.40 **Discussion** A. Cingolani, Roma; A. Di Biagio, Genova; S. Rusconi, Legnano MI
- 15.40-15.45 **PWH with low-level viremia** L. Sarmati, Roma
- 15.45-15.55 **Discussion** A. Cingolani, Roma; A. Di Biagio, Genova; L. Sarmati, Roma
- 15.55-16.00 **Discontinuations after switching to long-acting therapy** S. Nozza, Milano
- 16.00-16.10 **Discussion** A. Cingolani, Roma; A. Di Biagio, Genova; S. Nozza, Milano
- 16.10-16.15 **PWH with comorbidities and polypharmacy** S. Bonora, Torino
- 16.15-16.25 **Discussion** S. Bonora, Torino; A. Cingolani, Roma; A. Di Biagio, Genova



ORAL COMMUNICATIONS 15.25-16.25

AULA 6

Modern challenges in sexual health

Chairs: Mario Cascio (Milano), Paola Cinque (Milano)

- 15.25-15.30 **Introduction** M. Cascio, Milano; P. Cinque, Milano

OC 22 15.30-15.40 **Female sexual dysfunction: prevalence and risk factors in a cohort of women living with HIV**

M. Salvi¹, G. Tiecco¹, M. Alberti¹, A. Delbarba², F. Castelli¹, E. Quiros-Roldan¹

¹Department of Clinical and Experimental Sciences, Unit of Infectious and Tropical Diseases, University of Brescia and ASST Spedali Civili di Brescia, Brescia, Italy, ²Department of Clinical and Experimental Sciences, Unit of Endocrinology and Metabolism, ASST Spedali Civili di Brescia, Brescia, Italy



- OC 23** 15.42-15.52 **Knowledge, use and misuse of self-prescribed doxyPEP in a community-based PrEP service**
R. Rossotti^{1,2}, E. Caruso², D. Calzavara², P. Vinti², A. Bianchi², A. Tavelli^{2,3}, D. Moschese^{2,4}, G. Lapadula^{2,5}, C. Muccini^{2,6}, A. Soria^{2,5}, A. De Bona^{2,7}, M. Cernuschi^{2,6}, A. d'Arminio Monforte^{2,3}
¹Department of Infectious Diseases, ASST Grande Ospedale Metropolitano Niguarda, Milan, Italy, ²Milano Checkpoint ETS, Milan, Italy, ³ICONA Foundation, Milan, Italy, ⁴Division of Infectious Diseases, ASST Fatebenefratelli Sacco, Milan, Italy, ⁵Department of Infectious Diseases, IRCCS San Gerardo dei Tintori, Monza, Italy, ⁶Unit of Infectious Diseases, IRCCS San Raffaele Scientific Institute, Milan, Italy, ⁷Department of Infectious Diseases, ASST Santi Paolo e Carlo, Milan, Italy
- OC 24** 15.54-16.04 **Effectiveness of MenB vaccination against gonorrhoeae among PrEP users and PWH**
L. Labate^{1,2}, C. Marelli¹, E. Guarise², P.M. Postma², G. Massobrio^{1,2}, L. Taramasso¹, I. Schiavetti³, S. Bianchi¹, F. Centorrino¹, L. Mezzogori^{1,2}, C. Bartalucci^{1,2}, R. Schiavoni^{1,2}, L. Sticchi², M. Bassetti^{1,2}, A. Di Biagio^{1,2}
¹IRCCS Ospedale Policlinico San Martino, Genoa, Italy, ²Department of Health Sciences, University of Genoa, Italy, ³Department of Health Sciences, Section of Biostatistics, University of Genova, Genova, Italy
- OC 25** 16.06-16.16 **HPV test in anal specimens: a preliminary evaluation on sampling quality**
A. Rizzo¹, D. Moschese², F. Salarì¹, A. Giacomelli², M.V. Cosso², C. Fusetti², S. Reato², G. Carozzo², V. Micheli¹, A. Gori², A. Lombardi¹, M.R. Gismondo¹
¹Laboratory of Clinical Microbiology, Virology and Bioemergencies, ASST Fatebenefratelli Sacco, Milan, Italy, ²Department of Infectious Disease, ASST Fatebenefratelli Sacco, Milan, Italy
- 16.18-16.25 **Conclusion** M. Cascio, Milano; P. Cinque, Milano

**SHORT COMMUNICATIONS** 15.25-16.25**AULA 7****Factors affecting treatment success: from pharmacology to drug resistance**

Chairs: Annapaola Callegaro (Milano), Emanuele Focà (Brescia)

- 15.25-15.28 **Introduction** A. Callegaro, Milano; E. Focà, Brescia
- SC 25** 15.28-15.35 **The impact of pharmacogenetics on long-acting cabotegravir and rilpivirine plasma exposures in the clinical setting**
J. Cusato¹, M. Ferrara², M. Antonucci², T. Razvan Goldan¹, S. Soloperto¹, G. Di Perri³, A. D'Avolio¹, A. Calcagno³, S. Bonora³
¹Laboratory of Clinical Pharmacology and Pharmacogenetics, Department of Medical Sciences, University of Turin, Amedeo di Savoia Hospital, Turin, Italy, ²Amedeo di Savoia Hospital, ASL Città di Torino, Turin, Italy, ³Unit of Infectious Diseases, Department of Medical Sciences, University of Turin, Amedeo di Savoia Hospital, Turin, Italy
- SC 26** 15.35-15.42 **The case of dolutegravir plus darunavir antiretroviral regimens: Is it always useful to double the drug doses?**
D. Cattaneo¹, A.L. Ridolfo¹, A. Giacomelli¹, A. Castagna², S. Antinori¹, C. Gervasoni¹
¹Department of Infectious Diseases, ASST Fatebenefratelli Sacco University Hospital, Milan, Italy, ²Department of Infectious Diseases, IRCCS San Raffaele Scientific Institute, Milan, Italy
- 15.42-15.46 **Discussion**
- SC 27** 15.46-15.53 **Comparative analysis of islatravir and tenofovir in vitro activity in NRTI resistant HIV-1 harbouring the M184V/I mutation**
N. Bartolini¹, C. Paletti¹, F. Giammarino^{1,2}, F. Saladini¹, I. Vicenti¹, L. Fiaschi¹, C. Biba¹, I. Varasi¹, M. Fabbiani^{1,3}, R. Riccardi⁴, R. Lolatto⁵, V. Spagnuolo⁵, A. Castagna^{5,6}, M. Zazzi¹
¹Department of Medical Biotechnologies, University of Siena, Siena, Italy, ²Division of Infectious Diseases, Department of Medicine Huddinge, Karolinska Institutet, Stockholm, Sweden, ³Infectious and Tropical Diseases Unit, Azienda Ospedaliero-Universitaria Senese, Siena, Italy, ⁴Infectious Disease Unit, IRCCS, Policlinico Sant'Orsola, Department Medical Surgical Science, University of Bologna, Bologna, Italy, ⁵Infectious Diseases, IRCCS San Raffaele Scientific Institute, Milan, Italy, ⁶Vita-Salute San Raffaele University, Milan, Italy
- SC 28** 15.53-16.00 **Evaluation of HIV-1 drug resistance in newly diagnosed individuals in Italy according to subtype over the period 2017-2023**
A.C. Ka'e^{1,2}, F. Bassani^{3,4}, O. El Khalili⁵, A. Bezenchek⁵, F. Carli⁶, A. Pupo⁷, E. Gentilini Cacciola⁷, L. Pezzati³, L. Duca¹, I. Vicenti⁸, W. Gennari⁹, F. Lombardi¹⁰, A. Shallivari⁵, F. Saladini⁸, V. Micheli¹¹, A. Cozzi-Lepri¹², A. Lai⁴, M.M. Santoro¹, S. Rusconi^{3,4}
¹Department of Experimental Medicine, University of Rome Tor Vergata, Rome, Italy, ²Chantal Biya International Reference Centre for research on HIV/AIDS Prevention and Management (CIRCB), Yaounde, Cameroon, ³Infectious Diseases Unit, Ospedale di Legnano, ASST Ovest Milanese, Legnano, Italy, ⁴Department of Biomedical and Clinical Sciences (DIBIC), University of Milan, Milan, Italy, ⁵InformaPRO SRL, EuResist Network GEIE, Rome, Italy, ⁶Infectious Diseases and Hepatology Unit, Azienda Ospedaliero-Universitaria di Parma, Parma, Italy, ⁷Infectious Diseases Unit, La Sapienza University, Rome, Italy, ⁸Department of Medical Biotechnology, University of Siena, Siena, Italy, ⁹Clinical Microbiology Unit, University Hospital of Modena, Modena, Italy, ¹⁰Virology Lab, Cattolica University of Rome, Rome, Italy, ¹¹Clinical Microbiology, Virology and Bioemergencies Diagnosis, L. Sacco University Hospital, Milan, Italy, ¹²Centre for Clinical Research, Epidemiology, Modelling and Evaluation (CREME), Institute for Global Health, University College London, London, UK



SC 29 16.00-16.07 **Resistance detected in PBMCs predicts virological rebound in HIV-1 suppressed people with HIV-1 switching to modern antiretroviral regimens**

F. Lombardi¹, E. Gentilini Cacciola², F. Carli³, F. Saladini⁴, F. Bassani⁵, I. Vicenti⁴, W. Gennari⁶, A. Pupo², L. Duca⁷, A.C. Ka'e⁸, C. Muscatello⁹, L. Pezzati⁵, O. El Khalili⁷, A. Shallvari¹⁰, V. Micheli¹¹, A. Bezenchek¹⁰, A. Cozzi-Lepri¹², S. Rusconi⁵, M.M. Santoro¹
¹UOC Malattie Infettive, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy, ²Department of Public Health and Infectious Diseases, "Sapienza" University of Rome, Rome, Italy, ³UO Malattie Infettive ed Epatologia, Azienda Ospedaliero-Universitaria di Parma, Italy, ⁴Department of Medical Biotechnologies, University of Siena, Siena, Italy, ⁵S.C. Malattie Infettive, ASST Ovest Milanese, Legnano General Hospital and DIBIC, Università degli Studi di Milano, Italy, ⁶Microbiology and Virology Unit, University Hospital, University of Modena and Reggio Emilia, Modena, Italy, ⁷Department of Experimental Medicine, University of Rome, Tor Vergata, Rome, Italy, ⁸Chantal Biya International Reference Centre for Research on HIV/AIDS Prevention and Management University of Yaoundé, Yaoundé, Cameroon, ⁹Infectious Diseases Unit, Department of Medical and Surgical Sciences, University of Foggia, Foggia, Italy, ¹⁰InformaPRO SRL, EuResist Network GEIE, Rome, Italy, ¹¹Laboratory of Clinical Microbiology, Virology and Bioemergencies, ASST Fatebenefratelli Sacco University hospital, Milan, Italy, ¹²Institute for Global Health, Centre for Clinical Research, Epidemiology, Modelling and Evaluation, London, UK

SC 30 16.07-16.14 **Ultra-deep sequencing of near full-length HIV-1 genomes for detecting natural resistance to lenacapavir and fostemsavir**

E. Lazzari¹, G. Rozera¹, R. Gagliardini², V. Mazzotta², L. Fabeni¹, F. Forbici¹, G. Berno¹, E. Girardi³, A. Antinori², F. Maggi¹, I. Abbate¹
¹Laboratory of Virology, National Institute for Infectious Diseases Lazzaro Spallanzani – IRCCS, Rome, Italy, ²Clinical Department, National Institute for Infectious Diseases Lazzaro Spallanzani – IRCCS, Rome, Italy, ³Scientific Direction, National Institute for Infectious Diseases Lazzaro Spallanzani – IRCCS, Rome, Italy

16.14-16.22 **Discussion**16.22-16.25 **Conclusion**

A. Callegaro, Milano; E. Focà, Brescia

**SPECIAL SESSION** 15.25-17.25**AULA GERMANIA****Approaching Chemsex user: a multidisciplinary practice****Chairs:** Massimo Cernuschi (Milano), Giorgia Fracca (Milano)*With an unrestricted educational grant from ViiV Healthcare***Discussants:** Massimo Cernuschi (Milano), Donatello Zagato (Milano)

Chemsex refers to the use of one or more drugs by MSM before or during sexual activity with one or more partners, organized through geolocation meeting apps and involving specific social interaction dynamics. It's a phenomenon known within the MSM community for many years, but recently, the need for competent support for problematic Chemsex use, which increased during the pandemic, has emerged. However, support is currently scarce. The market is constantly producing new, cheaper substances with unclear effects, posing unpredictable risks. Users may struggle to recognize their problematic use, partly due to stigma and due to its difference from the stereotype of more common and studied substance use, like opioids or cocaine, making it harder to seek help before the situation becomes severe or irreversible. Chemsex can facilitate the spread of STIs, including HIV, due to lowered inhibitions. While many engage in Chemsex without severe consequences, for others, it can develop into a dangerous addiction that's hard to overcome. Some substances can lead to potentially irreversible psychotic crises. There's an urgent need for training among infectious disease, psychiatry, psychology, emergency department professionals, pharmacologists, and addiction service workers, involving users, volunteers and professional operators.

15.25-15.35 **Welcome and introduction**

M. Cernuschi, Milano; G. Fracca, Milano

15.35-15.55 **PrEP and chemsex, description of the phenomenon in the Milan checkpoint cohort**

E. Caruso, Milano

15.55-16.15 **NPS (Novel Psychoactive Substances) epidemiological overview and toxicological monitoring**

M. Ciambella, Roma

16.15-16.35 **MDPV (methylenedioxypropylvalerone): a survey on awareness and knowledge among users of a Milanese PrEP service**

A.M. Bianchi, Milano

16.35-16.55 **Chemsex and possible implications on antiretroviral therapy**

D. Moschese, Milano

16.55-17.15 **ROUND TABLE****Build shared knowledge between users, volunteers, social and health workers**

Moderator: M. Cernuschi, Milano

Discussants: D. Calzavara, Milano; E. Caruso, Milano; M. Cernuschi, Milano
M. Ciambella, Roma; G. Fracca, Milano; F. Leserri, Roma; D. Moschese, Milano17.15-17.25 **Closing remarks**

M. Cernuschi, Milano; G. Fracca, Milano



**SYMPOSIUM** 16.30-17.30**AULA LAZZATI****The future of STI prevention and care: one size does not fit all**

Chairs: Anna Maria Geretti (Roma), Sandro Mattioli (Bologna)

Join our symposium on STI prevention and care. Against a backdrop of evolving landscapes in healthcare and policy, we will probe into emerging aspects of STI surveillance, placing Italy within the European context. Hosted by the Journal Sexually Transmitted Infections, a discourse on standards will navigate the complexities of delivering equity of care to varied demographics. We will challenge conventional wisdom by debating the necessity of routine STI screening in asymptomatic individuals using PrEP, an area of contention with significant implications for resource allocation, patient management and antibiotic stewardship. Expert opinions will illuminate diverse perspectives and audience participation will enrich the discourse.

16.30-16.45 **STI surveillance in Italy: what's hidden under the carpet?** B. Suligoj, Roma16.45-17.00 **Standards of STI care: what good will look like "Hosted by STI, a BMJ journal"** V. Padovese, Malta**Debate: do we need to reduce STI screening in asymptomatic PrEP users?**17.00-17.07 **The argument against** S. Nozza, Milano17.07-17.14 **The argument for** N. Girometti, London UK17.14-17.30 **Q&A and take away points** Moderators: A.M. Geretti, Roma; S. Mattioli, Bologna**ORAL COMMUNICATIONS** 16.30-17.30**AULA 5****The complexities of HIV infection**

Chairs: Antonella d'Arminio Monforte (Milano), Sergio Lo Caputo (Foggia)

16.30-16.35 **Introduction** A. d'Arminio Monforte, Milano; S. Lo Caputo, Foggia**OC 26** 16.35-16.45 **All-cause mortality in people diagnosed with HIV in Italy in 1995-2019: data from the ICONA cohort**

A. Giacomelli¹, S. Lanini^{2,10}, S. De Benedittis³, A. De Vito⁴, M. Mazzitelli⁵, M. Ceccarelli⁶, R. Gagliardini², G. Madeddu⁴, E. Quirós-Roldán⁷, D. Checchi⁸, G. Lapadula⁹, C. Tascini¹⁰, A. Tavelli³, A. Antinori², E. Girardi¹¹, A. d'Arminio Monforte³ on behalf of Icona Foundation Study Group

¹III Infectious Diseases Unit, Department of Biomedical and Clinical Sciences, Università degli Studi di Milano, Milan, Italy, ²Clinical Infectious Diseases Department, National Institute for Infectious Diseases Lazzaro Spallanzani IRCCS, Rome, Italy, ³ICONA Foundation, Milan, Italy, ⁴Unit of Infectious Disease, Department of Medicine, Surgery and Pharmacy, University of Sassari, Sassari, Italy, ⁵Infectious and Tropical Diseases Unit, Padua University Hospital, Padua, Italy, ⁶Department of Clinical and Experimental Medicine, University of Messina, Messina, Italy, ⁷Department of Clinical and Experimental Sciences, Unit of Infectious and Tropical Diseases, University of Brescia and ASST Spedali Civili di Brescia, Brescia, Italy, ⁸Department of System Medicine, Tor Vergata University, Rome, Italy, ⁹Department of Infectious Diseases, IRCCS San Gerardo dei Tintori, University of Milano Bicocca, Monza, Italy, ¹⁰Dipartimento di Medicina dell'Università di Udine, U.O. Malattie Infettive, Università di Udine e Azienda Sanitaria Universitaria Integrata di Udine, Udine, Italy, ¹¹Scientific Direction, National Institute for Infectious Diseases, Lazzaro Spallanzani IRCCS, Rome, Italy

OC 27 16.47-16.57 **Burden of advanced HIV disease (AHD) among antiretroviral therapy (ART)-experienced persons with HIV (PWH) in Italy over the past 20 years**

A. Mondì¹, A. Cozzi-Lepri², V. Mazzotta¹, S. Nozza³, A. Cingolani⁴, L. Taramasso⁵, A. Giacomelli⁶, F. Bai⁷, S. Lanini⁸, V. Bono⁷, A. Ianniello⁹, L. Comi¹⁰, C. Papalini¹¹, C. Mussini¹², E. Girardi¹³, A. Antinori¹, on behalf of Icona Foundation Study Group

¹Clinical and Research Infectious Diseases Department, National Institute for Infectious Diseases Lazzaro Spallanzani IRCCS, Rome, Italy, ²Centre for Clinical Research, Epidemiology, Modelling and Evaluation (CREME), Institute for Global Health, University College London, London, UK, ³Infectious Diseases Unit, Vita Salute San Raffaele University, Milan, Italy, ⁴Section of Infectious Diseases, Department of Safety and Bioethics, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome, Italy, ⁵Infectious Disease Clinic, IRCCS Policlinico San Martino Hospital, Genoa, Italy, ⁶III Infectious Disease Unit, ASST Fatebenefratelli Sacco, Milan, Italy, ⁷Department of Health Sciences, ASST Santi Paolo e Carlo, Clinic of Infectious Diseases, University of Milan, Milan, Italy, ⁸Department of Medicine, University of Udine, Udine, Italy, ⁹Division I of Infectious and Tropical Diseases, ASL Città di Torino, Torino, Italy, ¹⁰Infectious Disease Unit, ASST Papa Giovanni XXIII, Bergamo, Italy, ¹¹Infectious Diseases Clinic, Santa Maria della Misericordia Hospital, Università degli Studi di Perugia, Perugia, Italy, ¹²Infectious Diseases Unit, Azienda Ospedaliero-Universitaria Policlinico of Modena, Modena, Italy, ¹³Scientific Direction, National Institute for Infectious Diseases, Lazzaro Spallanzani IRCCS, Rome, Italy

OC 28 16.59-17.09 **Kidney transplantation in people living with HIV: ten-year experience in Modena**

A. Cervo¹, M. Albertini², I. Baldisserotto², F. Casari², E. Ghidoni², F. Romani², V. Todisco², G. Mori³, E. Franceschini^{1,2}, G. Donati^{2,3}, C. Mussini^{1,2}, G. Guaraldi^{1,2}

¹Infectious Diseases Unit, University Hospital of Modena, Modena, Italy, ²University of Modena and Reggio Emilia, Modena, Italy, ³Nephrology, Dialysis and Transplant Unit, University Hospital of Modena, Modena, Italy



OC 29 17.11-17.21 **HIV advanced naive: the forgotten test**

A. Narducci¹, R. Simac¹, I.F. Bottalico¹, S. Ferrara¹, T. Santantonio¹, C. Santoro², A. Saracino², A. Dargenio², R. Schiavoni³, L. Mezzogori³, A. Di Biagio³, A. Santoro⁴, G.C. Marchetti⁴, C. Tincati⁴, S. Lo Caputo¹

¹Infectious Diseases Unit, A.O.U. Policlinico Foggia, University of Foggia, Foggia, Italy, ²Infectious Diseases Unit, A.O.U. Consorziale Policlinico Bari, University of Bari, Bari, Italy, ³Infectious Diseases Unit, IRCCS San Martino, University of Genova, Genova, Italy, ⁴Infectious Diseases Unit, ASST Santi Paolo e Carlo, University of Milano, Milano, Italy

17.23-17.30 **Conclusion**

A. d'Arminio Monforte, Milano; S. Lo Caputo, Foggia

**ORAL COMMUNICATIONS** 16.30-17.30**AULA 6****Immunological features in people living with HIV**

Chairs: Giuseppe Nunnari (Messina), Daria Lucia Trabattoni (Milano)

16.30-16.35 **Introduction**

G. Nunnari, Messina; D.L. Trabattoni, Milano

OC 30 16.35-16.45 **Scant effect of cART on mucosal immune cells during acute HIV infection**

C. Tincati¹, V. Bono¹, M. Augello¹, R. Rovito¹, S. Marozin¹, A. Santoro¹, F. Bai¹, A. Muscatello², A. Bandera², A. Calcagno³, A. Gori⁴, S. Rusconi⁵, S. Nozza⁶, G. Marchetti¹

¹Clinic of Infectious Diseases and Tropical Medicine, San Paolo Hospital, ASST Santi Paolo e Carlo, Department of Health Sciences, University of Milan, Milan, Italy, ²Infectious Diseases Unit, Foundation IRCCS Ca' Granda Ospedale Maggiore Policlinico, Department of Pathophysiology and Transplantation, University of Milan, Milan, Italy, ³Unit of Infectious Diseases, Department of Medical Sciences at Amedeo di Savoia Hospital, University of Turin, Turin, Italy, ⁴Department of Clinical Sciences, Infectious Diseases and Immunopathology, L. Sacco Hospital, Università di Milano, Milan, Italy, ⁵Infectious Diseases Unit, ASST Ovest Milanese Ospedale di Legnano, Department of Biomedical and Clinical Sciences, University Milan, Legnano, Italy, ⁶Infectious Diseases Unit, Vita-Salute San Raffaele University, Milan, Italy

OC 31 16.47-16.57 **Viro-immunological reservoirs characterization in PBMCs and GALT in individuals on dual and triple-ART regimens**

S. Khan¹, M. Compagno², C. Matteucci¹, L. Piermatteo³, L. Benedetti², L. Duca¹, R. Scutari^{1,4}, V. Petrone¹, A. De Nicolò⁵, C.A. Chenwi^{1,6}, O. El Khalili¹, L. Ferrari², E. Teti², A. Bertoli^{1,7}, V. Malagnino², M. Iannetta², A. D'Avolio⁵, G. Di Perri⁵, V. Sviccheri³, R. Salpini³, S. Grelli^{1,7}, L. Sarmati², M. Andreoni², F. Ceccherini-Silberstein¹

¹Department of Experimental Medicine, University of Rome Tor Vergata, Rome, Italy, ²Department of System Medicine, Clinical Infectious Diseases, University of Rome Tor Vergata, Rome, Italy, ³Department of Biology, University of Rome Tor Vergata, Rome, Italy, ⁴Multimodal Laboratory Research Unit, Bambino Gesù Children's Hospital, IRCCS, Rome, Italy, ⁵Laboratory of Clinical Pharmacology and Pharmacogenetics, Department of Medical Sciences; University of Turin, Italy, ⁶Chantal Biya International Reference Center for Research on HIV and AIDS prevention and management (CIRCB), Yaounde, Cameroon, ⁷Virology Unit, Tor Vergata University Hospital, Rome, Italy

OC 32 16.59-17.09 **Oxidative stress in virologically suppressed people with HIV: Is dual antiretroviral therapy associated with a more favourable profile?**

F. Lombardi^{1,2}, S. Belmonti¹, A. Sanfilippo², A. Borghetti¹, V. Iannone², P.F. Salvo², M. Fabbiani^{3,4}, E. Visconti¹, S. Di Giambenedetto^{1,2}

¹Fondazione Policlinico Universitario A. Gemelli IRCCS, UOC Malattie Infettive, Roma Italia, ²Dipartimento di Sicurezza e Bioetica, Università Cattolica del Sacro Cuore, Roma, Italia, ³Department of Medical Biotechnologies, University of Siena, Siena, Italy, ⁴Infectious and Tropical Diseases Unit, Azienda Ospedaliera Universitaria Senese, Siena, Italy

OC 33 17.11-17.21 **Characterization of specific T-cell responses to a Three-Doses nonavalent HPV Vaccine Schedule in PLWH on ART**

E. Tortellini¹, M. Guardiani¹, F. Dominelli¹, C. Falvino², C. Fosso¹, M. Barresi¹, S. Corazza², S.G. De Maria², S. Garattini², A. Carrao^{1,2}, M.A. Zingaropoli¹, F. Mengoni¹, C. Giambi⁴, C. Del Borgo², R. Marocco², M. Lichtner^{2,3}

¹Department of Public Health and Infectious Diseases, Sapienza University of Rome, Rome, Italy, ²Infectious Diseases Unit, SM Goretti Hospital, Sapienza University of Rome, Latina, Italy, ³Department of NESMOS, Sapienza University of Rome, Rome, Italy, ⁴UOS Profilassi e sorveglianza malattie infettive, SM Goretti Hospital, Sapienza University of Rome, Latina, Italy

17.23-17.30 **Conclusion**

G. Nunnari, Messina; D.L. Trabattoni, Milano



**SHORT COMMUNICATIONS** 16.30-17.30**AULA 7****COVID-19 Unmasked: role of immunity and early treatment**

Chairs: Alessandra Bandera (Milano), Vincenzo Esposito (Napoli)

16.30-16.33 **Introduction**

A. Bandera, Milano; V. Esposito, Napoli

SC 31**16.33-16.40 SARS-CoV-2 vaccination influence in development of Long-COVID clinical phenotypes***M. Antonacci¹, P. Pasculli¹, M.A. Zingaropoli¹, F. Dominelli¹, Y.C. Fosso Ngangue¹, G.M. Masci², F. Iafrate², V. Panebianco², C. Catalano³, G. Galardo⁴, P. Palange¹, C.M. Mastroianni¹, M.R. Ciardi¹*¹Department of Public health and infectious diseases, Sapienza University of Rome, Rome, Italy, ²Department of Department of Human Neurosciences, Sapienza University of Rome, Rome, Italy, ³Department of Radiological, Oncological and Pathological Sciences, Policlinico Umberto I, Sapienza University of Rome, Rome, Italy, ⁴Medical Emergency Unit, Sapienza University of Rome, Policlinico Umberto I, Rome, Italy**SC 32****16.42-16.49 A machine learning tool to operationalize Intrinsic Capacity in predicting recovery from post-acute sequelae COVID-19***V. Guidetti¹, F. Motta¹, J. Milic², A. Tili³, V. Todisco³, M. Pellegrino³, A. Gallerani³, G. Cuomo³, M. Menozzi³, G. Mancini³, M. Cesari⁴, F. Mandreoli¹, G. Guaraldi^{2,3}*¹Department of Physical, Computer and Mathematical Sciences, University of Modena and Reggio Emilia, Modena, Italy, ²Department of Surgical, Medical, Dental and Morphological Sciences, University of Modena and Reggio Emilia, Modena, Italy, ³Department of Infectious Diseases, Azienda Ospedaliero-Universitaria, Policlinico of Modena, Modena, Italy, ⁴Department of Ageing and Life Course, World Health Organization**SC 33****16.51-16.58 MicroRNAs in SARS-CoV-2 infection: a comparative analysis in immunocompromised versus non-immunocompromised patients***C. Siniscalchi, A. Di Fraia, M. Starace, C. Minichini, S. Imbriani, C. Rizzozi, K. Geloshi, R. Astorri, A. Russo, C. Sagnelli, M. Pisaturo, N. Coppola*

Infectious Diseases Unit, Department of Mental Health and Public Medicine, University of Campania "Luigi Vanvitelli", Naples, Italy

SC 34**17.00-17.07 Impact of Early Antiviral Therapy on Time to SARS-CoV-2 Clearance in High-Risk COVID-19 Patients: A Propensity Score Matching Study***M. Colaneri^{1,2}, F. Fama¹, F. Fassio³, D. Holmes¹, G. Scaglione¹, A. Lai⁴, A. Gori^{1,2,4}, A. Riva⁵, M. Schiavini¹, for the Ospedale Luigi Sacco "COVID-19 Hotspot" study group*¹Infectious Diseases and Immunopathology, Department of Clinical Sciences, Università di Milano, L. Sacco Hospital, Milan, Italy, ²Centre for Multidisciplinary Research in Health Science (MACH), University of Milano, Milano, Italy, ³Department of Public Health, Experimental and Forensic Medicine, Unit of Biostatistics and Clinical Epidemiology, University of Pavia, Pavia, Italy, ⁴Department of Biomedical and Clinical Sciences, University of Milan, Milano, Italy, ⁵Institute of Infectious Diseases & Tropical Medicine, III Division, ASST Fatebenefratelli Sacco, Luigi Sacco Hospital, Milan, Italy**SC 35****17.09-17.16 Efficacy and safety of Sotrovimab vs oral antivirals in Omicron waves: a retrospective analysis***C. Cacace¹, G. Granata¹, A. Russo¹, M. Pisaturo¹, E. Allegorico², A. Troise², M. Vanni², F.G. Numis², N. Coppola¹*¹Department of Mental and Physical Health and Preventive Medicine, University of Campania "Luigi Vanvitelli", Naples, Italy, ²Emergency Unit, PO Santa Maria delle Grazie, Pozzuoli, Italy**SC 36****17.18-17.25 SARS-CoV-2-specific neutralizing activity and cytokine profile in newborns of vaccinated and/or infected and vaccinated mothers***C. Yanetti¹, M. Stracuzzi², M. Garziano^{1,3}, M. Micheloni², M.L. Murno¹, G.V. Zuccotti⁴, M. Clerici^{3,5}, V. Giacomei², D. Trabattani¹*¹University of Milan, Department of Biomedical and Clinical Sciences, Milan, Italy, ²Ospedale L. Sacco, Paediatric Infectious Disease Unit, Milan, Italy, ³University of Milan, Department of Pathophysiology and Transplantation, Milan, Italy, ⁴Ospedale dei Bambini V. Buzzi, Department of Paediatrics, Milan, Italy, ⁵IRCCS Don Carlo Gnocchi Foundation, Milan, Italy

17.27-17.30

Conclusion

A. Bandera, Milano; V. Esposito, Napoli





SPECIAL SESSION 17.35-18.30 ICAR-CROI Awards 2024

AULA LAZZATI

Chairs: Roberto Cauda (Roma), Massimo Galli (Milano), Adriano Lazzarin (Milano)

This session is devoted to Young Italian Researchers - under 40 - who had an abstract accepted at CROI 2024. The following prizes will be announced and awarded: two prizes for the best Clinical and Basic Science abstracts.

17.35-17.45 **Introduction**

R. Cauda, Roma

17.45-18.00 **The Italian Young Investigators who had an abstract accepted at CROI 2024**

M. Galli, Milano; A. Lazzarin, Milano



M. Augello San Paolo Hospital, ASST Santi Paolo e Carlo - University of Milan, Milan

- **Immune responses to an original/BA.4-5 Bivalent Booster of SARS-CoV-2 mRNA vaccine in PWH on ART**

Mentor: G.C. Marchetti (Milan)

N.B. Bana Niguarda Great Metropolitan Hospital - University of Milano Bicocca, Milan

- **A matter of time: factors associated with delayed nPEP initiation**

Mentors: M. Puoti (Milan), R. Rossotti (Milan)

E.N. Cavallari Policlinico Umberto I University Hospital, Rome

- **Evaluation of the performance of different high resolution Anoscopy triage strategies in MSM LWH**

Mentor: G. d'Ettore (Rome)

C.A. Chenwi, University of Rome Tor Vergata, Rome

- **Prevalence and resistance profiles of "unusual" HCV subtypes in Italy**

Mentor: F. Ceccherini Silberstein (Rome)

S. D'Anna, University of Rome Tor Vergata, Rome

- **Intrahepatic HDV activity is fueled by integrated HBV DNA-derived HBs independently from CccDNA size**

Mentor: V. Svicher (Rome)

A. D'Auria, Sapienza University of Rome, Rome

- **MPXV replication induces an IFN response and is suppressed by IFN-**

Mentor: C. Scagnolari (Rome)

C. Di Chiara, University of Padua, Padua

- **SARS-CoV-2 infection and hospitalization in immunocompromised children: a population-based study**

Mentor: C. Giaquinto (Padua)

F. Di Gennaro, University of Bari "Aldo Moro", Bari

- **Real-life experience on the use of Remdesivir: a propensity score matched analysis**

Mentor: A. Saracino (Bari)

M. Ferrara, Amedeo di Savoia Hospital - University of Turin, Turin

- **Antiretrovirals drug concentrations in post-mortem tissues for different body compartments: preliminary results from the Last Gift project**

Mentor: S. Bonora (Turin)

M. Fracella, Sapienza University of Rome, Rome

- **Synergistic effects of HIV, HPV, and Polyomaviruses on interferon response in male anal mucosa**

Mentor: G. d'Ettore (Rome)

M. Garziano, University of Milan, Milan

- **SARS-CoV-2 natural infection elicits cross-reactive immunity to OC43**

Mentor: M. Biasin (Milan)

S. Lazzarin, Luigi Sacco Hospital - University of Milan, Milan

- **Jarisch-Herxheimer reaction in patients with syphilis with or without prior antibiotic prophylaxis**

Mentor: D. Moschese (Milan)



M. Mazzitelli, University of Padua, Padua

- **Outcome of a multidimensional intervention for insomnia in a Cohort of people living with HIV**

Mentor: A. Cattelan (Padua)

V. Mazzotta, INMI Lazzaro Spallanzani IRCCS, Rome

- **Predictors of Mpox duration and severity in the Italian multicenter mpox ICONA Cohort**
- **Pooled analysis of randomized trials comparing drug efficacy for early COVID-19 during omicron waves**

- **Predictors of failure to COVID-19 early therapies and drugs efficacy comparison by emulation trial**

Mentor: A. Antinori (Rome)

L. Mezzadri, University of Milano-Bicocca - San Gerardo Hospital, Monza

- **Transaminase elevations among patients with occult HBV infection on two-drug antiretroviral regimens**

Mentor: G. Lapadula (Milan)

D. Moschese, Luigi Sacco Hospital - University of Milan, Milan

- **Plausibility of sexual behavior changes and role of vaccination in Mpox outbreak control among MSM**

Mentor: A. Gori (Milan)

A.R. Raccagni, Vita-Salute San Raffaele University, Milan

- **Lymphogranuloma venereum among men who have sex with men: 7 versus 21 days Doxycycline effectiveness**

Mentor: S. Nozza (Milan)

R. Rovito, University of Milan, Milan

- **Lipidome composition and weight changes at 48week 3TC-DTG and FTC/TAF/BIC: data of the ICONA Cohort**

Mentor: G.C. Marchetti (Milan)

A. Russo, University of Campania Luigi Vanvitelli, Naples

- **A model to eliminate viral Hepatitis infection in migrants: a prospective Study in Southern Italy**

Mentor: M. Pisaturo (Naples)

P.F. Salvo, Catholic University of the Sacred Heart, Rome

- **Seroprevalence of Mpox IgG antibodies in a Cohort of PLWH in Rome, during the 2022 outbreak**

Mentor: S. Di Giambenedetto (Rome)

I. Saulle, University of Milan, Milan

- **ERAPs control in vitro and ex-vivo SARS-CoV-2 infection by triggering antiviral immune response**

Mentor: M. Biasin (Milan)

M. Strano, Vita-Salute San Raffaele University, Milan

- **High plasma GFAP in older PWH with low Nadir CD4 supports legacy brain injury and reactive gliosis**

Mentor: P. Cinque (Milan)

C. Vanetti, University of Milan, Milan

- **Exacerbation of the RSV infectivity by SARS-CoV-2 in an in-vitro Co-Infection cellular model**

Mentor: M. Biasin (Milan)

18.00-18.30 **ICAR-CROI Awards for the best Clinical and Basic Science abstract 2024**

R. Cauda, Roma;
M. Galli, Milano; A. Lazzarin, Milano



**PARALLEL SESSION** 18.30-19.30**AULA 6****Screening HIV all'interno del Pronto Soccorso
(un progetto congiunto SIMIT/SIMEU)***Chairs:* Massimo Andreoni (Roma), Fabio De Iaco (Torino)18.30-18.45 **Saluti e introduzione**

M. Andreoni, Roma; F. De Iaco, Torino

18.45-19.10 **Lo screening HIV all'interno del pronto soccorso**

Referenti SIMEU: A. Fabbri, Napoli; B. Susi, Roma

Referenti SIMIT: F.M. Fusco, Napoli;

G.C. Marchetti, Milano; C. Tincati, Milano

19.10-19.20 **Discussione**19.20-19.30 **Conclusioni**

M. Andreoni, Roma; F. De Iaco, Torino

**PARALLEL SESSION** 18.30-19.30**AULA 7****Meeting Prestigio***Chair:* Antonella Castagna (Milano)**PARALLEL SESSION** 18.30-19.30**AULA GERMANIA****Sierocoinvolto***Chair:* Silvia Bellucci (Roma)

Con la partecipazione di Antonella Cingolani e Antonio di Biagio

Conigli Bianchi e PrEP in Italia presentano "Sierocoinvolto, la rivoluzione sessuale riparte dall'HIV" assieme alle persone che hanno scritto il libro. Un viaggio attraverso emozionanti racconti autobiografici che testimoniano quanto l'HIV sia molto di più che un tema meramente scientifico.

**PARALLEL SESSION** 08.00-09.00**AULA GERMANIA****Investigator Meeting of EDOLAS Study****Chairs:** Andrea Antinori (Roma), Franco Maggiolo (Fabro TR)08.00-08.15 **Introduzione**

A. Antinori, Roma; F. Maggiolo, Fabro TR

08.15-08.25 **Protocollo EDOLAS**

R. Gagliardini, Roma

08.25-08.40 **Status centri e status arruolamenti**

R. Gagliardini, Roma

08.40-08.55 **Discussione**08.55-09.00 **Conclusioni**

A. Antinori, Roma

**KEYNOTE LECTURES** 09.00-10.00**AULA LAZZATI****Chairs:** Andrea Cossarizza (Modena), Annalisa Saracino (Bari)09.00-09.30 **New emerging and re-emerging viral infection in Europe and in Italy**

E. Petersen, Arthus DK

Infectious diseases are dynamic. Outbreaks of known diseases continue to surprise us and new diseases appear, often from zoonotic reservoirs (H5N1 influenza, SARS, Nipah, MERS, SFTS, H7N9 influenza, arboviruses), and some became endemic. The lecture will address new emerging and re-emerging infection in Europe and in Italy.

09.30-10.00 **Insights into SARS-CoV-2: an immunological journey throughout imprinting, vaccine responses and risk of subsequent infections**

A. Sette, La Jolla USA

Immunological memory is the basis of protective immunity provided by vaccines and previous SARS-CoV-2 infections. Understanding the diverse mechanisms of developing immunological memory against SARS-CoV-2 could help to define post-infection immunity and address appropriate vaccination strategies. This lecture gives a deep insight into the multiple branches of the adaptive immune system (CD4, CD8 and B cells and antibodies) during SARS-CoV-2 infection.

**SYMPOSIUM** 10.05-11.05**AULA LAZZATI****From RCT to clinical practice: evidences in treatment and prevention of LA regimens****Chairs:** Annamaria Cattelan (Padova), Carlo Federico Perno (Roma) *With an unrestricted educational grant from ViiV Healthcare*

Antiretroviral therapy is evolving toward longer-duration administrations that can improve adherence and quality of life in PWVH. The first fully LA-comprehensive regimen for the treatment of HIV infection in virologically controlled patients, consisting of cabotegravir and rilpivirine, has recently become available; EMA also recently approved cabotegravir for the prevention of HIV infection for people at risk. The objective of this symposium will be to summarize the development of this regimen, the molecule, and the impact of the treatment in the Italian reality and the possible impact of the drug in the prevention setting.

10.05-10.20 **Introduction: new frontiers in cabotegravir development**

J. Thornhill, London UK

10.20-10.30 **Implementation of LA regimens in Italy: data from the ICONA Cohort**

A. Cingolani, Roma

10.30-10.45 **Real World Evidence of effectiveness of LA regimens**

C. Muccini, Milano; L. Taramasso, Genova

10.45-10.55 **Perspectives in PrEP LA regimens**

V. Mazzotta, Roma

10.55-11.05 **Discussion**

**EXPERT MEETING** 10.05-11.05**AULA 5****Vaccination in immunocompromised people: let's protect the vulnerable**

Chairs: Massimo Andreoni (Roma), Claudio Maria Mastroianni (Roma)

Discussants: Ivan Gentile (Napoli), Loredana Sarmati (Roma), Antonietta Spadea (Roma)

The immunocompromised patient is among the ones at greater risk of infections, and therefore vaccinations become fundamental for its management. Among vaccinations recommended for immunocompromised patients the main are against: herpes zoster, pneumococcus, gonorrhoea and meningococcus. In this process, the infectious disease specialist has a central role for both the patient and the other specialists involved. One of the strategic objectives of the Global Vaccine Action Plan is for the benefits of immunisation to be equitably extended to all people. This approach encompasses special groups at increased risk of vaccinepreventable diseases, such as those with chronic and immune-compromising medical conditions or at increased risk of disease due to immunosenescence. Despite the remarkable success of global vaccination programmes, vulnerable populations (VPs) – who are particularly susceptible to infectious diseases – are often undervaccinated and are at much higher risk of recurrence, complications than the general population. There is concern that the immunosuppressive medications used in these patients place them at even greater risk and therefore vaccinations such as herpes zoster, VRS, pneumococcus and meningococcus become fundamental in these population.

**ORAL COMMUNICATIONS** 10.05-11.05**AULA 6****Tailored approaches to antiretroviral therapy**

Chairs: Stefano Bonora (Torino), Antonio Cascio (Palermo)

10.05-10.10 **Introduction**

S. Bonora, Torino; A. Cascio, Palermo

OC 34 10.10-10.20 **Clinical outcome of switching to a dual drug regimen (2DR) vs. switching or remaining on a triple (3DR) regimen in the setting of a viral load ≤ 50 copies/mL**C. Mussini¹, A. Di Biagio², E. Quiros Roldan³, V. Mazzotta⁴, A. Costantini⁵, G. D'Ettorre⁶, A. Giacometti⁵, A. Vergori⁴, A. Tavelli⁷, M. Andreoni⁸, A. Castagna⁹, F. Maggiolo⁴, A. Antinori⁴, A. d'Arminio Monforte⁷, A. Cozzi-Lepri¹⁰, on behalf of the Icona Foundation Cohort Study

¹Infectious Diseases Unit, Azienda Ospedaliero-Universitaria Policlinico di Modena, Modena, Italy, ²Department of Specialist Medicine, Infectious Disease Clinic, IRCCS Ospedale Policlinico San Martino, Genoa, Italy, ³Department of Clinical and Experimental Sciences, Unit of Infectious and Tropical Diseases, University of Brescia and ASST Spedali Civili di Brescia, Brescia, Italy, ⁴Clinical and Research Infectious Diseases Department, National Institute for Infectious Diseases, Lazzaro Spallanzani IRCCS, Rome, Italy, ⁵Department of Biomedical Sciences & Public Health, Polytechnic University of Marche, Ancona, Italy, ⁶Department of Public Health and Infectious Diseases, Umberto I Hospital, Sapienza University of Rome, Rome, Italy, ⁷ICONA Foundation, Milan, Italy, ⁸Policlinico Tor Vergata, University of Rome "Tor Vergata", Rome, Italy, ⁹Infectious Diseases Unit, IRCCS San Raffaele Scientific Institute, Milan, Italy, ¹⁰Institute for Global Health, University College London, London, United Kingdom

OC 35 10.22-10.32 **Cumulative risk of discontinuation of modern first-line ART by reason for stopping and type of ART initiated: findings from the ICONA cohort**M. Poliseni¹, M. Giotta², F. Marascia^{3,4}, G. Micheli⁵, F. Portunato⁶, C. Seguiti⁷, E. Zappulo⁸, A. Vergori⁹, E. Quiros-Roldan⁷, S. Lo Caputo¹⁰, A. Saracino¹, A. Tavelli¹¹, A. Antinori⁹, A. d'Arminio Monforte¹¹, A. Cozzi-Lepri¹², on behalf of Icona Foundation Study Group

¹Clinic of Infectious Diseases, Department of Precision and Regenerative Medicine and Jonian Area (DiMePreJ), A.O.U.C. Policlinico di Bari, Bari, Italy, ²School of Medical Statistics and Biometry, Department of Interdisciplinary Medicine, University of Bari "Aldo Moro", Bari, Italy, ³Department of Health Promotion, Mother and Child Care, Internal Medicine and Medical Specialties "G. D'Alessandro", University of Palermo, Palermo, Italy, ⁴Infectious and Tropical Diseases Unit, Sicilian Regional Reference Center for the Fight against AIDS, AOU Policlinico "P. Giaccone", Palermo, Italy, ⁵Dipartimento di Sicurezza e Bioetica - Sezione di Malattie Infettive, Università Cattolica del Sacro Cuore, Rome, Italy, ⁶Infectious Diseases Unit, IRCCS AOU San Martino-IST, University of Genoa, Genoa, Italy, ⁷Fondazione Poliambulanza Istituto Ospedaliero, UOC Medicina Generale, Brescia, Italy, ⁸Department of Clinical Medicine and Surgery, Section of Infectious Diseases, University of Naples "Federico II", Naples, Italy, ⁹Clinical Infectious Diseases Department, National Institute for Infectious Diseases Lazzaro Spallanzani IRCCS, Rome, Italy, ¹⁰Clinic of Infectious Diseases, Department of Clinical and Surgical Sciences, University of Foggia, Foggia, Italy, ¹¹ICONA Foundation, Milan, Italy, ¹²Centre for Clinical Research, Epidemiology, Modelling and Evaluation (CREME), Institute for Global Health, University College London, London, UK

OC 36 10.34-10.44 **CD4 T-cell, CD4/CD8 ratio improvement and a general reduction in inflammatory biomarkers with low level viremia (LLV) up to Week 192 with Fostemsavir (FTR) based regimens in individuals with multidrug-resistant (MDR) HIV-1**Y. Spagnuolo¹, N. Gregori², I. Marcon², F. Du³, B. Li³, M. Wang³, M. Prakash⁴, A. Clark⁴

¹Infectious Diseases, IRCCS San Raffaele Scientific Institute, Milan, Italy, ²ViiV Healthcare, Italy, UK, ³GSK, Collegeville, PA, USA, ⁴ViiV Healthcare, Brentford, UK

OC 37 10.46-10.56 **Well-being in people with HIV after one year of long-acting cabotegravir and rilpivirine**E. Alberton^{1,2}, S. Diotallevi¹, R. Lolatto¹, T. Clemente^{1,2}, B. Trentacapilli^{1,2}, C. Candela^{1,2}, S. Nozza^{1,2}, N. Gianotti¹, A. Castagna^{1,2}, C. Muccini¹

¹IRCCS San Raffaele Scientific Institute, Infectious Disease, Milan, Italy, ²Vita-Salute San Raffaele University, Milan, Italy

10.58-11.05 **Conclusion**

S. Bonora, Torino; A. Cascio, Palermo





SHORT COMMUNICATIONS 10.30-11.30

AULA 7

Hot topics in the epidemiology of relevant chronic and respiratory viral infections

Chairs: Giulia Valeria Calvino (Roma), Giuseppe Lapadula (Monza)

10.30-10.33 **Introduction**

G.V. Calvino, Roma; G. Lapadula, Monza

SC 37 10.33-10.40 HIV infection among migrants present in Italy from 2012 to 2022: incidence and characteristics*V. Regine, L. Pugliese, B. Suligo*
Istituto Superiore di Sanità, Rome, Italy**SC 38 10.42-10.49 High rates of anal polyomaviruses and HPV co-infection among people living with HIV***M. Fracella¹, S. Passerini², G. Bugani², F. Frasca^{1,2}, A. D'Auria¹, E. Coratti¹, L. Santinelli², D. Benvenuto³, E.N. Cavallari², C.M. Mastroianni², G. Antonelli^{1,4}, A. Pierangeli¹, G. d'Ettore², V. Pietropaolo², C. Scagnolari¹*¹Laboratory of Virology, Department of Molecular Medicine, Sapienza University of Rome, Rome, Italy, ²Department of Public Health and Infectious Diseases, Sapienza University of Rome, Rome, Italy, ³Infectious Diseases Institute, Department of Safety and Bioethics, Università Cattolica del Sacro Cuore, Rome, Italy, ⁴Microbiology and Virology Unit, Sapienza University Hospital "Policlinico Umberto I", Rome, Italy**SC 39 10.51-10.58 Trends of toxoplasma antibody prevalence in naive people living with HIV in Italy. Data from the ICONA cohort***G. Bozzi¹, M. Giotta², A. Ranzani³, F. Conti⁴, A. Raimondi⁵, D. Tesoro⁶, A. Giacomelli⁷, A. Tavelli⁸, M.C. Moioli⁵, N. Bobbio⁹, G. Toti¹⁰, A. Gori¹¹, A. Di Biagio¹², A. Bandera¹, A. d'Arminio Monforte⁸, on behalf of the ICONA cohort*¹Clinic of Infectious Diseases, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy, ²School of Medical Statistics and Biometry, Department of Interdisciplinary Medicine, University of Bari "Aldo Moro", Bari, Italy, ³IRCCS "San Gerardo dei Tintori", Monza, Italy, ⁴Infectious Diseases Unit, Alessandro Manzoni Hospital, Lecco, Italy, ⁵Department of Infectious Diseases, ASST Grande Ospedale Metropolitano Niguarda, Milan, Italy, ⁶Unit of Infectious Diseases, ASST Santi Paolo e Carlo, Milan, Italy, ⁷III Infectious Diseases Unit, ASST FBF-Sacco, Milan, Italy, ⁸ICONA Foundation, Milan, Italy, ⁹Department of Infectious Diseases, Galliera Hospital, Genoa, Italy, ¹⁰Infectious Diseases Department SOC 1, USL Centro Firenze, Santa Maria Annunziata Hospital, Florence, Italy, ¹¹Department of Biomedical and Clinical Sciences L. Sacco, University of Milan, ASST FBF-Sacco, Milan, Italy, ¹²Infectious Diseases Clinic, IRCCS Policlinico San Martino Hospital, Genoa, Italy**SC 40 11.00-11.07 Epidemiological evolution of Hepatitis C Virus infection and treatment outcomes in Tuscany (Italy): a comprehensive analysis spanning the direct-acting antiviral era and the impact of the COVID-19 pandemic***M.P. Tramonti Fantozzi¹, L. Ceccarelli², E. De Vita¹, D. Petri¹, P. Colombatto³, C. Stasi⁴, B. Rossetti⁵, M. Brunetto⁶, C. Bianco⁷, D. Redi⁷, D. Tacconi⁷, A. Agostini⁸, F. Panza⁸, M. Fabbiani⁸, S. Modica⁸, S. Moneta⁹, S. Iacopini⁹, S. Luchi⁹, S. Chigiotti⁹, G. Ottaviano⁹, C. Nencioni⁹, A.L. Zignego¹⁰, E. Mariabelli¹¹, P. Pierotti¹¹, P. Blanc¹¹, R. Berni¹², C. Silvestri¹², L. Tavoschi¹*¹Department of Translational Research and of New Surgical and Medical Technologies, University of Pisa, Pisa, Italy, ²Infectious Diseases Unit, Department of Medical and Surgical Science, Hospital S. Orsola-Malpighi, University of Bologna, Bologna, Italy, ³Hepatology Unit, Pisa University Hospital, Pisa, Italy, ⁴Careggi University Hospital, Florence, Italy, ⁵Division of Infectious Diseases, AUSL Toscana Sud Est, Grosseto Hospital, Grosseto, Italy, ⁶Department of Clinical and Experimental Medicine, University of Pisa and Hepatology Unit, Pisa University Hospital, Pisa, Italy, ⁷Division of Infectious Diseases, Arezzo Hospital, Arezzo, Italy, ⁸Infectious and Tropical Diseases Unit, Siena University Hospital, Siena, Italy, ⁹Division of Infectious Diseases and Hepatology San Luca Hospital, AUSL Toscana Nord Ovest, Lucca, Italy, ¹⁰Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy, ¹¹Division of Infectious Diseases 1-2, AUSL Toscana Centro, Florence, Italy, ¹²Epidemiology Unit, Tuscany Regional Health Agency, Florence, Italy**SC 41 11.09-11.16 Cases of untyped Influenza A virus in northern Italy***I. Giberti¹, F. Stefanelli², N. Randazzo², B. Galano², G. Garzillo¹, G. Guarona¹, V. Chessa², R. Qosja², S. Varesano¹, B. Giusto², V. Ricucci²*¹Department of Health Sciences (DiSSal), University of Genoa, Genoa, Italy, ²Hygiene Unit, IRCCS Ospedale Policlinico San Martino, Genoa, Italy**SC 42 11.18-11.25 Respiratory syncytial virus viral load and co-infection in a very large cohort of pediatric patients, which role in the disease severity?***R. Scutari^{1,2}, V.C. Di Maio², L. Colagrosso², L. Forquè^{1,2}, G. Linardos², L. Coltella², S. Ranno², E. Galeno², M. Pisani², A.C. Vittucci³, A. Villani², C. Russo², C.F. Perno^{1,2}*¹Multimodal Research Area, Microbiology and Diagnostics of Immunology Unit, Bambino Gesù Children's Hospital IRCCS, Rome, Italy, ²Microbiology and Diagnostic Immunology Unit, Bambino Gesù Children's Hospital IRCCS, Rome, Italy, ³Department of Emergency, Acceptance and General Pediatrics, Bambino Gesù Children's Hospital, Rome, Italy11.27-11.30 **Conclusion**

G.V. Calvino, Roma; G. Lapadula, Monza



**SYMPOSIUM** 11.10-12.35**Deep into HIV treatment Guidelines****AULA LAZZATI****Chairs:** Antonella Castagna (Milano), Annamaria Cattelan (Padova)**Discussants:** Roy M. Gulick (New York USA), Esteban Martinez (Barcelona ES)

Advances in antiretroviral therapy have changed the life expectancy of PWH which is now almost comparable to that of HIVnegative individuals. Following a long-life therapy involves facing various challenges, such as choosing the initial therapy, optimizing it if necessary, and developing alternative regimens in case of treatment failure ; this is made possible by the availability of new drugs with different mechanisms of action and different modes of administration. The aim of this symposium is to provide the most up-to-date information on current guidelines for the antiretroviral treatment and give insights into ART strategies and drugs. Discussion and comparison between members/authorities of international HIV treatment guideline and (young) physicians who daily address these issues will lead to this achievement.

11.10 - 11.15	Introduction	A. Castagna, Milano; A. Cattelan, Padova
	Critical issues and solutions within the DHHS and EACS guidelines. Focus on:	
11.15-11.25	Initial antiretroviral therapy	A. Giacomelli, Milano
11.25-11.35	Discussion	R.M. Gulick, New York USA; E. Martinez, Barcelona ES
11.35-11.45	Optimization of antiretroviral therapy	A. Borghetti, Pisa
11.45 - 11.55	Discussion	R.M. Gulick, New York USA; E. Martinez, Barcelona ES
11.55-12.05	Virological failure	V. Spagnuolo, Milano
12.05-12.15	Discussion	R.M. Gulick, New York USA; E. Martinez, Barcelona ES
12.15-12.25	Antiretroviral therapy in pregnancy	L. Taramasso, Genova
12.25-12.35	Discussion	R.M. Gulick, New York USA; E. Martinez, Barcelona ES

**MEET THE EXPERT AND ORAL COMMUNICATIONS** 11.10-12.50 **AULA BAUSOLA****Critical clinical aspects underlining the control of viral hepatitis and emerging viral infections****Chairs:** Giampiero Carosi (Brescia), Carlo Torti (Roma)

11.10-11.25	Programs of microelimination of HCV infection: which setting and who to reach?	M. Andreoni, Roma
	<i>An estimated 130-170 million people worldwide are infected with the hepatitis C virus, and there are about 2.8 million new infections each year. In Italy, there are currently about 100 new cases (incidence) of acute hepatitis giving a clinically manifest form each year, while the percentage of the Italian population (prevalence) that has a persistent (chronic) infection is not precisely known. It is believed, however, that this percentage is higher than 3 percent in people born before 1950 and increases progressively with age, but is considerably lower in younger generations. Moreover, the prevalence of the disease is higher in southern Italy and the islands than in central and northern regions. Due to the possibility of using new drugs that are extremely effective against HCV, WHO has launched a project to eradicate HCV infection by 2030. Italy is currently engaged with a screening campaign for the emergence of the undeclared in order to reach the goal indicated by WHO.</i>	
11.25-11.30	Discussion	
11.30-11.45	Recent progress in understanding dengue	E. Nicastrì, Roma
	<i>Summer 2023 saw as many as 4 introductions of different Dengue viral genotypes in our country: 3 small outbreaks in the Lazio region and one in the Lombardy region. The identification for the first time of dozens of dengue cases in a major European metropolitan city such as Rome deserves reflections in terms of training of frontline health workers, availability of diagnostic tests including rapid ones, early identification of cases, and integration with territorial and regional epidemiological prevention services, municipal services for pest control, and regional zoophylactic institutes for other vector control measures. Last but not least, the current epidemic in Central and South America is surprising in size and persistence of the wide circulation of Dengue virus in two consecutive years: several factors could explain the phenomenon, which, however, remains unexpected.</i>	
11.45-11.50	Discussion	
11.50-11.55	Oral Communications introduction	G. Carosi, Brescia; C. Torti, Roma



- OC 38** 11.55-12.05 **Persistent HBV cryptic activity is frequently revealed among anti-HBc positive/HBsAg negative people living with HIV infection during HBV-active ART and can jeopardize the full control of HIV replication**
 L. Piermatteo¹, R. Salpini¹, S. D'Anna¹, C. Castelli¹, I. Grossi¹, T. Mulas², A. Di Lorenzo², A. Bertoli^{3,4}, M. Iannetta², L. Sarmati¹, V. Svicher¹, V. Malagnino²
¹Department of Biology, Tor Vergata University, Rome, Italy, ²Department of System Medicine, Tor Vergata University, Rome, Italy, ³Department of Experimental Medicine, Tor Vergata University, Rome, Italy, ⁴Virology Unit, Tor Vergata University Hospital, Rome, Italy
- OC 39** 12.07-12.17 **Chronic HDV coinfection (CHD) is characterized by a different HBsAg isoforms composition respect to HBV mono-infection with higher middle- and large-HBs levels paralleling the replicative and cytolytic activity of HDV**
 A. Magnapera¹, L. Piermatteo¹, S. D'Anna¹, A. Olivero², L. Duca³, G. Torre¹, C. Castelli¹, E. Teti⁴, A. Di Lorenzo⁴, V. Malagnino⁴, M. Iannetta⁴, L. Baiocchi⁵, S. Francioso⁵, I. Lenci⁵, F. Ceccherini-Silberstein³, M. Milella⁶, A. Saracino⁶, A. Ciancio², L. Sarmati⁴, P. Lampertico⁷, M. Rizzetta², G.P. Caviglia², V. Svicher¹, R. Salpini¹
¹Department of Biology, University of Rome Tor Vergata, Rome, Italy, ²Department of Medical Sciences, University of Turin, Turin, Italy, ³Department of Experimental Medicine, University of Rome Tor Vergata, Rome, Italy, ⁴Department of Systems Medicine, Infectious Disease Clinic, Tor Vergata University, Rome, Italy, ⁵Hepatology Unit, Policlinico Tor Vergata, Rome, Italy, ⁶Department of Biomedical Sciences and Human Oncology, Clinic of Infectious Diseases, University of Bari "Aldo Moro", Bari, Italy, ⁷Division of Gastroenterology and Hepatology, Foundation IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy
- OC 40** 12.19-12.29 **Investigating seroprevalence of IgG against Dengue virus (DENV) in a cohort of people with HIV (PLWH) in a non-endemic country after an autochthonous outbreak: are we ready for next season?**
 P.F. Salvo¹, F. Lombardi², A. Sanfilippo, V. Massaroni, G. Baladin², V. Iannone¹, D. Farinacci², R.J. Steiner¹, C. Torti^{1,2}, S. Di Giambenedetto^{1,2}
¹Dipartimento di Scienze Mediche e Chirurgiche, Università Cattolica del Sacro Cuore, Rome, Italy, ²UOC Malattie Infettive, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome, Italy
- OC 41** 12.31-12.41 **Viral Respiratory Infections in Patients with Haematological Diseases over 10 Years: a single-center Experience**
 P. Bono¹, A. Parisi¹, M. Sciumè², G. Bozzi³, C. Biassoni¹, G. Giacomel¹, A. Valzano¹, S. Allaria¹, E. Tagliaferri², R. Ungaro³, A. Bandera^{3,4}, N.S. Fracchiolla², A. Callegaro¹, C. Alteri^{1,5}
¹Clinical Microbiology and Virology Unit, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milano, Italy, ²Hematology Unit, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milano, Italy, ³Infectious Diseases Unit, Department of Internal Medicine, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milano, Italy, ⁴Department of Pathophysiology and Transplantation, School of Medicine and Surgery, University of Milan, Italy, ⁵Department of Oncology and Hemato-Oncology, University of Milan, Italy

12.43-12.50 **Conclusion**

G. Carosi, Brescia; C. Torti, Roma

**SPECIAL SESSION** 11.10-12.10**AULA 5****Vaccines Pipeline: a glimpse of the future**

Chairs: Giulia Carla Marchetti (Milano), Maurizio Zazzi (Siena)

An open discussion between researchers and R&D representatives of pharmaceutical companies that aims to outline and shape the future of vaccines development in the next decade.

- 11.10-11.20 **Introduction: "Vaccine development, regulatory aspects, and marketing authorisation"** A. Ammassari, Roma
- 11.20-11.30 **Ennio De Gregorio**, Head of Research and Development Center Vaccines Italy at GSK
- 11.30-11.40 **Mel Kohn**, Executive Director Medical Affairs at MSD
- 11.40-11.50 **Alessandro Zollo**, Medical Head Vaccines & Immunotherapy Italy at AstraZeneca
- 11.50-12.10 **Q&A and Discussion**



**ORAL COMMUNICATIONS** 11.10-12.10**AULA 6****Awareness in Sexual Health: U=U and prevention**

Chairs: Salvatore Cecere (Bologna), Benedetto Maurizio Celesia (Catania)

11.10-11.15 **Introduction**

S. Cecere, Bologna; B.M. Celesia, Catania

OC 42 11.15-11.25 **Information and Misinformation on HIV and the Narration of the Evidence U=U: a mixed method analysis on social media in Italy***V. Casigliani¹, A. Santoro², A. Chinelli¹, A. Agostini², G. Giupponi³, F. Zollo², L. Tavoschi¹*¹Department of Translational research and new technologies in Medicine and Surgery, University of Pisa, Pisa, Italy, ²Ca' Foscari University of Venice, Venezia, Italy, ³Lila Onlus - Italian League for the Fight against AIDS, Italy**OC 43** 11.25-11.35 **"U=U impossibile sbagliare" awareness campaign: impact assessment among PLWH***A. Tavelli¹, A. Cingolani², L. Cosmaro³, S. De Benedittis¹, N. Frattini⁴, G.V. Calvino⁵, F.M. Fusco⁶, A. Costantini⁷, A. Di Biagio⁸, B.M. Celesia⁹, M. Guastavigna¹⁰, M. Cernuschi^{11,4}, D. Calzavara¹¹, A. Antinori¹², F. Von Schloesser¹³, A. d'Arminio Monforte¹, on behalf of Icona Foundation Study Group*¹ICONA Foundation, Milan, Italy, ²Clinic of Infectious Diseases, Catholic University, Rome, Italy, ³LILA ONLUS, Milan, Italy, ⁴A.S.A. ONLUS, Milan, Italy, ⁵ANLAIDS ONLUS NAZIONALE, Rome, Italy, ⁶P.O. 'D. Cotugno', Azienda Ospedaliera dei Colli, Naples, Italy, ⁷Clinical Immunology Unit, Azienda Ospedaliero Universitaria delle Marche - Università Politecnica delle Marche, Ancona, Italy, ⁸Infectious Disease Clinic, IRCCS Ospedale Policlinico San Martino, Genoa, Italy, ⁹Unit of Infectious Diseases, ARNAS Garibaldi Hospital, University of Catania, Catania, Italy, ¹⁰S.C. Malattie Infettive e Tropicali I, ASL Città di Torino, Amedeo di Savoia Hospital, Turin, Italy, ¹¹Milano Checkpoint ETS, Milan, Italy, ¹²Clinical Infectious Diseases Department, National Institute for Infectious Diseases Lazzaro Spallanzani IRCCS, Rome, Italy, ¹³NADIR Onlus, Rome, Italy11.35-11.39 **Discussion****OC 44** 11.39-11.49 **Loss of "U=U status" in Women with HIV: insights into possible reasons for a higher risk compared to Men***R. Fontana Del Vecchio¹, C. Marelli², A. Tavelli³, C. Costa⁴, V. Barocci⁵, S. Gambino⁶, J. Testa⁷, M. Merelli⁸, E. Zappulo⁹, L. Taramasso², G. Madeddu¹⁰, C. Pinnetti¹¹, A. Cingolani¹², A. d'Arminio Monforte³, A. Cozzi-Lepri¹³ on behalf of Icona Foundation Study Group*¹Department of Infectious Diseases, Umberto I Public Hospital, Siracusa, Italy, ²Department of Specialist Medicine, Infectious Disease Clinic, IRCCS Ospedale Policlinico San Martino, Genoa, Italy, ³ICONA Foundation, Milan, Italy, ⁴Infectious Diseases Department, SOC 1, USL Centro Firenze, Santa Maria Annunziata Hospital, Florence, Italy, ⁵Department of Biomedical Sciences & Public Health, Polytechnic University of Marche, Ancona, Italy, ⁶Infectious Diseases Unit, Bolzano Hospital, Bolzano, Italy, ⁷Infectious Diseases Unit, Busto Arsizio Hospital, ASST Valle Olona, Busto Arsizio (VA), Italy, ⁸Azienda Sanitaria Universitaria del Friuli Centrale, Udine, Italy, ⁹Department of Clinical Medicine and Surgery, Section of Infectious Diseases, University of Naples "Federico II", Naples, Italy, ¹⁰Unit of Infectious Disease, Department of Medicine, Surgery and Pharmacy, University of Sassari, Sassari, Italy, ¹¹Clinical Department of Infectious Diseases, National Institute for Infectious Diseases Lazzaro Spallanzani IRCCS, Rome, Italy, ¹²Clinic of Infectious Diseases, Catholic University, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome, Italy, ¹³Centre for Clinical Research, Epidemiology, Modelling and Evaluation (CREME), Institute for Global Health, University College London, London, UK**OC 45** 11.49-11.59 **DoxyPEP is already used in two community-based centers in Bologna and Rome. An explorative survey***M. Stizoli¹, M. Barracchia¹, S. Mattioli², L. del Negro¹, F. Leserri¹*¹Plus Roma, Roma, Italy, ²Plus Nazionale, Bologna, Italy11.59-12.03 **Discussion**12.03-12.10 **Conclusion**

S. Cecere, Bologna; B.M. Celesia, Catania

**THEMED DISCUSSIONS** 11.35-12.35**AULA 7****Because the virus matters**

Chairs: Bianca Bruzzone (Genova), Annalisa Mondì (Roma)

11.35-11.38 **Introduction**

B. Bruzzone, Genova; A. Mondì, Roma

TD 11 11.38-11.45 **Viral Blips among People Living with HIV following recommended vaccines***B. Trentacapilli¹, A.R. Raccagni¹, S. Diotallevi², R. Lolatto², D. Canetti², E. Messina², V. Spagnuolo^{1,2}, M. Ranzenigo², M. Bottanelli¹, C. Maci¹, A. Castagna^{1,2}, S. Nozza^{1,2}*¹Infectious Diseases Unit, Vita-Salute San Raffaele University, Milan, Italy, ²Infectious Diseases Unit, IRCCS San Raffaele Scientific Institute, Milan, Italy**2024**

- TD 12** 11.45-11.52 **Clinical presentation of newly diagnosed PWH in the last four-years period post COVID-19 pandemic, in a single center in Rome: a retrospective observational study**
V. Iannone¹, A. Carbone¹, G. Lenzi¹, G. Baldin², P.F. Salvo¹, R. Passerotto², A. Cingolani^{1,2}, S. Di Giambenedetto^{1,2}, C. Torti^{1,2}, F. Lombardi²
¹Catholic University of Sacred Heart, Infectious Diseases Unit, Rome, Italy, ²UOC Infectious Diseases, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy
- TD 13** 11.52-11.59 **Clinical and Immunovirological Features of Potential Post Treatment HIV Controllers**
E. Focà¹, S. Rapino¹, M. Ferrara², G. Tiecco¹, F. Bai³, B. Fioretti¹, T. Roatta², M. Sala³, S. Bonora², G. Marchetti³, A. Calcagno²
¹Division of Infectious and Tropical Diseases, ASST Spedali Civili Hospital, University of Brescia, Brescia, Italy, ²Unit of Infectious Diseases, Department of Medical Sciences, University of Torino, Torino, Italy, ³Division of Infectious Diseases, ASST Santi Paolo e Carlo Hospital, University of Milan, Milan, Italy
- TD 14** 11.59-12.06 **Two-drugs regimens did not influence HIV-1 DNA in people living with HIV**
A. Nava¹, R. Rossotti², G. Cavazza³, E. Nicolini⁴, A. Raimondi², A. Corbetta¹, E. Franchetti¹, L. Chianura², C. Moio², M. Puoti², C. Vismara¹, D. Fanti¹
¹SC. Clinical Microbiology- ASST Grande Ospedale Metropolitano Niguarda, Milan, Italy, ²SC. Infectious Diseases – ASST Grande Ospedale Metropolitano Niguarda, Milan, Italy, ³School of Medicine and Surgery, University Bicocca, Milan, Italy, ⁴Resident Student Microbiology and Virology; University of Milan, Italy
- TD 15** 12.06-12.13 **Virological performance and resistance-associated mutations in people living with HIV switching to bictegrovir/emtricitabine/tenofovir alafenamide in the Italian ARCA cohort: the BIC-BARRIER Study**
L. Pezzati¹, F. Conti², A. Cozzi Lepri³, W. Gennari⁴, C. Mussini⁵, E. Pontali⁶, A. Volpe⁷, I. Vicenti⁸, A. Saracino⁷, B. Rossetti⁹, B. Bruzzone¹⁰, A. Shallvari¹¹, L. Albini¹², D. Corsini¹¹, M. Zazzi⁸, S. Rusconi¹³, ARCA Study Group
¹ASST Ovest Milanese, Infectious Diseases Unit, Legnano, Italy, ²ASST Lecco, Infectious Diseases Unit, Lecco, Italy, ³Institute for Global Health - UCL, Centre for Clinical Research, Epidemiology, Modelling and Evaluation (CREME), London, United Kingdom, ⁴Azienda Ospedaliero-Universitaria di Modena, SDD Virologia - Microbiologia molecolare, Modena, Italy, ⁵Università degli Studi di Modena-Reggio Emilia, Infectious Diseases Unit, Modena, Italy, ⁶Ente Ospedaliero Ospedali Galliera, Infectious Diseases Unit, Genova, Italy, ⁷Università degli Studi di Bari "Aldo Moro", Infectious Diseases Unit, Bari, Italy, ⁸Università degli Studi di Siena, Dipartimento di Biotecnologie Mediche, Siena, Italy, ⁹USL Sud-Est Toscana, Ospedale della Misericordia, Infectious Diseases Unit, Grosseto, Italy, ¹⁰Azienda Ospedaliero-Universitaria San Martino, Hygiene Unit, Genova, Italy, ¹¹InformaPRO S.r.l., EuResist Network GEIE, Roma, Italy, ¹²Gilead Sciences Srl, Milano, Italy, ¹³DIBIC, University of Milan, Legnano, Italy
- 12.13-12.35 **Discussion**

**EXPERT MEETING** 12.35-13.35**AULA 5****The unheard voices. Perspectives of "difficult" patients**

Chairs: Mario Cascio (Milano), Giovanni Guaraldi (Modena)

With an unrestricted educational grant from ViiV Healthcare

In recent years, antiretroviral therapies have become extremely effective with a good tolerability profile. Much attention is now paid to the impact of the disease and drugs on the quality of life of people living with HIV, and increasingly PROs are part of evaluations of a treatment regimen. There are particularly complex situations - HTE, frail populations - where the quality aspect may sometimes not be the focus by prioritizing efficacy. In this symposium we want to draw attention to the importance of using PROs in these populations as well, considering the availability of new treatments.

- 12.35-12.50 **From collection of PROs to identification of novel outcomes** A. Cingolani, Roma
- 12.50-13.05 **Evidence and perspective from patients engagement studies** A. Milinkovic, London UK
- 13.05-13.20 **HTE patients: which outcomes to consider from patient' perspective?** A. Castagna, Milano
- 13.20-13.35 **Discussion**



**SYMPOSIUM** 12.40-13.40**AULA LAZZATI****HIV, lights and shadows on new treatment strategies:
focus on new drug classes****Chairs:** Francesca Ceccherini Silberstein (Roma), Stefano Rusconi (Legnano MI)

Antiretroviral therapy has changed the life expectancy of people with HIV infection (PWH) and drastically improved their quality of life. New drugs for remaining needs are flourishing and progressively reaching the clinical arena. Nevertheless, there are still many pending issues related to their management and efficacy. One of the key topics is the definition of their resistance profile, in vitro and in vivo, in different groups of people with HIV, either naive or drug-experienced; secondly, how to properly assess their pharmacological properties; thirdly, how to leverage new methodologies to determine drug resistance to these drugs in clinical practice. This symposium will shed light on these very important matters for the proper management of people with HIV.

12.40-12.55	In vitro and in vivo efficacy	R. Gagliardini, Roma
12.55-13.00	Discussion	
13.00-13.15	Pharmacology	A. D'Avolio, Torino
13.15-13.20	Discussion	
13.20-13.35	Resistance	F. Saladini, Siena
13.35-13.40	Discussion	

**SYMPOSIUM** 12.55-13.55**AULA BAUSOLA****New knowledge in chronic viral infections (HBV, HDV, CMV)****Chairs:** Nicola Coppola (Napoli), Loredana Sarmati (Roma)

New important evidences are available on some chronic viral infection. As regard HBV infection the use of new and different therapeutical targets may allow a functional cure of an infection that afflict millions of persons in the world. Recently, the introduction of bulevirtide and the study on other antiviral targets open new scenario in the management of HDV chronic hepatitis. Finally, it seems to be the time to introduce an antimicrobial stewardship strategy also for CMV infection.

12.55-13.10	From virological suppression to HBV functional cure: is an achievable goal so far by the new drugs?	M. Brunetto, Pisa
13.10-13.15	Discussion	
13.15-13.30	HDV from pathogenesis to novel therapies	M. Puoti, Milano
13.30-13.35	Discussion	
13.35-13.50	Is this the time to introduce CMV stewardship?	G. Gentile, Roma
13.50-13.55	Discussion	

**SHORT COMMUNICATIONS** 13.00-13.50**AULA 7****Bridging innate and adaptive immunity in viral infections****Chairs:** Saverio Parisi (Padova), Ilaria Vicenti (Siena)

13.00-13.03	Introduction	S. Parisi, Padova; I. Vicenti, Siena
-------------	---------------------	--------------------------------------

- SC 43** 13.03-13.10 **Modulation of Cytomegalovirus (CMV) T cells response in PLWH after switching to long-acting (LA) cabotegravir plus rilpivirine**
M. Guardiani¹, E. Tortellini¹, A. Carraro¹, M.A. Zingaropoli¹, F. Dominelli¹, C. Falvino¹, S. Garattini¹, P. Zuccalà², R. Marocco², G. Mancarella², F. Mengoni¹, O. Turriziani³, V. Vullo¹, C.M. Mastroianni¹, C. Del Borgo², M. Lichtner^{2,4}
¹Sapienza University of Rome, Department of Public Health and Infectious Diseases, Rome, Italy, ²Sapienza University of Rome, Infectious Diseases Unit, SM Goretti Hospital, Latina, Italy, ³Sapienza University of Rome, Laboratory of Virology, Department of Molecular Medicine, Rome, Italy, ⁴Sapienza University of Rome, Department of Neurosciences, Mental Health, and Sense Organs, NESMOS, Rome, Italy



- SC 44** 13.12-13.19 **T cells profile in persons living with HIV (PLWH) with Progressive Multifocal Leucoencefalopathy (PML)**
 E. Cimini¹, M. Chiuchiarelli², E. Tartaglia³, S. Notari¹, R. Casetti¹, A. Mondì⁴, F. Cecilia⁴, F. Frondizi², E. Matteini², C. Torti^{2,5}, G. Matusali³, F. Maggi³, A. Antinori⁴, A. Cingolani^{2,5}, C. Pinnetti⁴
¹Laboratory of Cellular Immunology and Pharmacology, INMI-IRCCS Lazzaro Spallanzani, Rome, Italy, ²Dipartimento di Scienze Mediche e Chirurgiche, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome, Italy, ³Laboratory of Virology, INMI-IRCCS Lazzaro Spallanzani, Rome, Italy, ⁴Clinical and Research Infectious Diseases Department, INMI-IRCCS Lazzaro Spallanzani, Rome, Italy, ⁵Dipartimento di Sicurezza e Bioetica - Sezione di Malattie Infettive, Università Cattolica del Sacro Cuore, Rome, Italy
- SC 45** 13.21-13.28 **Comparing T-Spot and In-House IGRA for Assessing SARS-CoV-2-Specific Cell-Mediated Immunity**
 L. Benedetti¹, L. Ferrari², A. Ruggiero³, N. Braccialarghe¹, L. Piermatteo⁵, L. Sarmati^{1,2}, A.M. Geretti^{1,2,4}, M. Iannetta¹
¹Department of Systems Medicine, University of Rome Tor Vergata, Rome, Italy, ²Infectious Diseases Unit, Fondazione PTV, University of Rome Tor Vergata, Rome, Italy, ³Department of Neuroscience, Biomedicine and Movement Sciences, University of Verona, Verona, Italy, ⁴School of Immunity and Microbial Sciences, King's College London, London, United Kingdom, ⁵Department of Biology, University of Rome Tor Vergata, Rome, Italy
- SC 46** 13.30-13.37 **Vδ2 T cells effector response in PLWH and PLWoH up to three months from mpox infection**
 E. Cimini¹, E. Tartaglia², A. Coppola¹, S. Notari¹, V. Mazzotta³, G. Matusali², R. Casetti¹, G. Grassi¹, A. Mondì³, A. Oliva³, S. Gili¹, F. Cristofanelli¹, M. Tempestilli¹, G. Prota⁴, E. Girardi⁵, F. Maggi², A. Antinori³
¹Laboratory of Cellular Immunology and Pharmacology, INMI-IRCCS L. Spallanzani, Rome, Italy, ²Laboratory of Virology, INMI-IRCCS L. Spallanzani, Rome, Italy, ³Clinical Department, INMI-IRCCS L. Spallanzani, Rome, Italy, ⁴Biological bank, INMI-IRCCS L. Spallanzani, Rome, Italy, ⁵Scientific Direction, INMI-IRCCS L. Spallanzani, Rome, Italy
- SC 47** 13.39-13.46 **Are neutralizing autoantibodies to type I interferon novel disease determinants in people living with HIV?**
 G. Bugani¹, F. Frasca^{1,2}, A. D'Auria², M. Fracella², L. Maddaloni¹, L. Santinelli¹, G. Ceccarelli¹, C.M. Mastroianni¹, A. Pierangeli², O. Turriziani², G. Antonelli², G. d'Ettore¹, C. Scagnolari²
¹Department of Public Health and Infectious Diseases, Sapienza University of Rome, Italy, ²Virology Laboratory, Department of Molecular Medicine, Sapienza University of Rome, Italy

13.48-13.50 **Conclusion**

S. Parisi, Padova; I. Vicenti, Siena

**PARALLEL SESSION** 13.20-14.20**AULA GERMANIA****Meeting Community - Report campaign "U=U: impossibile sbagliare"**

Chair: Filippo Schloesser (Roma)

13.20-13.50 **Report campaign "U=U: impossibile sbagliare"**

D. Calzavara, Milano; N. Frattini, Milano

13.50-14.20 **Impact of the Italian campaign "U=U: impossibile sbagliare" on people with HIV housed in CICA's network accommodation**

L.A.R. Rancilio, Milano

**MEET THE EXPERT DREAM AND THEMED DISCUSSIONS** 13.40-14.50 **AULA 5****Crossing borders and fighting inequalities**

Chairs: Enrico Girardi (Roma), Francesco Maraglino (Roma)

Since its beginning in 2002, DREAM has been driving significant advancements in the fight against AIDS in Africa:

- In 2002, the introduction of ART with free access in countries where there was nothing
- In 2004, anticipation of the start of therapy compared to existing protocols, triple therapy instead of monotherapy for pregnant women
- Since 2006, routine monitoring of viral load

Currently, DREAM is present in 10 African countries with centers of excellence and national reference laboratories, with 50 active care centers and day hospitals, and 28 molecular biology laboratories. Today, access to therapy is a reality even in the poorest countries, but we are working to reach those who have been left behind: children (especially in West Africa), girls and young women, who are among the groups with the highest incidence; the male population, which does not have easy access to health facilities. Alongside this, there are new challenges:

- non-communicable diseases associated with HIV infection
- the emergence of strains resistant to even the new first-line treatments
- TB co-infection posing problems of sometimes complex diagnosis,
- HPV infection in HIV-positive women, molecular diagnosis of HPV, and vaccination.



- 13.40-13.55 **DREAM after 20 years: where we are and who still need to be reached** G. Guidotti, Roma
- 13.55-14.00 **Discussion**
- TD 16** **14.00-14.07 Active close contact investigation of tuberculosis through Computer-Aided Detection and stool Xpert MTB/RIF among people living in Oromia region, Ethiopia: a preliminary results**
G. Guido¹, S. Cotugno¹, F.V. Segala¹, W. Nigussa², B. Kenate³, A. Tsegaye², B. Gulo², F. Cavallin¹, A.B. Asmare², F. Manenti⁴, E. Facci², M. Tilahun⁵, G. Putoto⁵, F. Di Gennaro¹, A. Saracino¹
¹Department of Precision and Regenerative Medicine and Ionian Area (DiMePre-J), University of Bari Aldo Moro, Bari, Italy, ²Doctors with Africa CUAMM, Wolisso; Etiopia, ³Oromia Regional Health Bureau; Etiopia, ⁴Doctors with Africa CUAMM, Padova, Italy, ⁵Armauer Hansen Research Institute (AHRI), Addis Ababa, Etiopia
- TD 17** **14.07-14.14 The impact of COVID-19 on the Virological Suppression in People Living with HIV Followed up at the Hospital Divina Providência in Luanda, Angola**
A. Calcagno¹, C. Pizzi², B. Pocongo³, N. Ronzoni⁴, F. Alladio¹, F. Ngiambudulu⁵, C. Castilletti⁴, A. Kalume⁶, G. Di Perri¹, F.G. Gobbi^{4,7}
¹Unit of Infectious Diseases, Department of Medical Sciences, University of Torino, Italy, ²Cancer Epidemiology Unit, Department of Medical Sciences, University of Turin and CPO Piemonte, Turin, Italy, ³Instituto Nacional de Luta Contra SIDA – MINSa, Luanda, Angola, ⁴Department of Infectious - Tropical Diseases and Microbiology, IRCCS Sacro Cuore Don Calabria Hospital, Negrar (VR), Italy, ⁵Instituto Nacional de Investigação em Saúde (National Institute for Health Research) – INIS, Luanda, Angola, ⁶Hospital Divina Providência, Luanda, Angola, ⁷Department of Clinical and Experimental Sciences, University of Brescia, Brescia, Italy
- TD 18** **14.14-14.21 Trends in HIV-related stigma and gender inequality indicators: findings from a peer-based intervention prevention program in rural northern Uganda**
G. Micheli¹, M. Chiuchiarelli², A. Pierantozzi³, R. Lukwiya⁴, B. Odong⁵, F. Opira⁴, C. Seguiti⁶, F.S. Alozi⁷, R. Cauda¹, K. De Gaetano Donati², C. Torti^{1,2}, A. Cingolani^{1,2} for 'Pe Atye Kena, no longer alone' study group
¹Dipartimento di Sicurezza e Bioetica - Sezione di Malattie Infettive, Università Cattolica del Sacro Cuore, Rome, Italy, ²Dipartimento di Scienze mediche e Chirurgiche, Fondazione Policlinico Universitario Agostino Gemelli IRCCS Rome, Italy, ³AIFA-Agenzia Italiana del farmaco, Rome, Italy, ⁴"Comboni Samaritans of Gulu" Health Center, Gulu, Uganda, ⁵Medical Teams International, Kitgum, Uganda, ⁶Fondazione Poliambulanza Istituto Ospedaliero, UOC medicina generale, Brescia, Italy, ⁷Università Cattolica S. Cuore, Patologia Speciale Medica e Semeiotica Medica, Rome, Italy
- TD 19** **14.21-14.28 High In-hospital Mortality and Significant Prevalence of HIV among Patients Admitted to a Tuberculosis Ward at Divina Providência Hospital in Luanda - Angola, 2023**
A. Lopes Sucuma¹, R. Huits², N. Francisco³, F. Alladio², A. Kalume³, N. Ronzoni², E. Salvador², P. Cattaneo², F. Gobbi², A. Calcagno⁴
¹Department of Clinical and Biological Sciences, University of Turin, Turin, Italy, ²Department of Infectious Tropical Diseases and Microbiology, IRCCS Sacro Cuore Don Calabria Hospital, Negrar, Verona, Italy, ³Microbial and Immunological Research Group, National Institute for Health Research, Luanda, Angola, ⁴Unit of Infectious Diseases, Department of Medical Sciences, University of Turin, Amedeo di Savoia Hospital, Turin, Italy, ⁵Divina Providencia Hospital, Luanda, Angola
- 14.28-14.50 **Discussion**



SYMPOSIUM 13.50-15.00

AULA LAZZATI

Striving for an HIV cure: from post-treatment control to a natural cure

Chairs: Chiara Agrati (Roma), Camilla Tincati (Milano)

The symposium is meant to address different topics concerning the delicate equilibrium between protective and pathogenetic role of the immune system over HIV infection in cohorts exhibiting a peculiar relation with the virus. In particular, a comprehensive review on the correlates of protection characterizing the immune response in cohorts of HIV-exposed uninfected children born from HIV-infected mothers and elite controllers will be provided. The possibility of reprogramming dysfunctional CD8+ T cells to promote properties associated with natural HIV control will be harnessed as well. The critical revision of all these information will be essential to dissect and identify new potential targets/pathways to be exploited in the setting up of innovative therapeutic approaches.

- 13.50-14.05 **Generation of myeloid-derived induced pluripotent stem as a platform to study uninfected donors carrying C-C type 5Δ32 mutation** D. Mavilio, Rozzano MI
- 14.05-14.20 **Exceptional elite controllers: do they truly exist?** M.S. Clerici, Milano
- 14.20-14.25 **Discussion**
- 14.25-14.40 **NK cells in HIV-1 landscape: Insights from Human and NHP models** C. Petitdemange, Paris FR
- 14.40-14.55 **bNAbs for HIV management and cure** G.C. Marchetti, Milano
- 14.55-15.00 **Discussion**





ORAL COMMUNICATIONS 14.00-15.00

AULA BAUSOLA

A tale of two pandemics: molecular insights on SARS-CoV-2 and HIV

Chairs: Emanuele Nicastrì (Roma), Maria Santoro (Roma)

14.00-14.05 **Introduction**

E. Nicastrì, Roma; M. Santoro, Roma

OC 46 14.05-14.15 Genomic epidemiology of the main SARS-CoV-2 variants circulating in Italy during the Omicron era

*A. Bergna*¹, *A. Lai*¹, *F. Sagradi*², *S. Menzo*³, *N. Mancini*⁴, *B. Bruzzone*⁵, *S. Rusconi*⁶, *G. Marchegiani*⁷, *N. Clementi*⁸, *D. Francisci*⁹, *I. Vicenti*¹⁰, *H. Djaya Mbissam*¹, *C. della Ventura*¹, *L. Lanfranchi*², *S. Testa*², *S. Caucci*³, *C. Acciarri*³, *L. Carioti*⁷, *A. Occhinero*¹¹, *F. Novazzi*⁴, *A.P. Genoni*⁴, *F. Drago Ferrante*⁴, *V. De Pace*⁵, *M. Ferraris*⁵, *M. Ogliastrò*⁵, *A. Gabrieli*^{1,12}, *M. De Paschale*¹², *G. Canavesi*⁶, *M.C. Bellocchi*⁷, *M. Iannetta*¹³, *L. Sarmati*¹³, *A. Riva*¹, *S. Antinori*¹, *G. Zehender*¹, and SARS-CoV-2 ITALIAN RESEARCH ENTERPRISE – (SCIRE) collaborative Group

¹Department of Biomedical and Clinical Sciences, University of Milan, Milan, Italy, ²Unit of Infectious Diseases, Azienda Socio-Sanitaria Territoriale Cremona, Cremona, Italy, ³Department of Biomedical Sciences and Public Health, Virology Unit, Polytechnic University of Marche, Ancona, Italy, ⁴University of Insubria, Department of medicine and Technological Innovation; Ospedale di Circolo e Fondazione Macchi, Laboratory of Medical Microbiology and Virology, Varese, Italy, ⁵Hygiene Unit, IRCCS AOU San Martino-IST, Genoa, Italy, ⁶Ospedale Civile di Legnano ASST Ovest Milanese - University of Milan, Legnano, Italy, ⁷Department of Experimental Medicine, University of Rome "Tor Vergata", Rome, Italy, ⁸Laboratory of Microbiology and Virology, Università "Vita-Salute" San Raffaele, Milan, Italy, ⁹Department of Medicine and Surgery, Clinic of Infectious Diseases, "Santa Maria della Misericordia" Hospital, University of Perugia, Perugia, Italy, ¹⁰Department of Medical Biotechnologies, University of Siena, Siena, Italy, ¹¹Clinic of Infectious Diseases – AOU delle Marche, Ancona, Italy, ¹²Unit of Microbiology, Legnano Hospital, ASST Ovest Milanese, Legnano, Italy, ¹³Clinical Infectious Diseases, Department of System Medicine, Tor Vergata University, Rome, Italy

OC 47 14.15-14.25 Genomic characterization of SARS-CoV-2 Omicron variants and clinical presentation in immunocompromised and nonimmunocompromised adult people

*L. Carioti*¹, *G. Marchegiani*¹, *L. Coppola*², *M. Iannetta*², *L. Alborghetti*², *V. Malagnino*², *L. Benedetti*², *M.M. Santoro*¹, *M. Andreoni*², *L. Sarmati*², *C. Alteri*^{3,4}, *F. Ceccherini-Silberstein*¹, *M.C. Bellocchi*¹

¹University of Rome Tor Vergata, Rome, Italy, ²Clinical Infectious Diseases, Department of System Medicine, Tor Vergata University, Rome, Italy, ³Department of Oncology and Hemato-Oncology, University of Milan, Italy, ⁴Clinical Microbiology and Virology Unit, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milano, Italy

14.25-14.29 **Discussion****OC 48 14.29-14.39 Analysis of chromosome integration sites of HIV-1 DNA in PBMC of PWH showing plasma HIV-1 RNA detected only by the LTR target with Aptima HIV-1 Quant Dx assay**

*G. Sberna*¹, *G. Bero*¹, *G. Rozera*¹, *C. Gruber*¹, *I. Abbate*¹, *R. Gagliardini*², *V. Mazzotta*², *I. Mastroianni*², *A. Antinori*², *F. Maggi*¹, *A. Amendola*¹

¹Laboratory of Virology, National Institute for Infectious Diseases I.R.C.C.S. L. Spallanzani, Rome, Italy, ²Clinical and Research Infectious Diseases Department, National Institute for Infectious Diseases I.R.C.C.S. L. Spallanzani, Rome, Italy

OC 49 14.39-14.49 Post-translational HIV-1 integrase modification sites might be affected by complex and prolonged treatment history associated with multidrug resistance: a proof of concept study from the PRESTIGIO registry

*D. Armenia*¹, *V. Spagnuolo*², *L. Galli*², *T. Clemente*^{2,3}, *R. Lolatto*², *D. Minisci*⁴, *L. Pagnucco*⁵, *R. Pincino*⁶, *V. Malagnino*⁷, *T. Mulas*⁷, *L. Sarmati*⁷, *M. Zazzi*⁸, *M.M. Santoro*⁹, *A. Castagna*^{2,3}

¹Saint Camillus International University of Health Sciences, Rome, Italy, ²Infectious Diseases, IRCCS San Raffaele Scientific Institute, Milan, Italy, ³Vita-Salute San Raffaele University, Milan, Italy, ⁴University Division of Infectious and Tropical Diseases, University of Brescia and ASST Spedali Civili Hospital, Brescia, Italy, ⁵Division of Infectious Diseases, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy, ⁶Ospedale di Sanremo-ASL 1 Imperiese, Sanremo, Italy, ⁷Policlinic of Rome Tor Vergata, Rome, Italy, ⁸Department of Medical Biotechnologies, University of Siena, Siena, Italy, ⁹Department of Experimental Medicine, University of Rome "Tor Vergata", Rome, Italy

14.49-14.53 **Discussion**14.53-15.00 **Conclusion**

E. Nicastrì, Roma; M. Santoro, Roma





ORAL COMMUNICATIONS 14.00-15.00

PrEP and prevention strategies**AULA 6**

Chairs: Maria Luisa Cosmaro (Milano), Annalisa Saracino (Bari)

14.00-14.05 **Introduction**

M.L. Cosmaro, Milano; A. Saracino, Bari

OC 50 14.05-14.15 Implementation of PrEP in Italy: results of PrIDE survey*S. Nozza¹, V. Mazzotta², T. Masoero³, A. Tavelli³, F. Leserri⁴, L. Taramasso⁵, D. Tesoro⁶, E. Caruso⁷, A. d'Arminio Monforte³, F.M. Fusco⁸, M. Menozzi⁹, E. Milano¹⁰, D. Moschese¹¹, R. Rossotti¹², F. Barbaro¹³, S. Cecere¹⁴, M. Giglia¹⁵, S. Venturelli¹⁶, M. Cernuschi⁷, A. Castagna¹, A. Antinori²*

¹Infectious Diseases Unit, Vita Salute San Raffaele University, Milan, Italy, ²Clinical and Research Infectious Diseases Department, National Institute for Infectious Diseases, Lazzaro Spallanzani IRCCS, Rome, Italy, ³ICONA Foundation, Milan, Italy, ⁴Plus Roma, Rome, Italy, ⁵Infectious Disease Clinic, IRCCS Ospedale Policlinico San Martino, Genova, Italy, ⁶Unit of Infectious Diseases, ASST Santi Paolo e Carlo, Milan, Italy, ⁷Milano Checkpoint ETS, Milan, Italy, ⁸P.O. "D. Cotugno", Azienda Ospedaliera dei Colli, Naples, Italy, ⁹Department of Infectious Diseases, Azienda Ospedaliero-Universitaria, Policlinico of Modena, Modena, Italy, ¹⁰Clinic of Infectious Diseases, Department of Precision and Regenerative Medicine and Ionian Area, Polyclinic of Bari, University Hospital Polyclinic, University of Bari, Bari, Italy, ¹¹I Division of Infectious Diseases, Luigi Sacco Hospital, ASST Fatebenefratelli Sacco, Milan, Italy, ¹²Department of Infectious Diseases, ASST Grande Ospedale Metropolitano Niguarda, School of Medicine and Surgery, Milan, Italy, ¹³Department of Medicine, Infectious Diseases Unit, University Hospital of Padova, Padova, Italy, ¹⁴Bologna checkpoint, Bologna, Italy, ¹⁵Infectious Diseases Unit, IRCCS Policlinico di Sant'Orsola, University of Bologna, Bologna, Italy, ¹⁶Infectious Diseases Unit, ASST Papa Giovanni XXIII, Bergamo, Italy, ¹⁷Infectious Diseases

OC 51 14.15-14.25 HIV pre-exposure prophylaxis (PrEP) efficacy, adherence and persistence in an Italian multicentric cohort: ItaPrEP study*Y. Mazzotta¹, D. Calzavara², A. Tavelli³, S. Lanini⁴, R. Esvan¹, A. De Bona⁵, S. Mattioli⁶, E. Caruso³, De Zottis¹, D. Tesoro⁵, L. Badia⁶, S. Nozza⁷, A. Cingolani⁸, A. Bianchi³, R. Bellagamba¹, M. Pedone⁶, N. Frattini³, A. Oliva¹, R. Repossi³, R. Rossotti⁹, C. Mastroianni¹⁰, C. Torti⁸, G. Marchetti⁵, A. Castagna⁷, A. d'Arminio Monforte², M. Cernuschi³, A. Antinori¹*

¹HIV/AIDS Unit, INMI L. Spallanzani IRCCS, Roma, Italy, ²Milano Checkpoint, Milano, Italy, ³Fondazione Icona, Milano, Italy, ⁴Clinica Malattie Infettive, Università di Udine, Italy, ⁵ASST Santi Paolo e Carlo, University of Milano, Italy, ⁶PLUS aps (BLQ Checkpoint), Bologna, Italy, ⁷HSR San Raffaele Scientific Institute, Milano, Italy, ⁸Fondazione Policlinico A. Gemelli, Catholic University, Roma, Italy, ⁹ASST Niguarda Hospital, Milano, Italy, ¹⁰Sapienza University, Roma, Italy

14.25-14.29 **Discussion****OC 52 14.29-14.39 Overcoming HPV vaccination barriers in target populations: the VACCINAMILANO experience***P. Raimondo¹, D. Dalu², E. Caruso³, C. Fusetti¹, C. Fasola², D. Calzavara³, F. Barone¹, F. Manoni², M.V. Cossu¹, L. Ruggieri², A. Giacomelli¹, R. Repossi³, M.S. Cona², N. Frattini³, N. La Verde², A. Gori¹, M. Cernuschi³, D. Moschese¹*

¹Department of Infectious Diseases, Luigi Sacco University Hospital – Milan, Italy, ²Oncology Unit, Luigi Sacco University Hospital – Milan, Italy, ³Milano Checkpoint ETS – Milan, Italy

OC 53 14.39-14.49 HIV screening strategies in the Emergency department to reveal hidden infections*F. Romano¹, A. Santoro², A. Lazzaro¹, L. Santinelli¹, F. Biamonte², L. Colombo³, G. Galardo⁴, C. Tincati², C.M. Mastroianni¹, G.C. Marchetti², G. d'Ettore¹*

¹Department of Public Health and Infectious Diseases, Sapienza University of Rome, Policlinico Umberto I of Rome, Rome, Italy, ²Clinic of Infectious Diseases, San Paolo Hospital, ASST Santi Paolo e Carlo, Department of Health Sciences, University of Milan, Milan, Italy, ³Emergency Department, San Paolo Hospital, ASST Santi Paolo e Carlo, Milan, Italy, ⁴Medical Emergency Unit, Sapienza University of Rome, Rome, Italy

14.49-14.53 **Discussion**14.53-15.00 **Conclusion**

M.L. Cosmaro, Milano; A. Saracino, Bari





ORAL COMMUNICATIONS 14.00-15.00

AULA 7

HIV associated comorbidities: matters of the heart

Chairs: Paolo Bonfanti (Monza), Paolo Maggi (Caserta)

14.00-14.05 Introduction

P. Bonfanti, Monza; P. Maggi, Caserta

OC 54 14.05-14.15 Incidence of metabolic syndrome in people with HIV in Italy who started ART since 2008: data from the ICONA cohort*E. Bruzzesi¹, A. Tavelli², R. Salpini³, A. Carraro⁴, M. Camici⁵, C. Papalini⁶, G.E. Recchia⁷, C.R. Santoro⁸, M.V. Cossu⁹, A. Guida¹⁰, A. Mondì², G. Marchetti¹¹, G. Guaraldi¹², A. d'Arminio Monforte², S. Nozza^{1,13}, on behalf of ICONA Foundation Study Group*¹Infectious Diseases Unit, Vita-Salute San Raffaele University, Milan, Italy, ²ICONA Foundation, Milan, Italy, ³Department of Biology, University of Rome Tor Vergata, Rome, Italy, ⁴Infectious Diseases Unit, SM Goretti Hospital, Sapienza University of Rome, Latina, Italy, ⁵Clinical and Research Infectious Diseases Department, national Institute for Infectious Diseases Lazzaro Spallanzani IRCCS, Rome, Italy, ⁶Infectious Diseases Clinic, Santa Maria della Misericordia Hospital, Università degli Studi di Perugia, Perugia, Italy, ⁷Department of Public Health and Infectious Diseases, Sapienza University of Rome, Rome, Italy, ⁸Infectious Diseases Clinic, University of Bari, Bari, Italy, ⁹Department of Infectious Diseases, ASST Fatebenefratelli Sacco University Hospital, Milan, Italy, ¹⁰Infectious Diseases and Gender Medicine Unit, Cotugno Hospital, AO dei Colli, Naples, Italy, ¹¹Clinic of Infectious Diseases, ASST Santi Paolo e Carlo, Department of Health Sciences, University of Milan, Milan, Italy, ¹²Department of Surgical, Medical, Dental and Morphological Sciences, University of Modena, Modena, Italy, ¹³Infectious Diseases Unit, IRCCS San Raffaele Scientific Institute, Milan, Italy**OC 55 14.17-14.27 Current and temporal exposure to integrase strand transfer inhibitors are not associated with hypertension or arterial stiffness in people with HIV***G. Alfano¹, J. Milic², M. Mantovani⁴, F. Calandra Buonauro⁴, F. Motta³, M. Menozzi⁴, G. Cuomo⁴, G. Mancini⁴, C. Mussini^{2,4}, G. Donati¹, G. Guaraldi^{2,4}*¹Nephrology Dialysis and Transplant Unit, University Hospital of Modena, Modena, Italy, ²Department of Surgical, Medical, Dental and Morphological Sciences, University of Modena and Reggio Emilia, Modena, Italy, ³Department of Physical, Computer and Mathematical Sciences, University of Modena and Reggio Emilia, Modena, Italy, ⁴Department of Infectious Diseases, Azienda Ospedaliero-Universitaria, Policlinico of Modena, Modena, Italy**OC 56 14.29-14.39 Metabolic and weight changes in people with HIV after switching to long-acting therapy with cabotegravir and rilpivirine: results from the SCohLART study***M. Bottanelli¹, N. Gianotti², S. Diotallevi², R. Lolatto², V. Spagnuolo², D. Canetti², S. Bagaglio², V. Gordo Perez², T. Clemente¹, C. Candela¹, S. Nozza^{1,2}, A. Castagna^{1,2}, C. Muccini²*¹Vita-Salute San Raffaele University, Milan, Italy, ²Infectious Diseases Unit, IRCCS San Raffaele Scientific Institute, Milan, Italy**OC 57 14.41-14.51 Carotid intima media thickness (IMT) and statins prescriptions in the real life setting of the Archi Prevalent cohort***B.M. Cesia¹, S. Martini², E.D. Ricci³, L. Galli⁴, A. Masiello⁵, C. Muccini⁴, S. Zacà⁶, S. Ferrara⁷, G. Di Filippo⁸, M.S. Paternò Raddusa¹, A. Tartaglia⁹, R. Basile¹⁰, D. Angiletta⁶, A. Castagna⁴, P. Maggi^{2,5}*¹Unit of Infectious Diseases, Department of Clinical and Experimental Medicine, ARNAS Garibaldi Hospital, University of Catania, Catania, Italy, ²Department of Mental Health and Public Medicine, Section of Infectious Diseases, University of Campania, Luigi Vanvitelli, Naples, Italy, ³Fondazione ASIA Onlus, Milan, Italy, ⁴Clinic of Infectious Diseases, San Raffaele Scientific Institute, Vita-Salute San Raffaele University, Milan, Italy, ⁵AORN Sant'Anna e San Sebastiano of Caserta, Caserta, Italy, ⁶Department of Emergency and Organ Transplantation, University of Bari School of Medicine, Bari, Italy, ⁷Department of Medical and Surgical Sciences, Section of Infectious Diseases, University of Studies of Foggia, Foggia, Italy, ⁸Department of Medicine and Surgery, Section of Infectious Diseases, University Federico II of Naples, Napoli, Italy, ⁹Azienda Ospedaliera di Foggia, Foggia, Italy, ¹⁰Section of Infectious Diseases, Grande Ospedale Metropolitano, Bianchi Melacrino Morelli, Reggio Calabria, Italy

14.53-15.00 Conclusion

P. Bonfanti, Monza; P. Maggi, Caserta



**SYMPOSIUM** 15.05-16.05
Meet the Expert in HIV**AULA LAZZATI****Chairs:** Paolo Maggi (Caserta), Ada Moznich (Milano)

The field of HIV medicine continues to be dynamic and innovative, even after more than 40 years since the first report of AIDS. This session is based on expert opinions which explore the latest developments in cutting-edge issues in HIV clinical management.

- 15.05-15.20 **HIV genotypic resistance test: clinical use for today and future challenges** C.F. Perno, Roma
- 15.20-15.25 **Discussion**
- 15.25 15.40 **Screening for non AIDS-related cancers: what we currently do and what we should do** E. Vaccher, Aviano PN
- 15.40-15.45 **Discussion**
- 15.45-16.00 **Do not forget the children: pioneering progress in pediatric HIV care ...not only drugs** V. Giacomet, Milano
- 16.00-16.05 **Discussion**

**ORAL COMMUNICATIONS** 15.05-16.05**AULA BAUSOLA****What is left to say on COVID-19 today?****Chairs:** Marco Iannetta (Roma), Claudio Maria Mastroianni (Roma)

- 15.05-15.10 **Introduction** M. Iannetta, Roma; C.M. Mastroianni, Roma
- OC 58** **15.10-15.20 Inflammatory milieu and specific T cells response after three months and one year from SARS-CoV-2 infection**
E. Cimini¹, C. Cimaglia², E. Tartaglia³, M. Camici⁴, S. Notari¹, F. Colavita³, G. Matusali³, I. Mastroianni⁴, V. Mazzotta⁴, P. Chinello⁴, P. Mencarini², M. L. Giancola⁴, A. Abdeddaim⁴, R. Casetti¹, G. Grassi¹, S. Gili¹, F. Cristofanelli¹, F. Maggi³, P. Piselli², E. Girardi⁵, C. Agrati⁶, A. Antinori⁴, A. Vergori⁴
¹Laboratory of Cellular Immunology and Pharmacology, INMI-IRCCS Lazzaro Spallanzani, Rome, Italy, ²Clinical Epidemiology Unit, INMI-IRCCS Lazzaro Spallanzani, Rome, Italy, ³Laboratory of Virology, INMI-IRCCS Lazzaro Spallanzani, Rome, Italy, ⁴Clinical Department, INMI-IRCCS Lazzaro Spallanzani, Rome, Italy, ⁵Scientific Direction, INMI-IRCCS Lazzaro Spallanzani, Rome, Italy, ⁶Unit of Pathogen Specific Immunity, IRCCS Ospedale Pediatrico Bambino Gesù, Rome, Italy
- OC 59** **15.22-15.32 Clinical features and impact on mortality of COVID-19 epidemics in patients with Non-Hodgkin lymphoma: long-term results from a tertiary center in Italy**
E. Zappulo¹, L. Ametrano¹, S. Barbato², L. Fusco¹, A. Severino², F. Pane², I. Gentile¹
¹Department of Clinical Medicine and Surgery—Infectious Diseases Unit, University of Naples Federico II, Naples, Italy, ²Department of Clinical Medicine and Surgery – Haematology Unit, University of Naples Federico II, Naples, Italy
- OC 60** **15.34-15.44 Time to anti-cancer treatment resumption after SARS-CoV-2 infection in patients with active hematological disease undergoing off-label combined antiviral treatments**
E. Matteini¹, C. Pinnetti², F. Frondizi¹, E. Rando¹, M. Chiuchiarelli¹, E. Metafuni³, I. Mastroianni², E. Alma³, V. Mazzotta², R. Santangelo⁴, S. Marchetti⁵, M. Sanguinetti⁴, S. Sica³, C. Torti^{1,6}, A. Antinori², A. Cingolani^{1,6}
¹Dipartimento di Sicurezza e Bioetica - Sezione di Malattie Infettive, Università Cattolica del Sacro Cuore, Rome, Italy, ²Clinical and Research Infectious Diseases Department, National Institute for Infectious Diseases, Lazzaro Spallanzani IRCCS, Rome, Italy, ³Ematologia e Trapianto di cellule staminali emopoietiche, Dipartimento di Scienze di Laboratorio ed Infettivologiche, Italy, ⁴Department of Laboratory and Hematological Sciences Fondazione Policlinico Gemelli, IRCCS, Department of Basic, Biotechnological Sciences, Intensive Care and Perioperative Clinics Catholic University School of Medicine, Italy, ⁵Department of Laboratory and Hematological Sciences Fondazione Policlinico Gemelli, IRCCS, Italy, ⁶Dipartimento di Scienze Mediche e Chirurgiche, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome, Italy
- OC 61** **15.46-15.56 SARS-CoV-2 intra-host evolution during acute infection in COVID-19 patients**
C. della Ventura¹, A. Bergna¹, C.L. Ciobotariu², H. Chmes¹, M. Corbellino², A. Riva^{1,2}, S. Antinori^{1,2}, G. Zehender¹, A. Lai¹
¹Department of Biomedical and Clinical Sciences, University of Milan, Milan, Italy, ²III Division of Infectious Diseases, ASST Fatebenefratelli Sacco, Luigi Sacco Hospital, Milan, Italy
- 15.58-16.05 **Conclusion** M. Iannetta, Roma; C.M. Mastroianni, Roma





ORAL COMMUNICATIONS 15.05-16.05

AULA 5

HIV associated comorbidities: pressing matters

Chairs: Sergio Carbonara (Bisceglie BT), Carmela Pinnetti (Roma)

15.05-15.10 Introduction

S. Carbonara, Bisceglie BT; C. Pinnetti, Roma

OC 62 15.10-15.20 Cancers in people living with HIV: an observational study in the cohort of Modena over 27 years*F. Prandini¹, M. Menozzi², F. Casari¹, D. Lusetti¹, B. Fontana¹, M. Ricciardetto¹, E. Ghidoni¹, F. Calandra¹, E. Martini¹, G. Guaraldi¹, C. Mussini¹*¹Department of Infectious Diseases, University of Modena and Reggio Emilia, Modena, Italy, ²Department of Infectious Diseases, AOU Modena, Modena, Italy**OC 63 15.22-15.32 CNS relapse risk in HIV-positive patients affected by DLBCL and HGBL - a retrospective study of the MUSTHAL cohort***G. Rindone¹, M. Rossi², F. Sabbatini², P. Columpsi², D. Dalu³, C. Fasola³, P. Vitiello⁴, C. Viganò⁵, E. Suardi⁶, C. Gambacorti Passerini^{1,7}, P. Bonfanti^{2,7}, A. Bandera^{8,9}, L. Verga¹*¹Hematology department IRCCS San Gerardo dei Tintori, Monza, Italy, ²Infectious diseases department IRCCS San Gerardo dei Tintori, Monza, Italy, ³Oncology department ASST Fatebenefratelli Sacco, Milano, Italy, ⁴Hematology department Ospedale di Busto Arsizio, Busto Arsizio, Italy, ⁵Oncology department Ospedale Manzoni, Lecco, Italy, ⁶Infectious diseases department ASST Santi Paolo e Carlo, Milano, Italy, ⁷University of Milano-Bicocca, Milano, Italy, ⁸Infectious diseases department IRCCS Ca' Granda Policlinico di Milano, Milano, Italy, ⁹University of Milano, Milano, Italy**OC 64 15.34-15.44 Cognitive Performance in Older People with and without HIV in the GEPO Cohort***A. Calcagno¹, A. Tommasi², L. Patetta³, J. Milic⁴, A. Coin⁵, C. Mussi⁶, S. Calza⁷, B.M. Celesia⁸, S. Gardin⁹, D. Azzolino³, E. Lenotti¹⁰, M. Ferrara¹, B. Fioretti¹¹, G. Madeddu¹², F. Barrera¹, G. Orofino¹³, G. Guaraldi⁴, E. Focà¹¹*¹Unit of Infectious Diseases, Department of Medical Sciences, University of Turin, Turin, Italy, ²Department of Infectious Diseases, Azienda Ospedaliero-Universitaria di Perugia, Perugia, Italy, ³Geriatric Unit, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico di Milano, Milano, Italy, ⁴Department of Mother, Child and Adult Medicine and Surgical Science, Infectious Disease Clinic, University of Modena and Reggio Emilia, Modena, Italy, ⁵Geriatric Unit, University of Padova, Padova, Italy, ⁶Centre of Gerontological Evaluation and Research, University of Modena and Reggio Emilia, Modena, Italy, ⁷Unit of Biostatistics and Bioinformatics, Department of Molecular and Translational Medicine, University of Brescia, Brescia, Italy, ⁸Division of Infectious Diseases, Department of Clinical and Molecular Biomedicine, University of Catania, ARNAS Garibaldi, Catania, Italy, ⁹Unit of Infectious Diseases, Department of Internal Medicine, Azienda Ospedaliero-Universitaria di Padova, Padova, Italy, ¹⁰Geriatric Unit, University of Brescia and ASST Spedali Civili Hospital, Brescia, Italy, ¹¹Department of Infectious and Tropical Diseases, University of Brescia and ASST Spedali Civili Hospital, Brescia, Italy, ¹²Unit of Infectious and Tropical Diseases, Department of Medical, Surgical and Experimental Sciences, University of Sassari, Sassari, Italy, ¹³Unit of Infectious Diseases, 'Divisione A', Amedeo di Savoia Hospital, ASLTO2, Torino, Italy**OC 65 15.46-15.56 Increasing prevalence of cognitive frailty in people living with HIV***J. Milic¹, S. Renzetti², S. Calza³, F. Motta⁴, L. Lazzarini⁵, M. Cocchi⁶, V. Todisco⁶, A. Tili⁶, M.C. Pellegrino⁶, M. Menozzi⁶, G. Cuomo⁶, G. Mancini⁶, C. Mussi¹, C. Mussini^{6,7}, A. Calcagno⁸, G. Guaraldi^{6,7}*¹Department of Biomedical and Metabolic Sciences and Neuroscience, University of Modena and Reggio Emilia, Modena, Italy, ²Department of Medical-Surgical Specialties, Radiological Sciences and Public Health, University of Brescia, Brescia, Italy, ³Department of Molecular and Translational Medicine, University of Brescia, Brescia, Italy, ⁴Department of Physical, Computer and Mathematical Sciences, University of Modena and Reggio Emilia, Modena, Italy, ⁵School of Medicine, University of Modena and Reggio Emilia, Modena, Italy, ⁶Department of Infectious Diseases, Azienda Ospedaliero-Universitaria, Policlinico di Modena, Modena, Italy, ⁷Department of Surgical, Medical, Dental and Morphological Sciences, University of Modena and Reggio Emilia, Modena, Italy, ⁸Unit of Infectious Diseases, Department of Medical Sciences, Amedeo di Savoia Hospital, University of Torino, Torino, Italy

15.58-16.05 Conclusion

S. Carbonara, Bisceglie BT; C. Pinnetti, Roma



ORAL COMMUNICATIONS 15.05-16.05

AULA 6

Highlighting the diversity of people living with HIV

Chairs: Nicola Gianotti (Milano), Giovanni Mazzola (Caltanissetta)

15.05-15.10 Introduction

N. Gianotti, Milano; G. Mazzola, Caltanissetta



- OC 66** 15.10-15.20 **Socio-demographic, clinical and therapeutic features of persons with HIV (PWH) currently in care in Italy: data from the ICONA cohort**
A. d'Arminio Monforte¹, A. Rodano¹, I. Fanti¹, C.F. Perno², D. Segala³, A. Santoro⁴, M.B. Pasticci⁵, L. Calza⁶, A. Carraro⁷, A. Cingolani⁸, M. Puoti⁹, A. Castagna¹⁰, S. Lo Caputo¹¹, A. Tavelli¹, A. Antinori¹² on behalf of Icona Foundation Study Group
¹ICONA Foundation, Milan, Italy, ²IRCCS Bambino Gesù Pediatric Hospital, Rome, Italy, ³Pathology Department, University of Brescia, ASST Spedali Civili di Brescia, Brescia, Italy, ⁴Clinica di Malattie Infettive, ASST Santi Paolo e Carlo-Presidio Ospedaliero San Paolo, Milano, Italy, ⁵Infectious Diseases Unit, Santa Maria Terni Hospital, Terni, Italy, ⁶Infectious Diseases Unit, IRCCS Policlinico di Sant'Orsola, University of Bologna, Bologna, Italy, ⁷Department of Public Health and Infectious Diseases, Sapienza University of Rome, Rome, Italy, ⁸Clinic of Infectious Diseases, Catholic University, Rome, Italy, ⁹Department of Infectious Diseases, ASST Grande Ospedale Metropolitano Niguarda, Milan, Italy, ¹⁰Infectious Diseases Unit, IRCCS San Raffaele Scientific Institute, Milan, Italy, ¹¹Clinic of Infectious Diseases, Department of Clinical and Surgical Sciences, University of Foggia, Foggia, Italy, ¹²National Institute for Infectious Diseases Lazzaro Spallanzani, IRCCS, Roma, Italy
- OC 67** 15.22-15.32 **Low prevalence of optimal health-related quality of life in real-world data among people with HIV**
J. Milic¹, E. Gnoatto Perondi¹, F. Motta², V. Menozzi³, M. Simion³, F. Romani³, M. Menozzi³, G. Cuomo³, G. Mancini³, C. Mussini^{1,3}, G. Guaraldi^{1,3}
¹Department of Surgical, Medical, Dental and Morphological Sciences, University of Modena and Reggio Emilia, Modena, Italy, ²Department of Physical, Computer and Mathematical Sciences, University of Modena and Reggio Emilia, Modena, Italy, ³Department of Infectious Diseases, Azienda Ospedaliero-Universitaria, Policlinico of Modena, Modena, Italy
- OC 68** 15.34-15.44 **African women living with HIV in Modena: far from fulfilling the gap**
F. Casari¹, A. Cervo², M. Pellegrino¹, C. Puzzolante², M. Menozzi², G. Guaraldi^{1,2}, C. Mussini^{1,2}
¹Department of Infectious Diseases, University of Modena and Reggio Emilia, Modena, Italy, ²Department of Infectious Diseases, AOU Modena, Modena, Italy
- OC 69** 15.46-15.56 **Pregnant women living with HIV: the experience of IRCCS San Gerardo dei Tintori**
A. Ranzani¹, G. Lapadula^{1,2}, F. D'Aloia⁴, S. Ornaghi^{2,3}, A. Locatelli^{2,3}, P. Bonfanti^{1,2}, F. Sabbatini¹
¹S.C. Malattie Infettive, IRCCS San Gerardo dei Tintori, Monza, Italy, ²Università degli Studi Milano-Bicocca, Italy, ³S.C. Ostetricia, IRCCS San Gerardo dei Tintori, Monza, Italy, ⁴Scuola di specializzazione in Malattie Infettive e Tropicali, Università degli Studi di Milano-Bicocca, Italy
- 15.58-16.05 **Conclusion** N. Gianotti, Milano; G. Mazzola, Caltanissetta



SHORT COMMUNICATIONS 15.05-16.05

AULA 7

Stigma, awareness and education

Chairs: Francesco Mazzotta (Firenze), Laura Amelia Rachele Rancilio (Milano)

- 15.05-15.08 **Introduction** F. Mazzotta, Firenze; L.A.R. Rancilio, Milano
- SC 48** 15.08-15.15 **Stigma on Screen: A Systematic Review of Cinema's HIV Narrative between 2016 and 2023**
A. Colpani¹, G. Moi¹, L. Cutzu², G. Madeddu¹, A. De Vito^{1,3}
¹Unit of Infectious Disease, Department of Medicine, Surgery and Pharmacy, University of Sassari, Sassari, Italy, ²Università degli Studi di Sassari, DUMAS, Sassari, Italia, ³PhD School in Biomedical Science, Biomedical Science Department, University of Sassari, Sassari, Italy
- SC 49** 15.15-15.22 **Minority stress and stigmatizing attitudes towards HIV: a cross-sectional study among MSM on PrEP, people living with HIV and people not living with HIV in Italy**
F.M. Nimbi^{1,2}, I. Pennini², L. Palla³
¹Department of Dynamic and Clinical Psychology and Health Studies, Sapienza University of Rome, Italy, ²Arcigay Associazione Italiana LGBT, Bologna, Italy, ³Department of Public Health and Infectious Diseases, Sapienza University of Rome, Italy
- 15.22-15.26 **Discussion**
- SC 50** 15.26-15.33 **Experience of a community-based chemsex service: analysis of requests for help during the MDPV outbreak**
A. Bianchi¹, P.L. Vinti¹, A. Antonino¹, P. Testoni¹, F. Rossi¹, M. Manfredini¹, G. Fracca¹, D. Zagato¹, M. Cernuschi^{1,2}
¹ASA Onlus ODV, Milano, Italy, ²San Raffaele Hospital, Milano, Italy
- SC 51** 15.33-15.40 **Chemsex knowledge and use among PrEP-users and PWH: a survey on the Milanese scene**
C. Fusetti¹, E. Caruso², F. Barone¹, D. Calzavara², F. Caruso¹, R. Repposi², R. Fattore¹, A. Giacomelli¹, M.V. Cossu¹, C. Atzori¹, A. Gori^{1,3}, M. Cernuschi², D. Moschese^{1,2}
¹Department of Infectious Diseases, Luigi Sacco University Hospital, Milan, Italy, ²Milano Checkpoint ETS, Milan, Italy, ³Centre for Multidisciplinary Research in Health Science (MACH), University of Milan, Milan, Italy



2024

15.40-15.44 **Discussion****SC 52** 15.44-15.51 **Comprehensive sexual health education in Italian secondary schools: preliminary results of the EduForIST national project**

A. Chinelli¹, D. Martinelli², G. Paparatto¹, L. Bonaldo¹, M. Di Nino¹, A. Musco², M. Ubbiali³, M. Farinella⁴, L. Mangieri⁵, M. Rohani⁶, I. Pennini⁷, S. Bellini⁸, R. Galipò⁹, P. Meli¹⁰, N. Catucci¹¹, M. Di Tullio¹¹, V. De Falco¹², P. Fallace¹³, F. Rizzi¹⁴, B. Suligo¹⁵, M.C. Salfa¹⁵, P. Nardone¹⁵, D. Pierannunzio¹⁵, S. Donati¹⁵, S. Ciardullo¹⁵, L. Tavoschi¹

¹University of Pisa, Pisa, Italy, ²University of Foggia, Foggia, Italy, ³University of Verona, Verona, Italy, ⁴Circolo di cultura omosessuale Mario Mieli, Roma, Italy, ⁵Coordinamento Nazionale Comunità di Accoglienza (CNCA), Roma, Italy, ⁶Arcigay, Bologna, Italy, ⁷Arcigay, Padova, Italy, ⁸Lega Italiana per la Lotta all'AIDS (LILA), Firenze, Italy, ⁹Associazione Nazionale per la Lotta all'AIDS (ANLAIDS), Roma, Italy, ¹⁰Coordinamento Italiano Case Alloggio HIV/AIDS (CICA), Bergamo, Italy, ¹¹Lega Italiana per la Lotta all'AIDS (CamALI-LA), Bari, Italy, ¹²Associazione Nazionale per la Lotta all'AIDS (ANLAIDS) Campania, Napoli, Italy, ¹³ASL Napoli2 Nord, Napoli, Italy, ¹⁴Arcigay Friuli, Udine, Italy, ¹⁵Istituto Superiore di Sanità, Roma, Italy

SC 53 15.51-15.58 **From information to test: the experience with high school students**

C. Pellegri¹, D. Meli¹, P. Meli¹, I. Mercurio¹, E. Zanetti¹, F. Maggiolo², A. Cambareri³, S. Malvestiti⁴, S. Zuppardo⁵, F. Tognoli⁶, I. Fontana⁷

¹Cooperativa Don Giuseppe Monticelli – Bergamo, Italy, ²Bergamo Fast-Track City, Italy, ³ISS Ettore Majorana - Siate, Italy, ⁴ISIS Valle Seriana - Gazzaniga, Italy, ⁵IIS Caterina Caniana – Bergamo, Italy, ⁶Liceo Don Milani – Romano di Lombardia, Italy, ⁷Ufficio Scolastico Territoriale di Bergamo, Italy

15.58-16.02 **Discussion**16.02-16.05 **Conclusion**

F. Mazzotta, Firenze; L.A.R. Rancilio, Milano

**SPECIAL SESSION** 16.10-16.30**AULA LAZZATI****ICAR 2024 Awards and Closing remarks**

Chairs: Massimo Andreoni (Roma) Antonella Cingolani (Roma), Antonio Di Biagio (Genova), Massimo Farinella (Roma), Franco Maggiolo (Fabro TR), Giulia Carla Marchetti (Milano)

ICAR and SIMIT support and reward the young excellences of Italian research with special prizes announced and awarded during this Session.



ICAR 2024 Scientific Committee Awards: three prizes for the best Clinical, Basic Science and Social Science Abstracts

F. Maggiolo, Fabro TR



SIMIT Special Awards: five prizes for the best Oral Communications in: Clinical HIV, Clinical Hepatitis Virus, Clinical SARS-CoV-2, Virology and Immunopathogenesis, Epidemiology and Social Science

M. Andreoni, Roma



Special Award "Liliana del Cupolo": a prize for the best abstract in the field of Covid research in immunocompromised patients

L. Palla, Roma

Closing remarks and announcement of ICAR 2025

A. Cingolani, Roma; A. Di Biagio, Genova;
M. Farinella, Roma; G.C. Marchetti, Milano



19-21
GIUGNO
ROMA

UNIVERSITÀ CATTOLICA
DEL SACRO CUORE
CENTRO CONGRESSI
EUROPA

16° CONGRESSO NAZIONALE



**Italian Conference on AIDS and
Antiviral Research**

20
24



Presidenza del Congresso

A. Cingolani, Roma
A. Di Biagio, Genova
M. Farinella, Roma
G. C. Marchetti, Milano

RESEARCH and CARE: FROM BENCH, TO BEDSIDE, TO COMMUNITY

DIGITAL POSTER EXHIBITION

Antiretroviral therapy

- P 1 Efficacy and safety of doravirine/lamivudine/tenofovir disoproxil fumarate in people living with HIV-1 aged over 60 years**
L. Calza, M. Giglia, V. Colangeli, F. Baldasso, M. Cantini, I. Grassi, A. Poma, S. Cretella, P. Viale
Unit of Infectious Diseases I, IRCCS S.Orsola Hospital, University of Bologna, Bologna, Italy
- P 2 Description of a cohort of people with HIV infection on long-acting antiretroviral therapy**
A. Di Biagio¹, E. Gaggero²
¹Università degli Studi di Genova, Genua, Italy, ²Università degli Studi di Genova, Genua, Italy
- P 3 Effectiveness and safety of tenofovir alafenamide/emtricitabine/bictegravir as first line regimen in people with HIV: a retrospective observational study**
A. Giacomelli^{1,2}, M.V. Cossu³, D. Moschese³, G. Carrozzo^{1,2}, S. Reato^{1,2}, F. Sabaini^{1,2}, G. Pozza^{1,2}, M.L. Colombo^{1,2}, C. Fusetti^{1,3}, A.L. Ridolfo², C. Geravasoni², S. Antinori^{1,2}, A. Gori^{1,4,5}
¹Dipartimento di Scienze Biomediche e Cliniche, Università degli Studi di Milano, Milan, Italy, ²III Division of Infectious Diseases, ASST Fatebenefratelli Sacco, Luigi Sacco Hospital, Milan, Italy, ³Infectious Diseases Unit, ASST Fatebenefratelli Sacco, Luigi Sacco Hospital, Milan, Italy, ⁴Centre for Multidisciplinary Research in Health Science (MACH), University of Milano, Milano, Italy, ⁵II Infectious Diseases Unit, ASST Fatebenefratelli Sacco, Luigi Sacco Hospital, Milan, Italy
- P 4 Low level viremia at the beginning and in course of long-acting treatment with injectable cabotegravir and rilpivirine**
L. Taramasso¹, E. Ricci², A. De Vito³, N. Squillace⁴, S. Ferrara⁵, E. Pontali⁶, G. Cenderella⁷, G.F. Pellicanò⁸, E. Sarchi⁹, F. Lagi¹⁰, E. Salomoni¹¹, M.A. Carleo¹², O. Bargiacchi¹³, G. Madeddu³, A. Cascio¹⁴, B. Menzaghi¹⁵, G.V. De Socio¹⁶, K. Falasca¹⁷, P. Bonfanti¹⁸, A. Di Biagio^{1,18} for the CISA study group
¹Infectious Disease Clinic, IRCCS Ospedale Policlinico San Martino di Genova, Italy, ²Fondazione ASIA, Milan, Italy, ³Unit of Infectious Diseases, Department of Medicine, Surgery and Pharmacy, University of Sassari, Italy, ⁴Infectious Disease Unit, Fondazione IRCCS San Gerardo dei Tintori, Monza - University of Milano-Bicocca, Monza, Italy, ⁵Unit of Infectious Diseases, Department of Clinical and Experimental Medicine, University of Foggia, Foggia, Italy, ⁶Department of Infectious Diseases, Galliera Hospital, Genoa, Italy, ⁷Infectious Diseases Department, Sanremo Hospital, Sanremo, Italy, ⁸Unit of Infectious Diseases, Department of Human Pathology of the Adult and the Developmental Age 'G. Barresi', University of Messina, Messina, Italy, ⁹Infectious Diseases Unit, S. Antonio e Biagio e Cesare Arrigo Hospital, Alessandria, Italy, ¹⁰AOU Infectious and Tropical Diseases, Careggi Hospital, Florence, Italy, ¹¹SOC 1 USL-CENTRO FIRENZE, Unit of Infectious Diseases, Santa Maria Annunziata Hospital, Florence, Italy, ¹²Infectious Diseases and Gender Medicine Unit, Cotugno Hospital, AO dei Colli, Naples, Italy, ¹³Unit of Infectious Diseases, Ospedale Maggiore della Carità, Novara, Italy, ¹⁴Unit of Infectious Diseases, Department of Health Promotion, Mother and Child Care, Internal Medicine and Medical Specialties, University of Palermo, Palermo, Italy, ¹⁵Unit of Infectious Diseases, ASST della Valle Olona - Busto Arsizio, Varese, Italy, ¹⁶Unit of Infectious Diseases, Santa Maria Hospital, Perugia, Italy, ¹⁷Clinic of Infectious Diseases, Department of Medicine and Science of Aging, G. D'Annunzio University, Chieti-Pescara, Chieti, Italy, ¹⁸Department of Health Sciences (DISSAL), University of Genoa, Genoa, Italy
- P 5 Improved lipid profiles in adults living with HIV receiving doravirine-based regimens: week 52 analysis**
N. Braccialarghe¹, D. Zaçe¹, L.V. Rindi¹, L. Ansaldo¹, M. Compagno², E. Tefi², A.M. Geretti^{1,2,3}, L. Sarmati^{1,2}
¹Department of Systems Medicine, University of Rome Tor Vergata, Rome, Italy, ²Infectious Diseases Unit, Fondazione Policlinico Tor Vergata, Rome, Italy, ³School of Immunity and Microbial Sciences, King's College London, London, United Kingdom
- P 6 Feasibility of cabotegravir and rilpivirine long-acting injection specific program in a large center in Northern Italy: adherence, tolerability and costs**
G.M. Piccardi¹, G. Tiecco², S. Arsuffi², B. Fioretti², D. Minisci², C. Anzoni², R. Fazio¹, S. Turriceni², I. Polesini², F. Castelli², E. Quiros-Roldan², E. Focà²
¹SC Farmacia Aziendale, ASST Spedali Civili di Brescia, Brescia, Italy, ²Department of Clinical and Experimental Sciences, Unit of Infectious and Tropical Diseases, University of Brescia and ASST Spedali Civili di Brescia, Brescia, Italy
- P 7 Outdated Antiretroviral Regimens (OLD-ART): A Cross-Sectional Study on the Achilles' Heel of Outpatient Care**
G. Tiecco, M. Alberti, M. Salvi, M. Di Gregorio, L. Zeneli, E. Focà, F. Castelli, E. Quiros-Roldan
Department of Clinical and Experimental Sciences, Unit of Infectious and Tropical Diseases, University of Brescia and ASST Spedali Civili di Brescia, Brescia, Italy
- P 8 Experience with the use of prolonged-release injectable CAB/RPV in outpatients**
N. Bobbio, D. Fiorellino, S. Puppo, E. Blasi Vacca, S. Boni, F. Del Puente, M. Feasi, A. Parisini, S.R. Prinapori, Tigano, E. Pontali
Infectious Disease Department, Galliera Hospital, Genoa, Italy
- P 9 Cost/effectiveness analysis and assessment of adverse events associated with the administration of the long-acting cabotegravir - rilpivirine association**
D. Cicetti^{1,2}, S. Vitale^{1,2}, L. Appolloni^{1,2}, G. Pensalfine^{1,2}, M. Traficante^{1,2}, R. Caprara^{1,2}, L. Calza³, A. Stancari¹
¹IRCCS University Hospital Company - S.Orsola-Malpighi Polyclinic - Clinical Pharmacy, Research and Development, Bologna, Italy, ²IRCCS University Hospital Company - S.Orsola-Malpighi Polyclinic - Department of Infectious and Tropical Disease, Bologna, Italy, ³IRCCS Azienda Ospedaliero-Universitaria Policlinico S.Orsola - Malpighi - Dipartimento Interaziendale Gestione Integrata Rischio Infettivo, Bologna, Italy
- P 10 Unconventional use of Long-Acting CAB+RPV against HIV in PWH in need: real-world data at 48 weeks from an Italian bicentric cohort**
V. Iannone¹, R. Rossotti², N.B. Bana², G. Cavazza², F. D'Amico², F. Lombardi³, P.F. Salvo¹, G. Baldin³, S. Di Giambenedetto^{1,3}, D. Bernacchia⁴, G. Paganini⁴, A. Borghetti⁵, S. Rusconi⁴
¹Department of Medical and Surgical Science, Infectious Diseases, Catholic University of Sacred Heart, Rome, Italy, ²Department of Infectious Diseases, ASST Grande Ospedale Metropolitano Niguarda, School of Medicine and Surgery, Milan, Italy, ³UOC Infectious Diseases, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy, ⁴Infectious Diseases Unit, ASST Ovest Milanese, Legnano General Hospital, and DIBIC, University of Milan, Milan, Italy, ⁵Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy
- P 11 Central Nervous System and Neuropsychiatric adverse events in Women Living with HIV treated with INSTI-based regimens**
A. De Vito^{1,2}, P. Bonfanti³, E. Ricci⁴, B. Menzaghi⁵, G. Orofino⁶, N. Squillace³, P. Maggi⁷, C. Molteni⁸, E. Sarchi⁹, G.V. De Socio¹⁰, B.M. Celesia¹¹, F.G. Pellicanò¹², F. Lagi¹³, R. Gulminetti¹⁴, L. Taramasso¹⁵, L. Albini¹⁶, A. Di Biagio¹⁵, G. Madeddu¹
¹Unit of Infectious Disease, Department of Medicine, Surgery and Pharmacy, University of Sassari, Sassari, Italy, ²PhD School in Biomedical Science, Biomedical Science Department, University of Sassari, Sassari, Italy, ³Infectious Disease Unit, Fondazione IRCCS San Gerardo dei Tintori, Monza - University of Milano-Bicocca, Monza, Italy, ⁴Fondazione ASIA, Milan, Italy, ⁵Unit of Infectious Diseases, ASST della Valle Olona, Busto Arsizio (VA), Italy, ⁶Division I of Infectious and Tropical Diseases, ASL Città di Torino, Italy, ⁷Infectious Diseases Unit, AORN Sant'Anna e San Sebastiano, Caserta, Italy, ⁸Unit of Infectious Diseases, A. Manzoni Hospital, Lecco, Italy, ⁹Infectious Diseases Unit, S. Antonio e Biagio e Cesare Arrigo Hospital, Alessandria, Italy, ¹⁰Unit of Infectious Diseases, Santa Maria Hospital, Perugia, Italy, ¹¹Unit of Infectious Diseases, Garibaldi Hospital, Catania, Italy, ¹²Unit of Infectious Diseases, Department of Human Pathology of the Adult and the Developmental Age 'G. Barresi', University of Messina, Messina, Italy, ¹³AOU Infectious and Tropical Diseases, Careggi Hospital, Florence, Italy, ¹⁴Fondazione IRCCS Policlinico S. Matteo, Infectious Diseases, University of Pavia, Pavia, Italy, ¹⁵Infectious Diseases Unit, Ospedale Policlinico San Martino - IRCCS per l'Oncologia Department of Health's Sciences, University of Genoa, Genoa, Italy, ¹⁶Gilead Science S.r.l, Milan, Italy
- P 12 Switching from 3TC/DTG and RPV/DTG to Triple Drug and Dual PI-Based therapies for toxicity/intolerance: data from the ICONA cohort**
A. De Vito^{1,2}, A. Tavelli³, A. Giacomelli⁴, M. Mazzitelli⁵, M. Ceccarelli⁶, F. Balena⁷, L. Alessio⁸, M.L. Colombo⁹, S. Di Giambenedetto¹⁰, D. Canetti¹¹, R. Rossotti¹², R. Gagliardini¹³, S. Lo Caputo¹⁴, A. Cozzi-Leperi¹⁵, A. d'Armino Monforte³ on behalf of Icona Foundation Study Group
¹Unit of Infectious Disease, Department of Medicine, Surgery and Pharmacy, University of Sassari, Sassari, Italy, ²PhD School in Biomedical Science, Biomedical Science Department, University of Sassari, Sassari, Italy, ³ICONA Foundation, Milan, Italy, ⁴III Infectious Diseases Unit, ASST BFB-Sacco, Milan, Italy, ⁵Infectious and Tropical Diseases Unit, Padua University Hospital, Padua, Italy, ⁶Department of Clinical and Experimental Medicine, University of Messina, Messina, Italy, ⁷Clinic of Infectious Diseases, Department of Precision and Regenerative Medicine and Ionian Area, University of Bari, Bari, Italy, ⁸Azienda Ospedaliera di Rilevanza Nazionale e di Alta Specializzazione S. Anna e S. Sebastiano, Caserta, Italy, ⁹Department of Biomedical and Clinical

Sciences, Università degli Studi di Milano, Milan, Italy, ¹⁰Clinic of Infectious Diseases, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Catholic University, Rome, Italy, ¹¹Infectious Diseases Unit, IRCCS San Raffaele Scientific Institute, Milan, Italy, ¹²Department of Infectious Diseases, ASST Grande Ospedale Metropolitano Niguarda, School of Medicine and Surgery, Milan, Italy, ¹³National Institute for Infectious Diseases Lazzaro Spallanzani, IRCCS, Roma, Italy, ¹⁴Clinic of Infectious Diseases, Department of Clinical and Surgical Sciences, University of Foggia, Foggia, Italy, ¹⁵Centre for Clinical Research, Epidemiology, Modelling and Evaluation (CREME), Institute for Global Health, University College London, London, UK

- P 13 Efficacy and safety of B/F/TAF in naïve people with HIV: real life data from the SHiNE and SHiC cohorts**
G. Moi¹, A. De Vito^{1,2}, G. Conti³, B.M. Celesia³, S. Spampinato³, A. Marino³, C. Cali⁴, M.A. Di Rosolini⁴, A. Colpani¹, L. Corda¹, G. Sanna⁵, G. Angioni⁵, G. Nunnari³, G. Madeddu¹
¹Unit of Infectious Disease, Department of Medicine, Surgery and Pharmacy, University of Sassari, Sassari, Italy, ²PhD School in Biomedical Science, Biomedical Science Department, University of Sassari, Sassari, Italy, ³Department of Clinical and Experimental Medicine, University of Catania, Catania, Italy, ⁴Infectious and Tropical Diseases Unit, Modica Hospital, Ragusa, Italy
- P 14 Antiretroviral therapy: consumption, costs and demographic profile of patients treated at a University Hospital in Italy in 2023**
L. Martellone, A. Coluccia, M. Vaccaro, K. Malandrini, G. Polito
Policlinico Umberto I Hospital, Rome, Italy
- P 15 Real-life use of doravirine in ART-Experienced PLWH bearing drug resistance mutations: findings from a monocentric cohort study**
S. Cotugno, M. Polisenò, L. De Santis, G. Manco Cesari, G. Metrangolo, R. Novara, G. Brindicci, C.R. Santoro, F. Di Gennaro, A. Saracino
Department of Precision and Regenerative Medicine and Ionian Area (DiMePre-J), University of Bari Aldo Moro, Bari, Italy
- P 16 Long-term durability of dolutegravir + darunavir/cobicistat dual regimen in highly antiretroviral-experienced people living with HIV (DoDaco study)**
D. Ripamonti¹, L. Comi¹, A. Francavilla², D. Valentini², M.V. Cossu³, D. Moschese³, G. Lapadula⁴, L. Mezzadri⁴, P. Bonfanti⁴, M. Mazzitelli⁵, A.M. Cattelan⁵, M. Fabbiani⁶, T. Bini⁷, A. Giacomelli⁸
¹ASST Papa Giovanni XXIII, Bergamo, Italy, ²FROM - Fondazione per la Ricerca Ospedale di Bergamo – ETS, Bergamo, Italy, ³ASST Fatebenefratelli, Ospedale Luigi Sacco, Milano, Italy, ⁴University of Milano-Bicocca, Fondazione IRCCS San Gerardo dei Tintori, Monza, Italy, ⁵Padua University Hospital, Padova, Italy, ⁶Azienda Ospedaliero-Universitaria Senese, Siena, Italy, ⁷ASST Santi Paolo e Carlo, Milano, Italy
- P 17 Insights into patients perspectives: identifying barriers in the transition from oral to injectable antiretroviral treatment**
M. Polisenò¹, A. Vigna¹, M. Cibelli¹, N. De Gennaro¹, E. Milano¹, C. Grillo², F.R.P. Ieva², S.M. Ferrara², S. Lo Caputo², F. Di Gennaro¹, A. Saracino¹
¹Clinic of Infectious Diseases, Department of Precision and Regenerative Medicine and Ionian Area (DiMePreJ), A.O.U.C. Policlinico di Bari, Bari, Italy, ²Clinic of Infectious Diseases, Department of Clinical and Surgical Sciences, University of Foggia, Foggia, Italy
- P 18 Therapeutic switch to long acting cabotegravir/rilpivirine to overcome malabsorption due to ulcerative colitis in a person living with HIV, a case report**
F. Sabaini^{1,2}, G. Pozza^{1,2}, A. Giacomelli^{1,2}, C. Fusetti^{1,3}, S. Antinori^{1,2}
¹Department of Biomedical and Clinical Sciences, Università degli Studi di Milano, Italy, ²III Division of Infectious Diseases, ASST Fatebenefratelli Sacco, Luigi Sacco Hospital, Milano, Italy, ³II Division of Infectious Diseases, ASST Fatebenefratelli Sacco, Luigi Sacco Hospital, Milano, Italy
- P 19 High lipid levels in patients living with HIV undergoing triple antiretroviral therapy**
L. Moffa¹, C. Tana², C. Ucciferri¹, K. Falasca¹, J. Vecchiet¹
¹Clinica Malattie Infettive, Università degli Studi Gabriele D'Annunzio, Chieti, Italy, ²Clinica di Geriatria, Università degli Studi Gabriele D'Annunzio, Chieti, Italy
- P 20 A real-life study in HIV-infected patients on NNRTI-regimen undergoing therapeutic optimization**
M. Trizzino¹, D. Arena², R. Gaudiano², R. Rubino¹, L. Pipitò², M. Piccione², I. Ganci², A. Cascio²
¹Infectious and Tropical Diseases Unit, Emergency and Urgency Department, Azienda Ospedaliera Universitaria Policlinico 'Paolo Giaccone', Palermo, Italy, ²Infectious and Tropical Diseases Unit, Department of Health Promotion, Mother and Child Care, Internal Medicine and Medical Specialties, Azienda Ospedaliera Universitaria Policlinico 'Paolo Giaccone', Palermo, Italy
- P 21 Efficacy and safety of switching to co-formulated DOR/TDF/3TC in HIV-1-infected, ART experienced adults: data from a single Italian Center in Florence, Italy**
G. Formica¹, G. Somma¹, F. Ducci¹, G. Toti¹, S.T. Kiro¹, J. Mencarini², C. Malcontenti², M. Pozzi², B. Borch², C. Fiorelli², I. Campolmi², G. Sterrantino¹, A. Bartoloni^{1,2}, F. Lagi²
¹Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy, ²Infectious and Tropical Diseases Unit, Careggi University Hospital, Florence, Italy
- P 22 Durability of doravirine/lamivudine/tenofovir disoproxil fumarate in a cohort of treatment-experienced people with HIV: a retrospective observational study**
A. Rabbione¹, S. Pagano¹, M.V. Cossu², D. Moschese², A. Giacomelli¹, A. Gori^{3,4}, S. Antinori^{1,5}, C. Gervasoni¹
¹III Division of Infectious Diseases, ASST Fatebenefratelli Sacco, Luigi Sacco Hospital, Milano, Italy, ²I Division of Infectious Diseases, ASST Fatebenefratelli Sacco, Luigi Sacco Hospital, Milano, Italy, ³II Infectious Disease Unit, Ospedale Luigi Sacco, ASST Fatebenefratelli Sacco, Milano, Italy, ⁴Centre for Multidisciplinary Research in Health Science (MACH), Università degli Studi di Milano, Milano, Italy, ⁵Department of Biomedical and Clinical Sciences, Università degli Studi di Milano, Italy
- P 23 Durability and effectiveness of dual versus triple INSTI-based antiretroviral therapy in a real-world cohort in Palermo**
R. Gaudiano¹, M. Trizzino², B. Romanin², M. Piccione², D. Arena², E. De Luca³, A. Cascio^{1,2}
¹Department of Health Promotion, Mother and Child Care, Internal Medicine and Medical Specialties "G D'Alessandro", University of Palermo, Palermo, Italy, ²Infectious and Tropical Disease Unit and Sicilian Regional Reference Center for the Fight against AIDS, AOU Policlinico "P. Giaccone", Palermo, Italy, ³Hospital Pharmacy, AOU Policlinico "P. Giaccone", Palermo, Italy
- P 24 Experienced PWH switching to 3TC/TDF/DOR in outpatient setting: real-life data on Lipid changes and ASCVD risk from an Italian multicenter cohort**
V. Iannone¹, A. Ciccullo², D. Moschese³, F. Lombardi⁴, A. Giacomelli³, M. Fabbiani⁵, F. Lagi⁶, C. Papalini⁷, A. De Vito⁸, M.V. Cossu³, G. Madeddu⁸, D. Francisci⁷, S. Di Giambenedetto^{1,4}, A. Borghetti⁹
¹Department of Medical and Surgical Science, Infectious Diseases, Catholic University of Sacred Heart, Rome, Italy, ²Infectious Diseases Unit, San Salvatore Hospital, L'Aquila, Italy, ³Division of Infectious Diseases, ASST Fatebenefratelli Sacco, Luigi Sacco Hospital, Milano, Italy, ⁴Department of Infectious Diseases, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy, ⁵Department of Medical Sciences, Infectious and Tropical Diseases Unit, University Hospital of Siena, Siena, Italy, ⁶Infectious and Tropical Diseases Unit, Careggi University Hospital, Florence, Italy, ⁷Department of Medicine, Clinic of Infectious Diseases, "Santa Maria della Misericordia" Hospital, University of Perugia, Perugia, Italy, ⁸Unit of Infectious Diseases, Department of Medicine, Surgery and Pharmacy, University of Sassari, Sassari, Italy, ⁹Department of Clinical and Experimental Medicine, Infectious diseases Unit, University of Pisa, Italy
- P 25 Switching to long-acting cabotegravir/rilpivirine: data from an Italian monocentric cohort**
M. Matone¹, D. Moschese¹, A. Giacomelli², M. Piscaglia¹, A. Capetti¹, G. Pozza², L. Galli³, M. Faenzi¹, S. Sportoletti¹, A. Riva², S. Antinori², A. Gori^{1,3,4}, M.V. Cossu¹
¹Department of Infectious Diseases, Unit I, L. Sacco Hospital, ASST Fatebenefratelli Sacco, Milano, Italy, ²Institute of Infectious Diseases & Tropical Medicine, III Division, ASST Fatebenefratelli Sacco, Luigi Sacco Hospital, Milano, Italy, ³Department of Infectious Diseases, Unit II, L. Sacco Hospital, ASST Fatebenefratelli Sacco, Milano, Italy, ⁴Centre for Multidisciplinary Research in Health Science (MACH), University of Milano, Milano, Italy
- P 26 Changing life perception in a heavy treated population living with HIV after long-acting regimen introduction**
G. Picchi¹, V. Cofini², S. Aviani¹, F. Ferri³, L. Cappelloni⁴, R. Preziosi¹, S. Farinelli¹, L. Caterini¹
¹Infectious Disease Department, Belcolle Hospitali, Strada Sarmartinese, Viterbo Italy, ²Department of Clinical Medicine, Life, Health and Environmental Sciences- MESVA, University of L'Aquila, Italy, ³Penitentiary medicine Department, Belcolle Hospitali, Strada Sarmartinese, Viterbo Italy, ⁴Infermieristic Degree Program, Faculty of Medicine, University "La Sapienza", Rome, Italy

- P 27 Virological failures in newly discovered people living with HIV treated with TAF/FTC/BIC as first line regimen**
F. Lamanna¹, D. Farinacci¹, A. D'Angelillo², R.A. Passerotto², E. Visconti¹, G. Baldin¹, A. Ciccullo³, F. Lombardi², S. Di Giambenedetto^{1,2}, A. Borghetti⁴
¹Fondazione Policlinico Universitario "A. Gemelli" IRCCS, Roma, Italia, ²Università Cattolica del Sacro Cuore, Roma, Italia, ³Ospedale San Salvatore, L'Aquila, Italia, ⁴UO Malattie Infettive, Università di Pisa, Pisa, Italia
- P 28 Treatment experienced PWH switching to 3TC/TDF/DOR: lipid profile changes over 144 Weeks of follow up in a single-center Italian cohort**
V. Iannone¹, P.F. Salvo¹, G. Baldin², F. Lombardi², A. Carbone¹, G. Lenzi¹, A. Borghetti³, S. Di Giambenedetto^{1,2}, A. Ciccullo⁴
¹Department of Medical and Surgical Science, Infectious Diseases, Catholic University of Sacred Heart, Rome, Italy, ²UOC Infectious Diseases, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy, ³Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy, ⁴Infectious Diseases Unit, San Salvatore Hospital, L'Aquila, Italy
- P 29 Efficacy and tolerability of INI-based 2-drug regime in viro-suppressed patients: a systematic review and a meta-analysis**
M.G. Palamone, A. Russo, S. Martini, M. Pisaturo, M. Russo, V. Zollo, R. Palladino, P. Grimaldi, N. Coppola
Department of Mental Health and Public Medicine - Infectious Disease Unit, University of Campania Luigi Vanvitelli, Naples, Italy
- P 30 Switch from Ibalizumab to Lenacapavir in a salvage therapy for a patient with multidrug-resistant HIV infection**
S. Martini¹, N. Cuomo², A. Russo¹, R. Palladino¹, A. Raddi², M. Pisaturo¹, N. Coppola¹
¹UOC Malattie infettive Università degli studi della Campania Luigi Vanvitelli, Napoli, Italy, ²AORN dei COLLI, Unità di Malattie Infettive Ospedale Cotugno, Napoli, Italy
- P 31 Optimisation of antiretroviral therapy through a spending review: a population-based approach**
M. Zordan¹, V. Barchi¹, A. Di Lorenzo¹, D. Checchi¹, M. Compagno¹, E. Teti¹, L. Sarmati², A.M. Geretti²
¹Clinical Infectious Diseases, Tor Vergata Hospital, Rome, Italy, ²Clinical Infectious Diseases, Department of System Medicine, Tor Vergata University, Rome, Italy
- P 32 Efficacy and tolerability of long-acting Cabotegravir/Rilpivirine in real-world setting, 52 weeks results**
F. Antonucci¹, M.M. Santoro², A. Bertoli^{2,3}, G. Torre³, S. Ferrara¹, C. Grillo¹, A. Narducci¹, F. Ceccherini-Silberstein², T. Santantonio¹, S. Lo Caputo¹
¹Department of Medical and Surgical Sciences, Infectious Diseases Unit, University of Foggia, Foggia, Italy, ²Department of Experimental Medicine, University of Rome Tor Vergata, Rome, Italy, ³Virology Unit, Tor Vergata University Hospital, Rome, Italy
- P 33 Long-Acting injectable regimen with Cabotegravir + Rilpivirine in people living with HIV: real-life experience from Modena HIV Clinic**
A. Soffritti¹, M. Menozzi², A. Cervo², C. Mussini²
¹University of Modena and Reggio Emilia, Modena Italy, Italy, ²Infectious Disease Clinic - AOU Policlinico Di Modena, Modena MO, Italy
- P 34 Patient profile characteristics when choosing different Dolutegravir-based dual therapies: impact on long term efficacy and durability**
E. Morelli^{1,2}, M. Sambo^{1,2}, A. Cinigiani^{1,2}, F. Panza^{1,2}, M. Crispo^{1,2}, S. Benedetti², C. Puttini², F. Montagnani^{1,2}, M. Tumbarello^{1,2}, M. Fabbiani^{1,2}
¹Department of Medical Biotechnologies, University of Siena, Siena, Italy, ²Infectious and Tropical Diseases Unit, Siena University Hospital, Siena, Italy
- P 35 Preliminary real world experience in a cohort of PLWH undergoing LA CAB/RPV in Latina: a heterogeneous population with homogeneous efficacy and satisfaction**
A. Carraro^{1,2}, R. Marocco², G. Mancarella^{1,2}, A. Zingaropoli¹, E. Tortellini¹, S. Guardiani¹, S. De Maria^{1,2}, S. Corazza¹, A. Grimaldi¹, A. Gasperin¹, P. Zuccalà², A. Parente^{1,2}, L. Ansaldo², M. D'Achille², V. Rossi², O. D'Onofrio², P. Addio³, C. Del Borgo², M. Lichtner⁴
¹Department of Public Health and Infectious Disease, Sapienza University of Rome, Rome, Italy, ²Infectious disease Unit, SM Goretti Hospital, Sapienza University of Rome, Latina, Italy, ³Pharmacy Unit, SM Goretti Hospital, Latina, Italy, ⁴Department of NESMOS, Sapienza University of Rome, Rome, Italy
- P 36 Long-acting injectable antiretroviral therapy: pursuing equity of access through shared decision-making**
E. Teti¹, M. Compagno¹, D. Checchi¹, T. Mulas¹, L. Ferrari¹, G. De Simone¹, A. Crea¹, C. Picarelli¹, V. Barchi¹, L.V. Rindi¹, A. Imeneo¹, G. Alessio¹, I. Fato¹, V. D'Aquila¹, A.R. Cavasio¹, R. Iannazzo¹, L. Minardi¹, B. Massa¹, C. Sorace¹, M. Zordan¹, L. Ansaldo¹, A. Di Lorenzo¹, L. Sarmati², A.M. Geretti²
¹Clinical Infectious Diseases, Tor Vergata Hospital, Rome, Italy, ²Clinical Infectious Diseases, Department of System Medicine, Tor Vergata University, Rome, Italy
- P 37 Feasibility of 3TC/DTG as a first-line strategy in the setting of rapid ART initiation: a retrospective study from the Pisan Cohort**
T. Matucci¹, A. Palomba¹, S. Occhineri¹, M.L. Vatteroni², L. Del Bono¹, M. Polidori¹, R. Iapoco¹, A. Borghetti¹, M. Falcone¹
¹U.O. Malattie Infettive, Azienda Ospedaliera Universitaria Pisana, Pisa, Italy, ²U.O. Virologia, Azienda Ospedaliera Universitaria Pisana, Pisa, Italy
- P 38 Evaluation of resistance-associated mutations to nucleotide reverse transcriptase inhibitors in patients treated with tenofovir disoproxil/lamivudine/doravirine**
D. Farinacci¹, F. Lamanna², R.A. Passerotto², R.J. Steiner², A. D'Angelillo², V. Iannone², G. Baldin¹, S. Di Giambenedetto^{1,2}
¹UOC Malattie Infettive e Tropicali, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy, ²Università Cattolica del Sacro Cuore, Rome, Italy
- P 39 Two is a company: results from a multicenter cohort of PLWHIV starting dolutegravir plus lamivudine as first-line regimen**
A. Ciccullo¹, G. Baldin², A. Cervo³, M.V. Cossu⁴, A. Grimaldi¹, A. Giacomelli⁵, S. Rusconi⁶, A. Borghetti⁶, C. Mussini³, S. Di Giambenedetto²
¹UOC Malattie Infettive, PO San Salvatore, L'Aquila, Italy, ²Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy, ³Azienda Ospedaliero Universitaria di Modena, Clinica Malattie Infettive e Tropicali, Modena, Italy, ⁴Department of Infectious Diseases, ASST Fatebenefratelli Sacco University Hospital, Milan, Italy, ⁵Infectious Diseases Unit, ASST Ovest Milanese Ospedale di Legnano, and DIBIC, University Milan, Legnano, Italy, ⁶Infectious Diseases Unit, Azienda Ospedaliero Universitaria Pisana, Pisa, Italy
- P 40 The Long Acting Therapy with CAB/RPV: experience at the Infectious Diseases Clinic of Perugia**
E. Schiaroli, S. Tordi, E. Svizzeretto, A. Tommasi, D. Francisci
Infectious Diseases Clinic of Perugia, Umbria, Italy
- P 41 Sexual quality of life and genital compartment inflammation in a cohort of patients undergoing long-acting cabotegravir/rilpivirine therapy**
A. Carraro^{1,2}, R. Marocco², G. Mancarella^{1,2}, A. Zingaropoli¹, E. Tortellini¹, S. Guardiani¹, C. Falvino¹, O. Turriziani³, S. De Maria^{1,2}, S. Corazza¹, A. Grimaldi¹, A. Gasperin¹, O. D'Onofrio², A. Carlesso², M. D'Achille², C. Del Borgo², M. Lichtner⁴
¹Department of Public Health and Infectious Disease, Sapienza University of Rome, Rome, Italy, ²Infectious disease Unit, SM Goretti Hospital, Sapienza University of Rome, Latina, Italy, ³Department of Molecular Medicine, Sapienza University of Rome, Rome, Italy, ⁴Department of NESMOS, Sapienza University of Rome, Rome, Italy
- P 42 Fostemsavir plus doravirine for the treatment of heavily treatment-experienced (HTE) people with HIV (PWH) with multi-drug resistant (MDR) HIV-1 infection: 48 weeks results in a real-life setting**
P.F. Salvo¹, V. Iannone¹, E. Visconti², F. Lamanna¹, R.A. Passerotto¹, R.J. Steiner¹, A. Carbone¹, S. Di Giambenedetto^{1,2}, G. Baldin²
¹Dipartimento di Scienze Mediche e Chirurgiche, Università Cattolica del Sacro Cuore, Rome, Italy, ²UOC Malattie Infettive, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome, Italy
- P 43 Incidence of transmitted drug resistance mutations among newly diagnosed HIV 1 patients: a 6-month retrospective analysis**
M. Cantini¹, R. Riccardi¹, F. Baldasso¹, A. Poma¹, L. Calza¹, I. Bon², P. Viale¹
¹Infectious Disease Unit, Department of Medical and Surgical Sciences, University of Bologna, Bologna, Italy, IRCCS S.Orsola Hospital, ²Microbiology Unit, IRCCS Policlinico di Sant'Orsola, University of Bologna, Bologna, Italy
- P 44 Cost-effectiveness of cabotegravir-rilpivirine LA vs. lamivudine/abacavir/dolutegravir and vs. bicitegravir/emtricitabine/tenofovir in the treatment of HIV+ patients in Italy, a short-term analysis**
D. Croce^{1,2}, F. De Nardo^{1,2}, F. Convenga¹, E. Croce², V. Aloviseti², G. Rizzardini³
¹CREMS, Castellanza, Italy, ²Università Carlo Cattaneo Liuc, Castellanza, Italy, ³ASST Fatebenefratelli Sacco, Milan, Italy

- P 45 Carotid Intima Media Thickness is increased in adolescent and young adults living with HIV**
M. Stracuzzi¹, F. Musto¹, C. Coppola¹, F. D'amarico², T. Porretta², V. Giacometti¹
¹Università degli studi di Milano, Luigi Sacco Hospital, Pediatric Infectious Diseases, Milan, Italy, ²Luigi Sacco Hospital, Vascular Surgery Unit, Milan, Italy
- P 46 20-year review of neurological outcomes in HIV-exposed uninfected children in a pediatric HIV referral center**
M. Stracuzzi, F. Musto, C. Coppola, A. Cargnelutti, G. Meraviglia, A. Dighera, V. Giacometti
Università degli studi di Milano, Luigi Sacco Hospital, Pediatric Infectious Diseases, Milan, Italy

Clinical HIV

- P 47 Heavily treatment-experienced (HTE) patients with multidrug-resistant HIV infection: population characteristics, treatment strategies, and clinical outcomes**
M. Giglia, C. Rigamonti, R. Riccardi, F. Malerba, S. Cretella, L. Calza
Unit of Infectious Diseases, IRCCS S. Orsola Hospital, University of Bologna, Bologna, Italy
- P 48 Factors influencing sleep disorders in people with HIV in a real-life setting**
F. Alberton^{1,2}, A. Castelnovo^{2,3}, S. Diotallevi¹, R. Lolatto¹, S. Marelli^{2,3}, M. Salsone^{2,3}, S. Nozza^{1,2}, V. Spagnuolo^{1,2}, N. Gianotti¹, L. Ferini-Strambati^{2,3}, A. Castagna^{1,2}
¹Infectious Diseases, IRCCS San Raffaele Scientific Institute, Milan, Italy, ²Vita-Salute San Raffaele University, Milan, Italy, ³Sleep Disorder Unit, IRCCS San Raffaele Scientific Institute, Milan, Italy
- P 49 An hospital-based integrated Healthy Life Program among PLWH: ongoing data from an outpatients clinic including Infectious Disease specialist, nutritionist, personal trainer and psychologist at "D. Cotugno" hospital, Naples, Italy**
M.A. Carleo¹, F.M. Fusco², M. Di Lorenzo¹, M. Vitale¹, L. Santoro¹, V. Rizzo¹, P. Rosario¹, A. Guida¹, R. Viglietti², O. Tambaro², F. Borrelli², V. Sangiovanni², V. Esposito¹
¹UOC Malattie Infettive e Medicina di genere, AO dei Colli – PO "D. Cotugno", Napoli, Italy, ²UOC Infezioni sistemiche e dell'immunodepresso, AO dei Colli – PO "D. Cotugno", Napoli, Italy
- P 50 Are new lipid lowering agents a good option for achieve lipid goal in HIV subjects?**
R. Ferri, G. Taraschi, J. Vecchiet, K. Falasca, C. Ucciferri
Department of Medicine and Science of Aging, University "G. D'Annunzio", Clinic of Infectious Diseases, Chieti, Pescara, Italy
- P 51 100% adherence to ART: a new paradigm in the long-acting era. Data from a cohort in Turin**
G. Orofino¹, M. Guastavigna¹, A. Ianniello¹, M. Ferrara², D. Arrue Diaz², V. Maccario², L. Di Girolamo², L. Ponzetta², G. Calleri¹
¹Tropical and Infectious Diseases Division A, Amedeo di Savoia Hospital, Turin, Italy, ²University of Turin, Turin, Italy
- P 52 Asymptomatic neurocognitive impairment in People Living With HIV infection (PLWH): are we misdiagnosing for someone?**
M.S. Paternò Raddusa, G. Emma, G. Conti, C. Giarratana, E. Pistarà, B. Bellocchi, E. Campanella, A. Bandiera, N. Villari, G. Nunnari, B.S. Cacopardo, B.M. Celesia
Unit of Infectious diseases. University of Catania. ARNAS Garibaldi Catania, Italy
- P 53 Pregnancy and birth outcomes in women living with HIV: real-life experience**
M. Mazzoccoli¹, N. Alfieri², A.M. Marconi², S. Dalzero², M. Ierardi², S.C. Simonetti², C. Tincati¹, F. Bai¹, T. Bini¹, G.C. Marchetti¹
¹Department of Infectious Diseases, San Paolo Hospital, Milan, Italy, ²Department of Obstetrics & Gynecology, San Paolo Hospital, Milan, Italy
- P 54 Prevalence of sleep disturbance in PLWHA. Time to action**
G. Orofino¹, A. Ianniello¹, M. Guastavigna¹, D. Arrue Diaz², P. Ragusa³, F. Bert³, G. Calleri¹
¹ASL City of Turin, Amedeo di Savoia Hospital, Tropical and Infectious Diseases, Turin, Italy, ²University of Turin, Medical Sciences Department, Turin, Italy, ³University of Turin, Department of Public Health and Pediatric Sciences, Turin, Italy
- P 55 Acute cardiac insufficiency in HIV: a jump into the past**
S. Esperi, A. Cervo, F. Casari, M. Del Monte, B. Fontana, F. Prandini, M. Menozzi, G. Guaraldi, C. Mussini
University of Modena e Reggio Emilia, Infectious Diseases Unit, University Hospital Policlinico di Modena, Italy
- P 56 Exploring effectiveness and tolerance: switching to long-acting cabotegravir plus rilpivirine therapy in virologically suppressed individuals with HIV**
C. Rigamonti¹, D. Marzolla¹, M. Giglia¹, S. Cretella², D. Cicetti², S. Vitale², L. Calza^{1,2}
¹Department of Medical and Surgical Sciences, Alma Mater Studiorum University of Bologna, Bologna, Italy, ²Infectious Diseases Unit, Department for Integrated Infectious Risk Management, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Italy
- P 57 Monitoring quality of life in PLWH using a patient reported outcomes (PRO) and screening tools for emotional and cognitive vulnerability**
S. Capodiec, A. Latini, S. Stingone, M. Zaccarelli, L. Gianserra, M.G. Donà, E. Giuliani, V. Cafaro, M. Giuliani
HIV/AIDS Unit, San Gallicano Dermatological Institute IRCCS, Rome, Italy
- P 58 Peroneal osteomyelitis by Mycobacterium haemophilum in a patient living with HIV**
E. Ghidoni¹, A. Cervo², B. Fontana¹, C. Mussini¹
¹Infectious Disease Unit - University of Modena and Reggio Emilia, Modena, Italy, ²Infectious Diseases Unit - AOU Policlinico of Modena, Modena, Italy
- P 59 Neutral Metabolic Impact of Long-Acting CAB+RPV in PLWH: A Tuscan Multicenter Observational Study (LAHIV)**
F. Lagi¹, G. Formica², E. Francelanci², M. Fognani², R. Paggi², G. Gasparro², M. Piccica³, A. Pampaloni⁴, D. Messeri⁵, B. Rossetti⁶, F. Panza⁷, S. Costarelli⁸, E. Riguccini⁹, G. Sarteschi¹⁰, M. De Gennaro¹¹, P. Corsi¹, M. Pozzi¹, G. Sterrantino², M. Tumbarello⁷, P. Blanc⁵, F. Bartalesi³, D. Aquilini⁴, C. Nencioni⁶, S. Luchi¹¹, D. Tacconi⁹, S. Sani⁸, A. Vincenti¹⁰, A. Bartoloni^{1,2}
¹Azienda Ospedaliero-Universitaria Careggi, Università degli Studi di Firenze, Italy, ²Dipartimento di medicina sperimentale e clinica, Università degli studi di Firenze, Italy, ³Ospedale Santa Maria Annunziata, USL Toscana Centro, Italy, ⁴Azienda Ospedaliera Prato, USL Toscana Centro, Italy, ⁵Azienda Ospedaliera Pistoia, USL Toscana Centro, Italy, ⁶Azienda Ospedaliera Grosseto, USL Toscana Sud-Est, Italy, ⁷Azienda Ospedaliero-Universitaria Siena, Università degli Studi di Siena, Italy, ⁸Azienda Ospedaliera Livorno, USL Toscana Nord-Ovest, Italy, ⁹Azienda Ospedaliera Arezzo, USL Toscana Sud-Est, Italy, ¹⁰Nuovo Ospedale Apuane, USL Toscana Nord-Ovest, Italy, ¹¹Azienda Ospedaliera Lucca, USL Toscana Nord-Ovest, Italy
- P 60 Efficacy, safety and discontinuation of rilpivirine and cabotegravir in HIV-1 virologically suppressed adults: a multicenter observational study in Tuscany (LAHIV study)**
F. Lagi¹, G. Formica², E. Francelanci², M. Fognani², R. Paggi², G. Gasparro², M. Piccica³, A. Pampaloni⁴, D. Messeri⁵, B. Rossetti⁶, M. Fabbiani⁷, S. Costarelli⁸, E. Riguccini⁹, G. Sarteschi¹⁰, M. De Gennaro¹¹, P. Corsi¹, M. Pozzi¹, G. Sterrantino², M. Tumbarello⁷, P. Blanc⁵, F. Bartalesi³, D. Aquilini⁴, C. Nencioni⁶, S. Luchi¹¹, D. Tacconi⁹, S. Sani⁸, A. Vincenti¹⁰, A. Bartoloni^{1,2}
¹Azienda Ospedaliero-Universitaria Careggi, Università degli Studi di Firenze, Italy, ²Dipartimento di medicina sperimentale e clinica, Università degli studi di Firenze, Italy, ³Ospedale Santa Maria Annunziata, USL Toscana Centro, Italy, ⁴Azienda Ospedaliera Prato, USL Toscana Centro, Italy, ⁵Azienda Ospedaliera Pistoia, USL Toscana Centro, Italy, ⁶Azienda Ospedaliera Grosseto, USL Toscana Sud-Est, Italy, ⁷Azienda Ospedaliero-Universitaria Siena, Università degli Studi di Siena, Italy, ⁸Azienda Ospedaliera Livorno, USL Toscana Nord-Ovest, Italy, ⁹Azienda Ospedaliera Arezzo, USL Toscana Sud-Est, Italy, ¹⁰Nuovo Ospedale Apuane, USL Toscana Nord-Ovest, Italy, ¹¹Azienda Ospedaliera Lucca, USL Toscana Nord-Ovest, Italy
- P 61 Salmonella spondylodiscitis and iliopsoas abscesses in a patient with HIV**
A. Boccia^{1,2}, I. Capriglione^{1,2}, G. Martone^{1,2}, A. Masiello², V. Iodice², F. Simeone², A. Iodice², F. Colucci^{1,2}, G. Di Caprio², A. Salzillo², P. Maggi^{1,2}
¹UOC Malattie Infettive, Università della Campania "L. Vanvitelli" Napoli, Italy, ²UOC Malattie Infettive, AORN "S. Anna e S. Sebastiano" Caserta, Italy

- P 62** **Viral blips in patients with Intestinal bowel syndrome (IBS): clinical case observation. Is dolutegravir plus lamivudine sufficiently protective against the risk of viral escape?**
M. Di Gregorio¹, C. Colangelo¹, P. Nasta²
¹Clinica di Malattie Infettive e Tropicali, Università degli Studi di Brescia e ASST Spedali Civili di Brescia, Italy, ²Clinica di Malattie Infettive e Tropicali, ASST Spedali Civili di Brescia, Italy
- P 63** **Prospective Memory and antiretroviral medication adherence in HIV**
V. Massaroni¹, V. Delle Donne², F. Lombardi³, S. Lamonica³, G. Lenzi¹, D. Farinacci³, A. Borghetti⁴, A. Ciccullo⁵, C. Torti^{1,3}, S. Di Giambenedetto^{1,3}
¹Infectious Diseases Institute, Department of Safety and Bioethics, Catholic University of Sacred Heart, Rome, Italy, ²Clinical Psychology Unit, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy, ³UOC Infectious Diseases, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy, ⁴Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy, ⁵Infectious Diseases Unit, San Salvatore Hospital, L'Aquila, Italy
- P 64** **MULTICentric HIV patients tracer For clinicAl assistanCe and rEsearch: feasibility, preliminary data from the MULTIFACE study**
F. Frondizi¹, E. Matteini¹, R. Iacopini², M. Chiuchiarelli¹, A. Luraschi², S. Lamonica¹, M.V. De Girolamo², S. Kyriazakos³, K. Kostopoulou³, A. Pnevmatikakis³, E. Visconti⁴, A. di Biagio^{5,6}, E. Quiros Roldan⁷, C. Torti^{1,4}, A. Cingolani^{1,4}, for MULTIFACE Working Group
¹Dipartimento di Sicurezza e Bioetica - Sezione di Malattie Infettive, Università Cattolica del Sacro Cuore, Rome, Italy, ²Gemelli Digital Medicine & Health Srl, Rome, Italy, ³Innovation Sprint Srl, Brussels, Belgium, ⁴Dipartimento di Scienze Mediche e Chirurgiche, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome, Italy, ⁵IRCCS Ospedale Policlinico San Martino, Genoa, Italy, ⁶Department of Health Sciences, University of Genoa, Italy, ⁷ASST Spedali Civili, Università degli Studi di Brescia, Italy
- P 65** **Exploring potential interactions between intramuscular cabotegravir(CAB)/rilpivirine(RPV) and methadone: a case report**
P.F. Salvo¹, G. Baldin², V. Iannone², M. Petrucci², F. Onorati², E. Visconti², G. Lenzi¹, A. D'angelillo¹, S. Di Giambenedetto^{1,2}
¹Dipartimento di Scienze Mediche e Chirurgiche, Università Cattolica del Sacro Cuore, Rome, Italy, ²UOC Malattie Infettive, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome, Italy
- P 66** **Patients' attitudes towards telehealth for HIV care: a single center survey**
L. Sasseti¹, M. Mazzitelli¹, D. Leoni¹, S. Gardin¹, A. Ferrari¹, E. Listori², L. Ferrara², A.M. Cattelan¹
¹Infectious Diseases Department of Padova - University - Hospital, Italy, ²Centre for Research on Health and Social Care Management - SDA Bocconi, Italy

Cooperation projects in low income countries

- P 67** **Prevalence of water-borne diseases among people exposed to climate disasters in Mozambique: a cross-sectional study**
F. Di Gennaro¹, F. Vladimiro Segala¹, E. Occa², E. Chambisse², F. Cavallin³, A. Nanombo², S. Cotugno¹, S. Cadorin², K. Chitnis⁴, A. Ghelardi⁴, G. Putoto⁵, A. Mussa⁶, A. Saracino¹
¹Clinic of Infectious Diseases, Department of Precision and Regenerative Medicine and Ionian Area - (DiMePre-J), University of Bari "Aldo Moro", Bari, Italy, ²Doctors with Africa CUAMM, Maputo, Mozambique, ³Independent statistician, Solagna, Italy, ⁴UNICEF Mozambique, ⁵Operational Research Unit, Doctors with Africa CUAMM, Padua, Italy, ⁶NIOOP Nucleo de Investigaçao Operacional del Pemba, Pemba, Mozambique

Epidemiology of viral infections

- P 68** **Recent infections in new HIV diagnoses: results of the national surveillance system**
L. Pugliese, V. Regino, B. Suligoj
Istituto Superiore di Sanità, Rome, Italy
- P 69** **Applications of excess event estimation to investigate mortality and infection spread during the covid19 pandemic**
L. Palla¹, D. Del Re², P. Meridiani³, L. Soffi³, M.T. Louidice⁴, M. Antinozzi¹, M.S. Cattaruzza¹
¹Department of Public Health and Infectious Diseases, Sapienza University, Rome, Italy, ²Department of Physics, Sapienza University, Rome, Italy, ³Istituto Nazionale Fisica Nucleare, Rome, Italy, ⁴Department of Developmental and Social Psychology, Sapienza University, Rome, Italy
- P 70** **Back to the measles – first evidence of viral circulation in Liguria, Northern Italy, 2024**
G. Garzillo¹, F. Stefanelli², N. Randazzo², G. Guarona¹, M. Lucente², C. Fraccalvieri², N. Nigro², V. Ricucci², E. Massaro¹, M. Ogliastrò¹, A. Orsi^{1,2}
¹Department of Health Sciences, University of Genoa, Genoa, Italy, ²Hygiene Unit, Policlinico San Martino Hospital, Genoa, Italy
- P 71** **Short-term mortality in people with HIV infection over the past two decades**
M. Melchio^{1,2}, M. Bavastro^{1,2}, L. Taramasso², C. Marelli², M. Bassetti^{1,2}, A. Di Biagio^{1,2}
¹Division of Infectious Diseases, Department of Health Sciences, University of Genoa, Genoa, Italy, ²Division of Infectious Diseases, IRCCS Ospedale Policlinico San Martino, Genoa, Italy
- P 72** **HIV screening and treatment in two penitentiaries in Northern Italy: a retrospective analysis**
A. Cambianica¹, S. Calza², S. Rapino¹, M. Inverardi¹, B. Fioretti¹, L.A. Visentin¹, I. Rossetti³, F. Roda³, F. Castelli¹, E. Quiros Roldan¹, E. Focà¹
¹Division of Infectious and Tropical Diseases, University of Brescia and ASST Spedali Civili Hospital, Brescia, Italy, ²Unit of Biostatistics and Biomathematics, Unit of Bioinformatics, Department of Molecular and Transitional Medicine, University of Brescia, ³Unit of Prison Health ASST Spedali Civili Hospital, Brescia, Italy
- P 73** **Clinical and Epidemiological Insights in Severe Influenza patients admitted to emergency department with respiratory symptoms in the fourth year of SARS-CoV-2 pandemic**
A. Parente^{1,2}, B. Kertusha^{1,2}, T. Tieghi¹, R. Marocco^{1,2}, C. Giambi³, G. Blanco⁵, F. De Cave⁵, A. Grimaldi², S. Corazza², U. Basile⁶, M. Lichtner⁴, C. Del Borgo^{1,2}
¹Infectious Diseases Unit, S.M. Goretti Hospital, Latina, Italy, ²Sapienza University of Rome, Department of Infectious Diseases and Public Health, Italy, ³Public Health Service, ASL Latina, Italy, ⁴Sapienza University of Rome, Department of NESMOS, Italy, ⁵Microbiology Unit, S.M. Goretti Hospital, Latina, Italy, ⁶Clinical Pathology Unit, S.M. Goretti Hospital, Latina, Italy
- P 74** **The changing landscape of hospitalized PLWH: how the referral of cases in a center Italy ward changed during the SARS-CoV-2 pandemic**
F. Pallotta^{1,2}, S. Fioriti¹, G. Cesaretti^{1,2}, I. Luchetti^{1,2}, A. Di Fortunato^{1,2}, A. Ficola^{1,2}, A. Iannacone^{1,2}, A. Ianovitz^{1,2}, V. Perticaroli^{1,2}, G. Gelo Signorino^{1,2}, V. Lauria^{1,2}, L. Brescini^{1,2}, O. Cirioni^{1,2}, A. Giacometti^{1,2}
¹Dipartimento di Scienze Biomediche e Sanità Pubblica, Università Politecnica delle Marche, Ancona, Italy, ²Clinica di Malattie Infettive, Azienda Ospedaliero- Universitaria delle Marche, Ancona, Italy

HIV coinfections and comorbidities

- P 75** **Weight gain and lipid change according to baseline comorbidities and previous antiretroviral regimen in cohort of people treated with bictegravir/emtricitabine/tenofovir alafenamide**
L. Taramasso¹, L. Labate², E.D. Ricci³, S. Bianchi¹, F. Centorrino¹, M. Bassetti^{1,2}, A. Di Biagio^{1,2}
¹Infectious Disease Clinic, IRCCS Polyclinic San Martino Hospital, Genoa, Italy, ²Department of Health Sciences (DISSAL), University of Genoa, Genoa, Italy, ³Fondazione ASIA, Milan, Italy

- P 76 Multidimensional characterization of erectile dysfunction in young man living with HIV: a cross-sectional study**
G. Tiecco¹, M. Di Gregorio¹, C. Colangelo¹, P. Facondo², A. Delbarba², C. Cappelli², S. Storti¹, M. Salvi¹, M. Alberti¹, E. Focà¹, F. Castelli¹, E. Quirós-Roldán¹
¹Department of Clinical and Experimental Sciences, SD of Infectious and Tropical Diseases, University of Brescia and ASST Spedali Civili di Brescia, Brescia, Italy, ²Department of Clinical and Experimental Sciences, SSD of Endocrinology and Metabolism, University of Brescia and ASST Spedali Civili di Brescia, Brescia, Italy
- P 77 The influence of blood brain barrier permeability on serum-to-CSF ratios of central nervous system biomarkers in people with HIV**
J. Cusato¹, M. Antonucci², M. Trunfo³, D. Imperiale⁴, E. Vuaran³, A. Palermi¹, G. Di Perri³, A. D'Avolio¹, S. Bonora³, A. Calcagno³
¹Laboratory of Clinical Pharmacology and Pharmacogenetics, Department of Medical Sciences, University of Turin, Amedeo di Savoia Hospital, Turin, Italy, ²SCDU Infectious Diseases, Amedeo di Savoia Hospital, ASL Città di Torino, Turin, Italy, ³Unit of Infectious Diseases, Department of Medical Sciences, University of Turin, Amedeo di Savoia Hospital, Turin, Italy, ⁴Unit of Neurology, Maria Vittoria Hospital, ASL Città Di Torino, Turin, Italy
- P 78 Nutrition support service focused on weight loss in an HIV outpatient clinic: our experience**
P. Vitiello¹, A. Arcuri², C. Abeli¹, J. Testa¹, B. Menzaghi¹, D. Radrizzani¹, F. Strambio De Castilla¹, M. Farinazzo¹, F. Franzetti¹
¹ASST Valle Olona, Infectious Diseases Unit, Busto Arsizio (VA), Italy, ²Fondazione IRCCS Policlinico San Matteo, Tropical and Infectious Diseases Unit, Pavia, Italy
- P 79 High-risk HPV genotypes are associated with anal cytologic abnormalities but not with malignant histological lesions in a cohort of people with HIV (PWH)**
N. Squillace¹, D.P. Bernasconi², V. Cogliandro¹, G. Lapadula¹, A. Soria¹, F. Sabbatini¹, E. Colella¹, M. Rossi¹, A. Cappelletti¹, G. Spreafico¹, A.M. Tamburini², B.E. Leone⁴, S. Malandrini⁵, A. Cavallero⁶, A. Di Lucia⁶, M. Braga⁶, P. Bonfanti¹
¹Infectious Diseases Unit, Fondazione IRCCS San Gerardo dei Tintori, University of Milano-Bicocca, Monza, Italy, ²Bicocca Bioinformatics Biostatistics and Bioimaging Centre - B4 School of Medicine and Surgery University of Milano-Bicocca, Monza, Italy, ³Department of Gastrointestinal Surgery, Scientific Institute San Raffaele, Milan, Italy, ⁴Pathology, Department of Medicine and Surgery, University of Milano-Bicocca, Fondazione San Gerardo Hospital, Monza, Italy, ⁵Microbiology Unit, Fondazione IRCCS San Gerardo dei Tintori, Monza, Italy, ⁶Department of Surgery, Fondazione IRCCS San Gerardo dei Tintori, University of Milano-Bicocca, Monza, Italy
- P 80 Challenging the Bounds of Co-Infection: A Case Study on Severe Monkeypox in an Untreated HIV Patient and the Role of Tecovirimat in Treatment Efficacy**
T. Semenzin¹, G. Matusali³, E. Sozio², P. Della Siega², F. Colavita³, E. Cimini³, V. Mazzotta³, F. Maggi³, C. Tascini^{1,2}, S. Lanini^{1,2}
¹Department of Medicine (DAME), University of Udine, Udine, Italy, ²U.O. Malattie Infettive, Azienda Sanitaria Universitaria Friuli Centrale, Udine, Italy, ³Laboratory of Virology, National Institute for Infectious Diseases Lazzaro Spallanzani IRCCS, Rome, Italy
- P 81 Risk factors associated with NAFLD in people living with HIV**
V. Brogna¹, N. Squillace¹, V. Cogliandro¹, E. Ricci², B. Menzaghi³, P. Maggi⁴, F. Colucci⁴, A. Di Biagio^{5,6}, L.A. Nicolini⁵, K. Falasca⁷, E. Salomoni⁸, P. Bonfanti¹
¹Infectious Disease Unit, Fondazione IRCCS San Gerardo dei Tintori, University of Milano-Bicocca, Monza, Italy, ²Fondazione ASIA Onlus, Buccinasco, Milano, Italy, ³Unit of Infectious Diseases, ASST della Valle Olona - Busto Arsizio, Varese, Italy, ⁴Infectious Diseases Unit, AORN Sant'Anna e San Sebastiano, Caserta, Italy, ⁵Infectious Diseases, IRCCS Ospedale Policlinico San Martino, Genoa, Italy, ⁶Department of Health Science (Dissal), University of Genoa, Genoa, Italy, ⁷Department of Medicine and Science of Aging, Clinic of Infectious Diseases, University "G. D'Annunzio", Chieti, Pescara, Italy, ⁸Unit of Infectious Diseases, Santa Maria Annunziata Hospital, Florence, Italy
- P 82 Correlation between lipid profile, subclinical atherosclerosis, hepatic fibrosteatosis, and bone mineral density in PLWH: comparison between TAF/FTC/BIC and TDF/3TC/DOR**
V. Iodice, A. Masiello, A. Del Villano, A. Boccia, I. Capriglione, F. Simeone, A. Iodice, P. Maggi
UOC Malattie Infettive - AORN "Sant'Anna e San Sebastiano" - Via Palasciano, Caserta, Italy
- P 83 Incidence of lung-cancer in a cohort of PWH: a retrospective single-center observational study**
G. Carrozza^{1,2}, S. Reato^{1,2}, G. Pozza^{1,2}, F. Sabaini^{1,2}, M.L. Colombo^{1,2}, M. Zacheo^{1,2}, A. Giacomelli^{1,2}, C. Gervasoni¹, M.L. Oreni³, A.L. Ridolfo¹, S. Antinori^{1,2}
¹III Infectious Diseases Unit, ASST Fatebenefratelli Sacco, Luigi Sacco Hospital, Milan, Italy, ²Università degli Studi di Milano, DIBIC Luigi Sacco, Milan, Italy, ³IRCCS Fondazione Don Carlo Gnocchi, Milan, Italy
- P 84 Prevalence, characteristics and outcomes of TB-IRIS among a cohort of PWH and TB**
C. Sepulcri¹, L. Crupi^{1,2}, E. Delfino², M. Cerchiaro^{1,2}, L. Taramasso², M. Bassetti^{1,2}, A. Di Biagio^{1,2}
¹Clinic of Infectious Diseases, Department of Health Sciences, University of Genoa, Genoa, Italy, ²Clinic of Infectious Diseases, IRCCS Ospedale Policlinico San Martino, Genova, Italy
- P 85 Correlation among bone, endothelial and hepatic damage in PLWH**
A. Masiello¹, V. Iodice¹, F. Laguardia², A. Boccia², I. Capriglione², A. Iodice¹, F. Simeone¹, P. Maggi¹
¹Infectious Diseases Unit, AORN Sant'Anna e San Sebastiano, Caserta, Italy, ²Infectious Disease Unit, University Hospital Luigi Vanvitelli, Naples, Italy
- P 86 Extrapulmonary TB diagnosed during cabotegravir/rilpivirine long acting therapy: a novel pharmacologic challenge**
G. Picchi¹, M. Tempestilli², C. Temperoni¹, P. Vassalini¹, A. Emiliozzi¹, J. Vergari¹, S. Farinelli¹, R. Preziosi¹, L. Caterini¹
¹Infectious Disease Department, "Belcolle" Hospital, Viterbo (VT) Italy, ²Laboratory of Cellular Immunology and Pharmacology, National Institute for Infectious Diseases "L. Spallanzani" IRCCS, Rome, Italy
- P 87 Bulevirtide: Treatment in people living with HIV**
L. Pagnucco, R. Gulminetti, R. Bruno
S.C. Malattie Infettive 1, Dipartimento Medico, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy
- P 88 Influence of AIDS-defining events on PLWH hospitalization: implications for DRGs and length of stay. A retrospective administrative data analysis**
G. Cavazza^{1,2}, N.B. Bana^{1,2}, F. Peracchi^{1,2}, E.D. Gennaro^{1,2}, A. Mulè³, L. Dentì⁴, C. Baiguera¹, M.C. Moiola¹, A. Raimondi¹, M. Merli¹, R. Rossotti¹, M. Puoti^{1,2}
¹Department of Infectious Diseases, ASST Grande Ospedale Metropolitano Niguarda, Milan, Italy, ²Department of Health Science, University of Milano-Bicocca, Milan, Italy, ³Department of Clinical and Experimental Sciences, Unit of Infectious and Tropical Diseases, University of Brescia and ASST Spedali Civili di Brescia, Brescia, Italy, ⁴Unit of Infectious and Tropical Diseases, University of Sassari, Sassari, Italy
- P 89 Prevalence of metabolic syndrome among PLWH assuming NVP containing regimens and INSTI based dual therapy**
F. Conti¹, L. Bradanini¹, A. Chiesa¹, N. Gemignani^{1,2}, C. Molteni¹, V. Morena¹, A. Pandolfo¹, S. Volpi¹, S. Pontiggia¹, G. Valsecchi¹, S. Piconi¹
¹Malattie Infettive Ospedale Manzoni ASST Lecco, Lecco, Italy, ²University of Milan, Milan, Italy
- P 90 Plasma markers of gastrointestinal mucosal barrier dysfunction in PLWH receiving cART**
V. Artusa¹, R. Zamarato¹, A. De Nicolò², A. D'Avolio², L. Benedetti³, M. Compagno³, V. Malagnino³, M. Iannetta³, L. Duca⁴, F. Ceccherini Silberstein⁴, M. Biasin¹, D. Trabatonni¹, M.S. Clerici^{5,6}
¹University of Milan, Department of Biomedical and Clinical Sciences, Milan, Italy, ²University of Turin, Department of Medical Sciences, Turin, Italy, ³Tor Vergata University, Department of System Medicine, Rome, Italy, ⁴Tor Vergata University, Department of Experimental Medicine, Rome, Italy, ⁵University of Milan, Department of Pathophysiology and Transplantation, Milan, Italy, ⁶IRCCS Don Carlo Gnocchi Foundation, Milan, Italy
- P 91 Characterization of bacterial infections in people living with HIV from January 2018 to January 2023**
C. Nonne¹, D.E. Compagnino¹, D. Tomolillo³, G. Sfora¹, R. Campagna¹, M.G. Leone¹, G. Antonelli^{1,2}, G. Raponi^{2,3}, O. Turriziani¹
¹Department of Molecular Medicine, Sapienza University of Rome, Rome, Italy, ²Laboratory for Clinical Microbiology, Sapienza University Hospital "Policlinico Umberto I", Rome, Italy, ³Department of Public Health and Infectious Diseases, Sapienza University of Rome, Rome, Italy

- P 92 Severe Neurological Manifestations and Medication Challenges in an Elderly Female Cancer Patient: a missed opportunity**
L. Bresciani¹, S. Di Bari¹, V. Filippi², A. Pennica¹, A. Cascianelli³, C. Pasquazzi², D. Bello¹, G. Kelmendi¹, F. Talamoni¹, S. Figliomeni¹, C. Torre¹, L. Fionda⁴, R. Reine⁴, M. Salvetti³, G. Fiorentino¹, M. Lichtner¹
¹U.O.C Malattie infettive, Azienda ospedaliero-universitaria Sant'Andrea- Università La Sapienza – Rome, Italy, ²U.O.C Malattie infettive, Azienda ospedaliero-universitaria Sant'Andrea- Rome, Italy, ³U.O.C Neurologia, Azienda ospedaliero-universitaria Sant'Andrea- Università La Sapienza – Rome, Italy, ⁴U.O.C Malattie infettive, Azienda ospedaliero – Rome, Italy
- P 93 Experience of collaboration between a PLWH Clinic and a clinical nutrition centre at a hospital in the north-east of Italy**
G. Battagin¹, S. Nicolè¹, F. Rigo¹, S. Milan², G. Giaretta², P. Pavan², V. Manfrin¹
¹UOC Malattie Infettive, AULSS8 "Berica" Vicenza, Italia, ²Servizio Igiene degli Alimenti e della Nutrizione, AULSS8 "Berica" Vicenza, Italy
- P 94 NK cell profile in the anal mucosa of MSM living with HIV: results from a single center clinical trial**
L. Santinelli¹, L. Maddaloni¹, G. Bugani¹, F. Romano¹, I. El Abboubi¹, M. Fracella¹, A. D'Auria¹, E.N. Cavallari¹, G. Ceccarelli¹, A. Pierangeli¹, C.M. Mastroianni¹, C. Scagnolari¹, G. d'Ettore¹
¹Department of Public Health and Infectious Diseases, Sapienza University of Rome, Italy, ²Laboratory of Virology, Department of Molecular Medicine, affiliated to Istituto Pasteur Italia, Sapienza University, Rome, Italy
- P 95 Prevalence and correlates of Hepatic Steatosis and Metabolic-associated Fatty Liver Disease in a cohort of People Living With HIV**
F. Panza^{1,2}, M. Crispo^{1,2}, D. Romano¹, M. Sambo^{1,2}, A. Bailoni^{1,2}, M. Barsotti¹, F. Pippi², M. Trezzi², F. Montagnani^{1,2}, M. Tumbarello^{1,2}, M. Fabbiani^{1,2}
¹Department of Medical Biotechnologies, University of Siena, Siena, Italy, ²Infectious and Tropical Diseases Unit, Siena University Hospital, Siena, Italy
- P 96 CNS-associated VZV vasculopathy in a young woman living with HIV**
V.M. Vitaletti¹, F. Bai¹, R. Castoldi¹, E. Zaninetta¹, G. Giannetta¹, T. Beringheli¹, A. Copes¹, A. Dusina¹, M. Chiamenti¹, K. Khouri Chalouhi², L. Gazzola¹, G.C. Marchetti¹
¹Infectious Diseases Department, San Paolo Hospital, University of Milan - Milan, Italy, ²Neuroradiology Department, San Paolo Hospital, University of Milan - Milan, Italy
- P 97 Exploring cardiovascular risk in people with HIV: the critical role of intima-media thickness**
M.S. Paternò Raddusa², B.M. Celestia¹, A. Marino¹, B. Cacopardo¹, C. Giarratana², S. Spampinato², A. Montineri³, M.C. Frasca³, C. Cocco³, G. Madeddu^{4,5}, A. De Vito^{4,5}, G. Nunnari¹
¹Unit of Infectious Diseases, Department of Clinical and Experimental Medicine, ARNAS Garibaldi Hospital, University of Catania Catania, Italy, ²Department of Clinical and Experimental Medicine, University of Messina Messina, Italy, ³Department of Infectious Diseases and Tropical Medicine, AOU Policlinico "G. Rodolico - San Marco", Catania, Italy, ⁴Unit of Infectious Disease, Department of Medicine, Surgery and Pharmacy, University of Sassari, Sassari, Italy, ⁵PhD School in Biomedical Science, Biomedical Science Department, University of Sassari, Sassari, Italy
- P 98 Periaortic BCGite in HIV**
L. Abbate¹, T. Tibidò¹, M. Casarini¹, D. Marzolla¹, G. Martelli², A. Rubin², E. Magistrelli², G. La Martire², F. Cristini²
¹Alma Mater Studiorum University of Bologna, Infectious Disease Department, S. Orsola-Malpighi hospital, Italy, ²Azienda USL di Forlì, Infectious Disease Department, Italy
- P 99 Poor sleep quality in people living with HIV**
L. Pagnucco, R. Gulminetti, A. Tavano, R. Bruno
S.C Malattie Infettive 1, Dipartimento Medico, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy
- P 100 Epicardial adipose tissue is increased in HIV infected adolescent and young adults**
M. Stracuzzi¹, F. Musto¹, C. Coppola¹, A. Marceca², G. Zuccotti³, A. Barosi², V. Giacometti¹
¹Paediatric Infectious Disease Unit, Luigi Sacco Hospital, Università degli Studi di Milano, Milan, Italy, ²Luigi Sacco Hospital, Cardiology Unit, Milan, Italy, ³Department of Pediatrics, Vittore Buzzi Hospital, Università degli Studi di Milano, Milan, Italy

Immunopathogenesis

- P 101 Auto-antibodies neutralizing type I and III IFNs in patients with WNV infection**
F. Frasca^{1,2}, A. D'Auria¹, M. Fracella¹, M. Comprì³, E. Diani⁴, G. Bugani², L. Maddaloni², E. Coratti¹, G. d'Ettore², G. Antonelli^{1,5}, D. Gibellini^{3,4}, C. Scagnolari¹
¹Virology Laboratory, Department of Molecular Medicine, Sapienza University, Rome, Italy, ²Department of Public Health and Infectious Diseases, Sapienza University, Rome, Italy, ³Unit of Microbiology, AOU Verona, Verona, Italy, ⁴Department of Diagnostic and Public Health, Microbiology Section, University of Verona, Verona, Italy, ⁵Microbiology and Virology Unit, Sapienza University Hospital "Policlinico Umberto I", Rome, Italy
- P 102 HIV acquisition at birth does not drive T-cell dysfunction in Heavily Treatment Experienced (HTE): data from the Prestigio Registry**
V. Bono¹, C. Tincati¹, V. Spagnuolo², L. Galli², A. di Biagio³, M. Augello¹, R. Rovito¹, E. Garlassi⁴, M.C. Moialti⁵, E. Focà⁶, A. Castagna⁷, G. Marchetti¹
¹Clinica di Malattie Infettive, San Paolo Hospital, University of Milan, Milan, Italy, ²Infectious Diseases, IRCCS San Raffaele Scientific Institute, Milan, Italy, ³Department of Infectious Disease, IRCCS AOU San Martino IST, (DISSAL), University of Genoa, Italy, ⁴Malattie Infettive Arcispedale S. Maria Nuova-IR-CSS, Reggio Emilia, Italy, ⁵Department of Infectious Diseases, ASST Grande Ospedale Metropolitano Niguarda, Milan, Italy, ⁶Division of Infectious and Tropical Diseases, ASST Spedali Civili Hospital, University of Brescia, Brescia, Italy
- P 103 Multidrug resistance is associated with different gene methylation in people with HIV: a matched cohort study with data from the PRESTIGIO Registry**
T. Clemente^{1,2}, G.M. Scotti³, E. Guidi³, A. Cervo⁴, S. Rusconi^{5,6}, G.C. Marchetti⁷, S. Diotallevi², S. Bagaglio², R. Lolatto², M. Tavio⁸, C. Torti⁹, B.M. Celestia¹⁰, A. Castagna^{1,2}, V. Spagnuolo², on the behalf of the PRESTIGIO Study Group
¹Vita-Salute San Raffaele University, Milan, Italy, ²Infectious Diseases, IRCCS San Raffaele Scientific Institute, Milan, Italy, ³Center for Omics Sciences, IRC-CSS Ospedale San Raffaele, Milan, Italy, ⁴Infectious Diseases Unit, Policlinico di Modena, Modena, Italy, ⁵Infectious Diseases Unit, ASST Ovest Milanese, Legnano General Hospital, Legnano, Italy, ⁶DIBIC, University of Milan, Milan, Italy, ⁷Clinic of Infectious Diseases, Department of Health Sciences, San Paolo Hospital, ASST Santi Paolo e Carlo, University of Milan, Milan, Italy, ⁸Infective Diseases, AOU Ospedali Riuniti, Ancona, Italy, ⁹Unit of Infectious and Tropical Diseases, University Magna Graecia, Catanzaro, Italy, ¹⁰Unit of Infectious Diseases, Garibaldi Hospital, Catania, Italy
- P 104 HIV latency is associated with changes in the Wnt1, β -catenin, TGF- β and BCL-2 signalling pathways**
L. Maddaloni¹, L. Santinelli¹, G. Bugani¹, M. Fracella², F. Frasca^{1,2}, Z. Michelini², M. Andreotti³, C.M. Mastroianni¹, C. Scagnolari², G. d'Ettore¹
¹Department of Public Health and Infectious Diseases, Sapienza University of Rome, Italy, ²Virology Laboratory, Department of Molecular Medicine, Sapienza University of Rome, Italy, ³Department of Therapeutic Research and Medicines Evaluation, Istituto Superiore di Sanità, Rome, Italy
- P 105 Is CAB/RPV-LA able to modulate residual immune activation in people living with HIV? A pilot single-arm longitudinal study**
M.A. Zingaropoli¹, A. Carraro¹, M. Guardiani¹, E. Tortellini¹, F. Dominelli¹, C. Del Borgo², R. Marocco², S. Garattini¹, S. Cacace¹, P. Zuccalà², V. Vullo¹, M.R. Ciardi¹, C.M. Mastroianni¹, M. Lichtner³
¹Department of Public Health and Infectious Diseases, Sapienza University of Rome, Rome, Italy, ²Infectious Diseases Unit, SM Goretti Hospital, Sapienza University of Rome, Latina, Italy, ³Department of Neurosciences, Mental Health, and Sense Organs, NESMOS, University of Rome, Rome, Italy
- P 106 Higher IP-10 values correlate with a viral cause of infection: a retrospective study based on novel tests**
B. Kertusha^{1,2}, A. Parente^{1,2}, T. Tieghi¹, E. Tortellini², M.S. Guardiani², F. Dominelli², J. Ronci³, C. Racco³, U. Basile³, R. Dal Piaz^{4,2}, M. Lichtner⁵, C. Del Borgo^{1,2}
¹Infectious Diseases Unit, S. M. Goretti Hospital, Latina, ²Sapienza University of Rome, department of Public Health and Infectious Diseases, ³Clinical Pathology Unit, S. M. Goretti Hospital, Latina, ⁴Emergency Department, S. M. Goretti Hospital, Latina, ⁵Sapienza University of Rome, NESMOS Department

Other infections in the immunocompromised host

- P 107 Cytomegalovirus specific T-cell response in people with multiple sclerosis under different disease-modifying therapies**
F. Dominelli¹, M.A. Zingaropoli¹, P. Pasculli¹, F. Ciccone¹, G. Ferrazzano², M. Guardiani¹, E. Tortellini¹, M. Antonacci¹, Y.C. Fosso Ngangué¹, M. Lichten³, C.M. Mastroianni¹, A. Conte^{2,4}, M.R. Ciardi¹
¹Department of Public Health and Infectious Diseases, Sapienza University of Rome, Rome, Italy, ²Department of Department of Human Neurosciences, Sapienza University of Rome, Rome, Italy, ³Department of Neurosciences Mental Health and Sensory Organs, Sapienza University of Rome, Rome, Italy, ⁴IRCCS Neuromed, Pozzilli, Italy
- P 108 Aspergillus spp infection in immunocompromised and non-neutropenic patients in Infection Intensive Care: a retrospective observational study**
D. Rubino¹, C. Fontana², S. Leone³, G.V. Stazi¹, A. Capone⁵, C. Pinnetti⁴, V. Sabatini¹, A. Vulcano², B. Bartolini², S. Carrara², S. Cicalini⁵, A. Antinori⁴, M.G. Bocci¹
¹Intensive Care Unit, National Institute for Infectious Diseases Lazzaro Spallanzani IRCCS, Rome, Italy, ²Microbiology and BioBank Unit, National Institute for Infectious Diseases Lazzaro Spallanzani, Rome, Italy, ³Clinical Epidemiologic Unit, National Institute for Infectious Diseases Lazzaro Spallanzani IRCCS, Rome, Italy, ⁴Clinical and Research Infectious Diseases Department, National Institute for Infectious Diseases, Lazzaro Spallanzani IRCCS, Rome, Italy, ⁵Systemic and Immune Depression-Associated Infection Unit, National Institute for Infectious Diseases, Lazzaro Spallanzani IRCCS, Rome, Italy
- P 109 Multidrug resistant bacteria (MDRB) and bed turnover: is it true that the fragile patient should be moved the least possible?**
C. Fanelli¹, L. Pistidda¹, R. Are², D. Pasero¹
¹Department of Pharmacy, Medicine, and Surgery, University of Sassari, Sassari, Italy, ²Infectious Diseases Unit, University Hospital of Sassari (AOUSS), Sassari, Italy
- P 110 Evaluation of HHV6 reactivation in gastric biopsy and blood samples in patients underwent allogeneic stem cell transplant (HSCT) for hematological malignancies: results from a retrospective single center analysis**
G.M.E. Colomba¹, G. Sapienza², M. Tuccio¹, S. Tringali², R. Bono², C. Rotolo², L. Castagna², O. Diquattro¹
¹U.O.C. Microbiologia e Virologia. AOOR "Villa Sofia - Cervello" - Palermo, Italy, ²Unità Trapianti di Midollo Osseo. AOOR "Villa Sofia - Cervello" - Palermo, Italy
- P 111 Challenges in an Immunocompromised Host: A Case of Disseminated Nocardiosis**
A. Gizzi¹, A. Mancuso², M. Abbott¹, F. Guida Marascia¹, C. Imburgia¹, G. Pipitone¹, I. Russotto², F. Onorato¹, D. Spicola¹, I. Alongi¹, L. Saporito³, A. Cascio², C. Iaria¹
¹Infectious Disease Unit, ARNAS Civico-Di Cristina, Palermo, Italy, ²Department of Health Promotion, Mother and Child Care, Internal Medicine and Medical Specialties "G. D'Alessandro", University of Palermo, Palermo, Italy, ³Microbiology and Virology Unit, ARNAS Civico-Di Cristina, Palermo, Italy

SARS-CoV-2 infection and long COVID

- P 112 SARS-CoV-2 natural infection, but not vaccine-induced immunity, elicits cross-reactive immunity to OC43**
M. Garziano¹, C. Vanetti², S. Strizzi², I. Saule¹, F. Limanaqi², V. Artusa¹, M. Cano Fiestas², P. Ogno², M. Clerici^{1,3}, D. Trabattoni², M. Biasin²
¹Dipartimento di Fisiopatologia Medico-Chirurgica e dei Trapianti, Università degli Studi di Milano, Italia, ²Dipartimento di Scienze Biomediche e Cliniche, Università degli Studi di Milano, Italia, ³Fondazione Don Gnocchi, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS), Milano, Italia
- P 113 Use of combination therapy with remdesivir, nirmatrelvir/ritonavir and sotrovimab in an immunocompromised patient with persistent severe SARS-CoV-2 acute respiratory syndrome**
G. D'Aguanno¹, P. Miraglia¹, C. Geraci¹, F. Savalli¹, M.C. Morsellino¹, S. Cianchino¹, F. Zichichi², F. Di Gaudio³, P. Colletti¹
¹Department of Infection Diseases (I.D.D), Paolo Borsellino Hospital (Marsala), Italy, ²School of Specialization in Infection and Tropical Diseases - Department PROMISE, School of Medicine and Surgery, University of Palermo, Italy, ³Department PROMISE, School of Medicine and Surgery, University of Palermo, Italy
- P 114 Exploring Early COVID-19 Therapies, Variants, and Viral Clearance Dynamics: Insights from a High-Risk Outpatients Study**
M. Colaneri^{1,5}, M. Matone², F. Fassio³, A. Lai⁴, A. Bergna⁴, C. della Ventura⁴, L. Galli¹, G. Scaglione¹, A. Gori^{1,4,5}, M. Schiavini¹
¹Department of Infectious Diseases, Unit II, L. Sacco Hospital, ASST Fatebenefratelli Sacco, Milan, Italy, ²Department of Infectious Diseases, Unit I, L. Sacco Hospital, ASST Fatebenefratelli Sacco, Milan, Italy, ³Department of Public Health, Experimental and Forensic Medicine, Unit of Biostatistics and Clinical Epidemiology, University of Pavia, Pavia, Italy, ⁴Department of Biomedical and Clinical Sciences, University of Milan, Milano, Italy, ⁵Centre for Multidisciplinary Research in Health Science (MACH), University of Milano, Milano, Italy
- P 115 Characteristics of Long COVID after two years of follow-up in a previously hospitalized population**
V. Cogliandro¹, N. Squillace¹, E. Rossi², M.C. Ferrara³, A. Monzani⁴, M. Pozzi⁵, V. Salvarani⁶, L. Valagussa⁷, I.C. Caramma¹, A. Cappelletti¹, L. Bonaffini¹, C. Ferrarese⁸, G. Foti⁹, M. Lettino⁷, F. Luppi^{4,9}, M.G. Strepparava^{6,9}, G. Bellelli^{3,9}, P. Bonfanti^{1,9}
¹Infectious Disease Unit, Fondazione IRCCS San Gerardo dei Tintori, Monza, Italy, ²Bicocca Center of Bioinformatics, Biostatistics and Bioimaging, University of Milano-Bicocca, Monza, Italy, ³Acute Geriatric Unit, Fondazione IRCCS San Gerardo dei Tintori, Monza, Italy, ⁴Respiratory Disease Unit, Fondazione IRCCS San Gerardo dei Tintori, Monza, Italy, ⁵Anesthesia and Intensive Care Unit, Fondazione IRCCS San Gerardo dei Tintori, Monza, Italy, ⁶Clinical Psychology Unit, Department of Mental Health, Fondazione IRCCS San Gerardo dei Tintori, Monza, Italy, ⁷Cardiology Division, Fondazione IRCCS San Gerardo dei Tintori, Monza, Italy, ⁸Neurology Unit, Fondazione IRCCS San Gerardo dei Tintori, Monza, Italy, ⁹School of Medicine and Surgery, University of Milano-Bicocca, Monza, Italy
- P 116 The evolving landscape of COVID-19: Characteristics and factors associated with disease severity and mortality in recent hospitalisations**
D. Zaçe¹, A. Çekrezi¹, E. Teti¹, V. Malagnino¹, L. Sarmati¹, M. Iannetta¹, A.M. Geretti^{1,2,3}
¹Department of Systems Medicine, Infectious Disease Clinic, Tor Vergata University, Rome, Italy, ²Dept of Infection, North Middlesex University Hospital, London, UK, ³School of Immunity and Microbial Sciences, King's College London, London, UK
- P 117 Prolonged combination treatment: an efficient and safe strategy for managing SARS-CoV-2 infection in immunocompromised patients**
C. Sepulcri¹, C. Bartalucci^{1,2}, C. Dentone², E. Balletto³, S. Dettori², M. Nofri², M. Mirabella², B. Bruzzone³, V. Ricucci³, G. Brucchi^{1,2}, L. Crupi^{1,2}, M. Bavastrro^{1,2}, C. Russo Artimagnella^{1,2}, M. Bassetti^{1,2}, M. Mikulska^{1,2}
¹Division of Infectious Diseases, Department of Health Sciences, University of Genoa, Genoa, Italy, ²Division of Infectious Diseases, IRCCS Ospedale Policlinico San Martino, Genoa, Italy, ³Hygiene Unit, IRCCS Ospedale Policlinico San Martino, Genoa, Italy
- P 118 Cytomegalovirus reactivation in non-severe COVID-19: two emblematic cases of oropharyngeal mucositis in immunocompromised patients**
R. Astorri², A. Russo^{1,2}, P. Medusa², N. Carro², A. Dell'Aquila², I. Palma², C. Rizzozi², K. Gjelogshi², S. Imbriani², C. Sagnelli^{1,2}, M. Pisaturo^{1,2}, N. Coppola^{1,2}
¹Infectious Disease Unit, Department of Mental Health and Public Medicine, University of Campania "L. Vanvitelli" - Naples, Italy, ²Infectious Disease Unit - AOU Vanvitelli, Naples, Italy
- P 119 Combination therapy in immunocompromised patients with COVID-19**
R. Papale, F.R.P. Ieva, I.F. Bottalico, F. De Gregorio, G.A. Minafra, T.A. Santantonio, S. Lo Caputo
U.O.C. of Infectious Diseases, Policlinico "Riuniti", University of Foggia, Italy
- P 120 Sex disparity in COVID infection: a retrospective study using serum electrophoretic analysis (SPE) in men and women infected by COVID-19**
F. Tomassetti^{1,2}, E. Cappa^{1,2}, R. Salierno^{1,2}, V. Rossi^{1,2}, F. Pacifici^{1,2}, M. Pieri^{1,2}, S. Bernardini^{1,2}, M. Morello^{1,2}
¹Department of Laboratory Medicine, "Tor Vergata" University Hospital, Rome, Italy, ²Department of Experimental Medicine, University of "Tor Vergata", Rome, Italy

Sexually transmitted infections

- P 121 Anorectal lesions: think twice**
V. Gennaro¹, C. Tettoni², A. Lucchini², S. Bonora^{1,2}
¹Università degli studi di Torino, Italia, ²ASL Città di Torino - Clinica Universitaria, Italia
- P 122 The use of pre-exposure prophylaxis (PrEP) in the control of HIV infection and other sexually transmitted diseases (STDs). Descriptive-observational analysis in an Italian polyclinic**
D. Cicetti^{1,2}, S. Vitale^{1,2}, L. Appolloni^{1,2}, G. Pensalfine^{1,2}, M. Traficante^{1,2}, R. Caprara^{1,2}, A. Poma³, F. Baldasso³, M. Cantini³, L. Calza³, V. Colangeli³, A. Stancari¹
¹IRCCS University Hospital Company - S.Orsola-Malpighi Polyclinic - Clinical Pharmacy, Research and Development, Bologna, Italy, ²IRCCS University Hospital Company - S.Orsola-Malpighi Polyclinic - Department of Infectious and Tropical Disease, Bologna, Italy, ³IRCCS University Hospital Company - S.Orsola-Malpighi Polyclinic - Intercompany Department Integrated Infectious Risk Management, Bologna, Italy
- P 123 Screening of sexually transmitted diseases: experience from Galliera hospital in Genoa**
R. Prinapori, D. Fiorellino, S. Puppo, E. Blasi Vacca, N. Bobbio, S. Boni, F. Del Puente, M. Feasi, A. Parisini, S. Tigano, E. Pontali
Infectious Disease Department, Galliera Hospital, Genoa, Italy
- P 124 A case of secondary syphilis with pulmonary involvement in a person living with HIV**
F. Guida Marascia¹, A. Gizzi¹, M. Abbott¹, G. Pipitone¹, C. Buscemi¹, C. Imburgia¹, A. Sanfilippo¹, G. Ciusa¹, S. Agrenzano¹, F. Di Lorenzo¹, A. Cascio², C. Iaria¹
¹Infectious Diseases Unit, ARNAS Civico-Di Cristina Hospital, Palermo, Italy, ²Infectious and Tropical Diseases Unit, Department of Health Promotion, Mother and Child Care, Internal Medicine and Medical Specialties, "G D'Alessandro, University of Palermo, AOUP P. Giaccone, Palermo, Italy
- P 125 Long distances for STI care. The case of the an ambulatory service in Bari**
L. Ronga¹, E. Milano², E. Ranieri¹, M. Mastrìa¹, F. Indraccolo¹, F. Campione², M. Chironna³, F. Di Gennaro², A. Saracino²
¹Section of Microbiology and Virology, University Hospital Policlinico, Bari, Italy, ²Clinic of Infection Diseases, University of Bari, University Hospital Policlinico, Bari, Italy, ³Department of Interdisciplinary Medicine, University of Bari Aldo Moro, Bari, Italy
- P 126 Meeting on HIV and sexually transmitted infections in a high school in Palermo, Italy**
L. Pipitò, M. Trizzino, R. Gaudiano, A. Gizzi, A. Cascio
Department of Health Promotion, Mother and Child Care, Internal Medicine and Medical Specialties "G D'Alessandro," University of Palermo, Palermo, Italy
- P 127 Sexual behaviour and age related incidence of sexually transmitted infections in PrEP's users**
F. Romano, M. Ridolfi, F. Alessi, E. Bogliolo, M. Maiorano, I. De Angelis, L. Santinelli, C.M. Mastroianni, G. d'Ettore
Department of Public Health and Infectious Diseases, Sapienza University of Rome, Policlinico Umberto I of Rome, Rome, Italy
- P 128 Prevalence of sexually transmitted infections in cisgender women coming to walk-in Center**
G. Catalano¹, S. Diotallevi¹, R. Lolatto¹, B. Trentacapilli¹, M. Ranzenigo¹, E. Bruzzesi¹, A. Castagna^{1,2}, S. Nozza^{1,2}
¹Infectious Diseases Unit, Vita-Salute San Raffaele University, Milan, Italy, ²Infectious Diseases Unit, IRCCS San Raffaele Scientific Institute, Milan, Italy
- P 129 Molecular assay-based extragenital screening for Chlamydia trachomatis and Neisseria gonorrhoeae in men who have sex with men**
R.J. Steiner¹, A. Vella², B. Posteraro^{3,4}, G. De Angelis^{2,3}, M. Sanguineti^{2,3}, D. Farinacci², C. Torti^{1,2}, S. Di Giambenedetto^{1,2}
¹Università Cattolica del Sacro Cuore, Rome, Italy, ²UOC Malattie Infettive e Tropicali, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy, ³Dipartimento di Scienze Biotechnologiche di Base, Cliniche Intensiveologiche e Periperatorie, Università Cattolica del Sacro Cuore, Roma, Italy, ⁴Dipartimento di Scienze Mediche e Chirurgiche Addominali ed Endocrino Metaboliche, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy
- P 130 M. genitalium macrolide and fluoroquinolone resistance in Ce.Mu.S.S. Cohort: a descriptive monocentric report**
M. Tutone¹, P. Sales¹, L. Bello¹, S. Del Monte¹, D. Agosta¹, G. Gregori², V. Ghisetti², A. Lucchini¹
¹Multidisciplinary Sexual Health Clinic (Ce.Mu.S.S.), ASL Città di Torino, Italy, ²Laboratory of Microbiology and Virology, ASL Città di Torino, Italy
- P 131 Emerging Sexually Transmitted Infections Outbreak: Dermatophytosis among Men who Have Sex with Men in Milan, Italy**
C. Maci¹, A.R. Raccagni¹, R. Lolatto¹, E. Messina², D. Canetti², C. Tassan Din², M. del Carmen Garcia Martearena¹, G. Torkjazi¹, M. Bottanelli¹, A. Castagna^{1,2}, S. Nozza^{1,2}
¹Vita-Salute San Raffaele University, Milan, Italy, ²IRCCS San Raffaele Scientific Institute, Milan, Italy
- P 132 Implementing anal cancer screening in gay and bisexual men who have sex with men starting from a community-based setting**
E.N. Cavallari¹, V.L. del Negro², F. Leserri², V. Mazzotta³, M. Ridolfi¹, R. Bellagamba³, F. Romano¹, F. De Zottis³, Y. El Abboubi¹, A. Antinori³, C.M. Mastroianni⁴, G. d'Ettore⁴
¹Department of Infectious Diseases Azienda Ospedaliero-Universitaria Policlinico Umberto I, Rome, Italy, ²Plus Roma, Rome, Italy, ³HIV Unit National Institute for Infectious Diseases Lazzaro Spallanzani IRCCS, Rome, Italy, ⁴Department of Public Health and Infectious Diseases "Sapienza" University, Rome, Italy
- P 133 Syphilis among PLWH: prevalence of the infection in relation to COVID-19 outbreak**
G. Sfara¹, R. Campagna¹, M.G. Leone¹, C. Nonne¹, D. Compagnino¹, M. Rossi¹, M.A. Zingaropoli², G. Antonelli¹, O. Turriziani¹
¹Department of Molecular Medicine, Sapienza University of Rome, Rome, Italy, ²Department of Public Health and Infectious Diseases, Sapienza University of Rome, Rome, Italy
- P 134 This goes out to the underdog: how not to neglect sexually transmitted infections**
A. Tili¹, A. Soffritti¹, B. Fontana¹, F. Calandra Bonaura¹, M. Menozzi¹, C. Puzzolante¹, C. Mussini^{1,2}
¹Azienda Ospedaliero-Universitaria, Policlinico of Modena, Modena, Italy, ²University of Modena and Reggio Emilia, Modena, Italy
- P 135 A case of syphilitic vitritis with complicated course**
F. Ceriegi, G. Marchetti, M. Cesaretti, G. Rolli, S. Bancallaro, L.R. Suardi, N. Cesta, A. Borghetti, M. Falcone
Infectious Diseases Unit, Azienda Ospedaliera Universitaria Pisana, Pisa, Italy

Social and behavioural science, marginalized groups, community aspects and community surveys

- P 136 Long Acting Therapy: what PLWHIV think about it**
S. Mattioli¹, V.L. del Negro², S. Cecere¹, F. Leserri²
¹Plus - Persone LGBT+ Sieropositivo - aps, Italy, ²Plus Roma aps, Italy
- P 137 Stigma and disinformation are still common in population approaching the Anlaids Forum**
A. Venturelli, C. Balotta, R. Galipò, V. Calvino, B. Marchini
Anlaids Onlus ETS, Rome, Italy
- P 138 Cosa sai di Hiv e altre IST**
B. Marchini², A. Venturelli¹, C. Balotta¹, M. Stagnitta³, C. Sfara⁴, G.M. Maglio²
¹Anlaids, Rome, Italy, ²Famiglia Nuova, Lodi, Italy, ³CNCA, Rome, Italy, ⁴Anlaids Umbria, Perugia, Italy

- P 139 Home delivery of ARV and HIV self-tests**
M. Cascio¹, M. Formisano¹, C. Nicoara³, M. Casamento², A. Moznich¹, D. Russo¹, M. Errico¹
¹NPS Italia Aps, Milano, Italy, ²NPS Sicilia ODV, Palermo, Italy
- P 140 Promoting Sexual Health Equity: A Community Engagement Model for Minor Ethnic Groups in Italy**
I.N. Emelurumonye¹, D. Calzavara², E. Caruso²
¹The Feminist Health CIC, Reading, United Kingdom, ²Milano Check Point ETS, Milan, Italy
- P 141 HIV prevention road map**
B. Mocchi, A. Pontis, A. Loddo, S. Campus
LILA Cagliari, Cagliari, Italy
- P 142 Ongoing psycho-social interventions: preliminary data of the "FRAGIL/mente" project**
A. Calluso, N. Catucci, M. Di Tullio, R. Giusto, M. Giannelli, S. Loiudice
C.A.M.A. - Centro Assistenza Malati Aids - OdV ETS - Bari - Italy
- P 143 Stigma and HIV. Perceptions in young people from Anlaid School**
R. Galipò^{1,3}, M. Bolletta¹⁰, M. Campanella⁴, L. Butini⁷, V. Calvino¹, L. Cipriani⁹, F. Caramaschi⁶, S. De Balzo², A. De Faveri⁸, S. Negri⁵, A. Palummieri¹, B. Marchini¹
¹Anlaid ETS, Roma, Italy, ²Anlaid Campania, Napoli, Italy, ³Anlaid Lazio, Roma, Italy, ⁴Anlaid Liguria, Genova, Italy, ⁵Anlaid Lombardia, Milano, Italy, ⁶Anlaid Mantova, Mantova, Italy, ⁷Anlaid Marche, Ancona, Italy, ⁸Anlaid Torino, Torino, Italy, ⁹Anlaid Treviso, Treviso, Italy, ¹⁰Anlaid Umbria, Perugia, Italy
- P 144 Adherence to HIV infection care at IRCCS San Raffaele Hospital: current status and Re-stART project**
D. Canetti¹, S. Diotallevi¹, R. Lolatto¹, A.R. Raccagni², V. Spagnuolo¹, C. Muccini¹, E. Bruzzesi², S. Nozza^{1,2}, A. Castagna^{1,2}, N. Gianotti¹
¹Unit of Infectious and Tropical Diseases, IRCCS San Raffaele Scientific Institute, Milan, Italy, ²Vita-Salute San Raffaele University, Milan, Italy
- P 145 Knowledge about Sexually Transmitted Infections and HIV awareness in an Italian adolescent and young adults group**
S. Tordi^{1,2}, V. Suriani², M. Ramadori², P. Diana³, E. Albertini³, F. Orlandi⁴, L. Novelli⁴, A. Gidari¹, D. Francisci¹
¹Infectious Diseases Unit, Santa Maria della Misericordia Hospital, University of Perugia, Perugia, Italy, ²ANLAIDS Umbria, Perugia, Italy, ³OMPHALOS LGBTI Center, Perugia, Italy, ⁴YAU - Young Angles Umbria, Perugia, Italy
- P 146 "What we wanted was what we needed" - rebuilding a community of memories and inclusive advocacy for emerging hepatitis C research via a community-led multilingual documentary production**
R. Pignata, G. Barbareschi, A. Kalogiannis, A. Cerioli
European AIDS Treatment Group, Brussels, Belgium
- P 147 HIV Tutor Care service at "D. Cotugno" hospital in Naples: a cooperative model between Public Institutions and Community Associations for the improving of well-being among Persons With HIV**
C. Oneto, D. Salerno, F.M. Fusco, M.A. Carleo, P. Rosario, V. Rizzo, A. Guida, V. Esposito
"D. Cotugno" hospital, Italy
- P 148 School intervention for STIs prevention**
C. Soligo¹, D. Zagato¹, A. Bianchi¹, P.M. Testoni¹, F. Rossi¹, M. Cernuschi^{1,2}
¹ASA Associazione Solidarietà AIDS ODV, Milano, Italy, ²San Raffaele Hospital, Milano, Italy
- P 149 Impact of social determinants of health on adherence rate to antiretroviral therapy in the clinical setting**
G. Maffei¹, E. Clemente², S. Bertini¹, F. Donato¹, F. Mollo³, S. Bonora², P. Crosasso¹, D. Piccioni¹, M. Ferrara²
¹S.D.S. Infectious Diseases Hospital Pharmacy, Amedeo di Savoia Hospital, Turin, Italy, ²Unit of Infectious Diseases, Department of Medical Sciences, University of Turin, Turin, Italy, ³Department of Drug Science and Technology, University of Turin, Turin, Italy
- P 150 Noi, donne**
D. Russo¹, M. Cascio¹, M. Formisano¹, C. Nicoara¹, A. Moznich¹, M. Errico¹, L. Taramasso²
¹NPS Italia Aps, Milano, Italy, ²Infectious Diseases Clinic, IRCCS Ospedale Policlinico San Martino, Genoa, Italy
- P 151 Assessment of comprehensive sexuality education: a framework of indicators to evaluate interventions in Italian secondary schools**
D. Martinelli¹, G. Papatratto^{2,3}, B. Suligo⁴, M. Salfa⁴, P. Nardone⁵, S. Donati⁵, D. Pierannunzio⁵, S. Ciardullo⁵, C. Silvestri⁶, M. Di Tullio⁷, A. Camposera-gna⁸, P. Meli⁹, C. Celato¹⁰, L. Bonaldo², M. di Nino², M. Ubbiali¹¹, A. Chinelli², L. Tavoschi²
¹Department of Medical and Surgical Sciences, University of Foggia, Foggia, Italy, ²Department of Translational Research and New Technologies in Medicine and Surgery, University of Pisa, Pisa, Italy, ³Health Science Interdisciplinary Research Centre, Sant'Anna School of Advanced Studies, Pisa, Italy, ⁴Department of Infectious Diseases, National Institute of Health, Rome, Italy, ⁵National Centre for Disease Prevention and Health Promotion, Italian National Institute of Health, Rome, Italy, ⁶Healthcare Regional Agency (ARS), Epidemiological Observatory, Tuscany, Italy, ⁷Italian League for The Fight Against AIDS (Cama-LILA), Bari, Italy, ⁸CNCA - Italian Coordination of Care Communities, Italy, ⁹Italian Coordination of Residential Homes For People With HIV/AIDS (CICA), Bergamo, Italy, ¹⁰UO Prevenzione DG Welfare Regione Lombardia - UO a valenza regionale "Promozione della Salute, ATS Città Metropolitana di Milano, Milano, Italy, ¹¹Department of Human Sciences, University of Verona, Verona, Italy
- P 152 Understanding and managing new HIV diagnoses in members of "generation Z" (1996-2010) in Milan, Italy: project GenZ HIV-support**
G. Bozzi¹, A. Giacomelli², P. Saltini^{1,3}, A. Liparoti^{1,3}, V. Castelli¹, B. Mariani¹, A. Muscatello¹, C. Bobbio¹, A. Gori^{3,4}, S. Negri⁴, A. Bandera^{1,3}
¹Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milano, Infectious Diseases, Milano, Italy, ²ASST Fatebenefratelli Sacco, III Infectious Diseases Unit, Milano, Italy, ³Unimi - Università degli Studi di Milano, Milano, Italy, ⁴ANLAIDS Sezione Lombarda, Milano, Italy
- P 153 PEP/PrEP for Bacterial STIs and HIV-PrEP: knowledge and use among MSM in Rome**
L. Gianserra, S. Stingone, S. Capodiecchi, M. Zaccarelli, V. Cafaro, M.G. Donà, E. Giuliani, M. Giuliani, A. Latini
San Gallicano Dermatological Institute IRCCS, Rome, Italy
- P 154 Proactive testing for sexually transmitted and endemic diseases at an open access clinic for migrants**
R. Ligresti, S. Pettenuzzo, A. Cordori, F. Bai, C. Tincati, T. Bini, G. Marchetti
Università degli studi di Milano, Ospedale San Paolo, Milano, Italy
- P 155 An alliance in communication: LILA training for journalists**
G. Dessi, G. Giupponi, L. Supino
LILA Nazionale, Como, Italy
- P 156 Chemsex, sexualized drug use and emotional vulnerability among MSM of a pilot survey of an STI/HIV center**
S. Capodiecchi, M. Zaccarelli, C. Stingone, E. Giuliani, V. Cafaro, L. Gianserra, M.G. Donà, A. Latini, M. Giuliani
San Gallicano Dermatological Institute IRCCS, Rome, Italy
- P 157 Go-come back-cure for HCV management: the role of the continuous presence of the infectious disease (ID) specialist at public health services dedicated to the assistance of addicted subjects (SerD) in Italy**
E. Rastrelli¹, A.M. Ialungo¹, S. Dell'Isola¹, F. Ferri¹, M. De Rosi², F. Bellitto², A. Marino², F. Mazza², A. Lagrutta², G. Starnini¹
¹UOC Medicina Protetta-Malattie Infettive Ospedale Belcolle, Viterbo, Italy, ²SerD ASL Viterbo, Viterbo, Italy
- P 158 HIV prevention in the high schools of Sardinia: the experience of LILA Cagliari**
G. Dessi¹, S.M. Pani², A. Mereu², C. Sardu², P. Contu²
¹LILA Cagliari OdV, Cagliari, Italy, ²Department of Medical Sciences and Public Health, University of Cagliari, Cagliari, Italy

- P 159 Access to healthcare by Transgender and Gender Non-conforming individuals: preliminary evidence from a cross-sectional study**
F. Fama^{1,2}, E. Caruso³, C. Fusetti¹, D. Calzavara³, R. Fattore¹, N. Frattini³, S. Negri⁴, M. Cossu¹, A. Giacomelli¹, M. Cernuschi^{3,5}, A. Gori^{1,2}, D. Moschese^{1,3}
¹Department of Infectious Diseases, Luigi Sacco University Hospital – Milan, Italy, ²Centre for Multidisciplinary Research in Health Science (MACH), University of Milan - Milan, Italy, ³Milano Checkpoint ETS – Milan, Italy, ⁴ANLAIDS Lombardia ETS, Milan, Italy, ⁵Infectious Diseases Unit, San Raffaele Scientific Institute - Milan, Italy
- P 160 ReTe AIDS: shared telephone counselling strategies to meet people's information needs on STIs**
P. Gallo, A. Colucci, E. Fanales Belasio, R. Valli, M. Schwarz, R. Dalla Torre, A. D'Agostini, ReTe AIDS
Unità Operativa Ricerca psico-socio-comportamentale, Comunicazione, Formazione - Dipartimento Malattie Infettive - Istituto Superiore di Sanità, Rome, Italy
- P 161 Specialized clinic experience at the Multidisciplinary Center for Sexual Health (Ce.Mu.S.S) in Turin for managing female genital mutilation victims: an integrated approach**
A. Fortunato¹, L. Bello², M. Romanisio³
¹Asl città di Torino, Turin, Italy, ²Asl città di Torino, Turin, Italy, ³Università di Torino, Turin, Italy
- P 162 Bridging gaps in HIV screening for marginalized communities: insights from a community-based center in Genoa, Italy**
P. Ferrari^{1,2,3}, G. Notore^{1,2}, T. Cerisola¹, G. Manzi¹, E. Pontali^{1,4}
¹ANLAIDS Sezione Liguria, Genoa, Italy, ²Department of Health Sciences (DISSAL), University of Genoa, Genoa, Italy, ³Social Epidemiology and Health Policy (SEHPO), University of Antwerp, Antwerp, Belgium, ⁴Department of Infectious Disease, Ente Ospedaliero Ospedali Galliera, Genoa, Italy
- P 163 Problematic chemsex: a multidisciplinary approach**
G. Fracca, M. Manfredini
ASA Associazione Solidarietà AIDS ODV, Milano, Italy
- P 164 Italian parents and teachers' attitudes and perceptions of a comprehensive sexuality education activity in secondary schools: the EduForIST national project**
A. Chinelli¹, D. Martinelli², G. Papparato¹, L. Bonaldo¹, M. Di Nino¹, A. Musco², M. Ubbiali³, M. Farinella⁴, P. Meli⁵, P. Fallace⁶, P. Nardone⁷, D. Pieranzio⁷, S. Donati⁷, S. Ciardullo⁷, L. Tavaschi¹
¹University of Pisa, Pisa, Italy, ²University of Foggia, Foggia, Italy, ³University of Verona, Verona, Italy, ⁴Circolo di cultura omosessuale Mario Mieli, Roma, Italy, ⁵Coordinamento Italiano Case Alloggio HIV/AIDS (CICA), Bergamo, Italy, ⁶ASL Napoli2 Nord, Napoli, Italy, ⁷Istituto Superiore di Sanità, Roma, Italy
- P 165 Association between emotional reactivity and Internalized Stigma among People Living with HIV**
V. Massaroni¹, V. Delle Donne², P.F. Salvo¹, V. Iannone¹, R.A. Passeroito¹, F. Lamanna¹, R.J. Steiner¹, A. Carbone¹, C. Torti^{1,3}, G. Baldin³
¹Infectious Diseases Institute, Department of Safety and Bioethics, Catholic University of Sacred Heart, Rome, Italy, ²Clinical Psychology Unit, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy, ³UOC Infectious Diseases, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy
- P 166 The health and care needs of women living with HIV today: a cross-sectional analysis**
C. Picarelli¹, T. Mulas¹, A. Crea¹, M. Compagno¹, D. Checchi¹, L. Ferrari¹, M. Zordan¹, A. Di Lorenzo¹, G. De Simone¹, E. Teti¹, V. Barchi¹, D. Kontogiannis¹, V. D'Aquila¹, R.A. Cavasio¹, G. Alessio¹, N. Braccialarghe¹, A. Imeneo¹, I. Fato¹, F. Angelone¹, M. Moccione¹, C. Aguglia¹, V. Tatou¹, L.V. Rindi¹, L. Sarmati², A.M. Geretti²
¹Clinical Infectious Diseases, Tor Vergata Hospital, Rome, Italy, ²Clinical Infectious Diseases, Department of System Medicine, Tor Vergata University, Rome, Italy
- P 167 The use of Lorenz Curves and Gini index for the evaluation of HIV viral load distribution in the community**
S. Arsuffi¹, M. Salvi¹, S. Calza², M. Alberti¹, G. Tiecco¹, B. Fioretti¹, E. Focà¹, F. Castelli¹, E. Quiros-Roldan¹
¹Clinica di Malattie Infettive e Tropicali, Università degli Studi di Brescia e ASST Spedali Civili di Brescia, ²Unità di Biostatistica e Biomatematica e Unità di Bioinformatica, Dipartimento di Medicina Molecolare e Traslaazionale, Università degli Studi di Brescia
- P 168 Mono symptomatic therapeutical group for chemsex addiction to MDPV**
G. Fracca, M. Manfredini
ASA Associazione Solidarietà Aids ODV, Milano, Italy
- P 169 How relevant is working with key populations?**
D. Meli¹, I. Mercurio¹, P. Meli¹, F. Maggiolo², C. Pellegrini³, F. Defendi⁴, E. Risi⁵, M. Del Vecchio⁶
¹Cooperativa Don Giuseppe Monticelli, Bergamo, Italy, ²Bergamo Fast-Track City, Bergamo, Italy, ³Associazione Comunità Emmaus, Chiuduno, Italy, ⁴Patronato San Vincenzo, Bergamo, Italy, ⁵La Melarancia ODV, Bergamo, Italy, ⁶Cooperativa di Bessimo, Bessimo, Italy
- P 170 Sleep disorders in People Living with HIV in integrase-inhibitors based regimen**
R.A. Passeroito¹, D. Farinacci², F. Lamanna¹, R.J. Steiner¹, A. D'Angelillo¹, E. Visconti², S. Di Giambenedetto^{1,2}
¹Università Cattolica del Sacro Cuore, Roma, Italy, ²UOC Malattie Infettive e Tropicali, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy
- P 171 Impact of the Italian campaign "U=U: impossibile sbagliare" on people with HIV housed in CICA's network accommodation**
P. Meli^{1,8}, L. Rancilio^{2,8}, M. Deghi^{3,8}, S. Autieri^{4,8}, F. De Bellis^{5,8}, B. Bortolotti^{3,8}, L. Iorfida^{6,8}, L. Saracini^{7,8}
¹Don Giuseppe Monticelli Soc. coop. Soc., Bergamo, Italy, ²Caritas Ambrosiana, Milano, Italy, ³Il Gabbiano ODV, Tirano, Italy, ⁴Soc. Coop. Soc. Servizi per l'Accoglienza, Cremona, Italy, ⁵Fondazione Opera Santi Medici Cosma e Damiano, Bitonto, Italy, ⁶Associazione Giobbe Onlus, Torino, Italy, ⁷Opere Caritative Francescane ODV, Ancona, Italy, ⁸Coordinamento Italiano Case Alloggio per persone con HIV/AIDS
- P 172 Better questions, deeper conversation. Blood donation among the LGBTQIA+ community: a gender-neutral survey**
I. Banchini, E. Vazzana, F. Biscotti
APS Arcigay Cassero Salute, Bologna, Italy

Testing, prevention and PrEP: clinical perspectives and community best practice

- P 173 Appropriateness and strategic value of Post-Exposure Prophylaxis (PEP) for HIV today: experience from an Infectious Diseases referral centre, March-December 2023, Italy**
F.M. Fusco, N. Sangiovanni, C. Camaioni, F. Borrelli, O. Tambaro, R. Viglietti, V. Bruner, R. Falanga, R. Pisapia, R. Di Sarno, A. Franco, V. Sangiovanni
"D. Cotugno" hospital, Azienda Ospedaliera dei Colli, Naples, Italy
- P 174 Two years analysis of COBATEST data in Ancona Checkpoint and our experience of "tele visita PrEP"**
S. Caucci^{1,3}, L. Saracini^{2,3}, P. Pauri³, L. Butini⁴
¹Department of Biomedical Sciences and Public Health, Università Politecnica delle Marche, Ancona, Italy, ²Ass. Opere Caritative Francescane, Ancona, Italy, ³Ancona Checkpoint, Ancona, Italy, ⁴Immunology Laboratory, Azienda Ospedaliera Universitaria delle Marche, Ancona, Italy
- P 175 "TelePrEP" – A pilot program for the delivery of remote PrEP services**
S. Penon¹, L. Cosmaro¹, F. Falzetta¹, M. Oldrini¹, D. Savarino¹, A.R. Raccagn², C. Candela², S. Nozza^{2,3}
¹Fondazione LILA Milano ETS, Milan, Italy, ²Vita-Salute San Raffaele University, Milan, Italy, ³Infectious Diseases Unit, IRCCS San Raffaele Scientific Institute, Milan, Italy
- P 176 Testing for HIV in CBVCT services adhering to the COBATEST Network - 2020-2023**
L. Cosmaro¹, S. Curradori¹, S. Penon¹, M. Cernuschi², D. Calzavara³, P. Russo³, M. Prandelli³, P. Meli⁴, I. Mercurio⁴
¹Fondazione LILA, Milano, Milan, Italy, ²ASA Milano, Milan, Italy, ³Milano Checkpoint, Milan, Italy, ⁴Bergamo Fast-track City, Bergamo, Italy

- P 177 Sexual assault is associated to loss to follow-up for non-occupational Post-Exposure Prophylaxis for HIV**
G. Bozzi¹, A. Liparoti^{1,2}, A. Pastena^{1,2}, G. Ancona¹, C. Bobbio², N. Iannotti¹, B. Mariani¹, A. Muscatello¹, A. Bandera^{1,2}
¹Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milano, Infectious Diseases, Milano, Italy, ²Unimi - Università degli Studi di Milano, Milano, Italy
- P 178 Evaluating tolerance and safety profiles of Pre-Exposure Prophylaxis (PrEP) for HIV: insights from renal and hepatic function monitoring**
G. Cuomo, M. Menozzi, M. Albertini, V. Todisco, L. Gozzi, E. Martini, D. Lusetti, G. Guaraldi, C. Mussini
Azienda Ospedaliero-Universitaria di Modena - Università di Modena e Reggio Emilia, Italy
- P 179 Renal toxicity in a cohort of PrEP users**
L. Labate^{1,2}, C. Marelli², F. Rismondo¹, L. Taramasso¹, I. Schiavetti³, L. Mezzogori^{1,2}, R. Schiavoni^{1,2}, C. Bartalucci^{1,2}, F. Centorrino¹, M. Bassetti^{1,2}, A. Di Biagio^{1,2}
¹IRCCS Ospedale Policlinico San Martino, Genoa, Italy, ²Department of Health's Sciences, University of Genoa, Italy, ³Department of Health Sciences, Section of Biostatistics, University of Genova, Genova, Italy
- P 180 Outreach programme in sex-on-premises venues: facilitating linkage to care and prevention services**
D. Zagato¹, P. Vinti¹, P.M. Testoni¹, A. Bianchi¹, A. Pezzotti¹, A. Teofilo¹, G. Perrotta¹, M. Scarci¹, V. Gambini¹, M. Cernuschi^{1,2}
¹ASA - Associazione Solidarietà AIDS ODV, Milano, Italy, ²HSR - Ospedale San Raffaele, Milano, Italy
- P 181 Alteration of transaminases in PrEP users: investigation of possible causal factors other than FTC/TDF**
C. Fusetti¹, M. Gerbi¹, F. Barone¹, S. Lazzarin¹, F. Caruso¹, R. Fattore¹, F. Petri¹, M.V. Cossu¹, A. Giacomelli¹, A. Gori^{1,2}, D. Moschese¹
¹Department of Infectious Diseases, Luigi Sacco University Hospital, Milan, Italy, ²Centre for Multidisciplinary Research in Health Science (MACH), University of Milan, Milan, Italy
- P 182 UniversiTest: peer to peer approaching. Informing and Testing**
M. Niglio, F. De Gregorio, C. Grillo, F.R.P. Ieva, R. Papale, A. Narducci, C. Muscatello, I.F. Bottalico, T.A. Santantonio, S. Lo Caputo
Unit of Infectious Diseases, A.O.U. Policlinico - Foggia, Italy
- P 183 Two and a half years of In- and Out-Hospital counselling and testing activities: two different and comprehensive preventive strategies**
G. Mancarella^{1,2}, A. Carraro², A. Gasperin¹, F. Izzo¹, D. Di Trento^{1,2}, S. Corazza¹, S. De Maria^{1,2}, A. Grimaldi¹, R. Marocco², V. Rossi², M. D'Achille², L. Lubrano³, V. Mercurio³, A. Petrillo³, A. Girardi³, V. Vitale³, C. Del Borgo², A. Carnevale³, M. Lichtner^{1,4}
¹Sapienza University of Rome, Latina, ²Infectious Diseases Unit, SM Goretti Hospital, Latina, ³Arcigay - Sei come sei, Latina, ⁴Department of NESMOS, Sapienza University of Rome, Rome, Italy
- P 184 HIV drug resistance test harbouring the RT M184V mutation in a PrEP (Pre Exposure Prophylaxis) administered sex worker**
V. Micheli¹, A. Foschi², F. Bracchitta¹, L. Morelli¹, F. De Poli¹, A. Rizzo¹, M. Cossu², A. Gori^{2,3}, M.R. Gismondo¹
¹Laboratory of Clinical Microbiology, Virology and Bioemergencies, ASST Fatebenefratelli Sacco L. Sacco University Hospital, Milan, Italy, ²Department of Infectious Diseases, Unit II, ASST Fatebenefratelli Sacco L. Sacco University Hospital, Milan, Italy, ³Centre for Multidisciplinary Research in Health Science (MACH), University of Milan, Milan, Italy
- P 185 Implementation of a provincial PrEP clinic: analysis by public refundability and new HIV infection diagnoses in Latina**
A. Carraro^{1,2}, L. Cimino¹, G. Mancarella^{1,2}, R. Marocco², S. De Maria^{1,2}, S. Corazza¹, A. Grimaldi¹, A. Gasperin¹, M. D'Achille², V. Rossi², A. Carlesso², M. Renzelli², L. De Angelis², O. D'Onofrio², P. Addio³, G. Bonanni³, C. Del Borgo², A. Carnevale⁴, M. Lichtner⁵
¹Department of Public Health and Infectious Disease, Sapienza University of Rome, Rome, Italy, ²Infectious disease Unit, SM Goretti Hospital, Sapienza University of Rome, Latina, Italy, ³Pharmacy Unit, SM Goretti Hospital, Latina, Italy, ⁴Arcigay Latina SeiComeSei, ⁵Department of NESMOS, Sapienza University of Rome, Rome, Italy
- P 186 Differentiated and simplified PrEP delivery in Italy: alignment with WHO guidance is needed**
P. Vinti¹, E. Caruso¹, V. Calvino², L. Cosmaro³, M. Farinella⁴, N. Frattini⁵, G. Giupponi⁶, F. Leseri⁷, S. Mattioli⁸, P. Meli⁹, A. Moznich¹⁰, S. Patrucco¹¹, I. Pennini¹², F. Schläsler¹³, M. Stizioli¹⁴, D. Calzavara¹
¹Milano Check Point ETS, Milano, Italy, ²ANLAIDS Nazionale ETS, Roma, Italy, ³Fondazione LILA Milano ETS, Milano, Italy, ⁴CCO Mario Mieli APS, Roma, Italy, ⁵ASA ODV, Milano, Italy, ⁶LILA Nazionale ONLUS, Como, Italy, ⁷Plus Roma APS, Roma, Italy, ⁸Plus APS, Bologna, Italy, ⁹CICA ETS, Milano, Italy, ¹⁰NPS Italia APS, Milano, Italy, ¹¹Arcobaleno AIDS ODV, Torino, Italy, ¹²Arcigay APS, Bologna, Italy, ¹³Nadir ETS, Roma, Italy, ¹⁴PrEP in Italia, Brescia, Italy
- P 187 Evaluation of injectable long acting cabotegravir as response to oral PrEP-related medical issues**
R. Rossotti^{1,2}, A. Tavelli³, A. Bianchi², D. Calzavara², E. Caruso², A. Soria^{2,4}, A. De Bona^{2,5}, C. Muccini^{2,6}, D. Moschese^{2,7}, R. Repossi², M. Cernuschi^{2,6}, A. d'Arminio Monforte³
¹ASST Grande Ospedale Metropolitano Niguarda, Milan, Italy, ²Milano Checkpoint, Milan, Italy, ³ICONA Foundation, Milan, Italy, ⁴IRCCS San Gerardo dei Tintori, Monza, Italy, ⁵ASST Santi Paolo e Carlo, Milan, Italy, ⁶IRCCS San Raffaele Scientific Institute, Milan, Italy, ⁷ASST Fatebenefratelli Sacco, Milan, Italy
- P 188 Sexual habits and STDs occurrence in people attending a new PrEP clinic in Brescia**
D. Minisci¹, S. Reale¹, D. Laurenda¹, G. Tiecco¹, S. Arsuffi¹, I. Polesini², V. Castellanelli², A. Matteelli¹, F. Castelli¹, E. Quiros Roldan¹, E Focà¹
¹Division of Infectious and Tropical Diseases, University of Brescia and ASST Spedali Civili Hospital, Brescia, Italy, ²ASST Spedali Civili Hospital, Brescia, Italy

Vaccines

- P 189 Strategies based on nudging to reduce vaccine hesitancy in PLWHA in a northern Italy center**
G. Orofino¹, M. Guastavigna¹, A. Ianniello¹, D. Arrue Diaz², E. Catellani³, M. Martella⁴, F. Bert⁴, G.D. Greco⁵, E. Remani⁶, G. Calleri¹
¹Tropical and Infectious Diseases Division A, Amedeo di Savoia Hospital, Turin, Italy, ²Medical Science Department, University of Turin, Turin, Italy, ³Hospital Pharmacy, ASLTO5, Italy, ⁴Public Health Department, University of Turin, Italy, ⁵SISP, ASL Città di Torino, Turin, Italy, ⁶Hospital Pharmacy, Amedeo di Savoia Hospital, Turin, Italy
- P 190 Vaccine uptake pre and post COVID-19 pandemic among PLWH**
E. Suardi, R. Ligresti, E. Zaninetta, L. Biasioli, B. Lundgren, A. Santoro, F. Di Bartolomeo, T. Bini, F. Bai, G. Marchetti
Clinic of Infectious Diseases and Tropical Medicine, San Paolo Hospital, ASST Santi Paolo e Carlo, Department of Health Sciences, University of Milan, Milan, Italy
- P 191 A systematic and evidence-based approach in vaccination of people living with HIV: the Notebook of Clinical Vaccinology**
S.M. Gherardi, P. Amoriello Lambertini, G. Adamo, G. Lobrano, N.R. Mallamace, C. Vazzoler, S. Pittalis, O. Zuccaro, V. Mazzocato, F. Conforti, F. Trani, G. Calaiocco
UOC Coordinamento delle attività vaccinali, ASL Rm2, Rome, Italy
- P 192 Antibody and Interferon response in HIV patients following mRNA-based SARS-CoV-2 vaccine**
A. D'Auria¹, F. Frasca¹, M. Fracella¹, E. Coratti¹, G. Bugani², L. Santinelli², L. Maddaloni², R. Campagna¹, G. Ceccarelli², C.M. Mastroianni², O. Turriziani¹, G. Antonelli^{1,3}, G. d'Ettore², C. Scagnolari¹
¹Department of Molecular Medicine, Laboratory of Virology, Sapienza University of Rome, Rome, Italy, ²Department of Public Health and Infectious Diseases, Sapienza University of Rome, Rome, Italy, ³Microbiology and Virology Unit, Sapienza University Hospital "Policlinico Umberto I", Rome, Italy

- P 193 Evaluation of functional antibodies against HIV Env and Tat proteins: analysis of antibody-dependent cell-mediated cytotoxicity (ADCC)**
M. Martino¹, A. Cafaro², E. Torreggiani¹, A. Caputo¹, A. Tripiciano², B. Dallan¹, D. Proietto¹, M. De Laurentis¹, E. Tassani¹, V. Francavilla², F. Mancini², M. Campagna², P. Monini², R. Gavioli¹, F. Nicoli¹, B. Ensolì²
¹Department of Chemical, Pharmaceutical and Agricultural Sciences, University of Ferrara, Ferrara, Italy, ²National HIV/AIDS Research Center (CNAIDS), Istituto Superiore di Sanità (ISS), Rome, Italy
- P 194 Correlation between immune response and adverse events in MS patients after Shingrix vaccine administration**
I. Fato¹, L. Benedetti¹, D. Landi¹, F. Napoli¹, V. Barchi¹, A. Di Lorenzo¹, A. Imeneo¹, G. Alessio¹, F. Angelone¹, B. Massa¹, M.A. Zingaropoli², P. Pasculli², C.M. Mastroianni², M.R. Ciardi², M. Andreoni¹, G.A. Marfia^{1,2}, L. Sarmati¹, M. Iannetta¹
¹Tor Vergata University, Department of Systems Medicine, Rome, Italy, ²Multiple Sclerosis Center, Policlinico Tor Vergata of Rome, Rome, Italy, ³Sapienza University, Department of Public Health and Infectious Diseases, Rome, Italy
- P 195 Evaluation of cell-mediated immunity to HPV nonavalent vaccine (Gardasil9®) in a cohort of people living with HIV**
L. Ansaldo¹, L. Benedetti², R.A. Cavasio², V. D'Aquila², R. Iannazzo², M. Compagno^{1,3}, M. Ciotti⁴, L. Sarmati^{2,3}, M. Iannetta^{2,3}
¹PhD Program in Microbiology, Immunology, Infectious Diseases and Transplants (MIMIT), Tor Vergata University, Rome, Italy, ²Department of Systems Medicine, University of Tor Vergata, Rome, Italy, ³Infectious Diseases Unit, Policlinico Tor Vergata, Rome, Italy, ⁴Clinical Microbiology and Virology, Virology Unit, Policlinico Tor Vergata, Rome, Italy
- P 196 PrEP access highlights worrisome gap in vaccination coverage against HPV and other vaccine preventable STIs**
R. Fattore, A. Giacomelli, M.V. Cossu, F. Barone, C. Fusetti, F. Caruso, G. Scaglione, F. Fama, M. Gerbi, P. Raimondo, A. Gori, D. Moschese
Department of Infectious Diseases, Luigi Sacco University Hospital, Milan, Italy
- P 197 Lactoferrin assumption in vaccinated subjects infected by Sars-CoV-2 may influence time length of negativization**
G. Costanza¹, T. Cosio², M. Ciotti¹, C. Lanna³, L. Rosa⁴, C. Galluzzi³, R. Gaziano², S. Grelli¹, P. Valenti⁴, L. Bianchi³, E. Campione³
¹Unit of Virology, Tor Vergata University Hospital, Rome, Italy, ²Department of Experimental Medicine, Tor Vergata University Hospital, Rome, Italy, ³Dermatology Unit, Department of Systems Medicine, Tor Vergata University Hospital, Rome, Italy, ⁴Department of Public Health and Infectious Diseases, University of Rome La Sapienza, Rome, Italy
- P 198 Analysis of Spike-specific immunity induced by IDLV-Spike in mice: comparison between females and males**
A. Gallinaro¹, C. Falce¹, A. Zappitelli², M.F. Pirillo¹, M. Borghi², A. Canitano¹, Z. Michelinì¹, S. Cecchetti³, M. Rosati¹, A. Tinari⁴, A. Di Virgilio⁵, A. Cara¹, D. Negri²
¹National Center for Global Health, ²Department of Infectious Diseases, ³Confocal Microscopy Unit NMR, Confocal Microscopy Area Core Facilities, ⁴Center for Gender Medicine, ⁵Center for Animal Research and Welfare, Istituto Superiore di Sanità, Rome, Italy
- P 199 Neutralizing antibodies titers against ten viral Spike protein variants of SARS-CoV-2 in the serum of patients receiving dialysis before and 30 days after the XBB1.5 updated mRNA vaccination**
G. Lipari¹, C. Pellaton², C. Fenwick², R. Gingis³, V. Fattizzo³, N. Landriani¹, C. Airaghi¹, S. Khemara³, A. Gabrieli³, G. Pantaleo², A. Riva³, M. Gallieni³, M. Tarkowski³
¹ASST Fatebenefratelli Sacco, Milan, Italy, ²Lausanne University Hospital, Lausanne, Switzerland, ³Università degli Studi di Milano, Milano, Italy
- P 200 Neutralizing antibody response to the highly divergent BA.2.86 SARS-CoV-2 lineages in vaccinated health care workers with or without subsequent infection**
I. Varasi¹, C. Biba¹, M. Bugger², A. Sonnerborg², F. Ceccherini-Silberstein³, M.M. Santoro³, R. Kaiser⁴, G.H. Rubio⁴, J.P.V. Pereira⁵, K. Serwin⁶, V. Gurksniene⁷, A. Dias⁸, R. Ribeiro⁹, J. Fonseca de Morais Caporalio¹⁰, J. Andrade Pinto¹⁰, F. Incardona^{11,12}, M. Zazzi¹, I. Vicenti¹, on behalf of the EuCARE project study group
¹Department of Medical Biotechnologies, University of Siena, Siena, Italy, ²Department of Medicine Huddinge Karolinska Institutet, Stockholm, Sweden, ³Department of Experimental Medicine, University of Rome Tor Vergata, Rome, Italy, ⁴Institute of Virology, University of Cologne, Cologne, Germany, ⁵Department of Gastroenterology, Hepatology and Infectious Diseases, Medical Faculty and University Hospital Duesseldorf, Heinrich Heine University, Duesseldorf, Germany, ⁶Department of Infectious, Tropical Diseases and Immune Deficiency, Pomeranian Medical University in Szczecin, Poland, ⁷Infection Control Department, Vilnius University Hospital Santaros Klinikos, Lithuania, ⁸Microbiology Laboratory, Centro Hospitalar de Lisboa Ocidental, Portugal, ⁹Occupational Medicine Service, Centro Hospitalar de Lisboa Ocidental, Portugal, ¹⁰School of Medicine, Federal University of Minas Gerais, Brazil, ¹¹Eu-Resist Network GEIE, Italy, ¹²InformaPRO S.r.l., Italy
- P 201 Hepatitis A virus protection status in cis males and transgender females who live with HIV and have sex with men: a retrospective observational study**
S. Reato^{1,2}, G. Carrozzo^{1,2}, A. Giacomelli^{1,2}, A.L. Ridolfo², S. Antinori^{1,2}
¹Dipartimento di Scienze Biomediche e Cliniche, Università degli Studi di Milano, Milan, Italy, ²III Division of Infectious Diseases, ASST Fatebenefratelli Sacco, Luigi Sacco Hospital, Milan, Italy
- P 202 Beyond the barriers: the impact of HPV vaccination program variation among MSM PLWH**
D. Laurenda¹, M. Inverardi¹, I. Izzo², S. Arsuffi¹, B. Fioretti¹, D. Castellì², S. Capone², P. Zanotti², F. Gaffurini², I. Polesini², E. Focà¹, E. Quiros-Roldan¹, F. Castelli¹
¹Division of Infectious and Tropical Diseases, University of Brescia and ASST Spedali Civili Hospital, Brescia, Italy, ²ASST Spedali Civili Hospital, Brescia, Italy
- P 203 Varicella Zoster Virus Vaccination in immunocompromised patients with haematological and rheumatological diseases: specific Tcell response measured with an in-house Interferon Gamma Release Assay**
L. Coppola^{1,2,3}, L. Benedetti¹, G. Montagnari¹, M. Compagno^{1,2,3}, L. Campogiani^{1,2,3}, V. Malagnino^{1,3}, F. Meconi⁴, M.S. Chimenti⁵, M. Andreoni^{1,3}, L. Sarmati^{1,3}, M. Iannetta^{1,3}, M. Andreoni^{1,3}, L. Sarmati^{1,3}, M. Iannetta^{1,3}
¹Department of Systems Medicine, University of Tor Vergata, Rome, Italy, ²PhD Program in Microbiology, Immunology, Infectious Diseases and Transplants (MIMIT), Tor Vergata University, Rome, Italy, ³Infectious Diseases Unit, Policlinico Tor Vergata, Rome, Italy, ⁴Haematological Diseases Unit, Policlinico Tor Vergata, Rome, Italy, ⁵Rheumatological Diseases Unit, Policlinico Tor Vergata, Rome, Italy
- P 204 Behavioral and epidemiological survey on compliance to receive new booster doses of anti-SARS-Cov2 vaccine in PLWH**
G. Del Duca¹, A. Vergori¹, I. Sperduti², A. Cozzi Lepri³, F. Drobniewski⁴, M. Fusto¹, M. Plazzi¹, V. Mazzotta¹, J. Paulicelli¹, R. Gagliardini¹, A. Antinori¹
¹Clinical and Research Department, National Institute for Infectious Diseases Lazzaro Spallanzani IRCCS, Rome, Italy, ²Biostatistics and Bioinformatics Unit-Scientific Direction, IRCCS Regina Elena National Cancer Institute, Rome, Italy, ³Centre for Clinical Research, Epidemiology, Modelling and Evaluation (CREME), Institute for Global Health, University College London, London, UK, ⁴Global Health, Tuberculosis and Microbiology, Infectious Diseases, Imperial College London, London, UK
- P 205 Specific T-cell responses to Varicella Zoster Virus glycoprotein E one year after vaccination with a recombinant adjuvanted subunit vaccine in people with multiple sclerosis on disease modifying treatments**
M. Iannetta^{1,2}, L. Benedetti¹, L. Coppola^{1,3}, G.F. Angelone¹, I. Fato¹, G. Montagnari¹, D. Landi⁴, F. Napoli⁴, V. Barchi¹, G. Alessio¹, A. Di Lorenzo¹, A. Imeneo¹, G. Mataluni⁴, C.G. Nicoletti⁴, E. Teti², M. Andreoni^{1,2}, G.A. Marfia^{4,5}, L. Sarmati^{1,2}
¹Department of Systems Medicine, University of Rome Tor Vergata, Rome, Italy, ²Infectious Diseases Unit, Policlinico Tor Vergata, Rome, Italy, ³PhD Program in Microbiology, Immunology, Infectious Diseases and Transplants (MIMIT), Tor Vergata University, Rome, Italy, ⁴University of Rome Tor Vergata, Multiple Sclerosis Clinical and Research Unit, Department of Systems Medicine, Rome, Italy, ⁵IRCCS Neuromed, Unit of Neurology, Pozzilli (IS), Italy

Viral hepatitis

- P 206 Risk of HBV reactivation and loss of anti-HBc in anti-CD20 treated multiple sclerosis patients: a six-year observational cohort study**
Y.C. Fosso Ngangue¹, P. Pasculli¹, M.A. Zingaropoli¹, F. Dominelli¹, F. Ciccone¹, M. Antonacci¹, G. Ferrazzano², A. Conte², C.M. Mastroianni¹, M.R. Ciardi¹
¹Department of Public Health and Infectious Diseases, Sapienza University of Rome, Italy, ²Department of Human Neurosciences, Sapienza University of Rome, Rome, Italy
- P 207 Bulevirtide for the treatment of hepatitis D: a case series**
F. Caruso¹, A. Giacomelli¹, S. Sollima¹, A. Gori^{1,2}, S. Antinori¹, C. Magni¹
¹Department of Infectious Diseases, Luigi Sacco Hospital, ASST Fatebenefratelli Sacco, Milan, Italy, ²Department of Pathophysiology and Transplantation, Centre for Multidisciplinary Research in Health Science (MACH), University of Milan, Milan, Italy
- P 208 HBs isoforms as innovative biomarkers in predicting virological response in chronic hepatitis delta patients treated with bulevirtide monotherapy**
S. D'Anna¹, R. Salpini¹, E. Degasperis², L. Duca³, M.P. Anolli², L. Piermatteo¹, D. Sambarino², M. Borghi², F. Facchetti², F. Ceccherini-Silberstein³, R. Perbellini², P. Lampertico^{2,4}, V. Svircher¹
¹Department of Biology, University of Rome Tor Vergata, Rome, Italy, ²Division of Gastroenterology and Hepatology, Foundation IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy, ³Department of Experimental Medicine, University of Rome Tor Vergata, Rome, Italy, ⁴Department of Pathophysiology and Transplantation, CRC "A. M. and A. Migliavacca" Center for Liver Disease, University of Milan, Milan, Italy
- P 209 First case of hepatitis B virus (HBV) reactivation in a patient with breast cancer receiving CDK4/6 inhibitor drugs**
F. Capriotti¹, L. Foroghi Biland¹, P. Rabatelli¹, A. Fabiano¹
University of Parma, Italy
- P 210 Bulevirtide effectiveness and safety in cirrhotic and non cirrhotic patients in Sardinia**
A.A. Mariani¹, C. Fanelli¹, F. Pes², L. Dentì¹, V. Fiore¹, A. Muredda¹, M.A. Seazzu¹, L. Chessa², A. Civolani², G. Alagna³, I. Maida¹
¹Department of Medicine, Surgery and Pharmacy, AOU Sassari, Italy, ²Policlinico Monserrato, AOU Cagliari, Italy, ³SSD Hepatology, AOU Sassari, Italy
- P 211 Hepatitis delta testing in adults with chronic hepatitis B virus infection attending for outpatient care: Who are those unscreened?**
A. Di Lorenzo¹, D. Kontogiannis¹, C. Sorace¹, A.M. Crea¹, E. Teti¹, V. Malagnino^{1,2}, M. Iannetta^{1,2,3}, A.M. Geretti^{1,2,3}, L. Sarmati^{1,2}
¹Infectious Disease Clinic, Policlinico Tor Vergata, Rome, Italy, ²Department of Systems Medicine, Tor Vergata University, Rome, Italy, ³Department of Infection, North Middlesex University Hospital, London, UK
- P 212 Dengue associated hepatitis: two case reports and literature review**
B. Kertusha^{1,2}, A. Parente^{1,2}, T. Tieghi¹, P. Fabietti¹, S. Cacace², R. Marocco^{1,2}, M. Lichtner³, C. Del Borgo^{1,2}
¹Infectious Diseases Unit, S. M. Goretti Hospital, Latina, ²Sapienza University of Rome, Department of Public Health and Infectious Diseases, ³Sapienza University of Rome, NESMOS Department
- P 213 HBV reactivation after immunosuppressive therapy: an open question**
M. Abbott¹, G. Valenti^{1,2}, A. Gizzi¹, S. Agrenzano¹, A. Ficalora¹, A. Mancuso^{1,2}, A. Sanfilippo¹, D. Spicola¹, I. Alongi¹, C. Buscemi¹, F. Onorato¹, A. Cascio², C. Iaria¹
¹UOC Malattie Infettive, ARNAS Civico-Di Cristina-Benfratelli, Palermo, Italy, ²Infectious and Tropical Diseases Unit, Department of Health Promotion, Mother and Child Care, Internal Medicine and Medical Specialties (PROMISE), University of Palermo, Palermo, Italy
- P 214 Natural history and management Pediatric HCV: 25 years experience of North Italian center**
F. Musto¹, M. Stracuzzi¹, V. Rubinacci¹, E. Crivellaro¹, C. Porro¹, A. Cibarelli¹, E. Ghidoni¹, G.V. Zuccotti^{2,3}, G. Giacomelli¹
¹Department of Pediatric Infectious Disease, Luigi Sacco Hospital, University of Milan, Italy, ²Department of Pediatrics, Vittore Buzzi Children's Hospital, University of Milan, Milan, Italy, ³Department of Biomedical and Clinical Science, University of Milan, Milan, Italy

Virology and pharmacology

- P 215 Optimization of HIV-1 Next Generation Sequencing genotyping drug resistance testing methods from both RNA and DNA on Ion GeneStudio S5 prime System**
L. Fabeni¹, F. Smoquina¹, F. Forbici¹, G. Bero¹, M. Rueca¹, G. Sberna¹, R. Gagliardini², V. Mazzotta², A. Vergori², I. Abbate¹, G. Rozera¹, A. Antinori², F. Maggi¹
¹Laboratory of Virology, National Institute for Infectious Diseases Lazzaro Spallanzani - IRCCS, Rome, Italy, ²Clinical and Research Infectious Diseases Department, National Institute for Infectious Diseases Lazzaro Spallanzani - IRCCS, Rome, Italy
- P 216 Evaluation of broad-spectrum piperazine-based compounds able to inhibit flavivirus and/or SARS-CoV-2 replication in a live virus assay**
C. Biba¹, I. Varasi¹, P.A. Cavallaro², F. Giammarino¹, N. Bartolini¹, J.M. Vega-Pérez³, F. Iglesias-Guerra³, A. Leggio², M. Vega-Holm³, I. Vicenti¹
¹Department of Medical Biotechnologies, UOC Microbiology and Virology, University of Siena, Siena University Hospital, Siena, Italy, ²Department of Pharmacy, Health and Nutritional Sciences, University of Calabria, Arcavacata di Rende (CS), Italy, ³Department of Organic and Medicinal Chemistry, Faculty of Pharmacy, University of Seville, Seville, Spain
- P 217 Idiosyncratic drug liver injury during long-acting HIV treatment: A Case Report**
L. Lundgren¹, G. Giannetta¹, L. Albertini¹, M. Pieruzzi¹, F. Bai¹, E. Suardi¹, D. Cattaneo², A. De Bona¹, C. Tincati¹, T. Bini¹, G.C. Marchetti¹
¹Clinic of Infectious Diseases, San Paolo Hospital, ASST Santi Paolo e Carlo, Department of Health Sciences, University of Milan - Milan (Italy), ²Department of Infectious Diseases, Luigi Sacco Hospital, ASST Fatebenefratelli Sacco, University of Milan - Milan (Italy)
- P 218 Comparative evaluation of 5 RT-PCR kits for Dengue virus detection**
C. Fracalvieri¹, M. Lucente¹, G. Garzillo², N. Nigro¹, B. Galano¹, G. Guarona², M. Ferraris¹, I. Giberti², B. Bruzzone¹, A. Domnich¹
¹Igiene Unit, Policlinico San Martino Hospital, Genoa, Italy, ²Department of Health Sciences, University of Genoa, Genoa, Italy
- P 219 Success rate of HIV DNA Sanger sequencing in PBMC and whole blood samples**
T. Alice¹, F. Cerutti¹, M.G. Milia¹, G. Gregori¹, E. Burdino¹, S. Monteleone¹, A. Bottoni¹, B. Simoncelli¹, E. Scuccimarra¹, V. Ghisetti¹
Laboratory of Microbiology and Virology, ASL Città di Torino, Italy
- P 220 Effects of DTG in cardiovascular system development in a model of zebrafish embryo**
S. Ferretti¹, C. Colangelo², D. Zizioli¹, I. Zanella^{1,3}, M. Alberti², F. Castelli², E. Quiros-Roldan²
¹Department of Molecular and Translational Medicine, University of Brescia, Brescia, Italy, ²Department of Clinical and Experimental Sciences, Unit of Infectious and Tropical Diseases, University of Brescia and ASST Spedali Civili di Brescia, Brescia, Italy, ³Cytogenetics and Molecular Genetics Laboratory, Diagnostic Department, ASST Spedali Civili di Brescia, Brescia, Italy
- P 221 HIV-DNA quantification as prediction of GRT success in HIV-DNA NGS**
F. Stefanelli¹, N. Randazzo¹, M. Lucente¹, C. Fracalvieri¹, S. Varesano¹, A. Domnich¹, L. Mezzogori², C. Bartalucci², S. Bianchi¹, A. Di Biagio^{2,3}, B. Bruzzone¹
¹Igiene Unit, IRCCS Policlinico San Martino Hospital, Genoa, Italy, ²Department of Specialist Medicine, Infectious Disease Clinic, IRCCS Policlinico San Martino Hospital, Genoa, Italy, ³Department of Health Sciences (DISSAL), University of Genoa, Genoa, Italy

- P 222 Erdosteine inhibits viral infection and modulates innate immunity and stress oxidative state in RSV-infected A549 cells**
S. Strizzi¹, F. Danzo², C. Vanetti¹, M. Biasin¹, D. Radovanovic², P. Santus², D. Trabattoni¹
¹Department of Biomedical and Clinical Sciences, Università degli Studi di Milano, Milan, Italy, ²Department of Biomedical and Clinical Sciences, Università degli Studi di Milano, Division of Respiratory Diseases, University Hospital "L. Sacco", Milan, Italy
- P 223 Comparison of Sanger sequencing and amplicon-based NGS approaches for the detection of HIV-1 drug resistance mutations**
L. Fiaschi, C. Biba, I. Varasi, N. Bartolini, C. Paletti, I. Vicenti, F. Saladini, M. Zazzi
 Department of Medical Biotechnologies, University of Siena, Siena, Italy
- P 224 Depth coverage and HIV-1 variability negatively affect the performance of the "HIV-1 solution v2" NGS sequencing kit for drug resistance monitoring**
F. Saladini¹, G. Marchegiani², V. Galli³, M. Vatteroni⁴, D. Spalletta², I. Giovannelli³, C. Carone³, R. Corsini⁵, L. Fiaschi¹, C. Biba¹, I. Vicenti¹, A. Bezenchek⁶, D. Armenia⁷, M. Zazzi¹, M. Santoro², on behalf of the NGS Network
¹Department of Medical Biotechnologies, University of Siena, Siena, Italy, ²Department of Experimental Medicine, University of Rome "Tor Vergata", Rome, Italy, ³Clinical Immunology, Allergy and Advanced Biotechnologies Unit, AUSL - IRCCS Reggio Emilia, Reggio Emilia, Italy, ⁴Virology Unit, AOU Pisana, Pisa, Italy, ⁵Infectious Diseases Unit, AUSL - IRCCS Reggio Emilia, Reggio Emilia, Italy, ⁶IPRO-InfomaPRO S.r.l., Rome, Italy, ⁷EuResist Network GEIE, Rome, Italy, ⁸UniCamillus, Saint Camillus International University of Health Sciences, Rome, Italy
- P 225 Case report on the effect of antiretroviral treatment on a young man with uncertain HIV diagnosis, immune dysfunction and high expression of HERVs**
C. Matteucci¹, A. Minutolo¹, R. Scutari^{1,2}, L. Benedetti³, V. Petrone¹, C. Cipriani¹, M. Zazzi⁴, G. Marchetti⁵, S. Grelli^{1,6}, E. Talassi⁷, S. Casari⁸, E. Balestrieri¹, F. Ceccherini-Silberstein¹
¹Department of Experimental Medicine, University of Rome Tor Vergata, Italy, ²Multimodal Laboratory Research Unit, Bambino Gesù Children's Hospital, IRCCS, Rome, Italy, ³Department of System Medicine, Clinical Infectious Diseases, University of Rome Tor Vergata, Rome, Italy, ⁴Department of Medical Biotechnologies, University of Siena, Siena, Italy, ⁵Santi Paolo e Carlo, Clinic of Infectious Diseases, University of Milan, Milan, Italy, ⁶Virology Unit, Policlinic of Tor Vergata, Rome, Italy, ⁷Unit of Neurology, Carlo Poma Hospital, Mantova, Italy, ⁸Unit of Infectious Diseases, Carlo Poma Hospital, Mantova, Italy

19-21
GIUGNO
ROMA

UNIVERSITÀ CATTOLICA
DEL SACRO CUORE
CENTRO CONGRESSI
EUROPA

16° CONGRESSO NAZIONALE



**Italian Conference on AIDS and
Antiviral Research**

20
24



Presidenza del Congresso

A. Cingolani, Roma
A. Di Biagio, Genova
M. Farinella, Roma
G. C. Marchetti, Milano

RESEARCH and CARE: FROM BENCH, TO BEDSIDE, TO COMMUNITY

GENERAL INFORMATION

Congress Venue



UNIVERSITÀ CATTOLICA DEL SACRO CUORE CENTRO CONGRESSI EUROPA

Largo Francesco Vito, 1
00168 Roma
<https://www.policlinicogemelli.it/>

How to reach the Conference Venue



Underground

Line A.

Direction 'Battistini' to 'Valle Aurelia', then the FL3 train (direction Cesano-Viterbo to 'Gemelli').
On the surface take one of the bus lines 994, 446, 146 and get off at 'Policlinico Agostino Gemelli'.



By train

- 13 km from **Roma Termini** station (27 min. by car)
 - 14 km from **Roma Tiburtina** station (30 min. by car)
- From Roma Termini take the metro **Line A** (direction 'Battistini' to 'Valle Aurelia'), then the FL3 line train (direction 'Cesano-Viterbo' to 'Gemelli').



By car

Grande Raccordo Anulare di Roma.

From SOUTH: exit 1 (via Aurelia) or exit 2 (via Boccea) or exit 4 (via Trionfale).
From NORTH exit 6 (via Flaminia).
Ample paid parking available inside the Policlinico.



By plane

30 km from Fiumicino International Airport (31 minutes by car).
Take the FL1 line towards 'Fara Sabina' get off at 'Trastevere'.
Take the FL3 line towards 'Viterbo' and get off at 'Gemelli'.

Press Office

Diessecom

Daniel Della Seta, diessecom@gmail.com

Daniele Toscano, studiodiessecomdue@gmail.com

Conference registration

To attend the Conference, you must submit the registration form through **MyICAR on the Conference website www.icar2024.it**.

After completing the form, you will receive an email with a link to confirm the activation of your personal account.

Official languages

Italian and English. No simultaneous translation provided.



Pre-Conference advanced courses and Congress dates

Pre-Conference advanced courses:

● **Wednesday, June 19** from 15.00 to 17.30

Conference:

● **Wednesday, June 19** from 15.00 to 20.45

● **Thursday, June 20** from 09.00 to 18.30

● **Friday, June 21** from 09.00 to 16.30

Conference Secretariat opening times

● **Wednesday, June 19** from 10.30 to 20.45

● **Thursday, June 20** from 08.00 to 19.30

● **Friday, June 21** from 08.00 to 17.00

Exhibition Area opening times

● **Wednesday, June 19** from 15.00 to 20.45

● **Thursday, June 20** from 09.00 to 18.30

● **Friday, June 21** from 09.00 to 16.30

Lunches

● **Thursday, June 20** from 12.30 to 14.30

● **Friday, June 21** from 12.30 to 14.30

In a dedicated area (Italia Room) inside the **Congress Center Europe**.



Instructions for Speakers and Presenting Authors

It is not possible to bring presentations directly to the lecture hall. All presentations have to be handed over at the Slide Center Room at least **2 hours before the session**. At the Slide Center Room, Speakers will have the possibility of:

- Reviewing power point presentations
- Last minute changes of power point presentations
- Being supported by technical staff
- Uploading power point presentation in the dedicated session conference room

All Speakers are requested to start their presentations with a Disclosure of Potential Conflicts of Interest slide.

A slides template for Speakers' presentations is available for download on the Conference website www.icar2024.it

Instructions for Oral Sessions

Oral Communications

Time allotted for each oral presentation is 10 minutes + 2 minutes for discussion. A maximum of 8/10 slides are required, plus the additional slide with the "Declaration of Potential Conflicts of Interest".



Short Communications

Time allotted for each oral presentation is 7 minutes + 2 minutes for discussion. A maximum of 6/7 slides are required, plus the additional slide with the "Declaration of Potential Conflicts of Interest".

Themed Discussions

Thematic sessions consisting of consecutive oral presentations, each of 7 minutes + a total final discussion of approximately 20 minutes. A maximum of 6/7 slides are required, plus the additional slide with the "Declaration of Potential Conflicts of Interest".

The ICAR scientific committee firmly believes that language is a powerful tool in shaping beliefs and influencing behaviours, particularly in the context of addressing the stigma surrounding chronic infections such as HIV and viral hepatitis. We urge conference attendees to prioritize person-centred language and be mindful of how their language and materials align with this principle. To assist in this effort, we recommend the adoption of UNAIDS-endorsed terminology, such as referring to people as "living with HIV" rather than "HIV-infected". Together, let us promote inclusivity and respect for all individuals affected by HIV and other chronic infections.

Digital Poster Exhibition

All the posters can be viewed through dedicated monitors located at **Università Cattolica Del Sacro Cuore**.

Don't forget to ask for the vouchers at the Poster 4 You desk to pick up the USB poster pendrive at the Gilead Sciences booth!



With an unrestricted educational grant from Gilead Sciences

Official events

RaccontART - 10° Edition

Presentation of the finalist works and Winners'Awards

Wednesday, June 19, Università Cattolica Del Sacro Cuore

• **Aula 5** **from 15.00 to 17.30**

The art competition launched by ICAR to students who are invited to present their views on HIV/AIDS, Covid and STIs through various forms of expression. The winners will be awarded by the Jury composed of leading representatives of the national cultural, scientific and technical world.



Special Awards

The work of young researchers and community representatives continues to be widely recognized by ICAR, not only through Scholarships, but also with special prizes. The 16th edition of ICAR Awards as follows:

ICAR-CROI Awards 2024

The absolute winners among the young Italian investigators who presented their work at CROI 2024

- **N. 1 Award** of € 1.000,00 for the best work in **Basic Science**
- **N. 1 Award** of € 1.000,00 for the best work in **Clinical Science**

Winners will be announced during the ICAR-CROI Awards 2024 Session in Aula Lazzati on Thursday June 20 from 17.35 to 18.30



ICAR 2024 Scientific Committee Awards

The 16th ICAR Chairs and Scientific Secretariat will announce the "Scientific Committee Awards": the ICAR Awards to the best abstracts

- **N. 1 Award** of € 1.000,00 for the best **Basic Science** abstract
- **N. 1 Award** of € 1.000,00 for the best **Clinical Science** abstract
- **N. 1 Award** of € 1.000,00 for the best **Social Science** abstract

Winners will be announced during the ICAR 2024 Special Awards Session in Aula Lazzati on Friday June 21 from 16.10 to 16.30



SIMIT Special Awards

The 16th ICAR Chairs and Scientific Secretariat wish to thank SIMIT for the Special Awards dedicated to Young Investigators, whose abstracts have been accepted.

Only young investigators under 45 years of age and regularly registered to SIMIT for years 2023 and 2024 will be selected.

- **N. 1 Award** of € 2.000,00 for the best **Clinical Hepatitis Virus** abstract
- **N. 1 Award** of € 2.000,00 for the best **Clinical HIV** abstract
- **N. 1 Award** of € 2.000,00 for the best **Clinical SARS-CoV-2** abstract
- **N. 1 Award** of € 2.000,00 for the best **Epidemiology and Social Science** abstract
- **N. 1 Award** of € 2.000,00 for the best **Virology and Immunopathogenesis** abstract

Abstracts will be evaluated at the Congress Venue by a dedicated SIMIT Commission and winners will be announced during the ICAR 2024 Special Awards Session in Aula Lazzati on Friday June 21 from 16.10 to 16.30



Special Award Liliana del Cupolo

Il Prof. Luigi Palla, Università degli Studi La Sapienza di Roma - istituisce e mette a disposizione **N. 1 premio** da € 1.000,00 in memoria della mamma "Liliana del Cupolo" per il **miglior abstract in ambito di ricerca Covid nel paziente immunocompromesso**.

La selezione è stata affidata ai Presidenti del Congresso e la consegna del premio sarà effettuata direttamente a cura del Prof. Palla durante la Special Awards Session in Aula Lazzati, venerdì 21 giugno dalle ore 16.10 alle ore 16.30



ICAR APP 2024

Designed to facilitate participation in ICAR 2024 and to respond to request for effective and high performance digital tools and supports. Two simple steps to access:

1. Download the ICAR App "ICAR Italian Conference" for free from the main stores (Apple Store and Google Play) "Minimum system requirements required for the App: Android 9.0 and iOS 14"

2. Login App: enter your personal login credentials (username and password) sent to you by the Organizing Secretariat Effetti

Menu Functions

1. PROGRAMMA SCIENTIFICO: Complete Scientific Programme day by day with detailed information about each session (title, speaker, time, room). Users can also select favorite Lectures, clicking on the calendar icon: these will be saved in My Agenda

2. MY AGENDA: User can customize their own Agenda using this function. ICAR 2024 App will create the list of favorite selected sessions in a chronological order

3. PROGRAM AT A GLANCE: To quickly check Programme, rooms and sessions schedule

4. ABSTRACT: All abstracts accepted, broken down by type of presentation (Oral, Poster) and Abstract Reviewers. From June 19, the Abstract Repository at your fingertips with keyword search, Authors names, Abstract IDs

5. SPECIAL AWARDS: The official rewards that ICAR assign to young investigators and Community ambassadors

6. RACCONTART: To access the Art Contest, consult the works in competition, learn about participating schools, and much more


7. INFORMAZIONI GENERALI: A menu item for the most useful and important links: Congress Venue, Transportation and much more...

8. ICAR SOCIAL: Direct links to ICAR 2024 Social. Stay connect #ICAR2024

9. SURVEY: Questionnaire to collect your opinions and impressions on the content and organizational aspects of the event.



**Inquadra il QRcode
e scarica l'App
con le credenziali
fornite dal
Provider Effetti**



With an unrestricted educational grant from Johnson & Johnson



ICAR for Participants

Community Village

A specific area of the **Congress Center** dedicated to the Community Village: a meeting point for all participants to visit the booths of patient associations and meet the Community activists.



Nice to ICAR you

The ICAR 2024 welcome point, in the Spagna foyer at the **Congress Center**: all registered participants can ask for all the informations and collect the ICAR 2024 T-shirt.



POSTER 4 YOU


A free service for selected posters' Authors to create their own posters and record their comments. **ICAR Poster 4 You USB pendrive** can be requested showing the coupon (available at the Poster 4 You desk) at the Gilead Sciences booth.

With an unrestricted educational grant from Gilead Sciences



ICAR Web Repository

After the Congress, on the official website **www.icar2024.it** you will find: ICAR 2024 web repository of abstracts, presentations, oral communications, short communications, themed discussions and accepted posters, podcasts and photo gallery.



ICAR SOCIAL

Direct links to ICAR 2024 Social.
 Stay connect #ICAR2024

www.instagram.com/ICARcongress

www.twitter.com/ICARcongress

www.facebook.com/ICARcongress



Participants are hereby informed that in some spaces where the conference and ancillary activities will take place, photographs/ video footage intended for online publication may be taken; participants will be notified through dedicated signage.



CME Accreditation

Conference

The 16th ICAR Conference has been accredited to the Italian Ministry of Health for 11,90 CME Credits.

Every single day has been accredited for the following professionals:

ID ECM Number	Credits	Professionals
Wednesday, June 19 150-408094	1,4	Medical Doctor (all disciplines)
Thursday, June 20 150-408149	5,6	Healthcare Assistant, Biologist, Professional Educator, SSN Public Pharmacist, Nurse, Psychologist (Psychology and Psychotherapy), Medical Technician of Biomedical Laboratory
Friday, June 21 150-408164	4,9	

Pre-Conference advanced courses

The 16th ICAR advanced Courses have been accredited to the Italian Ministry of Health for each single course:

ID ECM Number	Credits	Professionals
Immune response in viral infections: where we are with new knowledge 150-408048	2	Medical Doctor Allergology and Clinical Immunology; Dermatology and Venereology; Pharmacology and Clinical Toxicology; Gastroenterology; Hygiene, Epidemiology and Public Health; Infectious Diseases; Internal Medicine; Microbiology and Virology; Clinical Pathology (Laboratory of Chemical-Clinical Analysis and Microbiology). Healthcare Assistant, Biologist, Professional Educator, SSN Public Pharmacist, Nurse, Psychologist (Psychology and Psychotherapy), Medical Technician of Biomedical Laboratory
Addressing viral persistence today and tomorrow 150-408074	2	Medical Doctor Allergology and Clinical Immunology; Dermatology and Venereology; Pharmacology and Clinical Toxicology; Gastroenterology; Hygiene, Epidemiology and Public Health; Infectious Diseases; Internal Medicine; Microbiology and Virology; Clinical Pathology (Laboratory of Chemical-Clinical Analysis and Microbiology). Healthcare Assistant, Biologist, Professional Educator, SSN Public Pharmacist, Nurse, Psychologist (Psychology and Psychotherapy), Medical Technician of Biomedical Laboratory
Complexities of HIV management: when the going gets tough... the tough get going! 150-408080	2	Medical Doctor Allergology and Clinical Immunology; Dermatology and Venereology; Pharmacology and Clinical Toxicology; Gastroenterology; Hygiene, Epidemiology and Public Health; Infectious Diseases; Internal Medicine; Microbiology and Virology; Clinical Pathology (Laboratory of Chemical-Clinical Analysis and Microbiology). Healthcare Assistant, Biologist, Professional Educator, SSN Public Pharmacist, Nurse, Psychologist (Psychology and Psychotherapy), Medical Technician of Biomedical Laboratory
Ageing in people with HIV: a feasible challenge 150-408085	2	Medical Doctor Allergology and Clinical Immunology; Dermatology and Venereology; Pharmacology and Clinical Toxicology; Gastroenterology; Hygiene, Epidemiology and Public Health; Infectious Diseases; Internal Medicine; Microbiology and Virology; Clinical Pathology (Laboratory of Chemical-Clinical Analysis and Microbiology). Healthcare Assistant, Biologist, Professional Educator, SSN Public Pharmacist, Nurse, Psychologist (Psychology and Psychotherapy), Medical Technician of Biomedical Laboratory



CME Accreditation

Obtaining credits

Participants

To obtain credits, registered participants are required to:

- Wear the identification badge during working sessions
- Validate attendance by reading the bar-code placed on the badge, every day, before the start of the scientific work and in the evening, at the end of the scientific work
- Fill in the assessment and approval questionnaires for each individual conference day within the **MyICAR reserved area** in the official website **www.icar2024.it**

Speakers

Speakers will be given 1 credit for each 20 minutes consecutive teaching.

Moderators will be given 1 credit for each moderation session.

Speakers, moderators and discussants can decide to obtain credits as participants (see participants).

Attendance Tracking

Attendance of individual participants will be measured **by reading the bar-code** placed on the badge at the beginning and end of the scientific papers or each individual course and filling out the **online** evaluation questionnaire (**only one attempt will be allowed**) and approval rating, within one's **MyICAR** restricted area. The questionnaire for each work day will be available at the end of each day and will remain available for the following three days.

CME certification

Credits will be given only if a participant attends 90% of the working sessions and provides correct answers to at least 75% of the questions included in the final assessment questionnaire. The Provider will send CME certificates to the participants after the Conference.

SVC Assobiomedica

The Pre-Conference advanced courses and the Congress were evaluated as **compliant with the Code of Ethics** by the **Conference Evaluation System** (SVC) of Assobiomedica (Event Code: 2024-0409182232).



Registration fees

Pre-Conference advanced courses

Free of charge (registrations available on a "first come, first served" basis). Included congress kit (delegate bag, badge, certificate of attendance to the sessions of the day), CME registration and documentation.

Conference registration fees (22% VAT not included)

Over 35 years of age Physicians (all disciplines): Healthcare Assistant, Biologist, Professional Educator, SSN Public Pharmacist, Nurse, Medical Technician of Biomedical Laboratory, Psychologist, Psychotherapist	€ 850,00
Under 35 years of age Physicians (all disciplines): Healthcare Assistant, Biologist, Professional Educator, SSN Public Pharmacist, Nurse, Medical Technician of Biomedical Laboratory, Psychologist, Psychotherapist	€ 400,00
Students/PhD and Post-graduate medical trainees	Free
Members of HIV/AIDS Community	Free

The registration fee includes: congress kit (delegate bag, badge, certificate of attendance), coffee break, lunches at the congress on 20 and 21 June, CME registration, conference USB poster, Welcome Cocktail on the evening of June 19th, at the end of the proceedings.

Daily Conference registration fees (22% VAT not included)

Over 35 years of age Physicians (all disciplines): Healthcare Assistant, Biologist, Professional Educator, SSN Public Pharmacist, Nurse, Medical Technician of Biomedical Laboratory, Psychologist, Psychotherapist	€ 350,00
Under 35 years of age Physicians (all disciplines): Healthcare Assistant, Biologist, Professional Educator, SSN Public Pharmacist, Nurse, Medical Technician of Biomedical Laboratory, Psychologist, Psychotherapist	€ 200,00
Students/PhD and Post-graduate medical trainees	Free

The registration fee includes: attendance at the day's scientific session, congress kit (delegate bag, badge, certificate of attendance to the sessions of the day), coffee break and lunch of the day, CME registration and documentation, Conference USB poster.



19-21
GIUGNO
ROMA

UNIVERSITÀ CATTOLICA
DEL SACRO CUORE
CENTRO CONGRESSI
EUROPA

16° CONGRESSO NAZIONALE



**Italian Conference on AIDS and
Antiviral Research**

20
24



Presidenza del Congresso

A. Cingolani, Roma
A. Di Biagio, Genova
M. Farinella, Roma
G. C. Marchetti, Milano


RESEARCH and CARE: FROM BENCH, TO BEDSIDE, TO COMMUNITY

CONGRESS MAP



Università Cattolica del Sacro Cuore
CENTRO CONGRESSI EUROPA

PIANO TERRA



LEGENDA CENTRO CONGRESSI EUROPA

-  **Segreteria**

-  **Area lunch**

-  **Deposito bagagli**

LEGENDA POLO GIOVANNI XXIII

-  **Info point**

-  **Centro slide**

-  **Area relax**

-  **Area coffee break**



-  **programma scientifico**

-  **program di a glance**

-  **photo gallery**

-  **raccolta abstract e poster**



Università Cattolica del Sacro Cuore
POLO GIOVANNI XXIII

PIANO TERRA

Area espositiva

- 1 **ViiV** Healthcare
- 2 **MSD**
- 3 **Johnson&Johnson**
- 4 **Fondazione Icona**
ITALIAN CONFERENCE ON AIDS AND ANTIVIRAL RESEARCH
Co-located by Professor Mauro Soriani
- 5 **ReAdfiles**
- 5 **GILEAD**
Creating Possible

Desk

- 6 **Abbott**
- 7 **POSTER 4 YOU**
I CAE 2024

TUNNEL DI ACCESSO
DA CENTRO CONGRESSI
EUROPA



CONGRESS MAP

PIANO 1 - BALLATOIO



- 8 Villa Maraini
- 9 Mario Mieli
- 10 ARCOBALENO
- 11 ASA
- 12 EpaC
- 13 LILA
- 14 ARCIGAY
- 15 Milano Checkpoint
- 16 PLUS
- 17 C.I.C.A.
- 18 ANLAIDS
- 19 NPS Italia
- 20 Conigli Bianchi
- 21 Latina Checkpoint
- 22 SISM



19-21 GIUGNO ROMA UNIVERSITÀ CATTOLICA DEL SACRO CUORE
CENTRO CONGRESSI EUROPA

2024



16° CONGRESSO NAZIONALE

ICAR

Italian Conference on AIDS
and Antiviral Research

RESEARCH and CARE: FROM BENCH, TO BEDSIDE, TO COMMUNITY

effetti

THANKS TO THE SPONSORS

The Chairs, the Scientific Secretariat and CME Provider wish to thank the following Companies for the support given to the Congress, as unrestricted educational grants:

PLATINUM



Johnson & Johnson



SILVER



OTHERS



abbvie



Seguici su



www.icar2024.it

